
<html lang="en"     class="pb-page"  data-request-id="decb5623-c3c9-4842-824d-f26cb90ab37e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-7;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c02083;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer" /></meta><meta name="dc.Creator" content="Ryan V.  Quiroz" /></meta><meta name="dc.Creator" content="Michael H.  Reutershan" /></meta><meta name="dc.Creator" content="Sebastian E.  Schneider" /></meta><meta name="dc.Creator" content="David  Sloman" /></meta><meta name="dc.Creator" content="Brian M.  Lacey" /></meta><meta name="dc.Creator" content="Brooke M.  Swalm" /></meta><meta name="dc.Creator" content="Charles S.  Yeung" /></meta><meta name="dc.Creator" content="Craig  Gibeau" /></meta><meta name="dc.Creator" content="Daniel S.  Spellman" /></meta><meta name="dc.Creator" content="Danica A.  Rankic" /></meta><meta name="dc.Creator" content="Dapeng  Chen" /></meta><meta name="dc.Creator" content="David  Witter" /></meta><meta name="dc.Creator" content="Doug  Linn" /></meta><meta name="dc.Creator" content="Erik  Munsell" /></meta><meta name="dc.Creator" content="Guo  Feng" /></meta><meta name="dc.Creator" content="Haiyan  Xu" /></meta><meta name="dc.Creator" content="Jonathan M. E.  Hughes" /></meta><meta name="dc.Creator" content="Jongwon  Lim" /></meta><meta name="dc.Creator" content="Josep  Saurí" /></meta><meta name="dc.Creator" content="Kristin  Geddes" /></meta><meta name="dc.Creator" content="Murray  Wan" /></meta><meta name="dc.Creator" content="My Sam  Mansueto" /></meta><meta name="dc.Creator" content="Nicole E.  Follmer" /></meta><meta name="dc.Creator" content="Patrick S.  Fier" /></meta><meta name="dc.Creator" content="Phieng  Siliphaivanh" /></meta><meta name="dc.Creator" content="Pierre  Daublain" /></meta><meta name="dc.Creator" content="Rachel L.  Palte" /></meta><meta name="dc.Creator" content="Robert P.  Hayes" /></meta><meta name="dc.Creator" content="Sandra  Lee" /></meta><meta name="dc.Creator" content="Shuhei  Kawamura" /></meta><meta name="dc.Creator" content="Steven  Silverman" /></meta><meta name="dc.Creator" content="Sulagna  Sanyal" /></meta><meta name="dc.Creator" content="Timothy J.  Henderson" /></meta><meta name="dc.Creator" content="Yingchun  Ye" /></meta><meta name="dc.Creator" content="Yuanwei  Gao" /></meta><meta name="dc.Creator" content="Benjamin  Nicholson" /></meta><meta name="dc.Creator" content="Michelle R.  Machacek" /></meta><meta name="dc.Description" content="Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the post-translational symmetric dimethylation of protein substrates. PRMT5 plays a critical role..." /></meta><meta name="Description" content="Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the post-translational symmetric dimethylation of protein substrates. PRMT5 plays a critical role..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 23, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02083" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02083" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02083" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02083" /></link>
        
    
    

<title>The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02083" /></meta><meta property="og:title" content="The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0025.jpeg" /></meta><meta property="og:description" content="Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the post-translational symmetric dimethylation of protein substrates. PRMT5 plays a critical role in regulating biological processes including transcription, cell cycle progression, RNA splicing, and DNA repair. As such, dysregulation of PRMT5 activity is implicated in the development and progression of multiple cancers and is a target of growing clinical interest. Described herein are the structure-based drug designs, robust synthetic efforts, and lead optimization strategies toward the identification of two novel 5,5-fused bicyclic nucleoside-derived classes of potent and efficacious PRMT5 inhibitors. Utilization of compound docking and strain energy calculations inspired novel designs, and the development of flexible synthetic approaches enabled access to complex chemotypes with five contiguous stereocenters. Additional efforts in balancing bioavailability, solubility, potency, and CYP3A4 inhibition led to the identification of diverse lead compounds with favorable profiles, promising in vivo activity, and low human dose projections." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02083"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02083">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02083&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02083&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02083&amp;href=/doi/10.1021/acs.jmedchem.0c02083" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3911-3939</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02072" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02085" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ryan V. Quiroz</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ryan V. Quiroz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#06747f67682877736f74697c466b6374656d2865696b"><span class="__cf_email__" data-cfemail="17656e76793966627e65786d577a7265747c3974787a">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ryan+V.++Quiroz">Ryan V. Quiroz</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6840-9636" title="Orcid link">http://orcid.org/0000-0001-6840-9636</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael H. Reutershan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael H. Reutershan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+H.++Reutershan">Michael H. Reutershan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sebastian E. Schneider</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sebastian E. Schneider</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sebastian+E.++Schneider">Sebastian E. Schneider</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1233-8984" title="Orcid link">http://orcid.org/0000-0003-1233-8984</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Sloman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Sloman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Sloman">David Sloman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian M. Lacey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian M. Lacey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+M.++Lacey">Brian M. Lacey</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brooke M. Swalm</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brooke M. Swalm</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brooke+M.++Swalm">Brooke M. Swalm</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charles S. Yeung</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charles S. Yeung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charles+S.++Yeung">Charles S. Yeung</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7320-7190" title="Orcid link">http://orcid.org/0000-0001-7320-7190</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Craig Gibeau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Craig Gibeau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Craig++Gibeau">Craig Gibeau</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel S. Spellman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel S. Spellman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 770 Sumneytown Pike, Lansdale, Pennsylvania 19446, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+S.++Spellman">Daniel S. Spellman</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7155-2329" title="Orcid link">http://orcid.org/0000-0001-7155-2329</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Danica A. Rankic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Danica A. Rankic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Danica+A.++Rankic">Danica A. Rankic</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7326-8900" title="Orcid link">http://orcid.org/0000-0002-7326-8900</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dapeng Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dapeng Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dapeng++Chen">Dapeng Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David Witter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David Witter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David++Witter">David Witter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Doug Linn</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Doug Linn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Doug++Linn">Doug Linn</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erik Munsell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erik Munsell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erik++Munsell">Erik Munsell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guo Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guo Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guo++Feng">Guo Feng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haiyan Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haiyan Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haiyan++Xu">Haiyan Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jonathan M. E. Hughes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jonathan M. E. Hughes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan+M.+E.++Hughes">Jonathan M. E. Hughes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jongwon Lim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jongwon Lim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jongwon++Lim">Jongwon Lim</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3402-7810" title="Orcid link">http://orcid.org/0000-0003-3402-7810</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Josep Saurí</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Josep Saurí</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Josep++Saur%C3%AD">Josep Saurí</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kristin Geddes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kristin Geddes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 770 Sumneytown Pike, Lansdale, Pennsylvania 19446, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kristin++Geddes">Kristin Geddes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Murray Wan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Murray Wan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Murray++Wan">Murray Wan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">My Sam Mansueto</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">My Sam Mansueto</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=My+Sam++Mansueto">My Sam Mansueto</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicole E. Follmer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicole E. Follmer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicole+E.++Follmer">Nicole E. Follmer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patrick S. Fier</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patrick S. Fier</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+S.++Fier">Patrick S. Fier</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6102-815X" title="Orcid link">http://orcid.org/0000-0002-6102-815X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Phieng Siliphaivanh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Phieng Siliphaivanh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Phieng++Siliphaivanh">Phieng Siliphaivanh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pierre Daublain</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pierre Daublain</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pierre++Daublain">Pierre Daublain</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rachel L. Palte</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rachel L. Palte</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rachel+L.++Palte">Rachel L. Palte</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert P. Hayes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert P. Hayes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 770 Sumneytown Pike, Lansdale, Pennsylvania 19446, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+P.++Hayes">Robert P. Hayes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sandra Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandra Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++Lee">Sandra Lee</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1907-0263" title="Orcid link">http://orcid.org/0000-0003-1907-0263</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuhei Kawamura</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuhei Kawamura</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuhei++Kawamura">Shuhei Kawamura</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Steven Silverman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Steven Silverman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Silverman">Steven Silverman</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0792-7071" title="Orcid link">http://orcid.org/0000-0003-0792-7071</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sulagna Sanyal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sulagna Sanyal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sulagna++Sanyal">Sulagna Sanyal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy J. Henderson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy J. Henderson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+J.++Henderson">Timothy J. Henderson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yingchun Ye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingchun Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingchun++Ye">Yingchun Ye</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuanwei Gao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuanwei Gao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 770 Sumneytown Pike, Lansdale, Pennsylvania 19446, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuanwei++Gao">Yuanwei Gao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benjamin Nicholson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benjamin Nicholson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin++Nicholson">Benjamin Nicholson</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Michelle R. Machacek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michelle R. Machacek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michelle+R.++Machacek">Michelle R. Machacek</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02083&amp;href=/doi/10.1021%2Facs.jmedchem.0c02083" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3911–3939</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 23, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 December 2020</li><li><span class="item_label"><b>Published</b> online</span>23 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02083" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02083</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3911%26pageCount%3D29%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRyan%2BV.%2BQuiroz%252C%2BMichael%2BH.%2BReutershan%252C%2BSebastian%2BE.%2BSchneider%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.0c02083%26title%3DThe%2BDiscovery%2Bof%2BTwo%2BNovel%2BClasses%2Bof%2B5%252C5-Bicyclic%2BNucleoside-Derived%2BPRMT5%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26numPages%3D29%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3939%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02083"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2115</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02083" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ryan&quot;,&quot;last_name&quot;:&quot;V. Quiroz&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;H. Reutershan&quot;},{&quot;first_name&quot;:&quot;Sebastian&quot;,&quot;last_name&quot;:&quot;E. Schneider&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Sloman&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;M. Lacey&quot;},{&quot;first_name&quot;:&quot;Brooke&quot;,&quot;last_name&quot;:&quot;M. Swalm&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;S. Yeung&quot;},{&quot;first_name&quot;:&quot;Craig&quot;,&quot;last_name&quot;:&quot;Gibeau&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;S. Spellman&quot;},{&quot;first_name&quot;:&quot;Danica&quot;,&quot;last_name&quot;:&quot;A. Rankic&quot;},{&quot;first_name&quot;:&quot;Dapeng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Witter&quot;},{&quot;first_name&quot;:&quot;Doug&quot;,&quot;last_name&quot;:&quot;Linn&quot;},{&quot;first_name&quot;:&quot;Erik&quot;,&quot;last_name&quot;:&quot;Munsell&quot;},{&quot;first_name&quot;:&quot;Guo&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Haiyan&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;M. E. Hughes&quot;},{&quot;first_name&quot;:&quot;Jongwon&quot;,&quot;last_name&quot;:&quot;Lim&quot;},{&quot;first_name&quot;:&quot;Josep&quot;,&quot;last_name&quot;:&quot;Saurí&quot;},{&quot;first_name&quot;:&quot;Kristin&quot;,&quot;last_name&quot;:&quot;Geddes&quot;},{&quot;first_name&quot;:&quot;Murray&quot;,&quot;last_name&quot;:&quot;Wan&quot;},{&quot;first_name&quot;:&quot;My&quot;,&quot;last_name&quot;:&quot;Sam Mansueto&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;E. Follmer&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;S. Fier&quot;},{&quot;first_name&quot;:&quot;Phieng&quot;,&quot;last_name&quot;:&quot;Siliphaivanh&quot;},{&quot;first_name&quot;:&quot;Pierre&quot;,&quot;last_name&quot;:&quot;Daublain&quot;},{&quot;first_name&quot;:&quot;Rachel&quot;,&quot;last_name&quot;:&quot;L. Palte&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;P. Hayes&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Shuhei&quot;,&quot;last_name&quot;:&quot;Kawamura&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Silverman&quot;},{&quot;first_name&quot;:&quot;Sulagna&quot;,&quot;last_name&quot;:&quot;Sanyal&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;J. Henderson&quot;},{&quot;first_name&quot;:&quot;Yingchun&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Yuanwei&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;Nicholson&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;R. Machacek&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;3911-3939&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02083&quot;},&quot;abstract&quot;:&quot;Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the post-translational symmetric dimethylation of protein substrates. PRMT5 plays a critical role in regulating biological processes including transcription, cell cycle progression, RNA splicing, and DNA repair. As such, dysregulation of PRMT5 activity is implicated in the development and progression of multiple cancers and is a target of growing clinical interest. Described herein are the structure-based drug designs, robust synthetic efforts, and lead optimization strategies toward the identification of two novel 5,5-fused bicyclic nucleoside-derived classes of potent and efficacious PRMT5 inhibitors. Utilization of compound docking and strain energy calculations inspired novel designs, and the development of flexible synthetic approaches enabled access to complex chemotypes with five contiguous stereocenters. Additional efforts in balancing bioavailability, solubility, potency, and CYP3A4 inhibition led to t&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02083&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02083" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02083&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02083" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02083&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02083" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02083&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02083&amp;href=/doi/10.1021/acs.jmedchem.0c02083" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02083" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02083" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02083%26sid%3Dliteratum%253Aachs%26pmid%3D33755451%26genre%3Darticle%26aulast%3DQuiroz%26date%3D2021%26atitle%3DThe%2BDiscovery%2Bof%2BTwo%2BNovel%2BClasses%2Bof%2B5%252C5-Bicyclic%2BNucleoside-Derived%2BPRMT5%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D3911%26epage%3D3939%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292065" title="Nucleobases">Nucleobases</a>,</li><li><a href="/action/doSearch?ConceptID=290795" title="Quinolines">Quinolines</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the post-translational symmetric dimethylation of protein substrates. PRMT5 plays a critical role in regulating biological processes including transcription, cell cycle progression, RNA splicing, and DNA repair. As such, dysregulation of PRMT5 activity is implicated in the development and progression of multiple cancers and is a target of growing clinical interest. Described herein are the structure-based drug designs, robust synthetic efforts, and lead optimization strategies toward the identification of two novel 5,5-fused bicyclic nucleoside-derived classes of potent and efficacious PRMT5 inhibitors. Utilization of compound docking and strain energy calculations inspired novel designs, and the development of flexible synthetic approaches enabled access to complex chemotypes with five contiguous stereocenters. Additional efforts in balancing bioavailability, solubility, potency, and CYP3A4 inhibition led to the identification of diverse lead compounds with favorable profiles, promising <i>in vivo</i> activity, and low human dose projections.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55522" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55522" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Even with the tremendous advances made in oncology therapies over the past several years, most notably in immunotherapies such as checkpoint inhibitors,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> cancer still remains a daunting global health challenge. While efforts to harness and augment immune responses to tumors remain promising and worthwhile, new targets and approaches are still crucially needed to continue expanding the patient populations successfully managed with anticancer drugs. One epigenetic target of emerging and promising clinical potential is protein arginase methyltransferase 5 (PRMT5), a type II arginine methyltransferase that post-translationally modifies histone and other protein targets via symmetric dimethylation. This methylation of protein substrates catalyzed by PRMT5 plays a critical role in regulating key cellular processes including DNA repair, cell cycle progression, transcriptional regulation, and RNA splicing.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7">(2−7)</a> In turn, PRMT5 has been implicated as a potential oncogene whose upregulation results in tumor cell proliferation and invasiveness for numerous different cancers,<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7">(2−7)</a> including colorectal, lung, ovarian, prostate, and pancreatic cancers, and lymphoma, leukemia, and glioblastoma.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> This multipathway regulation culminating in broad-ranging tumorigenesis suggests that PRMT5 inhibition could serve as a powerful anticancer strategy. As such, numerous preclinical inhibitor discovery efforts have been pursued,<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19">(8−19)</a> and several pharmaceutical companies have recently initiated clinical trials with small-molecule PRMT5 inhibitors.<a onclick="showRef(event, 'ref4 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref6">(4,6)</a></div><div class="NLM_p">Active PRMT5 forms a hetero-octameric complex with adapter protein MEP50 and utilizes <i>S</i>-adenosylmethionine (SAM, <b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) as a cofactor to transfer a methyl group to the substrate arginine.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> The active site of the enzyme consists of a conserved SAM binding pocket and a nearby protein substrate binding pocket, which are connected by a short, narrow channel in the enzyme.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In addition to SAM, the endogenous ligand methylthioadenosine (MTA) also binds to and inhibits PRMT5 in a SAM-competitive manner. For some cancers, gene deletion of the enzyme responsible for metabolizing MTA, methylthioadenosine phosphorylase (MTAP), results in a natural partial inhibition of PRMT5 by accumulated MTA.<a onclick="showRef(event, 'ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25">(22−25)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Binding of SAM (green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X61">4X61</a>) to PRMT5 overlaid with the H4 peptide (salmon, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GQB">4GQB</a>). Main interactions highlighted with yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given these catalytic site structural features of PRMT5, three of the most commonly pursued classes of inhibitors include SAM-competitive, substrate-competitive, and dual SAM/substrate-competitive inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Such structurally diverse PRMT5 inhibitors with these mechanisms of action (MoAs) pursued preclinically and clinically have been extensively reviewed.<a onclick="showRef(event, 'ref4 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref6">(4,6)</a> Interestingly, another unique class of substrate-competitive inhibitors represented by EPZ015666 is SAM-uncompetitive inhibitors, which still require SAM to achieve PRMT5 inhibition.<a onclick="showRef(event, 'ref9 ref16'); return false;" href="javascript:void(0);" class="ref ref9 ref16">(9,16)</a> Allosteric inhibition,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> covalent inhibition,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and PROTAC-mediated inhibition<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> have also been reported but are beyond the scope of this paper. Of interest to us, dual SAM/substrate-competitive inhibitors occupy the SAM pocket and extend into the narrow groove that connects the substrate protein pocket, precluding both SAM and substrate binding, a mechanism that could be utilized for inhibitor design to perhaps enhance potency and prolong compound residence time.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p last">Given this backdrop and the significant potential of PRMT5 inhibition for the treatment of cancer, we initiated a robust medicinal chemistry effort to develop potent, selective, orally bioavailable, and low projected human dose nucleoside-derived PRMT5 inhibitors. Specifically, we designed, synthesized, and biologically evaluated multiple classes of novel 5,5-bicyclic nucleoside inhibitors, including a fused ribose-carbocycle core exemplified by the lead compound <b>34</b> and an all-carbon 5,5-fused core exemplified by <b>72</b>. These complex bicyclic compounds were exquisitely potent, efficacious, and structurally unique dual-competitive inhibitors compared to other known PRMT5 inhibitors. Furthermore, the development of modular and reliable synthetic routes enabled rapid exploration of SAR, which was critical to modulating solubility and CYP3A4 inhibition profiles alongside affinity and pharmacokinetic (PK) profiles. These efforts culminated in the discovery of two new classes of PRMT5 inhibitors with potential utility as cancer therapeutics due to their balanced overall properties, demonstration of <i>in vivo</i> tumor regression, and low predicted once daily (QD) human doses.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Modeling, Energy Calculations, and Initial Compound Design</h3><div class="NLM_p">Our approach to design PRMT5 inhibitors took inspiration from the natural cofactor SAM (<b>1</b>), as well as the known PRMT5 nucleoside-based inhibitors referenced above.<a onclick="showRef(event, 'ref4 ref6 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref4 ref6 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19">(4,6,8−19)</a> Furthermore, computational modeling was leveraged to investigate the intricate interactions between these ligands and their respective binding pockets to help enable analog design.</div><div class="NLM_p">Specifically, the crystal structure of SAM bound to PRMT5<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> revealed several critical interactions in the active site between the SAM cofactor and the receptor. Notably, the adenosine core diol engaged in a hydrogen bonding network with Tyr324 and Glu392, the purine C6-amino group hydrogen-bonded with Asp419, and the purine N1 nitrogen hydrogen-bonded with the main chain amide −NH of Met420 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Binding mode of SAM (<b>1</b>, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X61">4X61</a>). Prominent interactions with the protein are shown with yellow dashed lines. (B) Binding mode of the H4 peptide arginine residue in the PRMT5 catalytic site (pink, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FA5">5FA5</a>) overlaid with the SAM binding mode (green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X61">4X61</a>). The arginine is in close proximity to the methyl group of SAM, anchored by Glu444.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While the SAM pharmacophore highlighted the main nucleoside binding interactions essential to analog design, we also took an interest in dual-competitive compounds that engaged key residues in the channel connecting the cofactor and substrate binding pockets, specifically the catalytic residue Glu444, which anchors the protein substrate arginine and is part of the active site of PRMT5 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Along these lines, we took inspiration from previously developed SAM-mimetic compounds like JNJ64619178,<a onclick="showRef(event, 'ref4 ref29'); return false;" href="javascript:void(0);" class="ref ref4 ref29">(4,29)</a> which contains an aminoquinoline moiety that modeling suggested could indeed extend from the SAM binding pocket to the peptide binding site channel. The aminoquinoline was specifically modeled to engage in a bidentate hydrogen bond with Glu444 similarly to the substrate arginine residue, thereby putatively preventing both SAM and substrate binding.</div><div class="NLM_p">With this knowledge gleaned from SAM and previous PRMT5i chemical matter, we proposed that nucleoside-derived small molecules represented the most attractive approach toward utilizing the SAM pocket as a key anchor for the design of potent, dual-competitive inhibitors. As such, our design campaign sought to develop novel nucleoside cores and Glu444-interacting substituents to generate compounds that would functionally and optimally serve this goal. Given the specific geometry required to effectively bridge key interactions within both the SAM and peptide binding sites, we hypothesized that optimizing the conformational preference of the structure used to link the nucleobase, diol, and aminoquinoline moieties would be critical to achieving high-affinity binders.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Accordingly, we utilized docking and conformational analysis to prioritize the designs of geometrically privileged  cores. In particular, the calculation of strain energy incurred between ground state and bound state analog conformations was conducted.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In combination with binding free energy estimations, these strain energy calculations of bioactive conformations helped rank new designs and predict/explain potency trends (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Supporting Information</a> for details).</div><div class="NLM_p">The initial key finding utilizing these computational tools stemmed from representative compound <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). While <b>3</b> demonstrated that methyl substitution was tolerated at the 3′ position of a simple nucleoside, yielding an active inhibitor in our cellular PRMT5 target engagement (TE) assay, the introduction of this methyl group did induce strain in the conformation adopted by the linker connecting the ribose core and an aminoquinoline moiety. With this insight and the subsequent goal to lower the overall strain energy to better favor a desired bioactive conformation, we designed a 5,5-fused bicyclic ribose inhibitor wherein 3′ and 4′ were connected via a cyclopentane ring (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, <b>4</b>). Gratifyingly, not only did the calculations predict that such a cyclization would reduce the linker strain, but also compound <b>4</b> proved to be more potent <i>in vitro</i> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S1</a>). This data helped solidify our confidence that modeling and strain energy calculations could guide  designs to improve target affinity.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Inspired by <b>3</b>, designing a lower-strain 5,5-bicyclic system by fusing 3′ and 4′ led to the more potent inhibitor <b>4</b>. (B) Retention of the key nucleoside binding pharmacophore for <b>4</b> was validated by X-ray crystallography (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KIB">7KIB</a>). H-bonds shown in dashed yellow lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additional insight into our novel 5,5-fused PRMT5 inhibitor design came from the X-ray crystal structure of compound <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). The nucleoside diol and nucleobase retained the critical hydrogen bonding interactions that mimicked the adenosine moiety in SAM. Additionally, the aminoquinoline moiety could indeed extend into the channel connecting the SAM and substrate pockets, making a face-to-face pi stacking interaction with Phe327 and a bidentate hydrogen bond with Glu444, confirming <b>4</b>’s function as a dual-competitive inhibitor. With these key binding interactions, the 5,5-fused ring system could be used to  design compounds with exquisite potency in a favorable low-strain bioactive conformation.</div><div class="NLM_p">Capitalizing more generally on these computational tools, we leveraged docking and strain energy calculations for subsequent 5,5-bicyclic designs toward the goal of identifying compounds with predicted high affinity. Specifically, the docked binding affinity was estimated using a docking and refinement protocol including minimization steps and MMGBSA calculations, and the minimized pose was used as an input for the strain calculations, which was conducted using freeform (see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Supporting Information</a>). Ultimately, these strain energy calculations and affinity predictions were used in concert to rank order several 5,5-fused designs and compare them against 3′-methyl-substituted, 3′/4′-dimethyl-substituted, and hypothetical 4,5-, 6,5-, and 5,6-fused cores (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Gratifyingly, this analysis broadly supported the 5,5-fused designs as having a high probability of success (POS) for delivering high-affinity inhibitors, which was validated by the TE potencies for the designs that were ultimately synthesized.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Analysis of predicted protein–ligand interaction energy (MMGBSA) and predicted global strain identified different 5,5-fused cores as having a high POS for delivering high-affinity inhibitors, which was validated by TE potencies. Unfilled shapes were designed but not made.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">With these calculations establishing confidence in our 5,5-fused inhibitor designs, one modification that could be readily assessed was the change in the 5′ linker identity and stereochemistry. Four possible combinations were analyzed, namely, an ether linker vs a methylene linker and <i>S</i>- or <i>R</i>-stereochemistry at that linker position. Utilizing this analysis, we were able to prioritize the <i>S</i>-ether (“down”) linker and the <i>S</i>-methylene (“up”) linker for the bicyclic ribose systems (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S1</a>). These combinations were modeled to adopt the most preferred bioactive conformation to allow the nucleoside core to interact with the SAM pocket and the aminoquinoline to engage with the catalytic residue Glu444. In all, due to the  relatively lengthy syntheses of these complex inhibitors with five contiguous stereocenters, these modeling-informed insights were valuable tools for efficiently driving novel design progression.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthetic Chemistry for 5,5-Bicyclic Ribose Compounds</h3><div class="NLM_p">To enable the expansion of SAR and the optimization of compound properties to develop projected low-dose PRMT5 inhibitors, new synthetic routes  needed to be developed to access the complex core of <b>4</b>.  Few synthetic protocols have been reported for this class of bicyclic ribose scaffolds with a similar substitution pattern.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a> Leveraging this synthetic insight, our approach relied on a 14-step route beginning with the commercially available glucofuranose derivative <b>5</b>, as highlighted with the representative synthesis of ether-linked scaffolds shown below (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Representative Synthetic Route to Access Ether-Linked Bicyclic Ribose Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Oxidation of the 3′ alcohol of the protected glucofuranose <b>5</b> with IBX afforded ketone <b>6</b>, to which vinyl Grignard was added to afford tertiary allylic alcohol <b>7</b>. After protection of the 3′ alcohol, periodic acid was used for selective acetonide cleavage to afford 4′ aldehyde <b>9</b>. Following literature precedent,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> an Rh-mediated intramolecular cyclization between the 3′ olefin and 4′ aldehyde furnished the bicycle core <b>10</b>. After ketone reduction and acetonide deprotection, 3′ benzyloxy hydrogenation afforded triol <b>13</b>. Subsequent 2′/3′ acetonide protection and tosylation of the 5′ secondary alcohol afforded tosylate <b>15</b>, which was primed for an S<sub>N</sub>2 with phenol <b>16</b> to afford ether <b>17</b> with the desired stereochemistry suggested by modeling. Acid-mediated hydrolysis yielded triol <b>18</b>, which underwent an epoxide-opening addition<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> of nucleobase <b>19</b> to afford nucleoside <b>20</b>. When needed, final amination of the purine chloride afforded the generic inhibitor <b>21</b>. One beneficial feature of this route, besides its general ability to access complex chiral structures, was its late-stage modularity. By simply changing the left-hand-side quinoline moiety or the nucleobase added to the core, we could furnish numerous diverse analogs to modulate potency, physical properties, off-target profiles, and PK.</div><div class="NLM_p">In addition to these ether-linked compounds, we were also interested in accessing methylene-linked 5,5-bicyclic ribose analogs to expand the chemical space tested and tune linker strain. Importantly, the opposite stereochemistry at 5′ was desired for the methylene linker compared to the ether linker based on the strain energy and docking discussed above (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S1</a>). A slightly altered synthetic route was adopted to access such methylene-linked scaffolds based on the common intermediate <b>14</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Synthetic Route to Access Methylene-Linked Bicyclic Ribose Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Briefly, oxidation of the 5′ alcohol of <b>14</b> afforded ketone <b>22</b>, which was olefinated under Wittig conditions to give exocyclic olefin <b>23</b>. A hydroboration with 9-BBN gratifyingly provided the desired facial selectivity to afford a terminal alkyl borane, which was immediately subjected to Suzuki conditions with quinoline halide <b>24</b> (V = −I or −Br) to furnish methylene-linked bicycle <b>25</b>. Acid-mediated deprotection afforded triol <b>26</b>, which again underwent epoxide-mediated 7-deazapurine addition to afford nucleoside <b>27</b>. When necessary, a final amination afforded the generic inhibitor <b>28</b>. The relative stereochemical assignment of both ether- and methylene-linked representative analogs was confirmed by 2D NMR (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S2</a>).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> 5,5-Bicyclic Ribose Inhibitor <i>In Vitro</i> Profiling</h3><div class="NLM_p">To rigorously profile our PRMT5 inhibitors <i>in vitro</i>, we developed three tiers of assays to assess compound potency and proliferation inhibition. First, analogs were profiled in a simple biochemical (BC) assay containing a PRMT5/MEP50 complex in solution. Second, the cell-based TE assay measured levels of histone methylation. Finally, a B-cell Z138 lymphoma assay measured the proliferation inhibition efficacy of the inhibitors (details in <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Since most compounds in this series demonstrated tight binding kinetics and were of higher affinity than could be reliably measured in our standard biochemical assay format, cell-based TE and proliferation EC<sub>50</sub> values were the main drivers of SAR (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S3</a>, which also contains representative SPR data to help support the bisubstrate MoA). Utilizing the modular synthetic routes discussed above, a series of diverse analogs were synthesized and screened for PRMT5 potency (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>; structural elements for comparison are colored).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. 5,5-Bicyclic Ribose SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0013.gif" alt="" id="gr12" /></img><div></div></div><div class="NLM_p">As can be seen in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> (<b>4</b> and <b>29</b>–<b>33</b>), both ether-linked and methylene-linked 5,5-dual inhibitors had single-digit nanomolar EC<sub>50</sub> values in the cellular TE and proliferation inhibition assays. However, compounds <b>40</b> and <b>41</b> supported the importance of stereochemistry (and therefore linker strain) for compound potency, as was computationally predicted (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S1</a>). There was a significant loss of potency (>2000× and >8× for ether- and methylene-linked compounds, respectively, in the TE assay) when more strained linker conformations were adopted. Furthermore, subtle potency effects could be seen when the aminoquinoline halogen was exchanged. For <b>4</b> and <b>29</b>–<b>33</b>, −Br-substituted analogs were consistently the most potent in the proliferation assay, with an emerging trend of −Br > −Cl > −F. The −Br and −Cl compounds were equipotent in the TE assay, with both being more potent than −F. While modeling indicated that the larger size of the halogen atom could help fill a pocket to increase potency, other likely contributing factors were the impact of the halogen atom on the basicity of the quinoline nitrogen (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Table S1</a>), affecting the strong bidentate hydrogen bond, and its impact on the electronic properties of the quinoline aromatic ring, which engaged in a face-to-face pi stacking interaction with Phe327. Ultimately, changes to either the linker atom identity or the halogen atom were still well tolerated, and analogs with <10 nM TE potency were possible in all combinations.</div><div class="NLM_p">In addition to the C6-amino group on the nucleobase, compounds <b>34</b>–<b>39</b> demonstrated that a simple C6-methyl group was also tolerated for these inhibitors. While the amino-containing compounds in general demonstrated higher affinity, this data suggested that the purported hydrogen bond between this nucleobase C6-amino group and PRMT5 was not critical for potency and that, perhaps, interacting with the N1 atom was more important in that region. X-ray crystallography of the representative compound <b>34</b> also confirmed that all other major interactions were maintained with this class of inhibitors (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Finally, with the C6-methyl nucleobase, a similar potency trend for the quinoline halogen atoms was also seen, with −Br > −Cl > −F; in fact, this trend was generally more distinct for these methyl nucleobase compounds relative to their amino matched pairs for both the TE and Z138 assays.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. C6-methyl nucleobase inhibitor <b>34</b> retains key binding interactions (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KIC">7KIC</a>). H-bonds shown in dashed yellow lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While amino and methyl groups were well tolerated at C6 of the nucleobase, the SAR in this region of the inhibitor revealed some limitations. With no substituent on the nucleobase (compound <b>42</b>), a 27× loss in TE potency was observed relative to <b>4</b>, potentially due to the lack of filling of a crucial pocket or the change in the basicity of the adjacent N1 pyrimidine nitrogen. However, clear size limitations were also revealed. A larger cyclopropyl group (<b>43</b>) was ∼18× less potent, while an intermediate C6-aminomethyl group (<b>46</b> and <b>47</b>) was tolerated, albeit with an ∼4–8× loss in potency relative to the amine matched pairs.</div><div class="NLM_p">Conversely, on the other side of the core, removing the aminoquinoline halogen (<b>44</b>) resulted in the most potent inhibitor within this series. Specifically, <b>44</b> demonstrated significant effects in the TE and proliferation assays at the lowest concentrations tested. This data bolstered the hypothesis that enhancing the quinoline amine basicity (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Table S1</a>) and adjusting the overall aromatic electronics were more influential than filling the space in this region. Accordingly, replacing the halogen with a methyl group (<b>45</b>) was also advantageous, exhibiting subnanomolar potency.</div><div class="NLM_p last">Finally, other vectors on both the quinoline and nucleobase rings could be leveraged to generate potent inhibitors with unique properties. Compound <b>49</b> demonstrated that while a −F substitution on the C7-position of the purine was well tolerated, a methyl substitution on the C2-position of this ring (<b>48</b>) resulted in ∼2.5× reduced TE potency relative to <b>31</b>, albeit with a proliferation EC<sub>50</sub> still <10 nM. Compounds <b>50</b> and <b>51</b> highlighted a fluorine walk around the quinoline, with compound <b>50</b> showing the more preferred position for the added substituent. Overall, these synthesis- and design-enabled compounds afforded exquisitely potent PRMT5 inhibitors with a range of tolerated modifications.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> 5,5-Bicyclic Ribose Inhibitor PK and Solubility Profiling</h3><div class="NLM_p">As we were developing these promising PRMT5 inhibitors, the next tier of compound progression en route to a projected low-dose QD candidate was <i>in vivo</i> PK profiling. For these analogs, various linker, halogen atom, and substituent combinations could be leveraged to modulate physical chemical properties and PK. However, what became apparent early on was the fact that many of the C6-amino-substituted nucleobase compounds suffered from low bioavailability (%<i>F</i>) in rats (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. PK and Solubility Profiles for C6-Amino Nucleobase Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0015.gif" alt="" id="gr14" /></img><div></div></div><div class="NLM_p">Compounds <b>4</b> and <b>29</b>–<b>33</b> demonstrated this finding that regardless of linker or quinoline halogen identity, most 5,5-bicyclic ribose inhibitors with a C6-amino nucleobase showed reasonable rat clearance and MRT values but prohibitively low %<i>F</i> (≤10%), with the exception of compound <b>33</b> (which did not translate to dogs; data not shown). Additionally, while permeability was high for all compounds tested (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Table S2</a>), the less flexible aryl ether-linked analogs (<b>4</b> and <b>29–30</b>) had negligible pH 7 kinetic solubility, which improved with the methylene-linked matched pairs (<b>31</b>–<b>33</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Nonetheless, %<i>F</i> for <b>31</b>–<b>33</b> still remained low (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">Therefore, given that the C6-amino-substituted nucleobase was the one common factor among analogs with low %<i>F</i>, we wanted to test C6-Me-substituted analogs <i>in vivo</i>. We hypothesized that an increase in the lipophilicity (Log<i>D</i>) of the compounds could boost bioavailability through modulation of fraction absorbed (<i>F</i><sub>a</sub>) in spite of the potential that increasing lipophilicity could contribute to poor solubility.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Gratifyingly, this simple C6-exchange actually revealed a physical property sweet spot, with a dramatic improvement in %<i>F</i> as well as a maintenance, and at times, an improvement, in kinetic solubility accompanying the general increase in Log<i>D</i> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. PK and Solubility Profiles for C6-Methyl Nucleobase Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0017.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Not determined due to modest potency preventing compound progression.</p></div></div><div></div></div><div class="NLM_p">In fact, for every matched pair (compounds <b>34</b>–<b>39</b> vs <b>4</b> and <b>29</b>–<b>33</b>), the compounds demonstrated a substantial boost in %<i>F</i> with the methyl swap. The largest increase was seen from matched pairs <b>29</b> and <b>35</b>, which saw an increase from 2 %<i>F</i> to 71 %<i>F</i> (note that the higher Log<i>D</i> of <b>29</b> vs <b>35</b> is likely due to unique ionization effects, while the Log<i>P</i> still follows the trend, with values of 1.92 vs 2.41, respectively). Unbound clearance values and <i>in vitro</i> hepatocyte clearance values (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Table S3</a>) were not drastically different across the matched pairs (and, in fact, were generally higher for <b>34</b>–<b>39</b>), supporting the hypothesis that improvements in oral bioavailability were partly driven by Log<i>D</i> and <i>F</i><sub>a</sub>, as opposed to fraction escaping liver metabolism and excretion (<i>F</i><sub>h</sub>). Finally, compounds <b>33</b>, <b>36</b>, and <b>39</b> demonstrated that −F-substituted quinolines achieved the best solubility profile across all tested media (>100 μM in pH 2 and pH 7 buffers and FaSSIF), regardless of C6-amino or methyl substitution. This cumulative SAR provided key insights that helped us refine the balance between %<i>F</i>, Cl, MRT, and solubility across a discrete Log<i>D</i> range and substitution pattern.</div><div class="NLM_p">To further test these insights and SAR/PK/solubility sweet spots, compounds with more unique substitutions and physical chemical properties were additionally profiled (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK and Solubility Profiles for 5,5-Bicyclic Nucleoside Analogs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0018.gif" alt="" id="gr17" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0019.gif" alt="" id="gr18" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Not determined due to high plasma clearance.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Not determined due to assay failure.</p></div></div><div></div></div><div class="NLM_p">Compounds that replaced the quinoline halogen with a hydrogen or alkyl group showed exquisite potency (<b>44</b> and <b>45</b>), but extra-hepatic clearance emerged as a severe liability for compound progression. To try further balancing the lipophilicity necessary to improve %<i>F</i>, nucleobase analogs with methylated amino groups were synthesized (<b>46</b> and <b>47</b>). Compound <b>46</b> showed a dramatic improvement in %<i>F</i> relative to its amino matched pair <b>4</b> (68% vs 10%), but a very high unbound clearance dampened the significance of that increase. Inhibitor <b>47</b> had a more modest improvement in %<i>F</i> over compound <b>31</b> (20% vs 10%). Compound <b>48</b> with a C2-methyl group on the deazapurine, balanced with a C6-amine, unfortunately had a mere 11 %<i>F</i>, demonstrating that the C2-methyl did not have a similar effect as the C6-methyl. Compound <b>49</b> was designed with the hypothesis that an intramolecular hydrogen bond between the C7-F and C6-amine groups on the nucleobase could potentially mask PSA and one HBD to increase permeability without lowering the solubility. However, <b>49</b> showed the equivalent level of bioavailability compared to matched pair <b>33</b> (24% vs 28%, respectively), and it suffered from high clearance as well. Finally, additional −F-substituted quinoline inhibitors <b>50</b> and <b>51</b> highlighted another way we achieved increased Log<i>D</i> values relative to <b>33</b>. They both showed promising PK profiles with good MRT values (>1.5 h) and high solubility across the pH range, but %<i>F</i> remained modest at ∼30% (which got lower for <b>50</b> in dogs; data not shown).</div><div class="NLM_p">With the complexity of these compounds, understanding trends in potency, PK, and solubility were critical in prioritizing the best analogs to design, make, and test. The SAR gathered on these 5,5-bicyclic ribose dual-competitive PRMT5 inhibitors revealed three crucial discoveries that drove compound progression. First, methylene-linked analogs were generally more potent than the ether-linked matched pairs, and bromoquinolines were the most potent of the halogen series. Second, bioavailability emerged as a potential limiting factor for many of the compounds, but C6-methyl-substituted nucleobase inhibitors were far superior to the corresponding C6-amino-substituted nucleobases and other substitution patterns in achieving high %<i>F</i>. Log<i>D</i> and <i>F</i><sub>a</sub> (potentially also modulated by solubility) were possible contributing factors to oral bioavailability. Additionally, for <b>4</b> and <b>29</b>–<b>39</b>, the ether-linked compounds demonstrated lower clearance and higher MRT values. Third, fluoroquinoline analogs consistently had the best kinetic solubility across the three tested media for the halogen matched pairs, underscoring a delicate and, at times, mutually exclusive balance between potency, %<i>F</i>, clearance, MRT, and solubility for this 5,5-ribose series (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, includes compounds not exemplified in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Analysis of the balance between rat %<i>F</i>, Log<i>D</i>, rat MRT, and Z138 potency for 5,5-bicyclic ribose compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the above SAR, compound <b>34</b> emerged as a promising and balanced compound whose potency and PK profile could potentially lead to a low-dose prediction and good POS for conventional formulation (due in part to the development of a more soluble maleate salt form). Therefore, to assess the overall selectivity profile for these 5,5-bicyclic ribose PRMT5 inhibitors, analog <b>34</b> was thoroughly explored in a panel of 4 DNA methyltransferases and 36 methyltransferases, including PRMT 1, 3, 4, 6, 7, and 8. Significantly, <b>34</b> exhibited >4000-fold selectivity for PRMT5 compared to every other off-target tested, indicating that this class of bicyclic, dual-competitive inhibitors was highly selective for the desired target (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Table S4</a>).</div><div class="NLM_p">Additionally, we leveraged human dose predictions based on rat and dog allometry and Z138 potency to comprehensively assess progress regarding compound optimization and to triage compound progression. Gratifyingly, <b>34</b> indeed demonstrated a balanced profile and PK consistencies across species that led to a low QD human dose prediction (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Human Dose Prediction for the Lead Bicyclic Ribose PRMT5 Inhibitor <b>34</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0020.gif" alt="" id="gr19" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Target coverage = Z138 EC<sub>50</sub>.</p></div></div><div></div></div><div class="NLM_p last">Finally, due to the potential safety and efficacy risks associated with oncology therapy DDI,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> we monitored the reversible inhibition (RI) and time-dependent inhibition (TDI) of CYP3A4 for these analogs. While the C6-amino compounds exhibited little to no RI or TDI risk, C6-methyl inhibitors showed an increased risk, with <b>34</b> having a TDI ratio > 2.4 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Table S5</a>). While it appeared that one way to mitigate TDI was to lower the Log<i>D</i> of the analogs via appropriate halogen substitution (<b>38</b> and <b>39</b>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Table S5</a>), dialing out the DDI risk appeared difficult without sacrificing other favorable compound properties. Taken together, the 5,5-bicyclic ribose inhibitors were very promising lead scaffolds, and while the low-dose prediction (and low predicted <i>C</i><sub>max</sub>) of <b>34</b> conferred a low to moderate DDI risk, there was still a need for continued optimization and differentiation.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> All-Carbon 5,5-Bicyclic Inhibitors</h3><div class="NLM_p">While the novel 5,5-bicyclic ribose series achieved numerous favorable qualities including exquisite potency, tractable PK, and good solubility, we recognized that there was still room for improvement in balancing aspects like MRT, solubility, and CYP3A4 RI and TDI. Much of the SAR thus far seemed to indicate that achieving high affinity, good PK (high %<i>F</i> and long MRT), adequate solubility (≥50 μM), and low risk for CYP3A4-mediated DDI  at odds with one another. Therefore, to expand the chemical space sampled by these 5,5-bicyclic PRMT5 inhibitors, we considered core changes to more significantly alter physical properties. Specifically, we designed a class of all-carbon 5,5-bicyclic nucleoside inhibitors. One potential advantage of these compounds came from the possibility of combining a more lipophilic core with more polar moieties like the fluoroquinoline to achieve a more well-rounded profile.</div><div class="NLM_p last">Overall, these types of bicyclic nucleoside inhibitors are unprecedented in the literature, and we profiled these unique and structurally complex inhibitors to compare them to the 5,5-bicyclic ribose compounds toward progression of the best chemical matter. Similar to the bicyclic ribose compounds, these all-carbon compounds with a methylene linker were modeled with low strain energy and favorable binding energy. In contrast, the ether linker did not appear to be similarly well tolerated (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S1</a>), and so we focused on the methylene-linked variants.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Synthetic Chemistry for All-Carbon 5,5-Bicyclic Inhibitors</h3><div class="NLM_p">Given the novelty of these substituted all-carbon 5,5-bicyclic nucleoside-derived PRMT5 inhibitors, a new synthetic route had to be developed that would allow for the same modularity that was so advantageous for the bicyclic ribose series. Fortunately, there is a wealth of diverse strategies to access the general [3.3.0]octane skeleton to draw inspiration from, including, but not limited to, ring contraction,<a onclick="showRef(event, 'ref41 ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43 ref44">(41−44)</a> ring expansion,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> intramolecular Wittig cyclizations,<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> intramolecular aldol cyclizations,<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> Pinacol/radical couplings,<a onclick="showRef(event, 'ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref50 ref51 ref52">(50−52)</a> photorearrangement/addition,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> C-H insertion reactions,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> [3 + 2] cycloadditions,<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55,56)</a> and the Pauson–Khand carbonylative [2 + 2 + 1] cycloaddition.<a onclick="showRef(event, 'ref57 ref58 ref59 ref60 ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref57 ref58 ref59 ref60 ref61 ref62 ref63">(57−63)</a> Due to the ability to rapidly access an all-carbon 5,5-fused core with the necessary functionality to achieve the desired substitution pattern, we chose to pursue a Pauson–Khand approach for our synthesis. Therefore, a novel route was developed that enabled access to this unique class of PRMT5 inhibitors (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Representative Synthetic Route to Access All-Carbon 5,5-Bicyclic Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">First, the simple alkynol <b>52</b> was oxidized to afford aldehyde <b>53</b>. Vinyl Grignard addition followed by triphenylsilyl protection of the resulting alcohol afforded enyne <b>54</b>. Compound <b>54</b> was primed for an intramolecular Co-catalyzed Pauson–Khand reaction, which afforded bicyclo[3.3.0]octenone <b>56</b>. This reaction provided a mixture of <i>cis</i> and <i>trans</i> isomers as racemates, which could be readily separated by standard/chiral chromatography with absolute configuration confirmed by ECD (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S4</a>). The <i>trans</i> isomer drawn in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> (<b>56</b>) was carried forward to mimic the preferred stereochemistry of the 5,5-ribose system, which was also supported by modeling. Then, a subsequent stereospecific Luche reduction afforded enol <b>57</b>, which was acetate-protected to afford the protected enol <b>58</b>. Due to the lack of an anomeric center that is present in the ribose compounds, traditional nucleobase installation chemistry could not be easily applied to this all-carbon 5,5-bicyclic core. Therefore, the allyl acetate moiety was purposefully installed to enable Tsuji–Trost AAA chemistry to add the nucleobase, a powerful strategy that has been employed on monocyclic cyclopentene compounds in the literature.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Using a simple catalyst system with dppf as the ligand, the AAA chemistry was successfully employed to generate compound <b>59</b>. A stereospecific dihydroxylation then afforded diol <b>60</b> to complete the nucleoside core. An acid-mediated acetonide protection, which concomitantly deprotected the silyl group, afforded alcohol <b>61</b>. Oxidation and Wittig homologation then afforded exocyclic olefin <b>62</b>. Similar to the bicyclic ribose compounds, hydroboration of the exocyclic olefin followed by an immediate Suzuki coupling with <b>63</b> installed the methylene-linked quinoline. 2D NMR analysis confirmed the overall relative stereochemistry of the isolated inhibitor (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S5</a>). When necessary, an amination was conducted to convert the pyrimidine chloride to the amino group, and for every compound, a final TFA deprotection of the 2′/3′ acetonide afforded the generic analog <b>64</b>. This synthetic protocol represents a novel and modular strategy to generate these unique, structurally complex PRMT5 inhibitors.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> All-Carbon 5,5-Bicyclic Inhibitor <i>In Vitro</i> Profiling</h3><div class="NLM_p">Informed by the SAR of the 5,5-bicyclic ribose series, several select analogs were synthesized for the all-carbon core, which were also profiled in the cellular TE and Z138 assays (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. All-Carbon 5,5-Bicyclic SAR</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0021.gif" alt="" id="gr20" /></img><div></div></div><div class="NLM_p">As mentioned, strain energy calculations and the initial SAR allowed prioritization of methylene-linked analogs, and excitingly, these compounds proved to be equipotent and, at times, even more potent (e.g.,<b>39</b> vs <b>68</b>) than their 5,5-ribose matched pairs. In fact, every compound listed above demonstrated robust inhibition of proliferation in our Z138 cellular assay (EC<sub>50</sub> < 10 nM), underscoring the exquisite affinity of these novel inhibitors. Accordingly, for the C6-methyl-substituted nucleobase analogs (<b>66</b>–<b>68</b>), there appeared to be a less pronounced difference in potency for the −Br, −Cl, and −F quinoline derivatives compared to the ribose series, an advantage for identifying compounds with a range of PK and physical properties that would still yield low human dose predictions. Similarly, C7-substituted (<b>69</b> and <b>70</b>) and C2-substituted (<b>71</b>) deazapurine derivatives were very well tolerated in this all-carbon series, along with −F-substituted quinoline <b>72</b>, which was designed with the hopes of translating the PK SAR seen with bicyclic ribose inhibitor <b>50</b>. Finally, the ligand pharmacophore and bioactive conformation of these  inhibitors were confirmed by X-ray crystallography, closely matching those of the bicyclic ribose series, as seen in the structure of <b>72</b> in the PRMT5 binding pocket (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Key binding interactions were retained with all-carbon inhibitor <b>72</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KID">7KID</a>). H-bonds shown in dashed yellow lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> All-Carbon 5,5-Bicyclic Inhibitor PK and Solubility Profiling</h3><div class="NLM_p">While the potency of the all-carbon bicyclic inhibitors was in line with, and at times superior to, the 5,5-bicyclic ribose compounds, it was critical to also assess their PK and solubility profiles to determine if they still had a viable path forward. <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> highlights the relevant data for these compounds.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. All-Carbon 5,5-Bicyclic Analogs PK and Solubility Profiles</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0022.gif" alt="" id="gr21" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0023.gif" alt="" id="gr22" /></img><div></div></div><div class="NLM_p">Comparing inhibitors <b>66</b>–<b>68</b> with the other analogs in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> revealed the same SAR trend seen with the bicyclic ribose compounds, where the C6-methyl nucleobase was truly critical for achieving high levels of bioavailability. Modifying C2/C7 on the nucleobase (<b>69</b>–<b>71</b>) or the quinoline (<b>72</b>) with additional substituents could only provide a modest increase in %<i>F</i>, up to 24% for compound <b>72</b> compared to the 77% seen with <b>68</b>. Additionally, Log<i>D</i> and unbound clearance  tracked with the identity of the halogen on the quinoline similarly to the 5,5-ribose analogs, with −F < −Cl < −Br (<b>66</b>–<b>68</b>). Gratifyingly, solubility also remained high with this class of all-carbon inhibitors, again matching the trend of −F > −Cl > −Br (particularly at pH 7). Clearance and MRT values remained reasonable for the majority of compounds as well. In fact, although the %<i>F</i> remained modest, compounds like <b>71</b> and <b>72</b> demonstrated the potential of this series with MRT values ≥2.5 h (not seen with the bicyclic ribose compounds), and in general, 7 of 10 compounds in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> had MRT values ≥1.5 h. Finally, comparing the SAR of compounds <b>72</b> and <b>50</b> to their matched pairs (<b>69</b> and <b>33</b>, respectively) indeed suggested that while that specific −F substitution on the quinoline ring did not help boost %<i>F</i>, it may have blocked a site of metabolism, leading to lower clearance and higher MRT values. Taken together, the single-digit nanomolar potency, the ability to achieve high %<i>F</i> and solubility, and promising PK profiles established this all-carbon bicyclic core as a uniquely favorable scaffold. Additionally complementing the promising features of this core, representative potent compound <b>68</b> also demonstrated a good off-target selectivity profile in a broad panel analysis (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S6</a>).</div><div class="NLM_p">Further bolstering this encouraging data, all compounds in the series also carried a reduced risk of CYP3A4-mediated DDI given their reduced propensity for reversible or time-dependent inhibition (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Table S6</a>). In particular, compound <b>72</b> emerged as a standout, differentiated compound (TDI ratio = 1.0). Given the low nanomolar potency, as well as its attractive PK (low clearance, >2 h MRT) consistent across species, inhibitor <b>72</b> achieved a favorable, balanced compound profile with a low QD human dose prediction (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>), low-dose number, and minimal DDI risk.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Human Dose Prediction for the Lead All-Carbon Bicyclic PRMT5 Inhibitor <b>72</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0024.gif" alt="" id="gr23" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Target coverage = Z138 EC<sub>50</sub>.</p></div></div><div></div></div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 5,5-Bicyclic Inhibitor <i>In Vivo</i> Efficacy</h3><div class="NLM_p">Ultimately, compounds <b>34</b> and <b>72</b> were identified as novel 5,5-fused nucleoside-derived PRMT5 inhibitors with attractive, balanced profiles, low human dose predictions, and differentiated DDI risk. We elected to pursue the representative inhibitor <b>34</b> in a mouse Z138 <i>in vivo</i> tumor efficacy model to provide translational validation for these compounds (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for details). In this model, dose-dependent tumor growth inhibition (TGI) was monitored (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A), as were tumor levels of symmetric dimethylarginine (SDMA) markers on small-molecule ribonucleoprotein-associated protein B and B′ (SMB/B′), which served as a biomarker for PRMT5 target engagement (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In vivo</i> antitumor efficacy of PRMT5 inhibitor <b>34</b>. (A) Tumor growth inhibition curves for compound <b>34</b> at four different doses (PO) relative to vehicle control revealed significant TGI and even tumor regression. (B) Tumor SDMA-SMB/B′ levels were used as <i>in vivo</i> markers of target engagement, with <b>34</b> demonstrating a robust reduction in PRMT5 inhibition over the duration of the study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Gratifyingly, compound <b>34</b> demonstrated robust, potent antitumor efficacy in a dose-dependent manner, even causing significant tumor regression at the highest dose (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A, 60 mg QD, blue curve). To validate that the TGI and regression were due to PRMT5 inhibition, levels of SDMA-SMB/B′ were measured in the tumors, and at all doses during the course of the 14 day experiment (days 7 and 14), a dramatic reduction of the PRMT5 dimethylarginine mark was observed relative to the vehicle control (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). In addition, compound <b>34</b> was well tolerated in the study, with minimal to no body weight change relative to the control at all doses (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S7</a>). Taken together, this data suggested that these 5,5-bicyclic PRMT5 inhibitors exhibit significant, target-selective antitumor efficacy and tumor regression, representing a highly promising approach to the potential clinical treatment of cancer.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Through its regulation of numerous pathways involved in tumorigenesis, including DNA repair, RNA splicing, and cell cycle progression, PRMT5 is an exciting new target in continued efforts to develop more efficacious and more broad-reaching anticancer therapies. Our strategy to develop the most optimized, projected low-dose chemical matter for the inhibition of PRMT5 relied on computational docking, strain energy calculations, X-ray crystallography, robust synthetic strategies, and balancing SAR trends, ultimately leading to the design and evaluation of unique 5,5-bicyclic, nucleoside-based inhibitors. Specifically, we pursued a 5,5-bicyclic ribose core and an all-carbon 5,5-fused core, both of which were able to demonstrate exquisite potency, good PK, high solubility, low risk for DDI, and low predicted human doses. Lead compounds <b>34</b> and <b>72</b> were identified with overall balanced profiles and differentiated DDI risk. When taken <i>in vivo</i>, the representative compound <b>34</b> demonstrated robust TGI and even tumor regression, underscoring the highly promising potential of bringing these unique series of 5,5-fused PRMT5 inhibitors to the clinic. Further, in line with this paper, our work on other 5,5-bicyclic inhibitors, <i>in vitro</i> and <i>in vivo</i> models used to further profile the efficacy of these compounds, and the complete safety profile of these and other PRMT5 inhibitors we developed will be reported in other publications in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Chemistry General Materials and Methods</h3><div class="NLM_p last">All reagents and solvents were purchased from commercial sources and used as is without further purification. Reaction progress and synthetic intermediate analysis was assessed by LCMS (UV detection with ESI mass detection) when applicable using an Agilent instrument with a MeCN/water gradient with either TFA or NH<sub>4</sub>HCO<sub>3</sub> modifier. All reported yields are isolated yields unless otherwise stated. Silica gel chromatography and reverse-phase flash column chromatography were conducted with Teledyne ISCO CombiFlash instruments and commercially available prepacked columns. Reverse-phase preparative HPLC purification of final analogs was performed on an Agilent preparative HPLC instrument with UV and MS detection using a MeCN/water gradient with either TFA or NH<sub>4</sub>OH modifier. All reported compounds tested in the assays were ≥95% pure as determined by LCMS or HPLC UV analysis. The <sup>1</sup>H NMR spectra were collected at room temperature. Chemical shifts are reported in ppm relative to the listed deuterated solvent, and multiplicities, coupling constants (where applicable), and signal integrations are listed parenthetically. Final compounds were isolated as either TFA salts or the free base after purification. High-resolution mass spectrometry (HRMS) was performed on a Water Xevo G2 QTof instrument, with ESI+ ionization and 120 °C source temperature. The syntheses of <b>3</b> and novel nucleobases and aminoquinolines are described in the patent submitted for this work (WO2020/33288). Safety statement: given the highly potent nature of the final compounds whose preparations are detailed in this section and their demonstrated ability to inhibit PRMT5 <i>in vitro</i> and <i>in vivo</i>, proper procedures for the handling of these highly potent compounds should be followed at all times in accordance with institutional policies.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 5,5-Bicyclic Ribose Inhibitor Procedures</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Representative Synthetic Procedure for (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)oxy)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>4</b>)</h4><div id="sec4_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> Step 1: Synthesis of (3a<i>R</i>,5<i>R</i>,6a<i>S</i>)-5-((<i>R</i>)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyldihydrofuro[2,3-<i>d</i>][1,3]dioxol-6(5<i>H</i>)-one (<b>6</b>)</h5><div class="NLM_p last">To a solution of (3a<i>R</i>,5<i>S</i>,6<i>S</i>,6a<i>R</i>)-5-((<i>R</i>)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxol-6-ol (<b>5</b>, 500 g, 1.9 mol, 1.0 equiv) in MeCN (3 L) at 25 °C was slowly added IBX (807 g, 2.9 mol, 1.5 equiv) at 20–25 °C. The reaction mixture was then stirred at 85–90 °C for 3 h. The mixture was filtered and concentrated under reduced pressure. The product (3a<i>R</i>,5<i>R</i>,6a<i>S</i>)-5-((<i>R</i>)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyldihydrofuro[2,3-<i>d</i>][1,3]dioxol-6(5<i>H</i>)-one (<b>6</b>) was used crude in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.14 (d, <i>J</i> = 4.40 Hz, 1H), 4.45–4.31 (m, 3H), 4.06–4.00 (m, 2H), 1.46 (s, 3H), 1.43 (s, 3H), 1.34 (s, 6H).</div></div><div id="sec4_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> Step 2: Synthesis of (3a<i>R</i>,5<i>R</i>,6<i>R</i>,6a<i>R</i>)-5-((<i>R</i>)-2,2-Dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxol-6-ol (<b>7</b>)</h5><div class="NLM_p last">To a solution of (3a<i>R</i>,5<i>R</i>,6a<i>S</i>)-5-((<i>R</i>)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyldihydrofuro[2,3-<i>d</i>][1,3]dioxol-6(5<i>H</i>)-one (<b>6</b>, 500 g, 1.9 mol, 1.0 equiv) in dry THF (2.4 L) cooled down to 0–5 °C was added vinylmagnesium bromide (1 M, 3.87 L, 3.9 mol, 2.0 equiv) dropwise, maintaining the temperature at 0–5 °C. The reaction was then warmed to 15–20 °C and stirred for 30 min. Eight reactions run in parallel were combined. The reaction mixture was quenched by pouring into aqueous NH<sub>4</sub>Cl (10 L) at 0–5 °C. The aqueous phase was extracted with EtOAc (3 L × 3). The combined organic phase was washed with brine (2 L), dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:0 to 5:1 petroleum ether/EtOAc) to afford (3a<i>R</i>,5<i>R</i>,6a<i>R</i>)-5-((<i>R</i>)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxol-6-ol (<b>7</b>, 2.94 kg, 55%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.81 (d, <i>J</i> = 3.6 Hz, 1H), 5.77–5.67 (m, 1H), 5.40–5.36 (m, 1H), 5.29–5.26 (m, 1H), 5.24–5.19 (m, 1H), 4.20–4.16 (m, 1H), 4.08–4.06 (m, 1H), 4.02–3.96 (m, 1H), 3.79–3.69 (m, 2H), 1.49 (s, 3H), 1.36–1.20 (m, 9H).</div></div><div id="sec4_2_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> Step 3: Synthesis of (3a<i>R</i>,5<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(Benzyloxy)-5-((<i>R</i>)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxole (<b>8</b>)</h5><div class="NLM_p last">To a solution of NaH (140 g, 3.5 mol, 60% dispersion in mineral oil, 2.5 equiv) in DMF (2 L) at 15–20 °C was dropwise added a solution of (3a<i>R</i>,5<i>R</i>,6a<i>R</i>)-5-((<i>R</i>)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxol-6-ol (<b>7</b>, 400 g, 1.4 mol, 1.0 equiv) in DMF (0.4 L) at 15–20 °C. The reaction mixture was then stirred at 55–60 °C for 1 h before BnBr (574 g, 3.4 mol, 398 mL, 2.4 equiv) was added. The reaction mixture was stirred at 15–20 °C for another 5 h. The reaction was quenched by pouring the mixture into ice water (3 L). The resultant mixture was extracted with EtOAc (1 L × 3). The combined organic phase was washed with aqueous LiCl (1.5 L), dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting product (3a<i>R</i>,5<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(benzyloxy)-5-((<i>R</i>)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxole (<b>8</b>) was used crude in the next step without further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.40–7.24 (m, 5H), 5.89 (d, <i>J</i> = 3.3 Hz, 1H), 5.86–5.76 (m, 1H), 5.49–5.36 (m, 2H), 4.79 (d, <i>J</i> = 3.6 Hz, 1H), 4.55–4.46 (m, 2H), 4.14–4.02 (m, 2H), 3.90–3.85 (m, 1H), 3.74–3.69 (m, 1H), 1.50 (s, 3H), 1.30 (s, 3H), 1.27 (s, 3H), 1.24 (s, 3H).</div></div><div id="sec4_2_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> Step 4: Synthesis of (3a<i>R</i>,5<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-(Benzyloxy)-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxole-5-carbaldehyde (<b>9</b>)</h5><div class="NLM_p last">To a solution of (3a<i>R</i>,5<i>R</i>,6<i>R</i>,6a<i>R</i>)-6-(benzyloxy)-5-((<i>R</i>)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxole (<b>8</b>, 2 kg, 5.3 mol, 1.0 equiv) in EtOAc (10 L) at 15–20 °C was added periodic acid (1.25 kg, 5.5 mol, 1.03 equiv). The resultant mixture was stirred for 1 h. The reaction was filtered, and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (20:1 to 0:1 petroleum ether/EtOAc) to afford (3a<i>R</i>,5<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-(benzyloxy)-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxole-5-carbaldehyde (<b>9</b>, 1.68 kg, 52%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.58 (s, 1H), 7.26–7.43 (m, 5H), 5.97 (d, <i>J</i> = 3.20 Hz, 1H), 5.77 (dd, <i>J</i> = 11.20, 11.20 Hz, 1H), 5.38–5.54 (m, 2H), 4.59–4.73 (m, 4H), 1.62 (s, 3H), 1.40 (s, 3H).</div></div><div id="sec4_2_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Step 5: Synthesis of (3a<i>R</i>,4a<i>S</i>,7a<i>S</i>,7b<i>R</i>)-7a-(Benzyloxy)-2,2-dimethylhexahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>d</i>][1,3]dioxol-5-one (<b>10</b>)</h5><div class="NLM_p last">A mixture of [Rh(nbd)<sub>2</sub>]BF<sub>4</sub> (9.8 g, 26.3 mmol, 0.08 equiv) and 1,2-bis(diphenylphosphino)benzene (14.6 g, 32.7 mmol, 0.1 equiv) in DCE (300 mL) at 15–20 °C under N<sub>2</sub> was degassed three times with H<sub>2</sub> using a vacuum/purge cycle. Then, H<sub>2</sub> was bubbled through the solution for 15 min. The reaction mixture was flushed again with N<sub>2</sub> for 15 min to remove H<sub>2</sub>. Then, a solution of (3a<i>R</i>,5<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-(benzyloxy)-2,2-dimethyl-6-vinyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxole-5-carbaldehyde (<b>9</b>, 100 g, 329 mmol, 1.0 equiv) in DCE (400 mL) was added dropwise to the above catalyst solution at 15–20 °C under N<sub>2</sub>. The mixture was stirred at 75–80 °C for 12 h. The mixture was filtered, and the solvent was removed under reduced pressure to afford (3a<i>R</i>,4a<i>S</i>,7a<i>S</i>,7b<i>R</i>)-7a-(benzyloxy)-2,2-dimethylhexahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>d</i>][1,3]dioxol-5-one (<b>10</b>), which was used crude in the next step. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.40–7.31 (m, 5H), 5.96 (d, <i>J</i> = 3.6 Hz, 1H), 4.77 (d, <i>J</i> = 10.8 Hz, 1H), 4.67–4.61 (m, 2H), 4.19 (s, 1H), 2.58–2.43 (m, 3H), 1.82–1.68 (m, 1H), 1.66 (s, 3H), 1.42 (s, 3H).</div></div><div id="sec4_2_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> Step 6: Synthesis of (3a<i>R</i>,4a<i>R</i>,5<i>R</i>,7a<i>R</i>,7b<i>R</i>)-7a-(Benzyloxy)-2,2-dimethylhexahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>d</i>][1,3]dioxol-5-ol (<b>11</b>)</h5><div class="NLM_p last">To a mixture of (3a<i>R</i>,4a<i>S</i>,7a<i>S</i>,7b<i>R</i>)-7a-(benzyloxy)-2,2-dimethylhexahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>d</i>][1,3]dioxol-5-one (<b>10</b>, 400 g, 1.3 mol, 1.0 equiv) in MeOH (2.4 L) at 0–5 °C was added NaBH<sub>4</sub> (99.5 g, 2.6 mol, 2.0 equiv). The mixture was stirred at 0–5 °C for 1 h. Four reactions run in parallel were combined. The reaction was poured into ice water (3 L), and the aqueous phase was extracted with EtOAc (1 L × 3). The combined organic phase was washed with brine (500 mL), dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20:1 to 0:1 petroleum ether/EtOAc) to afford (3a<i>R</i>,4a<i>R</i>,5<i>R</i>,7a<i>R</i>,7b<i>R</i>)-7a-(benzyloxy)-2,2-dimethylhexahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>d</i>][1,3]dioxol-5-ol (<b>11</b>, 400 g, 25%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.16–7.14 (m, 4H), 7.10–7.05 (m, 1H), 5.66 (d, <i>J</i> = 3.6 Hz, 1H), 4.52 (d, <i>J</i> = 6.4 Hz, 1H), 4.43 (d, <i>J</i> = 3.6 Hz, 1H), 4.30–4.27 (m, 2H), 3.92–3.91 (m, 1H), 3.82–3.76 (m, 1H), 1.75–1.62 (m, 2H), 1.54–1.33 (m, 2H), 1.29 (s, 3H), 1.13 (s, 3H).</div></div><div id="sec4_2_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> Step 7: Synthesis of (3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-3a-(Benzyloxy)-2-methoxyhexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,6-diol (<b>12</b>)</h5><div class="NLM_p last">To a solution of TsOH·H<sub>2</sub>O (87.4 g, 460 mmol, 0.64 equiv) in MeOH (1.2 L) at 15–20 °C was added (3a<i>R</i>,4a<i>R</i>,5<i>R</i>,7a<i>R</i>,7b<i>R</i>)-7a-(benzyloxy)-2,2-dimethylhexahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>d</i>][1,3]dioxol-5-ol (<b>11</b>, 220 g, 718 mmol, 1.0 equiv). The mixture was stirred at 15–20 °C for 12 h. The reaction was poured into ice water (600 mL) and neutralized with aqueous Na<sub>2</sub>CO<sub>3</sub> (300 mL). The aqueous phase was extracted with EtOAc (600 mL × 4). The combined organic phase was washed with brine (600 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20:1 to 0:1 petroleum ether/EtOAc) to afford (3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-3a-(benzyloxy)-2-methoxyhexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,6-diol (<b>12</b>, 150.4 g, 75%) as a mixture of anomers as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.26–7.40 (m, 5H), 4.93–5.03 (m, 1H), 4.52–4.76 (m, 1H), 4.33–4.45 (m, 1H), 4.00–4.19 (m, 1H), 3.78–3.97 (m, 1H), 3.46 (d, <i>J</i> = 7.60 Hz, 3H), 2.98–3.04 (m, 1H), 2.20–2.34 (m, 1H), 1.82–2.12 (m, 4H).</div></div><div id="sec4_2_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Step 8: Synthesis of (3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-2-Methoxyhexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a,6-triol (<b>13</b>)</h5><div class="NLM_p last">Pd(OH)<sub>2</sub>/C (5 g, 7.1 mmol, 20 wt %, 0.04 equiv) was added to a solution of (3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-3a-(benzyloxy)-2-methoxyhexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,6-diol (<b>12</b>, 50 g, 178 mmol, 1.0 equiv) in MeOH (350 mL) at 15–20 °C under N<sub>2</sub>. Then, acetic acid (8.8 g, 8.37 mL, 146 mmol, 0.82 equiv) was added. The suspension was degassed under reduced pressure and purged with H<sub>2</sub> several times. The mixture was then stirred under H<sub>2</sub> (50 psi) at 50–55 °C for 12 h. Four reactions run in parallel were combined. The reaction mixture was filtered and concentrated under reduced pressure to afford (3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-2-methoxyhexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a,6-triol (<b>13</b>) as a mixture of anomers, which was used crude in the next reaction. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.01–4.95 (m, 1H), 4.24–4.16 (m, 2H), 3.81–3.80 (m, 1H), 3.49–3.47 (m, 3H), 2.39–2.07 (m, 3H), 2.06–1.94 (m, 2H), 1.73–1.64 (m, 2H).</div></div><div id="sec4_2_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Step 9: Synthesis of (3a<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-4-Methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-ol (<b>14</b>)</h5><div class="NLM_p last">To a solution of (3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-2-methoxyhexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a,6-triol (<b>13</b>, 30 g, 158 mmol, 1.0 equiv) in acetone (210 mL) were added TsOH·H<sub>2</sub>O (1.5 g, 7.9 mmol, 0.05 equiv) and 2,2-dimethoxypropane (41.1 g, 48.3 mL, 394 mmol, 2.5 equiv). The reaction was stirred at RT for 1 h. Two reactions run in parallel were combined. The reaction mixture was poured into water (1.5 L) and neutralized with aqueous Na<sub>2</sub>CO<sub>3</sub> (300 mL). The aqueous phase was extracted with DCM (400 mL × 4). The combined organic phase was washed with brine (300 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20:1 to 0:1 petroleum ether/EtOAc) to afford (3a<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-ol (<b>14</b>, 53.6 g, 74%) as a mixture of anomers as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.08–4.98 (m, 1H), 4.43–4.29 (m, 1H), 4.28–4.21 (m, 1H), 4.09–4.03 (m, 1H), 3.51–3.47 (m, 3H), 2.53–2.07 (m, 1H), 2.08–1.86 (m, 4H), 1.57–1.38 (m, 6 H).</div></div><div id="sec4_2_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Step 10: Synthesis of (3a<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-4-Methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl 4-methylbenzenesulfonate (<b>15</b>)</h5><div class="NLM_p last">To a solution of (3a<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-ol (<b>14</b>, 320 g, 1.4 mol, 1.0 equiv) in DCM (1.2 L) was added DMAP (424 g, 3.5 mol, 2.5 equiv) at RT. Then, TsCl (265 g, 1.4 mol, 1.0 equiv) was added. The reaction mixture was stirred overnight at RT. The resulting mixture was treated with saturated aqueous NH<sub>4</sub>Cl (1.8 L) and extracted with DCM (1 L × 3). The combined organic phase was washed with brine (1 L), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (10–20% EtOAc/petroleum ether) to afford (3a<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl 4-methylbenzenesulfonate (<b>15</b>, 508 g, 95% yield) as a mixture of anomers. ESI MS <i>m</i>/<i>z</i> = 402 [M + NH<sub>4</sub>]<sup>+</sup>.</div></div><div id="sec4_2_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> Step 11: Synthesis of 3-Bromo-7-(((3a<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl)oxy)quinolin-2-amine (<b>17</b>, X = Br)</h5><div class="NLM_p last">To a solution of (3a<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl 4-methylbenzenesulfonate (<b>15</b>, 508 g, 1.3 mol, 1.0 equiv) and 2-amino-3-bromoquinolin-7-ol (<b>16</b> (X = Br), 331 g, 1.4 mol, 1.05 equiv) in NMP (15.2 L) was added Cs<sub>2</sub>CO<sub>3</sub> (1.29 kg, 4.0 mol, 3.0 equiv). The reaction mixture was stirred at 110 °C for ∼3 days under an argon atmosphere. The reaction mixture was diluted with water (6 L) and extracted with EtOAc (6 L × 3). The combined organic phase was washed with brine (6 L × 3), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography (20–55% MeCN in H<sub>2</sub>O (with 0.5% TFA)). The product-containing fractions were collected, evaporated under reduced pressure, and extracted with EtOAc (22 L × 3) to afford 3-bromo-7-(((3a<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl)oxy)quinolin-2-amine (<b>17</b> (X = Br), 361 g, 61%) as a mixture of anomers. ESI MS <i>m</i>/<i>z</i> = 451/453 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_1_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Step 12: Synthesis of (3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)oxy)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-2,3,3a-triol (<b>18</b>, X = Br)</h5><div class="NLM_p last">A solution of 3-bromo-7-(((3a<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl)oxy)quinolin-2-amine (<b>17</b> (X = Br), 361 g, 800 mmol, 1.0 equiv) in HCl (4 L, 0.4 M, 1.6 mol, 2.0 equiv) and MeCN (7.22 L) was stirred at 90 °C for 16 h. The reaction mixture was quenched with saturated NaHCO<sub>3</sub> (5 L) and extracted with EtOAc (10 L × 5). The combined organic phase was washed with brine (5 L), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was slurried with MeCN (5 volumes, 60 °C to RT, overnight) to afford (3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)oxy)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-2,3,3a-triol (<b>18</b> (X = Br), 269.1 g, 85%) as a mixture of anomers. ESI MS <i>m</i>/<i>z</i> = 397/399 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Step 13: Synthesis of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)oxy)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>20</b>, X = Br, Y = Z = H, W = Cl)</h5><div class="NLM_p last">To a stirred solution of (3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)oxy)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-2,3,3a-triol (<b>18</b> (X = Br), 140 mg, 0.35 mmol, 1.0 equiv) in dry MeCN (8 mL) under argon at 0 °C was added a solution of (<i>E</i>)-diazene-1,2-diylbis(piperidin-1-ylmethanone) (133 mg, 0.53 mmol, 1.5 equiv) in MeCN (0.5 mL) dropwise (over 2 min), followed by tributylphosphine (0.141 mL, 0.56 mmol, 1.6 equiv) over 5 min at 0 °C. The reaction mixture was stirred at RT for 5 min, followed by heating to 35 °C for 45 min. Concurrently, to a stirred suspension of 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>19</b> (Y = Z = H, W = Cl), 101 mg, 0.66 mmol, 1.9 equiv) in dry MeCN (8 mL) was added DBU (0.1 mL, 0.66 mmol, 1.9 equiv) at RT. The reaction was stirred at RT for 30 min, and then the solution was transferred to the aforementioned epoxide-containing reaction mixture by means of a syringe. The resulting mixture was stirred at 35 °C for 2 h. The reaction mixture was treated with brine (50 mL) and extracted with EtOAc (100 mL × 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:0 to 9:1 DCM/MeOH) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)oxy)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>20</b> (X = Br, Y = Z = H, W = Cl), 130 mg, 69%) as an off-white solid. Note that we found that NaH was also an effective base for this reaction. ESI MS <i>m</i>/<i>z</i> = 532/534 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 8.27 (s, 1H), 8.18 (d, <i>J</i> = 3.9 Hz, 1H), 7.57 (d, <i>J</i> = 8.7 Hz, 1H), 6.88–6.83 (m, 3H), 6.61 (br s, 2H), 6.17 (d, <i>J</i> = 8.4 Hz, 1H), 5.53 (d, <i>J</i> = 7.2 Hz, 1H), 5.44 (s, 1H), 4.67 (d, <i>J</i> = 4.8 Hz, 1H), 4.48 (t, <i>J</i> = 7.8 Hz, 1H), 4.15 (s, 1H), 2.51–2.50 (m, 1H), 2.10–1.95 (m, 3H).</div></div><div id="sec4_2_1_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Step 14: Synthesis of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)oxy)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>4</b>)</h5><div class="NLM_p last">A solution of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)oxy)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>20</b> (X = Br, Y = Z = H, W = Cl), 55 mg, 0.10 mmol, 1.0 equiv) in 1,4-dioxane (15 mL) and NH<sub>3</sub>·H<sub>2</sub>O (15 mL) was stirred in a sealed tube at 90 °C for 10 h. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with saturated NH<sub>4</sub>Cl (30 mL). The mixture was extracted with DCM (25 mL × 5). The combined organic phase was washed with brine (50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (8% MeOH/DCM) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)oxy)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>4</b>, 16 mg, 30%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 8.09 (s, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 1H), 7.50 (d, <i>J</i> = 3.6 Hz, 1H), 7.05 (br s, 2H), 6.87–6.83 (m, 2H), 6.66 (d, <i>J</i> = 4.0 Hz, 1H), 6.53 (br s, 2H), 6.02 (d, <i>J</i> = 8.8 Hz, 1H), 5.36 (d, <i>J</i> = 7.2 Hz, 1H), 5.31 (s, 1H), 4.60 (d, <i>J</i> = 4.8 Hz, 1H), 4.40 (t, <i>J</i> = 7.6 Hz, 1H), 4.08 (s, 1H), 2.52–2.50 (m, 1H), 2.07–1.99 (m, 3H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>21</sub>BrN<sub>6</sub>O<sub>4</sub>: 513.0886; found: 513.0891.</div></div><div id="sec4_2_1_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-chloroquinolin-7-yl)oxy)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>29</b>)</h5><div class="NLM_p">Compound <b>29</b> was similarly synthesized according to the general procedure described for compound <b>4</b> using the appropriately substituted <b>16</b> and <b>19</b>.</div><div class="NLM_p last">Step 11: 79%, ESI MS <i>m</i>/<i>z</i> = 407 [M + H]<sup>+</sup>; step 12: 91%, ESI MS <i>m</i>/<i>z</i> = 353 [M + H]<sup>+</sup>; step 13: 60%, ESI MS <i>m</i>/<i>z</i> = 488 [M + H]<sup>+</sup>; step 14: 27%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (s, 2H), 7.59–7.50 (m, 2H), 7.06 (br s, 2H), 6.86–6.83 (m, 2H), 6.65–6.62 (m, 3H), 6.01 (d, <i>J</i> = 8.1 Hz, 1H), 5.38 (d, <i>J</i> = 6.9 Hz, 1H), 5.33 (s, 1H), 4.61–4.59 (m, 1H), 4.41 (t, <i>J</i> = 7.8 Hz, 1H), 4.06 (s, 1H), 2.08–1.97 (m, 4H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>21</sub>ClN<sub>6</sub>O<sub>4</sub>: 469.1391; found: 469.1382.</div></div><div id="sec4_2_1_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-fluoroquinolin-7-yl)oxy)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>30</b>)</h5><div class="NLM_p">Compound <b>30</b> was similarly synthesized according to the general procedure described for compound <b>4</b> using the appropriately substituted <b>16</b> and <b>19</b>.</div><div class="NLM_p last">Step 11: 67%, ESI MS <i>m</i>/<i>z</i> = 391 [M + H]<sup>+</sup>; step 12: 73%, ESI MS <i>m</i>/<i>z</i> = 337 [M + H]<sup>+</sup>; step 13: 43%, ESI MS <i>m</i>/<i>z</i> = 472 [M + H]<sup>+</sup>; step 14: 45%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (s, 1H), 7.73 (d, <i>J</i> = 11.6 Hz, 1H), 7.57–7.52 (m, 2H), 7.11 (br s, 2H), 6.87–6.85 (m, 2H), 6.69–6.66 (m, 3H), 6.02 (d, <i>J</i> = 8.4 Hz, 1H), 5.39 (d, <i>J</i> = 7.2 Hz, 1H), 5.33 (s, 1H), 4.59 (d, <i>J</i> = 4.8 Hz, 1H), 4.40 (t, <i>J</i> = 7.6 Hz, 1H), 4.08 (s, 1H), 2.50–2.45 (m, 1H), 2.07–1.97 (m, 3H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>21</sub>FN<sub>6</sub>O<sub>4</sub>: 453.1686; found: 453.1688.</div></div><div id="sec4_2_1_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)oxy)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>34</b>)</h5><div class="NLM_p">Compound <b>34</b> was similarly synthesized according to the general procedure described for compound <b>4</b> using the appropriately substituted <b>16</b> and <b>19</b>.</div><div class="NLM_p last">Step 13: 46% (NaO<i>t</i>Bu as a base). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.70 (s, 1H), 8.26 (s, 1H), 7.95 (d, <i>J</i> = 4.0 Hz, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 1H), 6.88–6.83 (m, 3H), 6.52 (br s, 2H), 6.15 (d, <i>J</i> = 8.4 Hz, 1H), 5.45 (d, <i>J</i> = 7.2 Hz, 1H), 5.39 (s, 1H), 4.64 (d, <i>J</i> = 4.8 Hz, 1H), 4.48 (t, <i>J</i> = 8.0 Hz, 1H), 4.14 (s, 1H), 2.69 (s, 3H), 2.56–2.50 (m, 1H), 2.10–1.99 (m, 3H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>BrN<sub>5</sub>O<sub>4</sub>: 512.0933; found: 512.0926.</div></div><div id="sec4_2_1_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-chloroquinolin-7-yl)oxy)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>35</b>)</h5><div class="NLM_p">Compound <b>35</b> was similarly synthesized according to the general procedure described for compound <b>4</b> using the appropriately substituted <b>16</b> and <b>19</b> (see <b>29</b> for the synthesis of triol).</div><div class="NLM_p last">Step 13: 24%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d<sub>6</sub></i>) δ 8.70 (s, 1H), 8.09 (s, 1H), 7.96 (d, <i>J</i> = 3.6 Hz, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 1H), 6.88–6.84 (m, 3H), 6.62 (br s, 2H), 6.15 (d, <i>J</i> = 8.4 Hz, 1H), 5.46 (d, <i>J</i> = 7.2 Hz, 1H), 5.40 (s, 1H), 4.64 (d, <i>J</i> = 5.6 Hz, 1H), 4.48 (t, <i>J</i> = 7.6 Hz, 1H), 4.13–4.12 (m, 1H), 2.69 (s, 3H), 2.56–2.54 (m, 1H), 2.08–2.01 (m, 3H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>ClN<sub>5</sub>O<sub>4</sub>: 468.1438; found: 468.1448.</div></div><div id="sec4_2_1_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-fluoroquinolin-7-yl)oxy)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>36</b>)</h5><div class="NLM_p">Compound <b>36</b> was similarly synthesized according to the general procedure described for compound <b>4</b> using the appropriately substituted <b>16</b> and <b>19</b> (see <b>30</b> for the synthesis of triol).</div><div class="NLM_p last">Step 13: 28%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.70 (s, 1H), 7.95 (d, <i>J</i> = 4.0 Hz, 1H), 7.74–7.72 (m, 1H), 7.57–7.54 (m, 1H), 6.89–6.83 (m, 3H), 6.67 (br s, 2H), 6.15 (d, <i>J</i> = 8.4 Hz, 1H), 5.46 (d, <i>J</i> = 6.8 Hz, 1H), 5.39 (s, 1H), 4.63 (d, <i>J</i> = 5.2 Hz, 1H), 4.50–4.46 (m, 1H), 4.13 (s, 1H), 2.69 (s, 3H), 2.53–2.50 (m, 1H), 2.09–1.98 (m, 3H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>4</sub>: 452.1734; found: 452.1743.</div></div><div id="sec4_2_1_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)oxy)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>40</b>)</h5><div class="NLM_p">Compound <b>40</b> was synthesized from the common intermediate <b>14</b>.</div><div class="NLM_p">Step 1: To a solution of (3a<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-ol (<b>14</b>, 2.0 g, 8.7 mmol, 1.0 equiv, mixture of anomers) in DMF (30 mL) was added NaH (0.869 g, 60 wt % in mineral oil, 21.7 mmol, 2.5 equiv) at 0 °C. The mixture was stirred at 0 °C for 1 h. Then, (bromomethyl)benzene (2.08 mL, 17.4 mmol, 2.0 equiv) was added at 0 °C. The reaction was stirred at RT overnight. The mixture was then diluted with water and extracted with EtOAc. The organic phase was washed with aqueous NaCl (10%), followed by brine, and then dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting crude orange oil containing (3a<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-6-(benzyloxy)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxole as a mixture of anomers was carried directly to the next step.</div><div class="NLM_p">Step 2: To a solution of (3a<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-6-(benzyloxy)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxole (2.8 g, 8.7 mmol, 1.0 equiv) in water (36.1 mL) and MeCN (51.4 mL) was added HCl (2.08 mL, 25.3 mmol, 2.9 equiv). The reaction was stirred at 80 °C for 4 h. The mixture was quenched with NaHCO<sub>3</sub> (2.13 g, 25.3 mmol, 2.9 equiv) at 0 °C and then extracted with EtOAc. The organic phase was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (0–60% (3:1 EtOAc/EtOH)/hexanes) to afford (3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-(benzyloxy)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-2,3,3a-triol (2.1 g, 91% (two steps)) as a mixture of anomers. ESI MS <i>m</i>/<i>z</i> = 289 [M + Na]<sup>+</sup>.</div><div class="NLM_p">Step 3: To a solution of 4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (160 mg, 1.2 mmol, 2.0 equiv) in anhydrous DMF (1.72 mL) was added NaH (72.1 mg, 60 wt % in mineral oil, 1.8 mmol, 3.0 equiv) quickly at 0 °C under argon. The mixture was stirred for 30 min at RT. To a second flame-dried round-bottom flask was added a solution of (3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-(benzyloxy)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-2,3,3a-triol (160 mg, 0.6 mmol, 1.0 equiv) in anhydrous MeCN (9 mL) under argon. This solution was cooled down to 0 °C, and then tributylphosphine (231 mg, 1.1 mmol, 1.9 equiv) and 1,1′-(azodicarbonyl)dipiperidine (273 mg, 1.1 mmol, 1.8 equiv) in MeCN (1 mL) were added. This second mixture was stirred for 30 min at RT. Then, the first mixture containing the nucleobase was transferred via a cannula into the second mixture at 0 °C. The resulting reaction was stirred for 1 h at RT. The mixture was then quenched with saturated NH<sub>4</sub>Cl (10 mL) at 0 °C and diluted with EtOAc/H<sub>2</sub>O (100 mL/30 mL). The organic layer was separated and washed with H<sub>2</sub>O (50 mL) and brine (50 mL). The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by reverse-phase CombiFlash chromatography (0–40-95% MeCN/H<sub>2</sub>O) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-(benzyloxy)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (95 mg, 42%) as a white solid. ESI MS <i>m</i>/<i>z</i> = 382 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 4: To a mixture of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-(benzyloxy)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (2.4 g, 6.3 mmol, 1.0 equiv) in 2,2-dimethoxypropane (50 mL) was added 4-methylbenzenesulfonic acid (0.108 g, 0.63 mmol, 0.1 equiv) at RT under argon. The reaction was stirred at 70 °C for 48 h. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (0–60% EtOAc/petroleum ether) to afford 7-((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-6-(benzyloxy)-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-4-yl)-4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (2.2 g, 83%) as a colorless oil. ESI MS <i>m</i>/<i>z</i> = 422 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 5: To a solution of 7-((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-6-(benzyloxy)-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-4-yl)-4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (3.5 g, 8.3 mmol, 1.0 equiv) in anhydrous MeOH (100 mL) was added Raney Ni (24 g, 50 wt % in water) quickly at RT under argon. The resulting mixture was stirred at 60 °C for 5 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (0–100% EtOAc/petroleum ether) to afford (3a<i>R</i>,4<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-2,2-dimethyl-4-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-ol (2.15 g, 78%) as a white solid. ESI MS <i>m</i>/<i>z</i> = 332 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 6: (3a<i>R</i>,4<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-2,2-Dimethyl-4-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-ol (50 mg, 0.15 mmol, 1.0 equiv), 3-bromo-<i>N</i>-(2,4-dimethoxybenzyl)-7-iodoquinolin-2-amine (113 mg, 0.226 mmol, 1.5 equiv), 4-(pyrrolidin-1-yl)pyridine (27 mg, 0.18 mmol, 1.2 equiv), cuprous iodide (3 mg, 0.015 mmol, 0.1 equiv), and potassium phosphate (128 mg, 0.6 mmol, 4.0 equiv) were added to a microwave vial charged with toluene (0.75 mL). The reaction was then heated at 120 °C overnight. The reaction was filtered, and the filtrate was concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (10–100% EtOAc/DCM) to afford 3-bromo-<i>N</i>-(2,4-dimethoxybenzyl)-7-(((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-2,2-dimethyl-4-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl)oxy)quinolin-2-amine (64 mg, 60%) as a white solid. ESI MS <i>m</i>/<i>z</i> = 702/704 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 7: To a solution of 3-bromo-<i>N</i>-(2,4-dimethoxybenzyl)-7-(((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-2,2-dimethyl-4-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl)oxy)quinolin-2-amine (64 mg, 0.091 mmol, 1.0 equiv) in DCM (0.91 mL) were added TFA (1.4 mL, 18.2 mmol, large excess) and one drop of water. The reaction was then heated to 50 °C for 4 h. The solution was concentrated under reduced pressure, and the residue was purified by reverse-phase preparative HPLC (MeCN/H<sub>2</sub>O) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)oxy)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>40</b>, 28 mg, 60%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63 (s, 1H), 8.24 (s, 1H), 7.78 (d, <i>J</i> = 3.8 Hz, 1H), 7.51 (d, <i>J</i> = 8.9 Hz, 1H), 6.94 (d, <i>J</i> = 2.2 Hz, 1H), 6.86 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 6.77 (d, <i>J</i> = 3.7 Hz, 1H), 6.54 (s, 2H), 6.14 (d, <i>J</i> = 8.2 Hz, 1H), 5.46 (d, <i>J</i> = 7.0 Hz, 1H), 5.39 (s, 1H), 4.86–4.81 (m, 1H), 4.41 (d, <i>J</i> = 5.3 Hz, 1H), 4.33 (t, <i>J</i> = 7.6 Hz, 1H), 2.64 (s, 3H), 2.29–2.23 (m, 1H), 2.21–2.12 (m, 1H), 2.12–2.03 (m, 1H), 1.73–1.64 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>BrN<sub>5</sub>O<sub>4</sub>: 512.0933; found: 512.0933.</div></div><div id="sec4_2_1_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-((2-Amino-3-chloroquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>41</b>)</h5><div class="NLM_p">Compound <b>41</b> was synthesized from the intermediate after step 5 for the synthesis of compound <b>40</b>.</div><div class="NLM_p">Step 1: To a mixture of (3a<i>R</i>,4<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-2,2-dimethyl-4-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-ol (2.0 g, 6.0 mmol, 1.0 equiv) in DCM (60 mL) was added Dess–Martin periodinane (4.61 g, 10.9 mmol, 1.8 equiv) at RT under argon. The resulting mixture was stirred at RT for 1.5 h. The reaction was then quenched with saturated aqueous NaHCO<sub>3</sub> (150 mL) and extracted with EtOAc (250 mL × 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0–100% EtOAc/petroleum ether) to afford (3a<i>R</i>,4<i>R</i>,5a<i>S</i>,8a<i>S</i>)-2,2-dimethyl-4-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)tetrahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6(5a<i>H</i>)-one (1.9 g, 96%) as a white solid. ESI MS <i>m</i>/<i>z</i> = 330 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 2: To a mixture of bromo(methyl)triphenylphosphorane (5.77 g, 16.2 mmol, 2.8 equiv) in THF (30 mL) was added <i>n</i>BuLi (6.0 mL, 2.5 M in hexane, 15 mmol, 2.6 equiv) at −10 °C under argon. The resulting mixture was stirred at −10 °C for 30 min. Then, (3a<i>R</i>,4<i>R</i>,5a<i>S</i>,8a<i>S</i>)-2,2-dimethyl-4-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)tetrahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6(5a<i>H</i>)-one (1.9 g, 5.8 mmol, 1.0 equiv) in THF (30 mL) was added dropwise at −10 °C. The reaction mixture was stirred at −10 °C for 1 h. The reaction was quenched with saturated aqueous NH<sub>4</sub>Cl (150 mL) and extracted with DCM (200 mL × 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0–60% EtOAc/petroleum ether) to afford 7-((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-6-methylenehexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-4-yl)-4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (1.04 g, 55%) as a white solid. ESI MS <i>m</i>/<i>z</i> = 328 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 3: To a mixture of chloro(1,5-cyclooctadiene)iridium(I) dimer (18 mg, 0.035 mmol, 0.05 equiv) and dppe (28 mg, 0.07 mmol, 0.1 equiv) in DCM (3 mL) was added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (281 μL, 1.8 mmol, 2.5 equiv) under N<sub>2</sub>. The mixture was degassed and backfilled with N<sub>2</sub> (three times). After stirring for 20 min at RT, a solution of 7-((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-6-methylenehexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-4-yl)-4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (230 mg, 0.7 mmol, 1.0 equiv) in DCM (3 mL) was added under N<sub>2</sub>. The mixture was degassed and backfilled with N<sub>2</sub> (three times), and the reaction was stirred at RT for 15 h. The reaction was then cooled down to 0 °C, quenched with MeOH (4 mL), and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (10–100% EtOAc/DCM) to afford 7-((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-6-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)hexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-4-yl)-4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (338 mg) as a still impure clear resin, which was used directly in the next reaction without further purification. ESI MS <i>m</i>/<i>z</i> = 456 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 4: To a vial containing 7-((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-6-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)hexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-4-yl)-4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (75 mg, 0.17 mmol, 1.0 equiv), 7-bromo-3-chloroquinolin-2-amine (51 mg, 0.198 mmol, 1.2 equiv), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> (27 mg, 0.033 mmol, 0.2 equiv) were added THF (2.75 mL) and water (0.55 mL). The mixture was degassed under N<sub>2</sub> (three times) and then charged with thallium(I) ethoxide (35.0 μL, 0.49 mmol, 3.0 equiv). The reaction was heated for several days at 65 °C. The reaction was then diluted with EtOAc and filtered. The filtrate was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (10–100% EtOAc/DCM) to afford 3-chloro-7-(((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-4-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl)methyl)quinolin-2-amine (16 mg, 15%), which was still impure but was used directly in the next step. ESI MS <i>m</i>/<i>z</i> = 506 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 5: To a solution of 3-chloro-7-(((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-4-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl)methyl)quinolin-2-amine (10 mg, 0.012 mmol, 1.0 equiv) in DCM (3 mL) was added one drop of water followed by TFA (0.46 mL, 5.9 mmol, large excess). The reaction was heated at 50 °C for 2 h. The reaction was concentrated under reduced pressure, and the crude residue was purified by SFC (Whelk-O (<i>R</i>,<i>R</i>), achiral prep, 35% MeOH (with 0.1% NH<sub>4</sub>OH) mobile phase) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>R</i>,6a<i>R</i>)-6-((2-amino-3-chloroquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>41</b>, 3.7 mg, 67%) as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.64 (s, 1H), 8.14 (s, 1H), 7.80 (d, <i>J</i> = 3.8 Hz, 1H), 7.58 (d, <i>J</i> = 8.2 Hz, 1H), 7.32 (s, 1H), 7.10 (d, <i>J</i> = 8.1 Hz, 1H), 6.77 (d, <i>J</i> = 3.7 Hz, 1H), 6.66 (s, 2H), 6.01 (d, <i>J</i> = 8.1 Hz, 1H), 5.47 (s, 1H), 5.31 (s, 1H), 4.33 (d, <i>J</i> = 8.1 Hz, 1H), 3.93–3.90 (m, 1H), 2.90–2.85 (m, 1H), 2.73–2.69 (m, 1H), 2.66 (s, 3H), 2.35–2.29 (m, 1H), 2.05–1.95 (m, 2H), 1.90–1.85 (m, 1H), 1.63–1.57 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>3</sub>: 466.1646; found: 466.1654.</div></div><div id="sec4_2_1_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)oxy)-2-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>42</b>)</h5><div class="NLM_p">Compound <b>42</b> was similarly synthesized according to the general procedure described for compound <b>4</b> using the appropriately substituted <b>19</b> (see <b>4</b> for the synthesis of triol).</div><div class="NLM_p last">Step 13: 18%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.08 (s, 1H), 8.85 (s, 1H), 8.26 (s, 1H), 8.02 (s, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 1H), 6.83 (t, <i>J</i> = 17.5 Hz, 3H), 6.51 (s, 2H), 6.19 (d, <i>J</i> = 8.2 Hz, 1H), 5.47 (d, <i>J</i> = 6.7 Hz, 1H), 5.40 (s, 1H), 4.65 (s, 1H), 4.51 (d, <i>J</i> = 8.4 Hz, 1H), 4.15 (s, 1H), 2.45–2.15 (m, 1H), 2.06 (br s, 3H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>22</sub>H<sub>20</sub>BrN<sub>5</sub>O<sub>4</sub>: 498.0777; found: 498.0777.</div></div><div id="sec4_2_1_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)oxy)-2-(4-(methylamino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>46</b>)</h5><div class="NLM_p">Compound <b>46</b> was similarly synthesized according to the general procedure described for compound <b>4</b> (see <b>4</b> for the synthesis of −Cl-substituted nucleobase).</div><div class="NLM_p last">Step 14: A sealed tube containing a solution of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)oxy)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>20</b> (X = Br, Y = Z = H, W = Cl), 30 mg, 0.056 mmol, 1.0 equiv) and methylamine (2.5 mL, 2 M in THF, 5.0 mmol, large excess) in 1,4-dioxane (2.5 mL) was stirred at 70 °C for 4 h. The mixture was then concentrated under reduced pressure. The residue was purified by reverse-phase CombiFlash (0–50–95% MeCN/5 mM aqueous NH<sub>4</sub>HCO<sub>3</sub> gradient) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)oxy)-2- (4-(methylamino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3<i>a</i>-diol (<b>47</b>, 16.7 mg, 56%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 8.18 (s, 1H), 7.58–7.49 (m, 3H), 6.87–6.83 (m, 2H), 6.65 (d, <i>J</i> = 3.6 Hz, 1H), 6.53 (br s, 2H), 6.03 (d, <i>J</i> = 8.0 Hz, 1H), 5.36 (d, <i>J</i> = 7.2 Hz, 1H), 5.31 (s, 1H), 4.61 (d, <i>J</i> = 5.2 Hz, 1H), 4.42 (t, <i>J</i> = 8.0 Hz, 1H), 4.09 (s, 1H), 2.98 (d, <i>J</i> = 4.4 Hz, 3H), 2.47–2.45 (m, 1H), 2.08–1.98 (m, 3H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>23</sub>BrN<sub>6</sub>O<sub>4</sub>: 527.1042; found: 527.1042.</div></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Representative Synthetic Procedure for (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-fluoroquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>33</b>)</h4><div id="sec4_2_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> Step 1: Synthesis of (3a<i>R</i>,5a<i>S</i>,8a<i>S</i>)-4-Methoxy-2,2-dimethyltetrahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6(5a<i>H</i>)-one (<b>22</b>)</h5><div class="NLM_p last">To a solution of oxalyl chloride (27.4 mL, 313 mmol, 4.0 equiv) in anhydrous DCM (360 mL) under N<sub>2</sub> was added a solution of DMSO (55.5 mL, 782 mmol, 10.0 equiv) in DCM (54 mL) at −78 °C. The solution was stirred at −78 °C for 30 min. Then, a solution of (3a<i>R</i>,5a<i>R</i>,6<i>R</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-ol (<b>14</b>, 18 g, 78 mmol, 1.0 equiv) in DCM (18 mL) was added. The reaction was stirred at −78 °C for 30 min before triethylamine (109 mL, 782 mmol, 10.0 equiv) was added. The solution was stirred at −78 °C for 30 min. The reaction was then quenched with H<sub>2</sub>O (100 mL) at 0 °C and then extracted with DCM (50 mL × 2). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was coevaporated with toluene (10 mL × 3) and then purified by silica gel column chromatography (0–40% EtOAc/hexanes) to afford (3a<i>R</i>,5a<i>S</i>,8a<i>S</i>)-4-methoxy-2,2-dimethyltetrahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6(5a<i>H</i>)-one (<b>22</b>, 14.03 g, 79%), which was isolated as two separate anomers (7.93 g of the less polar anomer as a light yellow solid and 6.1 g of the more polar anomer as a yellow orange oil). Note that we found that Dess–Martin periodinane was also effective for this transformation. Additionally, the anomers could be carried forward together or separately as there is an ultimate convergence to a common intermediate (triol <b>26</b>), but more commonly, one isomer was isolated and carried forward. <sup>1</sup>H NMR (less polar isomer) (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.97 (s, 1H), 4.39 (s, 1H), 4.15 (s, 1H), 3.09 (s, 3H), 2.49–2.41 (m, 2H), 2.39–2.29 (m, 2H), 1.38 (s, 3H), 1.36 (s, 3H). <sup>1</sup>H NMR (more polar isomer) (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.77 (d, <i>J</i> = 3.6 Hz, 1H), 4.53 (d, <i>J</i> = 3.6 Hz, 1H), 4.09 (s, 1H), 3.38 (s, 3H), 2.56–2.52 (m, 1H), 2.44–2.34 (m, 2H), 2.27–2.22 (m, 1H), 1.42 (s, 3H), 1.38 (s, 3H).</div></div><div id="sec4_2_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> Step 2: Synthesis of (3a<i>R</i>,5a<i>R</i>,8a<i>R</i>)-4-Methoxy-2,2-dimethyl-6-methylenehexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxole (<b>23</b>)</h5><div class="NLM_p last">To a solution of methyltriphenylphosphonium bromide (26.9 g, 75 mmol, 2.2 equiv) in anhydrous THF (79 mL) under N<sub>2</sub> was added <i>n</i>BuLi (32 mL, 2.5 M in hexane, 80 mmol, 2.3 equiv) dropwise at 0 °C. The heterogeneous mixture was stirred at RT for 30 min. The system was sonicated and cooled down to 0 °C. Then, a solution of (3a<i>R</i>,5a<i>S</i>,8a<i>S</i>)-4-methoxy-2,2-dimethyltetrahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6(5a<i>H</i>)-one (<b>22</b> (less polar anomer), 7.93 g, 34.7 mmol, 1.0 equiv) in anhydrous THF (79 mL) was added dropwise at 0 °C via an addition funnel over 20 min. The reaction mixture was allowed to warm slowly to RT. The reaction was then quenched with brine (20 mL) at RT. The mixture was extracted with EtOAc (50 mL × 2). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0–10% EtOAc/hexanes) to afford (3a<i>R</i>,5a<i>R</i>,8a<i>R</i>)-4-methoxy-2,2-dimethyl-6-methylenehexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxole (<b>23</b>, 6 g, 76%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 5.07 (s, 1H), 5.02 (s, 1H), 4.94 (s, 1H), 4.49 (s, 1H), 4.30 (s, 1H), 3.16 (s, 3H), 2.56–2.48 (m, 1H), 2.31–2.27 (m, 1H), 2.21–2.16 (m, 1H), 1.96–1.89 (m, 1H), 1.38 (s, 3H), 1.32 (s, 3H).</div></div><div id="sec4_2_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> Step 3: Synthesis of 3-Fluoro-7-(((3a<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl)methyl)quinolin-2-amine (<b>25</b>, A = B = C = H, X = F)</h5><div class="NLM_p last">To (3a<i>R</i>,5a<i>R</i>,8a<i>R</i>)-4-methoxy-2,2-dimethyl-6-methylenehexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxole (<b>23</b>, 2 g, 8.8 mmol, 1.0 equiv) was added 9-BBN solution (88 mL, 0.5 M in THF, 44.2 mmol, 5.0 equiv) at RT under argon. The reaction was then stirred at 50 °C for 1 h. To this reaction solution was then added a solution of K<sub>3</sub>PO<sub>4</sub> (9.39 g, 44.2 mmol, 5.0 equiv) in water (8 mL) at 0 °C under argon. The reaction was stirred at RT for 30 min. Then, a solution of 7-bromo-3-fluoroquinolin-2-amine (<b>24</b> (A = B = C = H, V = Br, X = F), 2.345 g, 9.73 mmol, 1.1 equiv) in THF (10 mL) and Pd(dppf)Cl<sub>2</sub> (0.976 g, 1.3 mmol, 0.15 equiv) was added at RT. The final reaction mixture was stirred at 75 °C for 2 h. The mixture was diluted with water (100 mL) and extracted with EtOAc (250 mL × 3). The combined organic phase was washed with brine (250 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0–40% EtOAc/petroleum ether) to afford 3-fluoro-7-(((3a<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl)methyl)quinolin-2-amine (<b>25</b> (A = B = C = H, X = F), 2.5 g, 73%) as a yellow solid. ESI MS <i>m</i>/<i>z</i> = 389 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.77 (d, <i>J</i> = 12.0 Hz, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 1H), 7.36 (s, 1H), 7.14 (d, <i>J</i> = 8.1 Hz, 1H), 6.70 (s, 2H), 4.98 (s, 1H), 4.23–4.21 (m, 1H), 4.18 (d, <i>J</i> = 5.7 Hz, 1H), 3.45 (s, 3H), 2.85–2.81 (m, 1H), 2.67–2.61 (m, 1H), 2.17–2.00 (m, 2H), 1.87–1.76 (m, 1H), 1.58–1.51 (m, 2H), 1.35 (s, 3H), 1.30 (s, 3H).</div></div><div id="sec4_2_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> Step 4: Synthesis of (3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-fluoroquinolin-7-yl)methyl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-2,3,3a-triol (<b>26</b>, A = B = C = H, X = F)</h5><div class="NLM_p last">A solution of 3-fluoro-7-(((3a<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-methoxy-2,2-dimethylhexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-6-yl)methyl)quinolin-2-amine (<b>25</b> (A = B = C = H, X = F), 600 mg, 1.6 mmol, 1.0 equiv) in MeCN (14.3 mL), H<sub>2</sub>O (9.6 mL), and HCl (0.82 mL) was stirred at 90 °C for 1 h. Then, the pH of the resulting solution was adjusted to pH 7 with 1 M NaOH at 0 °C. The solvent was removed under reduced pressure, and the crude residue was purified by silica gel column chromatography (0–15% MeOH/DCM (with 0.1% NH<sub>3</sub>·H<sub>2</sub>O)) to afford (3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-fluoroquinolin-7-yl)methyl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-2,3,3a-triol (<b>26</b> (A = B = C = H, X = F), 365 mg, 71%) as a mixture of anomers as a light yellow solid. ESI MS <i>m</i>/<i>z</i> = 335 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Step 5: Synthesis of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-fluoroquinolin-7-yl)methyl)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>27</b>, A = B = C = Y = Z = H, X = F, W = Cl)</h5><div class="NLM_p last">To a solution of (3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-fluoroquinolin-7-yl)methyl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-2,3,3a-triol (<b>26</b> (A = B = C = H, X = F), 0.5 g, 1.5 mmol, 1.0 equiv) in dry NMP (17 mL) was added tributylphosphine (0.862 g, 4.3 mmol, 2.8 equiv), followed by a solution of (<i>E</i>)-diazene-1,2-diylbis(piperidin-1-ylmethanone) (1 g, 4 mmol, 2.7 equiv) in NMP (4 mL) under N<sub>2</sub> at RT. The reaction mixture was stirred at RT for 1.5 h. Concurrently, into a separate flask under N<sub>2</sub> was added DBU (0.676 mL, 4.49 mmol, 3.0 equiv) to a solution of 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>19</b> (Y = Z = H, W = Cl), 0.46 g, 3 mmol, 2.0 equiv) in dry NMP (10 mL) at 0 °C, and then the suspension was stirred at RT for 1.5 h. This suspension was then transferred to the aforementioned crude epoxide-containing solution via a syringe at RT. The resulting mixture was stirred at RT overnight. The reaction was then quenched with saturated aqueous NH<sub>4</sub>Cl (80 mL) and extracted with EtOAc (60 mL × 4). The combined organic phase was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel column chromatography (15:1 DCM/MeOH). The product fractions were isolated, and this material was further purified by reverse-phase column chromatography (15–35% MeCN/H<sub>2</sub>O) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-fluoroquinolin-7-yl)methyl)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>27</b> (A = B = C = Y = Z = H, X = F, W = Cl), 0.315 g, 45%) as a yellow solid. Note that we also found that NaH was an effective base for this reaction. ESI MS <i>m</i>/<i>z</i> = 470 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 8.12 (d, <i>J</i> = 4.0 Hz, 1H), 7.75 (d, <i>J</i> = 12.0 Hz, 1H), 7.54 (d, <i>J</i> = 8.0 Hz, 1H), 7.30 (s, 1H), 7.11–7.09 (m, 1H), 6.83 (d, <i>J</i> = 4.0 Hz, 1H), 6.68 (s, 2H), 6.03 (d, <i>J</i> = 8.0 Hz, 1H), 5.40 (d, <i>J</i> = 7.2 Hz, 1H), 5.17 (s, 1H), 4.24 (t, <i>J</i> = 7.2 Hz, 1H), 4.05 (d, <i>J</i> = 5.6 Hz, 1H), 2.86–2.81 (m, 1H), 2.67–2.62 (m, 1H), 2.34–2.27 (m, 1H), 1.99–1.95 (m, 1H), 1.83–1.42 (m, 3H).</div></div><div id="sec4_2_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Step 6: Synthesis of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-fluoroquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>33</b>)</h5><div class="NLM_p last">A mixture of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-fluoroquinolin-7-yl)methyl)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>27</b> (A = B = C = R = Y = Z = H, X = F, W = Cl), 50 mg, 0.11 mmol, 1.0 equiv) and NH<sub>3</sub>·H<sub>2</sub>O (2 mL, 28 wt %, large excess) in dioxane (0.5 mL) was heated at 80 °C in a sealed tube overnight. The crude material was purified by reverse-phase column chromatography (15–35% MeCN/H<sub>2</sub>O) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-fluoroquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>33</b>, 34 mg, 71%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (s, 1H), 7.74 (d, <i>J</i> = 12.0 Hz, 1H), 7.53 (d, <i>J</i> = 8.4 Hz, 1H), 7.44 (d, <i>J</i> = 3.6 Hz, 1H), 7.29 (s, 1H), 7.09–7.05 (m, 3H), 6.68–6.66 (m, 3H), 5.88 (d, <i>J</i> = 8.4 Hz, 1H), 5.25–5.20 (m, 1H), 5.07–5.05 (m, 1H), 4.13 (d, <i>J</i> = 8.0 Hz, 1H), 3.95 (d, <i>J</i> = 5.6 Hz, 1H), 2.84–2.79 (m, 1H), 2.67–2.58 (m, 1H), 2.29–2.13 (m, 1H), 1.96–1.92 (m, 1H), 1.74–1.68 (m, 2H), 1.57–1.49 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>23</sub>FN<sub>6</sub>O<sub>3</sub>: 451.1894; found: 451.1895.</div></div><div id="sec4_2_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>31</b>)</h5><div class="NLM_p">Compound <b>31</b> was similarly synthesized according to the general procedure described for compound <b>33</b> using the appropriately substituted <b>19</b> and <b>24</b>.</div><div class="NLM_p last">Step 3: 50% (<b>24</b>, A = B = C = H, X = Br, V = I), ESI MS <i>m</i>/<i>z</i> = 449/451 [M + H]<sup>+</sup>; step 4: 95%, ESI MS <i>m</i>/<i>z</i> = 395/397 [M + H]<sup>+</sup>; step 5: 56%, ESI MS <i>m</i>/<i>z</i> = 530/532 [M + H]<sup>+</sup>; step 6: 62%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.30 (s, 1H), 8.09 (s, 1H), 7.54 (d, <i>J</i> = 8.4 Hz, 1H), 7.43 (d, <i>J</i> = 4.0 Hz, 1H), 7.28 (s, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 7.03 (br s, 2H), 6.67 (d, <i>J</i> = 3.6 Hz, 1H), 6.54 (br s, 2H), 5.88 (d, <i>J</i> = 8.0 Hz, 1H), 5.23 (d, <i>J</i> = 7.2 Hz, 1H), 5.04 (s, 1H), 4.13 (t, <i>J</i> = 7.6 Hz, 1H), 3.95 (d, <i>J</i> = 6.0 Hz, 1H), 2.82 (dd, <i>J</i> = 13.2, 8.0 Hz, 1H), 2.62 (dd, <i>J</i> = 14.4, 7.2 Hz, 1H), 2.24–2.22 (m, 1H), 1.96–1.92 (m, 1H), 1.70–1.68 (m, 2H), 1.57–1.51 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>23</sub>BrN<sub>6</sub>O<sub>3</sub>: 511.1093; found: 511.1099.</div></div><div id="sec4_2_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-chloroquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>32</b>)</h5><div class="NLM_p">Compound <b>32</b> was similarly synthesized according to the general procedure described for compound <b>33</b> using the appropriately substituted <b>19</b> and <b>24</b>.</div><div class="NLM_p last">Step 3: 78% (<b>24</b>, A = B = C = H, X = Cl, V = Br), ESI MS <i>m</i>/<i>z</i> = 405 [M + H]<sup>+</sup>; step 4: 77%, ESI MS <i>m</i>/<i>z</i> = 351 [M + H]<sup>+</sup>; step 5: 44%, ESI MS <i>m</i>/<i>z</i> = 486 [M + H]<sup>+</sup>; step 6: 64%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.12 (s, 1H), 8.09 (s, 1H), 7.56 (d, <i>J</i> = 8.1 Hz, 1H), 7.45 (d, <i>J</i> = 3.6 Hz, 1H), 7.28 (s, 1H), 7.10–7.00 (m, 3H), 6.68–6.65 (m, 3H), 5.90 (d, <i>J</i> = 8.1 Hz, 1H), 5.26 (d, <i>J</i> = 6.9 Hz, 1H), 5.07 (s, 1H), 4.13 (t, <i>J</i> = 7.8 Hz, 1H), 3.96 (d, <i>J</i> = 5.4 Hz, 1H), 2.85–2.81 (m, 1H), 2.65–2.58 (m, 1H), 2.27–2.24 (m, 1H), 1.97–1.93 (m, 1H), 1.75–1.60 (m, 2H), 1.59–1.54 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>23</sub>ClN<sub>6</sub>O<sub>3</sub>: 467.1598; found: 467.1593.</div></div><div id="sec4_2_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>37</b>)</h5><div class="NLM_p">Compound <b>37</b> was similarly synthesized according to the general procedure described for compound <b>33</b> using the appropriately substituted <b>19</b> and <b>24</b> (<b>24</b> amine was 4-methoxybenzyl (-PMB)-protected for the synthesis of <b>37</b>, but reaction conditions were the same as described in the general procedure, with the exception of a final deprotection step).</div><div class="NLM_p">Step 3: 86% (<b>24</b> (-PMB-protected), A = B = C = H, X = Br, V = I), ESI MS <i>m</i>/<i>z</i> = 569/571 [M + H]<sup>+</sup>; step 4: 63%, ESI MS <i>m</i>/<i>z</i> = 515/517 [M + H]<sup>+</sup>; step 5: 65%, ESI MS <i>m</i>/<i>z</i> = 630/632 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 6 (-PMB deprotection): A solution of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6a<i>R</i>)-6-((3-bromo-2-((4-methoxybenzyl)amino)quinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (150 mg, 0.21 mmol, 1.0 equiv) in TFA (2 mL) was stirred at 60 °C for 1 h. The reaction was then quenched with saturated aqueous NaHCO<sub>3</sub> (40 mL) and extracted with EtOAc (40 mL × 3).The combined organic phase was washed with brine (40 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by preparative TLC (8:1 DCM/MeOH) followed by reverse-phase CombiFlash (0–31–95% MeCN/5 mM aqueous NH<sub>4</sub>HCO<sub>3</sub> gradient) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>37</b>, 60 mg, 55%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69 (s, 1H), 8.30 (s, 1H), 7.87 (d, <i>J</i> = 3.6 Hz, 1H), 7.54 (d, <i>J</i> = 8.4 Hz, 1H), 7.27 (s, 1H), 7.08 (d, <i>J</i> = 8.4 Hz, 1H), 6.82 (d, <i>J</i> = 3.6 Hz, 1H), 6.53 (br s, 2H), 6.01 (d, <i>J</i> = 8.0 Hz, 1H), 5.30 (d, <i>J</i> = 6.8 Hz, 1H), 5.11 (s, 1H), 4.22 (t, J = 7.6 Hz, 1H), 4.00 (d, <i>J</i> = 5.6 Hz, 1H), 2.83 (dd, <i>J</i> = 13.6, 7.6 Hz, 1H), 2.70 (s, 3H), 2.64 (dd, <i>J</i> = 13.6, 7.6 Hz, 1H), 2.24–2.35 (m, 1H), 1.97 (dd, <i>J</i> = 12.4, 5.6 Hz, 1H), 1.79–1.68 (m, 2H), 1.58–1.52 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>24</sub>BrN<sub>5</sub>O<sub>3</sub>: 510.1141; found: 510.1158.</div></div><div id="sec4_2_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-chloroquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>38</b>)</h5><div class="NLM_p">Compound <b>38</b> was similarly synthesized according to the general procedure described for compound <b>33</b> using the appropriately substituted <b>19</b> and <b>24</b> (see <b>32</b> for details on triol synthesis).</div><div class="NLM_p last">Step 5: 32%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69 (s, 1H), 8.12 (s, 1H), 7.88 (d, <i>J</i> = 3.6 Hz, 1H), 7.54 (d, <i>J</i> = 8.0 Hz, 1H), 7.28 (s, 1H), 7.08 (dd, <i>J</i> = 8.4, 1.6 Hz, 1H), 6.82 (d, <i>J</i> = 3.6 Hz, 1H), 6.64 (br s, 2H), 6.00 (d, <i>J</i> = 8.4 Hz, 1H), 5.31 (d, <i>J</i> = 6.8 Hz, 1H), 5.12 (s, 1H), 4.22 (t, <i>J</i> = 8.0 Hz, 1H), 4.00 (d, <i>J</i> = 6.0 Hz, 1H), 2.85–2.79 (m, 1H), 2.69 (s, 3H), 2.65–2.60 (m, 1H), 2.33–2.25 (m, 1H), 1.98–1.93 (m, 1H), 1.80–1.67 (m, 2H), 1.58–1.51 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>3</sub>: 466.1646; found: 466.1654.</div></div><div id="sec4_2_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-fluoroquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>39</b>)</h5><div class="NLM_p">Compound <b>39</b> was similarly synthesized according to the general procedure described for compound <b>33</b> using the appropriately substituted <b>19</b> and <b>24</b> (see <b>33</b> for details on triol synthesis).</div><div class="NLM_p last">Step 5: 11%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69 (s, 1H), 7.87 (d, <i>J</i> = 4.0 Hz, 1H), 7.74 (d, <i>J</i> = 11.6 Hz, 1H), 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 7.28 (s, 1H), 7.07 (d, <i>J</i> = 8.0 Hz, 1H), 6.82 (d, <i>J</i> = 3.6 Hz, 1H), 6.66 (br s, 2H), 6.01 (d, <i>J</i> = 8.0 Hz, 1H), 5.31 (d, <i>J</i> = 7.2 Hz, 1H), 5.12 (s, 1H), 4.22 (d, <i>J</i> = 7.6 Hz, 1H), 4.01 (d, <i>J</i> = 6.0 Hz, 1H), 2.84–2.79 (m, 1H), 2.69 (s, 3H), 2.67–2.59 (m, 1H), 2.28–2.22 (m, 1H), 1.98–1.94 (m, 1H), 1.76–1.69 (m, 2H), 1.58–1.53 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>3</sub>: 450.1941; found: 450.1952.</div></div><div id="sec4_2_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)methyl)-2-(4-cyclopropyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>43</b>)</h5><div class="NLM_p">Compound <b>43</b> was similarly synthesized according to the general procedure described for compound <b>33</b> using the appropriately substituted <b>19</b> and <b>24</b> (see <b>31</b> for triol synthesis).</div><div class="NLM_p last">Step 5: 10%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (s, 1H), 8.31 (s, 1H), 7.86 (d, <i>J</i> = 3.8 Hz, 1H), 7.55 (d, <i>J</i> = 8.3 Hz, 1H), 7.28 (s, 1H), 7.09 (dd, <i>J</i> = 8.2, 1.4 Hz, 1H), 6.96 (d, <i>J</i> = 3.8 Hz, 1H), 6.55 (s, 2H), 6.00 (d, <i>J</i> = 8.1 Hz, 1H), 5.31 (d, <i>J</i> = 7.0 Hz, 1H), 5.12 (s, 1H), 4.22 (t, <i>J</i> = 7.6 Hz, 1H), 4.00 (d, <i>J</i> = 5.7 Hz, 1H), 2.86–2.79 (m, 1H), 2.67–2.60 (m, 1H), 2.58–2.53 (m, 1H), 2.33–2.24 (m, 1H), 2.00–1.94 (m, 1H), 1.83–1.67 (m, 2H), 1.60–1.51 (m, 1H), 1.24–1.20 (m, 2H), 1.16–1.12 (m, 2H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>26</sub>H<sub>26</sub>BrN<sub>5</sub>O<sub>3</sub>: 536.1297; found: 536.1311.</div></div><div id="sec4_2_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Aminoquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>44</b>)</h5><div class="NLM_p">Compound <b>44</b> was synthesized in one step from compound <b>37</b>.</div><div class="NLM_p last">Step 1: To a solution of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>37</b>, 20 mg, 0.039 mmol, 1.0 equiv) in MeOH (5 mL) were added triethylamine (4.0 mg, 0.039 mmol, 1.0 equiv) and anhydrous Pd/C (10 mg, 10% Pd/C) under argon. The resulting mixture was stirred at RT under an atmosphere of H<sub>2</sub> (∼1.2 atm) for 30 min. The mixture was filtered, and the filtrate was then concentrated under reduced pressure. The residue was purified by preparative HPLC (20–58% MeCN/10 mM aqueous NH<sub>4</sub>HCO<sub>3</sub>) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-aminoquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>43</b>, 7.4 mg, 44%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.69 (s, 1H), 7.87 (d, <i>J</i> = 3.6 Hz, 1H), 7.79 (d, <i>J</i> = 8.8 Hz, 1H), 7.48 (d, <i>J</i> = 8.0 Hz, 1H), 7.22 (s, 1H), 7.00 (d, <i>J</i> = 8.0 Hz, 1H), 6.82 (d, <i>J</i> = 3.6 Hz, 1H), 6.66 (d, <i>J</i> = 8.8 Hz, 1H), 6.31 (br s, 2H), 6.01 (d, <i>J</i> = 8.0 Hz, 1H), 5.29 (d, <i>J</i> = 7.2 Hz, 1H), 5.11 (s, 1H), 4.22 (t, <i>J</i> = 7.6 Hz, 1H), 4.01 (d, <i>J</i> = 5.6 Hz, 1H), 2.84–2.78 (m, 1H), 2.69 (s, 3H), 2.63–2.58 (m, 1H), 2.28–2.25 (m, 1H), 1.98–1.94 (m, 1H), 1.80–1.68 (m, 2H), 1.58–1.53 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub>: 432.2035; found: 432.2039.</div></div><div id="sec4_2_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-methylquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>45</b>)</h5><div class="NLM_p">Compound <b>44</b> was synthesized in one step from compound <b>31</b>.</div><div class="NLM_p last">Step 1: To a microwave tube were added (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-bromoquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>31</b>, 40 mg, 0.078 mmol, 1.0 equiv), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (19.6 mg, 0.16 mmol, 2.0 equiv), Pd(dppf)Cl<sub>2</sub> (14.4 mg, 0.020 mmol, 0.26 equiv), K<sub>2</sub>CO<sub>3</sub> (0.96 mL, 2 M in water, 1.92 mmol, 25.0 equiv), and DMF (2 mL) at room temperature under argon. The reaction mixture was irradiated for 1 h at 130 °C. The reaction mixture was cooled down to room temperature and combined with a previous batch. The solvent was removed under reduced pressure. The residue was purified by reverse-phase CombiFlash (0–45–95% MeCN/5 mM aqueous NH<sub>4</sub>HCO<sub>3</sub> gradient) followed by preparative HPLC (28–49% MeCN/10 mM aqueous NH<sub>4</sub>HCO<sub>3</sub>) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-amino-3-methylquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (22.6 mg, 37%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.10 (s, 1H), 7.65 (s, 1H), 7.47–7.45 (m, 2H), 7.25 (s, 1H), 7.06 (br s, 2H), 7.00 (dd, <i>J</i> = 8.0, 1.2 Hz, 1H), 6.68 (d, <i>J</i> = 4.0 Hz, 1H), 6.16 (br s, 2H), 5.90 (d, <i>J</i> = 8.4 Hz, 1H), 5.25 (d, <i>J</i> = 7.2 Hz, 1H), 5.07 (s, 1H), 4.14 (t, <i>J</i> = 7.6 Hz, 1H), 3.97 (d, <i>J</i> = 5.6 Hz, 1H), 2.84–2.79 (m, 1H), 2.63–2.58 (m, 1H), 2.28–2.22 (m, 1H), 2.19 (s, 3H), 1.95 (dd, <i>J</i> = 12.0, 4.4 Hz, 1H), 1.75–1.70 (m, 2H), 1.56–1.51 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>26</sub>N<sub>6</sub>O<sub>3</sub>: 447.2144; found: 447.2136.</div></div><div id="sec4_2_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-bromoquinolin-7-yl)methyl)-2-(4-(methylamino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>47</b>)</h5><div class="NLM_p">Compound <b>47</b> was similarly synthesized according to the general procedure described for compound <b>33</b> using the appropriately substituted <b>19</b> and <b>24</b>. This compound was carried through with a -PMB protecting group on the aminoquinoline similarly to compound <b>37</b>, and the reaction conditions were the same as described in the general procedure (see <b>37</b> for the synthesis of -PMB triol).</div><div class="NLM_p last">Step 5: 67%, ESI MS <i>m</i>/<i>z</i> = 650/652 [M + H]<sup>+</sup>; step 6 (similar to step 14 for compound <b>46</b>): ND (material used crude without purification), ESI MS <i>m</i>/<i>z</i> = 645/647 [M + H]<sup>+</sup>; step 7 (-PMB deprotection, similar to step 6 for <b>37</b>): 68% (two steps). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.31 (s, 1H), 8.19 (s, 1H), 7.60–7.53 (m, 2H), 7.45 (d, <i>J</i> = 3.6 Hz, 1H), 7.28 (s, 1H), 7.09 (dd, <i>J</i> = 8.2, 1.4 Hz, 1H), 6.67 (d, <i>J</i> = 3.6 Hz, 1H), 6.57 (s, 2H), 5.90 (d, <i>J</i> = 8.1 Hz, 1H), 5.25 (d, <i>J</i> = 7.1 Hz, 1H), 5.07 (s, 1H), 4.15 (t, <i>J</i> = 7.4 Hz, 1H), 3.96 (d, <i>J</i> = 5.7 Hz, 1H), 2.99 (d, <i>J</i> = 4.5 Hz, 3H), 2.85–2.79 (m, 1H), 2.65–2.60 (m, 1H), 2.30–2.22 (m, 1H), 1.97–1.92 (m, 1H), 1.77–1.66 (m, 2H), 1.58–1.50 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>25</sub>BrN<sub>6</sub>O<sub>3</sub>: 525.1250; found: 525.1262.</div></div><div id="sec4_2_2_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-2-(4-Amino-2-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-6-((2-amino-3-bromoquinolin-7-yl)methyl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>48</b>)</h5><div class="NLM_p">Compound <b>48</b> was similarly synthesized according to the general procedure described for compound <b>33</b> using the appropriately substituted <b>19</b> and <b>24</b> (see <b>31</b> for triol synthesis).</div><div class="NLM_p last">Step 5: ND, ESI MS <i>m</i>/<i>z</i> = 544/546 [M + H]<sup>+</sup>; step 6: 24% (two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, TFA salt) δ 8.60 (s, 1H), 7.74 (d, <i>J</i> = 3.7 Hz, 1H), 7.68 (d, <i>J</i> = 8.1 Hz, 1H), 7.39 (s, 1H), 7.24 (d, <i>J</i> = 7.8 Hz, 1H), 6.99 (d, <i>J</i> = 3.7 Hz, 1H), 5.90 (d, <i>J</i> = 8.1 Hz, 1H), 4.10 (d, <i>J</i> = 8.1 Hz, 1H), 4.03 (d, <i>J</i> = 5.8 Hz, 1H), 2.91–2.84 (m, 1H), 2.73–2.63 (m, 1H), 2.57 (s, 3H), 2.38–2.26 (m, 1H), 1.99–1.91 (m, 1H), 1.78–1.68 (m, 2H), 1.59–1.50 (m, 1H). Integration accounts for 19 of the 25 protons as exchangeable protons are not observed. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>25</sub>BrN<sub>6</sub>O<sub>3</sub>: 525.1250; found: 525.1261.</div></div><div id="sec4_2_2_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3-fluoroquinolin-7-yl)methyl)-2-(4-amino-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>49</b>)</h5><div class="NLM_p">Compound <b>49</b> was similarly synthesized according to the general procedure described for compound <b>33</b> using the appropriately substituted <b>19</b> and <b>24</b> (see <b>33</b> for triol synthesis).</div><div class="NLM_p last">Step 5: 54%, ESI MS <i>m</i>/<i>z</i> = 488 [M + H]<sup>+</sup>; step 6: 42%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.12 (s, 1H), 7.78 (d, <i>J</i> = 12.0 Hz, 1H), 7.56–7.51 (m, 2H), 7.32 (s, 1H), 7.12–7.06 (m, 3H), 6.70 (br s, 2H), 5.97–5.94 (m, 1H), 5.29 (d, <i>J</i> = 6.9 Hz, 1H), 5.09 (s, 1H), 4.03 (t, <i>J</i> = 7.8 Hz, 1H), 3.97 (d, <i>J</i> = 5.7 Hz, 1H), 2.84 (dd, <i>J</i> = 13.8, 8.1 Hz, 1H), 2.63 (dd, <i>J</i> = 12.9, 6.9 Hz, 1H), 2.28–2.22 (m, 1H), 1.96–1.91 (m, 1H), 1.78–1.65 (m, 2H), 1.57–1.46 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub>: 469.1799; found: 469.1805.</div></div><div id="sec4_2_2_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3,5-difluoroquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>50</b>)</h5><div class="NLM_p">Compound <b>50</b> was synthesized using a modified route compared to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, wherein the nucleobase was installed before the quinoline. That synthesis is described here from the common intermediate <b>10</b>.</div><div class="NLM_p">Step 1: To a stirred mixture of bromo(methyl)triphenylphosphorane (28.3 g, 79 mmol, 2.8 equiv) in THF (109 mL) was added <i>n</i>BuLi (28.3 mL, 2.5 M in hexane, 70.6 mmol, 2.5 equiv) dropwise at −60 °C under argon. The resulting mixture was stirred for 0.5 h at RT. Then, (3a<i>R</i>,4a<i>S</i>,7a<i>S</i>,7b<i>R</i>)-7a-(benzyloxy)-2,2-dimethyltetrahydro-3a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>d</i>][1,3]dioxol-5(4a<i>H</i>)-one (8.6 g, 28.3 mmol, 1.0 equiv) in THF (109 mL) was added at −60 °C. The reaction mixture was stirred for 2 h at RT. The mixture was quenched with brine (200 mL) at 0 °C and extracted with EtOAc (300 mL × 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0–30% EtOAc/petroleum ether) to afford (3a<i>R</i>,4a<i>R</i>,7a<i>R</i>,7b<i>R</i>)-7a-(benzyloxy)-2,2-dimethyl-5-methylenehexahydro-3a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>d</i>][1,3]dioxole (6.8 g, 80%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.34–7.25 (m, 5H), 5.87 (d, <i>J</i> = 4.0 Hz, 1H), 5.23–5.22 (m, 1H), 5.10–5.09 (m, 1H), 4.68 (d, <i>J</i> = 3.6 Hz, 1H), 4.59 (d, <i>J</i> = 11.2 Hz, 1H), 4.51 (d, <i>J</i> = 11.2 Hz, 1H), 4.44 (s, 1H), 2.49–2.39 (m, 2H), 2.22–2.16 (m, 1H), 1.63–1.55 (m, 1H), 1.51 (s, 3H), 1.32 (s, 3H).</div><div class="NLM_p">Step 2: To neat (3a<i>R</i>,4a<i>R</i>,7a<i>R</i>,7b<i>R</i>)-7a-(benzyloxy)-2,2-dimethyl-5-methylenehexahydro-3a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>d</i>][1,3]dioxole (6.8 g, 22.5 mmol, 1.0 equiv) was added a solution of TFA (45.3 mL) in water (11.33 mL) at 0 °C. The resulting mixture was then stirred for 15 min at RT. The mixture was neutralized with 2 M NaOH and extracted with EtOAc (200 mL × 4). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0–70% EtOAc/petroleum ether) to afford (3<i>R</i>,3a<i>S</i>,6a<i>R</i>)-3a-(benzyloxy)-6-methylenehexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-2,3-diol (5 g, 85%) as a colorless solid as a mixture of anomers in a 5:4 ratio. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.37–7.24 (m, 5H), 6.51–6.06 (m, 1H), 5.25–4.87 (m, 4H), 4.68–4.36 (m, 3H), 3.87–3.76 (m, 1H), 2.57–2.33 (m, 2H), 2.10–1.72 (m, 2H).</div><div class="NLM_p">Step 3: To a stirred solution of (3<i>R</i>,3a<i>S</i>,6a<i>R</i>)-3a-(benzyloxy)-6-methylenehexahydro-2<i>H</i>- cyclopenta[<i>b</i>]furan-2,3-diol (5.0 g, 19.1 mmol, 1.0 equiv) in dry MeCN (63 mL) under argon was added dropwise a solution of (<i>E</i>)-diazene-1,2-diylbis(piperidin-1-ylmethanone) (7.2 g, 28.6 mmol, 1.5 equiv) in MeCN (63 mL) via a syringe at RT. Then, tributylphosphine (7.6 mL, 30.5 mmol, 1.6 equiv) was added via a syringe over 5 min at RT. The reaction was stirred at 46 °C for 3 h. The resultant mixture was used in the next step directly. In parallel, to a solution of 4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>19</b> (Y = Z = H, W = Cl), 5.6 g, 36.2 mmol, 1.9 equiv) in dry MeCN (30 mL) under argon was added DBU (5.18 mL, 34.3 mmol, 1.8 equiv) at RT. The resulting mixture was stirred at RT for 30 min. Then, this solution was transferred to the aforementioned epoxide-containing solution by means of a syringe. The resulting mixture was stirred at 46 °C for 2 h and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0–30% EtOAc/petroleum ether) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6a<i>R</i>)-3a-(benzyloxy)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-6-methylenehexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3-ol (4.0 g, 53%) as an off-white solid. ESI MS <i>m</i>/<i>z</i> = 398 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.71 (s, 1H), 7.96 (d, <i>J</i> = 4.0 Hz, 1H), 7.45–7.28 (m, 5H), 6.80 (d, <i>J</i> = 3.6 Hz, 1H), 6.30 (d, <i>J</i> = 8.0 Hz, 1H), 5.83 (d, <i>J</i> = 6.8 Hz, 1H), 5.14 (d, <i>J</i> = 16.0 Hz, 2H), 4.92 (d, <i>J</i> = 12.0 Hz, 1H), 4.71 (d, <i>J</i> = 11.6 Hz, 1H), 4.67 (s, 1H), 4.61–4.58 (m, 1H), 2.84–2.78 (m, 1H), 2.56–2.51 (m, 1H), 2.19–2.13 (m, 1H), 2.09–2.04 (m, 1H).</div><div class="NLM_p">Step 4: To a solution of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6a<i>R</i>)-3a-(benzyloxy)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>] pyrimidin-7-yl)-6-methylenehexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3-ol (690 mg, 1.7 mmol, 1.0 equiv) in DCM (10 mL) was dropwise added trichloroborane (3.47 mL, 1 M in DCM, 3.5 mmol, 2.0 equiv) at −78 °C under argon. The solution was then stirred at −78 °C for 3 h. The reaction mixture was quenched with triethylamine (0.967 mL, 6.9 mmol, 4.0 equiv) and stirred at −78 °C for 30 min. Then, the reaction was poured into saturated aqueous NaHCO<sub>3</sub> (150 mL) at 0 °C and vigorously stirred for 30 min. The final mixture was extracted with EtOAc (200 mL × 3). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0–10% MeOH/DCM) to afford (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6a<i>R</i>)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-6-methylene hexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (500 mg, 80%, 85% purity by LCMS) as a yellow solid. ESI MS <i>m</i>/<i>z</i> = 308 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 7.95 (d, <i>J</i> = 4.0 Hz, 1H), 6.78 (d, <i>J</i> = 4.0 Hz, 1H), 6.21 (d, <i>J</i> = 8.0 Hz, 1H), 5.52 (d, <i>J</i> = 7.2 Hz, 1H), 5.38 (s, 1H), 5.12–5.07 (m, 2H), 4.44–4.34 (m, 2H), 2.78–2.69 (m, 1H), 2.51–2.42 (m, 1H), 2.08–2.03 (m, 1H), 1.72–1.64 (m, 1H).</div><div class="NLM_p">Step 5: To a mixture of (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6a<i>R</i>)-2-(4-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-6-methylenehexahydro-2<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (720 mg, 2.3 mmol, 1.0 equiv) in 2,2-dimethoxypropane (2 mL) was added 4-methylbenzenesulfonic acid (40.3 mg, 0.23 mmol, 0.1 equiv) at RT under argon. The mixture was stirred for 16 h at RT. The reaction was then quenched with NaHCO<sub>3</sub> (200 mg) at RT. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (0–30% EtOAc/petroleum ether) to afford 4-chloro-7-((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-6-methylenehexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (740 mg, 91%) as a colorless oil. ESI MS <i>m</i>/<i>z</i> = 348 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 7.87 (d, <i>J</i> = 4.0 Hz, 1H), 6.79 (d, <i>J</i> = 4.0 Hz, 1H), 6.36 (d, <i>J</i> = 3.6 Hz, 1H), 5.30 (d, <i>J</i> = 3.6 Hz, 1H), 5.15–5.14 (m, 2H), 4.68 (s, 1H), 2.58–2.41 (m, 3H), 2.04–1.93 (m, 1H), 1.57 (s, 3H), 1.39 (s, 3H).</div><div class="NLM_p last">Step 6: An amination was conducted similar to that of step 14 for compound <b>4</b> to afford 7-((3a<i>R</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-6-methylenehexahydrocyclopenta[2,3]furo[3,4-<i>d</i>][1,3]dioxol-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (82%). ESI MS <i>m</i>/<i>z</i> = 329 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (s, 1H), 7.29 (d, <i>J</i> = 3.6 Hz, 1H), 7.10 (s, 2H), 6.64 (d, <i>J</i> = 3.6 Hz, 1H), 6.20 (d, <i>J</i> = 4.4 Hz, 1H), 5.19 (d, <i>J</i> = 4.0 Hz, 1H), 5.13–5.11 (m, 2H), 4.55 (s, 1H), 2.63–2.42 (m, 3 H), 2.01–1.96 (m, 1 H), 1.55 (s, 3H), 1.38 (s, 3H). Step 7/8: A Suzuki coupling was conducted similar to that of step 3 for compound <b>33</b> (borylation was run at RT overnight and used <b>24</b> (B = C = H, A = X = F, V = Br), followed by a TFA-mediated 2′/3′ acetonide deprotection similar to that shown in step 2 to afford <b>50</b> (56%; two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (s, 1H), 7.79 (d, <i>J</i> = 11.4 Hz, 1H), 7.45 (d, <i>J</i> = 3.7 Hz, 1H), 7.13 (s, 1H), 7.06 (s, 2H), 6.98–6.90 (m, 3H), 6.68 (d, <i>J</i> = 3.6 Hz, 1H), 5.90 (d, <i>J</i> = 8.1 Hz, 1H), 5.26 (d, <i>J</i> = 7.1 Hz, 1H), 5.07 (s, 1H), 4.14 (t, <i>J</i> = 7.6 Hz, 1H), 3.97 (d, <i>J</i> = 5.7 Hz, 1H), 2.85–2.78 (m, 1H), 2.65–2.59 (m, 1H), 2.30–2.21 (m, 1H), 1.97–1.91 (m, 1H), 1.77–1.66 (m, 2H), 1.58–1.50 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub>: 469.1799; found: 469.1809.</div></div><div id="sec4_2_2_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> (2<i>R</i>,3<i>R</i>,3a<i>S</i>,6<i>S</i>,6a<i>R</i>)-6-((2-Amino-3,6-difluoroquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydro-3a<i>H</i>-cyclopenta[<i>b</i>]furan-3,3a-diol (<b>51</b>)</h5><div class="NLM_p">Compound <b>51</b> was similarly synthesized according to the general procedure described for compound <b>50</b> using the appropriately substituted <b>24</b>.</div><div class="NLM_p last">Step 7: 38%. ESI MS <i>m</i>/<i>z</i> = 509 [M + H]<sup>+</sup>; step 8 (using HCl in MeOH): 38%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.09 (s, 1H), 7.76 (d, <i>J</i> = 11.8 Hz, 1H), 7.44 (d, <i>J</i> = 3.7 Hz, 1H), 7.41–7.35 (m, 2H), 7.06 (s, 2H), 6.76–6.64 (m, 3H), 5.89 (d, <i>J</i> = 8.1 Hz, 1H), 5.25 (d, <i>J</i> = 7.1 Hz, 1H), 5.09 (s, 1H), 4.15 (t, <i>J</i> = 7.6 Hz, 1H), 3.97 (d, <i>J</i> = 5.7 Hz, 1H), 2.82–2.77 (m, 1H), 2.73–2.68 (dd, <i>J</i> = 13.9, 7.3 Hz, 1H), 2.34–2.24 (m, 1H), 1.99–1.93 (m, 1H), 1.78–1.66 (m, 2H), 1.58–1.51 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>23</sub>H<sub>22</sub>F<sub>2</sub>N<sub>6</sub>O<sub>3</sub>: 469.1799; found: 469.1812.</div></div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> All-Carbon 5,5-Bicyclic Inhibitor Procedures</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Representative Synthetic Procedure for (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-4-((2-Amino-3,5-difluoroquinolin-7-yl)methyl)-2-(4-amino-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>72</b>)</h4><div id="sec4_3_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Step 1: Synthesis of Pent-4-ynal (<b>53</b>)</h5><div class="NLM_p last">To a solution of pent-4-yn-1-ol (<b>52</b>, 1.0 kg, 11.9 mol, 1.0 equiv) in DME (10 L) was added IBX (3.99 kg, 14.2 mol, 1.2 equiv). The reaction was stirred at 80 °C for 5 h. Four reactions conducted in parallel were combined, and the resulting mixture was then filtered. The filtrate (44 L) containing crude pent-4-ynal (<b>53</b>) was used directly in the next reaction. Note that on a smaller scale, this reaction was also typically run with DMP in DCM at RT.</div></div><div id="sec4_3_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Step 2: Synthesis of Hept-1-en-6-yn-3-ol (<b>54</b>)</h5><div class="NLM_p last">A solution of pent-4-ynal (<b>53</b>, 900 g, 10.9 mol, 1.0 equiv) in DME (11 L) was added to vinylmagnesium bromide (16.4 L, 1 M in THF, 16.4 mol, 1.5 equiv) at 0–5 °C. The resulting solution was stirred for 1 h at 0–5 °C. Four reactions run in parallel were combined, and the mixture was poured into saturated aqueous NH<sub>4</sub>Cl (20 L) and then diluted with DCM (8 L). The organic layer was separated, and the aqueous layer was re-extracted with DCM (4 L). The combined organic phase was washed with brine (10 L), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford crude hept-1-en-6-yn-3-ol (<b>54</b>, 4.0 kg) as a yellow oil, which was used directly in the next reaction.</div></div><div id="sec4_3_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> Step 3: Synthesis of (Hept-1-en-6-yn-3-yloxy)triphenylsilane (<b>55</b>)</h5><div class="NLM_p last">To a solution of hept-1-en-6-yn-3-ol (<b>54</b>, 1.0 kg, 9.08 mol, 1.0 equiv), pyridine (1.44 kg, 1.47 L, 18.1 mol, 2.0 equiv), and DMAP (1.33 kg, 10.8 mol, 1.2 equiv) in DCM (10 L) was added chlorotriphenylsilane (2.94 kg, 9.99 mol, 1.1 equiv) at 0–5 °C. The reaction was stirred at RT for 2 h. Four reactions run in parallel were combined, and the mixture was concentrated under reduced pressure. The resulting crude residue was purified by silica gel column chromatography (50:1 to 10:1 petroleum ether/EtOAc) to afford (hept-1-en-6-yn-3-yloxy)triphenylsilane (<b>55</b>, 9.0 kg, 51% over three steps) as a yellow oil. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.65–7.61 (m, 6H), 7.45–7.41 (m, 3H), 7.39–7.35 (m, 6H), 5.85–5.78 (m, 1H), 5.06–4.99 (m, 2H), 4.42 (q, <i>J</i> = 6.2 Hz, 1H), 2.27–2.15 (m, 2H), 1.87–1.78 (m, 2H), 1.77–1.70 (m, 1H).</div></div><div id="sec4_3_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Step 4: Synthesis of (6<i>S</i>,6a<i>S</i>)-6-((Triphenylsilyl)oxy)-4,5,6,6a-tetrahydropentalen-2(1<i>H</i>)-one (<b>56</b>)</h5><div class="NLM_p last">A solution of (hept-1-en-6-yn-3-yloxy)triphenylsilane (<b>55</b>, 900 g, 2.4 mol, 1.0 equiv) and dicobalt octacarbonyl (900 g, 2.6 mol, 1.08 equiv) in MeCN (9 L) was stirred at 80 °C for 3 h. Ten reactions were run in parallel and the crude mixtures were combined and concentrated under reduced pressure. The crude material was purified by silica gel column chromatography (1:0 to 5:1 petroleum ether/EtOAc) to afford <i>trans</i>-6-[(triphenylsilyl)oxy]-1,2,4,5,6,6a-hexahydropentalen-2-one (1700 g, 18%) as a purple solid. (Note that on a smaller scale (4.7 g of <b>55</b>) with a similar procedure, separate <i>trans</i> and <i>cis</i> isomer peaks were isolated in a 1:1 ratio for a combined yield of 57%). The racemic <i>trans</i> material (1000 g) was then subjected to chiral prep-SFC (Chiralcel OJ column, 25% MeOH mobile phase, concentrated in a timely manner at 30 °C to prevent any decomposition) to afford (6<i>S</i>,6a<i>S</i>)-6-((triphenylsilyl)oxy)-4,5,6,6a-tetrahydropentalen-2(1<i>H</i>)-one (<b>56</b>, peak 1, 380 g, 38% recovery off the chiral column) as a light purple solid. ESI MS <i>m</i>/<i>z</i> = 397 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.65–7.61 (m, 6H), 7.47–7.43 (m, 3H), 7.42–7.37 (m, 6H), 5.80–5.78 (m, 1H), 3.93 (q, <i>J</i> = 8.8 Hz, 1H), 3.18–3.12 (m, 1H), 2.83–2.74 (m, 1H), 2.49–2.41 (m, 1H), 2.37 (dd, <i>J</i> = 18.1, 6.2 Hz, 1H), 2.21–2.10 (m, 2H), 1.73 (dd, <i>J</i> = 18.1, 3.1 Hz, 1H). [α]<sub class="stack">D</sub><sup class="stack">27</sup> = −131.2° (<i>c</i> = 0.99 g/100 mL in MeOH). See the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S3</a>) for details on absolute structure determination of the undesired <i>R</i>,<i>R</i>-<i>trans</i> isomer, which therefore enabled us to determine which peak was the desired <i>S</i>,<i>S</i>-<i>trans</i> isomer.</div></div><div id="sec4_3_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Step 5: Synthesis of (2<i>R</i>,6<i>S</i>,6a<i>S</i>)-6-((Triphenylsilyl)oxy)-1,2,4,5,6,6a-hexahydropentalen-2-ol (<b>57</b>)</h5><div class="NLM_p last">A solution of (6<i>S</i>,6a<i>S</i>)-6-((triphenylsilyl)oxy)-4,5,6,6a-tetrahydropentalen-2(1<i>H</i>)-one (<b>56</b>, 236 g, 595 mmol, 1.0 equiv) and CeCl<sub>3</sub>·7H<sub>2</sub>O (222 g, 595 mmol, 1.0 equiv) in EtOH (5 L) and THF (3.5 L) was cooled down to −30 to −35 °C. Then, NaBH<sub>4</sub> (24.7 g, 655 mmol, 1.1 equiv) was added in portions. The reaction was stirred for 1 h at −30 to −35 °C. The reaction was quenched by pouring into saturated aqueous NH<sub>4</sub>Cl (10 L). The mixture was extracted with DCM (5 and 2 L), and the combined organic phase was concentrated under reduced pressure to afford crude (2<i>R</i>,6<i>S</i>,6a<i>S</i>)-6-((triphenylsilyl)oxy)-1,2,4,5,6,6a-hexahydropentalen-2-ol (<b>57</b>, 222 g) as a white solid. This material was used directly in the next reaction. ESI MS <i>m</i>/<i>z</i> = 421 [M + Na]<sup>+</sup>.</div></div><div id="sec4_3_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> Step 6: Synthesis of (2<i>R</i>,6<i>S</i>,6a<i>S</i>)-6-((Triphenylsilyl)oxy)-1,2,4,5,6,6a-hexahydropentalen-2-yl acetate (<b>58</b>)</h5><div class="NLM_p last">To a solution of (2<i>R</i>,6<i>S</i>,6a<i>S</i>)-6-((triphenylsilyl)oxy)-1,2,4,5,6,6a-hexahydropentalen-2-ol (<b>57</b>, 222 g crude, 557 mmol, 1.0 equiv) in DCM (2 L) were added DMAP (136 g, 1.1 mol, 2.0 equiv) and pyridine (132 g, 1.7 mol, 3.0 equiv) at RT. The solution was then cooled down to 0–5 °C, and Ac<sub>2</sub>O (114 g, 1.11 mol, 2.0 equiv) was added dropwise. The reaction was stirred at RT for 2 h. The reaction was quenched by pouring into saturated aqueous NH<sub>4</sub>Cl (2 L). The mixture was extracted with DCM (500 and 200 mL). The combined organic phase was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (1:0 to 5:1 petroleum ether/EtOAc) to afford (2<i>R</i>,6<i>S</i>,6a<i>S</i>)-6-((triphenylsilyl)oxy)-1,2,4,5,6,6a-hexahydropentalen-2-yl acetate (<b>58</b>, 231 g, 88% over two steps) as a colorless oil. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 7.66–7.62 (m, 6H), 7.46–7.42 (m, 3H), 7.41–7.37 (m, 6H), 5.82–5.77 (m, 1H), 5.24–5.20 (m, 1H), 3.93 (q, <i>J</i> = 8.0 Hz, 1H), 2.98–2.91 (m, 1H), 2.49–2.43 (m, 1H), 2.40–2.32 (m, 1H), 2.20–2.12 (m, 1H), 2.09–2.04 (m, 2H), 1.99 (s, 3H), 1.14–1.08 (m, 1H).</div></div><div id="sec4_3_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> Step 7: Synthesis of 4-Chloro-5-fluoro-7-((2<i>R</i>,6<i>S</i>,6a<i>S</i>)-6-((triphenylsilyl)oxy)-1,2,4,5,6,6a-hexahydropentalen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>59</b>, Y = F, W = Cl, Z = H)</h5><div class="NLM_p last">To a solution of 4-chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (40.8 g, 238 mmol, 1.5 equiv), dppf (52.8 g, 95.3 mmol, 0.6 equiv), KO<i>t</i>Bu (26.7 g, 238 mmol, 1.5 equiv), and allylpalladium(II) chloride dimer (2.91 g, 7.95 mmol, 0.05 equiv) in THF (1.4 L) at 10–20 °C was added a solution of (2<i>R</i>,6<i>S</i>,6a<i>S</i>)-6-((triphenylsilyl)oxy)-1,2,4,5,6,6a-hexahydropentalen-2-yl acetate (<b>58</b>, 70 g, 158 mmol, 1.0 equiv) in THF (700 mL) under N<sub>2</sub>. The reaction was heated at 40 °C for 3 h under N<sub>2</sub>. Four reactions that were run in parallel were combined, and the mixture was poured into water (2 L) and diluted with EtOAc (3 L). The organic layer was separated, and the aqueous phase was re-extracted with EtOAc (1 L). The combined organic phase was washed with brine (3 L), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:0 to 1:1 petroleum ether/EtOAc) to afford 4-chloro-5-fluoro-7-((2<i>R</i>,6<i>S</i>,6a<i>S</i>)-6-((triphenylsilyl)oxy)-1,2,4,5,6,6a-hexahydropentalen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>59</b> (Y = F, W = Cl, Z = H), 230 g, 66%) as a yellow solid. ESI MS <i>m</i>/<i>z</i> = 552 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.59 (s, 1H), 7.66–7.63 (m, 6H), 7.44–7.41 (m, 3H), 7.40–7.37 (m, 6H), 6.78 (d, <i>J</i> = 2.4 Hz, 1H), 6.18 (s, 1H), 5.18 (s, 1H), 3.98 (q, <i>J</i> = 8.1 Hz, 1H), 3.16–3.12 (m, 1H), 2.62–2.54 (m, 1H), 2.51–2.44 (m, 1H), 2.32–2.23 (m, 1H), 2.23–2.15 (m, 2H), 1.12–1.05 (m, 1H).</div></div><div id="sec4_3_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> Step 8: Synthesis of (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-2-(4-Chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-4-((triphenylsilyl)oxy)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>60</b>, Y = F, W = Cl, Z = H)</h5><div class="NLM_p last">To a solution of 4-chloro-5-fluoro-7-((2<i>R</i>,6<i>S</i>,6a<i>S</i>)-6-((triphenylsilyl)oxy)-1,2,4,5,6,6a-hexahydropentalen-2-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>59</b> (Y = F, W = Cl, Z = H), 57.5 g, 104 mmol, 1.0 equiv) in THF (1.1 L) and H<sub>2</sub>O (550 mL) were added OsO<sub>4</sub> (2.65 g, 10.4 mmol, 0.54 mL, 0.1 equiv) and NMO (28.1 g, 208 mmol, 2.0 equiv) at 0–5 °C. The reaction was stirred at 0 °C for 3 h. Four reactions run in parallel were combined, and the mixture was poured into saturated aqueous Na<sub>2</sub>SO<sub>3</sub> (1 L) and then diluted with EtOAc (1.5 L). The organic layer was separated, and the aqueous phase was extracted with EtOAc (800 mL). The combined organic phase was concentrated under reduced pressure to afford crude (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-2-(4-chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-4-((triphenylsilyl)oxy)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>60</b> (Y = F, W = Cl, Z = H), 220 g crude) as a black oil, which was used directly in the next reaction. ESI MS <i>m</i>/<i>z</i> = 586 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> Step 9: Synthesis of (3a<i>S</i>,4<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-(4-Chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-ol (<b>61</b>, Y = F, W = Cl, Z = H)</h5><div class="NLM_p last">To a solution of (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-2-(4-chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-4-((triphenylsilyl)oxy)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>60</b> (Y = F, W = Cl, Z = H), 55 g, 94 mmol, 1.0 equiv) in acetone (800 mL) at 10–20 °C was added H<sub>2</sub>SO<sub>4</sub> (9.20 g, 5.0 mL, 94 mmol, 1.0 equiv). The reaction was stirred at 20 °C for 4 h. Four reactions run in parallel were combined, and the mixture was poured into saturated aqueous Na<sub>2</sub>CO<sub>3</sub> (1 L) and diluted with EtOAc (1 L). The organic phase was separated, and the aqueous phase was re-extracted with EtOAc (500 mL). The combined organic phase was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (10:1 to 1:2 petroleum ether/EtOAc) to afford (3a<i>S</i>,4<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-(4-chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-ol (<b>61</b> (Y = F, W = Cl, Z = H), 80 g, 52% over two steps) as a yellow oil. Note that on a smaller scale, this reaction was typically run with <i>p</i>-TsOH and 2,2-dimethoxypropane in DCM. ESI MS <i>m</i>/<i>z</i> = 368 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 7.08 (d, <i>J</i> = 2.6 Hz, 1H), 4.93–4.87 (m, 1H), 4.72 (d, <i>J</i> = 7.2 Hz, 1H), 4.13–4.10 (m, 1H), 2.61–2.54 (m, 2H), 2.43–2.36 (m, 1H), 2.27–2.22 (m, 1H), 2.15–1.95 (m, 3H), 1.61 (s, 3H), 1.40 (s, 3H). Integration accounts for 18 of the 19 protons as the exchangeable OH proton is not observed.</div></div><div id="sec4_3_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> Step 10: Synthesis of (3a<i>S</i>,4<i>R</i>,5a<i>S</i>,8a<i>R</i>)-4-(4-Chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-6<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-one</h5><div class="NLM_p last">A solution of (3a<i>S</i>,4<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-(4-chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-ol (<b>61</b> (Y = F, W = Cl, Z = H), 20 g, 54 mmol, 1.0 equiv) and IBX (28.2 g, 101 mmol, 1.5 equiv) in MeCN (400 mL) was stirred at 80 °C for 5 h. Four reactions run in parallel were combined, and the mixture was filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1:0 to 1:1 petroleum ether/EtOAc) to afford (3a<i>S</i>,4<i>R</i>,5a<i>S</i>,8a<i>R</i>)-4-(4-chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-6<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-one (60 g, 75%) as a light yellow solid. Note that DMP at RT was typically employed on a smaller scale. ESI MS <i>m</i>/<i>z</i> = 366 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.61 (s, 1H), 6.99–6.98 (m, 1H), 5.00–4.96 (m, 1H), 4.95–4.90 (m, 1H), 2.88–2.75 (m, 1H), 2.75–2.72 (m, 2H), 2.56–2.44 (m, 4H), 1.57 (s, 3H), 1.41 (s, 3H).</div></div><div id="sec4_3_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> Step 11: Synthesis of 4-Chloro-7-((3a<i>S</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-6-methylenehexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-4-yl)-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>62</b>, Y = F, W = Cl, Z = H)</h5><div class="NLM_p last">To a solution of methyltriphenylphosphonium bromide (64.4 g, 180 mmol, 3.3 equiv) in THF (200 mL) was added <i>n</i>BuLi (54.6 mL, 2.5 M, 136 mmol, 2.5 equiv) dropwise at 0–5 °C. The reaction was then stirred at 30 °C for 3 h. Then, (3a<i>S</i>,4<i>R</i>,5a<i>S</i>,8a<i>R</i>)-4-(4-chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-6<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-one (20 g, 55 mmol, 1.0 equiv) was added at approximately −45 to −50 °C. The reaction was then stirred at 0–10 °C for 1 h. Three reactions run in parallel were combined, and the mixture was poured into saturated NH<sub>4</sub>Cl (1 L), cooled down in an ice bath, and diluted with EtOAc (800 mL). The organic layer was separated, and the aqueous phase was re-extracted with EtOAc (400 mL). The combined organic phase was washed with brine (1 L), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50:1 to 10:1 petroleum ether/EtOAc) to afford 4-chloro-7-((3a<i>S</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-6-methylenehexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-4-yl)-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>62</b> (Y = F, W = Cl, Z = H), 27 g, 45%) as a light yellow solid. ESI MS <i>m</i>/<i>z</i> = 364 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_1_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> Step 12: Synthesis of 7-(((3a<i>S</i>,4<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-(4-Chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-yl)methyl)-3,5-difluoroquinolin-2-amine</h5><div class="NLM_p last">To a solution of 4-chloro-7-((3a<i>S</i>,4<i>R</i>,5a<i>R</i>,8a<i>R</i>)-2,2-dimethyl-6-methylenehexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-4-yl)-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>62</b> (Y = F, W = Cl, Z = H), 9.0 g, 25 mmol, 1.0 equiv) in THF (90 mL) was added 9-BBN (148 mL, 0.5 M, 74 mmol, 3.0 equiv) at 10–20 °C. The reaction was stirred at 10–20 °C for 12 h under argon. Then, K<sub>3</sub>PO<sub>4</sub> (124 mL, 1 M aqueous, 124 mmol, 5.0 equiv) was added, and the mixture was stirred at 10–20 °C for 30 min. Then, <i>t</i>-BuOK (3.46 mL, 1 M, 3.46 mmol, 0.14 equiv), cataCXium A-Pd-G2 (1.82 g, 2.72 mmol, 0.11 equiv), and 7-bromo-3,5-difluoroquinolin-2-amine (<b>63</b> (X = A = F, V = Br), 7.69 g, 29.7 mmol, 1.2 equiv) were added. The reaction was then stirred for 4 h at 50 °C under argon. Three reactions run in parallel were combined, and the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (20:1 to 1:2 petroleum ether/EtOAc) to afford 7-(((3a<i>S</i>,4<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-(4-chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-yl)methyl)-3,5-difluoroquinolin-2-amine (21 g, 52%) as a yellow solid. ESI MS <i>m</i>/<i>z</i> = 544 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> Step 13: Synthesis of 7-(((3a<i>S</i>,4<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-(4-Amino-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-yl)methyl)-3,5-difluoroquinolin-2-amine</h5><div class="NLM_p last">A mixture of 7-(((3a<i>S</i>,4<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-(4-chloro-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-yl)methyl)-3,5-difluoroquinolin-2-amine (3.0 g, 5.5 mmol, 1.0 equiv) in NH<sub>3</sub>/MeOH (30 mL, 7 M, 210 mmol, 38 equiv) was heated at 120 °C for 3 h in a microwave reactor. Seven reactions run in parallel were combined, and the mixture was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (20:1 to 1:2 petroleum ether/EtOAc) and SFC (Chiralcel OD-3 column, 10–40% MeOH (with 0.05% isopropylamine) mobile phase) to afford 7-(((3a<i>S</i>,4<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-(4-amino-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-yl)methyl)-3,5-difluoroquinolin-2-amine (12.5 g, 60%) as a yellow solid. Note that on a small scale, the crude product after removing the solvent was typically taken directly to the final deprotection step and then purified. ESI MS <i>m</i>/<i>z</i> = 525 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.25 (s, 1H), 7.76–7.73 (m, 1H), 7.23 (s, 1H), 6.85–6.83 (m, 1H), 6.75 (s, 1H), 5.38–5.34 (m, 2H), 5.16 (s, 2H), 4.83–4.76 (m, 1H), 4.70–4.67 (m, 1H), 2.76–2.71 (m, 2H), 2.69–2.48 (m, 2H), 2.29–2.15 (m, 3H), 1.98–1.92 (m, 2H), 1.70–1.55 (m, 1H), 1.52 (s, 3H), 1.33 (s, 3H).</div></div><div id="sec4_3_1_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> Step 14: Synthesis of (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-4-((2-Amino-3,5-difluoroquinolin-7-yl)methyl)-2-(4-amino-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>72</b>)</h5><div class="NLM_p last">To a solution of 7-(((3a<i>S</i>,4<i>R</i>,5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-4-(4-amino-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-2,2-dimethylhexahydro-5<i>H</i>-pentaleno[1,6a-<i>d</i>][1,3]dioxol-6-yl)methyl)-3,5-difluoroquinolin-2-amine (42.1 mg, 0.08 mmol, 1.0 equiv) in DCM (1.22 mL) and water (0.385 mL) was added TFA (0.928 mL, 12.0 mmol, 150 equiv). The reaction was stirred at RT for 4 h. The mixture was then concentrated under reduced pressure, and the crude material was purified by reverse-phase column chromatography (MeCN/H<sub>2</sub>O with 0.1% NH<sub>4</sub>OH modifier) to afford (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-4-((2-amino-3,5-difluoroquinolin-7-yl)methyl)-2-(4-amino-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>72</b>, 27.3 mg, 70% over two steps) as a white solid. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.30 (s, 1H), 7.99 (d, <i>J</i> = 11.1 Hz, 1H), 7.88 (s, 1H), 7.20 (s, 1H), 7.06 (d, <i>J</i> = 10.9 Hz, 1H), 4.84–4.78 (m, 1H), 3.76 (d, <i>J</i> = 10.3 Hz, 1H), 2.79–2.66 (m, 2H), 2.48–2.37 (m, 1H), 2.20–2.13 (m, 1H), 1.87–1.80 (m, 1H), 1.79–1.70 (m, 2H), 1.69–1.64 (m, 1H), 1.64–1.55 (m, 1H), 1.50–1.41 (m, 1H). Integration accounts for 17 of the 23 protons as exchangeable protons are not considered. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>23</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 485.1913; found: 485.1911.</div></div><div id="sec4_3_1_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-4-((2-Amino-3-bromoquinolin-7-yl)methyl)-2-(4-amino-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>65</b>)</h5><div class="NLM_p">Compound <b>65</b> was similarly synthesized according to the general procedure described for compound <b>72</b> using the appropriately substituted <b>19</b> and <b>63</b>.</div><div class="NLM_p last">Step 7: 65%, ESI MS <i>m</i>/<i>z</i> = 534 [M + H]<sup>+</sup>; step 8: ND (used crude), ESI MS <i>m</i>/<i>z</i> = 568 [M + H]<sup>+</sup>; step 9: 62% (two steps), ESI MS <i>m</i>/<i>z</i> = 350 [M + H]<sup>+</sup>; step 10: 90%, ESI MS <i>m</i>/<i>z</i> = 348 [M + H]<sup>+</sup>; step 11: 49%, ESI MS <i>m</i>/<i>z</i> = 346 [M + H]<sup>+</sup>; step 12: 54% (<b>63</b>, V = I), ESI MS <i>m</i>/<i>z</i> = 568/570 [M + H]<sup>+</sup>; step 13: ND (used crude), ESI MS <i>m</i>/<i>z</i> = 549/551 [M + H]<sup>+</sup>; step 14: 73% (two steps). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>, TFA salt) δ 8.73 (s, 1H), 8.35 (s, 1H), 7.82 (d, <i>J</i> = 3.6 Hz, 1H), 7.75 (d, <i>J</i> = 8.2 Hz, 1H), 7.43 (s, 1H), 7.33 (d, <i>J</i> = 8.3 Hz, 1H), 6.96 (d, <i>J</i> = 3.6 Hz, 1H), 4.77 (q, <i>J</i> = 10.3 Hz, 1H), 3.86 (d, <i>J</i> = 10.3 Hz, 1H), 2.82–2.71 (m, 2H), 2.48–2.43 (m, 1H), 2.17 (q, <i>J</i> = 9.4 Hz, 1H), 1.85 (dd, <i>J</i> = 12.3, 5.9 Hz, 1H), 1.82–1.76 (m, 2H), 1.72–1.66 (m, 1H), 1.65–1.57 (m, 1H), 1.49–1.42 (m, 1H). Integration accounts for 19 of the 25 protons as exchangeable protons are not observed. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>25</sub>BrN<sub>6</sub>O<sub>2</sub>: 509.1300; found: 509.1312.</div></div><div id="sec4_3_1_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-4-((2-Amino-3-bromoquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>66</b>)</h5><div class="NLM_p">Compound <b>66</b> was similarly synthesized according to the general procedure described for compound <b>72</b> using the appropriately substituted <b>19</b> and <b>63</b>.</div><div class="NLM_p last">Step 7: 53%, ESI MS <i>m</i>/<i>z</i> = 514 [M + H]<sup>+</sup> (note that alternatively, compounds with a C6-methyl nucleobase could be made by converting the C6-Cl via a Negishi reaction with dimethyl zinc after the Wittig homologation); step 8: ND (used crude), ESI MS <i>m</i>/<i>z</i> = 548 [M + H]<sup>+</sup>; step 9: 86% (two steps), ESI MS <i>m</i>/<i>z</i> = 330 [M + H]<sup>+</sup>; step 10: ND (used crude), ESI MS <i>m</i>/<i>z</i> = 328 [M + H]<sup>+</sup>; step 11: 24% (two steps), ESI MS <i>m</i>/<i>z</i> = 326 [M + H]<sup>+</sup>; step 12: 97% (<b>63</b>, V = I, racemic material <b>62</b> used for this step), ESI MS <i>m</i>/<i>z</i> = 548/550 [M + H]<sup>+</sup>; step 13 (deprotection): 70%. (The racemic material was then separated by chiral SFC (AS-H column, 30% MeOH (with 0.1% NH<sub>4</sub>OH) mobile phase), and the data for the more active peak was shown (peak 1).) ESI MS <i>m</i>/<i>z</i> = 508/510 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 8.31 (s, 1H), 7.82 (d, <i>J</i> = 3.6 Hz, 1H), 7.56 (d, <i>J</i> = 8.2 Hz, 1H), 7.28 (s, 1H), 7.10 (dd, <i>J</i> = 8.2, 1.3 Hz, 1H), 6.71 (d, <i>J</i> = 3.6 Hz, 1H), 6.53 (s, 2H), 4.83–4.75 (m, 2H), 4.67 (s, 1H), 3.95 (dd, <i>J</i> = 10.3, 7.5 Hz, 1H), 2.75–2.66 (m, 2H), 2.65 (s, 3H), 2.48–2.42 (m, 1H), 2.18 (q, <i>J</i> = 9.4 Hz, 1H), 1.85 (dd, <i>J</i> = 12.3, 5.9 Hz, 1H), 1.80 (t, <i>J</i> = 9.6 Hz, 2H), 1.70–1.64 (m, 1H), 1.64–1.55 (m, 1H), 1.49–1.43 (m, 1H).</div></div><div id="sec4_3_1_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-4-((2-Amino-3-chloroquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>67</b>)</h5><div class="NLM_p">Compound <b>67</b> was similarly synthesized according to the general procedure described for compound <b>72</b> using the appropriately substituted <b>19</b> and <b>63</b> (see <b>66</b> for the synthesis of <i>exo</i>-olefin).</div><div class="NLM_p last">Step 12: 52% (<b>63</b>, V = Br, RuPhos Pd G3 catalyst), ESI MS <i>m</i>/<i>z</i> = 504 [M + H]<sup>+</sup>; step 13 (deprotection): 34%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 8.13 (s, 1H), 7.82 (d, <i>J</i> = 3.6 Hz, 1H), 7.56 (d, <i>J</i> = 8.2 Hz, 1H), 7.28 (s, 1H), 7.10 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 6.71 (d, <i>J</i> = 3.6 Hz, 1H), 6.62 (s, 2H), 4.83–4.75 (m, 2H), 4.67 (s, 1H), 3.95 (dd, <i>J</i> = 10.2, 7.5 Hz, 1H), 2.76–2.66 (m, 2H), 2.65 (s, 3H), 2.49–2.42 (m, 1H), 2.18 (q, <i>J</i> = 9.4 Hz, 1H), 1.88–1.78 (m, 3H), 1.71–1.64 (m, 1H), 1.64–1.55 (m, 1H), 1.50–1.42 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>26</sub>ClN<sub>5</sub>O<sub>2</sub>: 464.1853; found: 464.1855.</div></div><div id="sec4_3_1_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-4-((2-Amino-3-fluoroquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>68</b>)</h5><div class="NLM_p">Compound <b>68</b> was similarly synthesized according to the general procedure described for compound <b>72</b> using the appropriately substituted <b>19</b> and <b>63</b> (see <b>66</b> for the synthesis of <i>exo</i>-olefin).</div><div class="NLM_p last">Step 12: 94% (<b>63</b>, V = Br, RuPhos Pd G3 catalyst), ESI MS <i>m</i>/<i>z</i> = 488 [M + H]<sup>+</sup>; step 13 (deprotection): 40%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 7.82 (d, <i>J</i> = 3.6 Hz, 1H), 7.75 (d, <i>J</i> = 11.8 Hz, 1H), 7.55 (d, <i>J</i> = 8.2 Hz, 1H), 7.29 (s, 1H), 7.10 (d, <i>J</i> = 8.6 Hz, 1H), 6.71 (d, <i>J</i> = 3.6 Hz, 1H), 6.67 (s, 2H), 4.83–4.74 (m, 2H), 4.67 (s, 1H), 3.95 (dd, <i>J</i> = 10.2, 7.4 Hz, 1H), 2.76–2.66 (m, 2H), 2.65 (s, 3H), 2.48–2.41 (m, 1H), 2.18 (q, <i>J</i> = 9.4 Hz, 1H), 1.88–1.77 (m, 3H), 1.71–1.64 (m, 1H), 1.64–1.55 (m, 1H), 1.50–1.42 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>2</sub>: 448.2149; found: 448.2151.</div></div><div id="sec4_3_1_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-4-((2-Amino-3-fluoroquinolin-7-yl)methyl)-2-(4-amino-5-fluoro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>69</b>)</h5><div class="NLM_p">Compound <b>69</b> was similarly synthesized according to the general procedure described for compound <b>72</b> using the appropriately substituted <b>19</b> and <b>63</b>.</div><div class="NLM_p last">Step 7: 44%, ESI MS <i>m</i>/<i>z</i> = 552 [M + H]<sup>+</sup>; step 8: ND (used crude), ESI MS <i>m</i>/<i>z</i> = 586 [M + H]<sup>+</sup>; step 9: 78% (two steps), ESI MS <i>m</i>/<i>z</i> = 368 [M + H]<sup>+</sup>; step 10: 98%, ESI MS <i>m</i>/<i>z</i> = 366 [M + H]<sup>+</sup>; step 11: 27%, ESI MS <i>m</i>/<i>z</i> = 364 [M + H]<sup>+</sup>; step 12: 56% (<b>63</b>, V = Br, RuPhos Pd G3 catalyst), ESI MS <i>m</i>/<i>z</i> = 526 [M + H]<sup>+</sup>; step 13: ND (used crude), ESI MS <i>m</i>/<i>z</i> = 507 [M + H]<sup>+</sup>; step 14: 75% (two steps). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86–8.52 (m, 4H), 8.32–8.24 (m, 2H), 7.88 (s, 1H), 7.77 (d, <i>J</i> = 8.2 Hz, 1H), 7.48 (s, 1H), 7.36 (d, <i>J</i> = 8.2 Hz, 1H), 4.85–4.78 (m, 1H), 3.76 (d, <i>J</i> = 10.3 Hz, 1H), 2.84–2.77 (m, 1H), 2.77–2.71 (m, 1H), 2.49–2.35 (m, 2H), 2.18–2.11 (m, 1H), 2.04–1.90 (m, 1H), 1.87–1.81 (m, 1H), 1.78–1.72 (m, 2H), 1.71–1.66 (m, 1H), 1.65–1.57 (m, 1H), 1.48–1.41 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>24</sub>H<sub>24</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub>: 467.2007; found: 467.2020.</div></div><div id="sec4_3_1_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-4-((2-Amino-3-fluoroquinolin-7-yl)methyl)-2-(4-amino-5-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>70</b>)</h5><div class="NLM_p">Compound <b>70</b> was similarly synthesized according to the general procedure described for compound <b>72</b> using the appropriately substituted <b>19</b> and <b>63</b>.</div><div class="NLM_p last">Step 7: 76%, ESI MS <i>m</i>/<i>z</i> = 548 [M + H]<sup>+</sup>; step 8: ND, ESI MS <i>m</i>/<i>z</i> = 582 [M + H]<sup>+</sup>; step 9: 96% (two steps), ESI MS <i>m</i>/<i>z</i> = 364 [M + H]<sup>+</sup>; step 10: 88%, ESI MS <i>m</i>/<i>z</i> = 362 [M + H]<sup>+</sup>; step 11: 20%, ESI MS <i>m</i>/<i>z</i> = 360 [M + H]<sup>+</sup>; step 12: 51% (<b>63,</b> V = Br, RuPhos Pd G3 catalyst), ESI MS <i>m</i>/<i>z</i> = 522 [M + H]<sup>+</sup>; step 13: ND (used crude) ESI MS <i>m</i>/<i>z</i> = 503 [M + H]<sup>+</sup>; step 14: 62% (two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.11 (s, 1H), 7.78 (d, <i>J</i> = 11.8 Hz, 1H), 7.57 (d, <i>J</i> = 8.2 Hz, 1H), 7.36 (s, 1H), 7.29 (d, <i>J</i> = 12.1 Hz, 3H), 7.11 (d, <i>J</i> = 8.3 Hz, 1H), 6.77 (s, 2H), 5.00–4.57 (m, 3H), 3.82 (d, <i>J</i> = 10.3 Hz, 1H), 2.76–2.62 (m, 2H), 2.49–2.43 (m, 1H), 2.41 (s, 3H), 2.14 (q, <i>J</i> = 8.9 Hz, 1H), 1.83 (dd, <i>J</i> = 12.1, 5.7 Hz, 1H), 1.76–1.64 (m, 3H), 1.62–1.51 (m, 1H), 1.49–1.41 (m, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>27</sub>FN<sub>6</sub>O<sub>2</sub>: 463.2258; found: 463.2268.</div></div><div id="sec4_3_1_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>S</i>,6a<i>R</i>)-2-(4-Amino-2-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)-4-((2-amino-3-fluoroquinolin-7-yl)methyl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>71</b>)</h5><div class="NLM_p">Compound <b>71</b> was similarly synthesized according to the general procedure described for compound <b>72</b> using the appropriately substituted <b>19</b> and <b>63</b>.</div><div class="NLM_p last">Step 7: 55%, ESI MS <i>m</i>/<i>z</i> = 548 [M + H]<sup>+</sup>; step 8: ND (used crude), ESI MS <i>m</i>/<i>z</i> = 582 [M + H]<sup>+</sup>; step 9: 84% (two steps), ESI MS <i>m</i>/<i>z</i> = 364 [M + H]<sup>+</sup>; step 10: 88%, ESI MS <i>m</i>/<i>z</i> = 362 [M + H]<sup>+</sup>; step 11: 32% (two steps), ESI MS <i>m</i>/<i>z</i> = 360 [M + H]<sup>+</sup>; step 12: 51% (<b>63</b>, V = Br, RuPhos Pd G3 as a catalyst), ESI MS <i>m</i>/<i>z</i> = 522 [M + H]<sup>+</sup>; step 13: ND (used crude), ESI MS <i>m</i>/<i>z</i> = 503 [M + H]<sup>+</sup>; step 14: 38% (two steps). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.76 (d, <i>J</i> = 11.8 Hz, 1H), 7.56 (d, <i>J</i> = 8.2 Hz, 1H), 7.38 (s, 1H), 7.30 (s, 1H), 7.11 (d, <i>J</i> = 8.2 Hz, 1H), 6.59 (s, 1H), 4.70–4.65 (m, 1H), 3.87 (d, <i>J</i> = 9.9 Hz, 1H), 2.77–2.64 (m, 2H), 2.46 (ddd, <i>J</i> = 12.9, 8.2, 5.3 Hz, 1H), 2.39 (s, 3H), 2.14 (q, <i>J</i> = 9.3 Hz, 1H), 1.84 (dd, <i>J</i> = 12.3, 5.9 Hz, 1H), 1.79–1.64 (m, 2H), 1.57 (qd, <i>J</i> = 12.4, 6.0 Hz, 1H), 1.45 (td, <i>J</i> = 12.5, 6.6 Hz, 1H). Integration accounts for 21 of the 27 protons as exchangeable protons are not considered. HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>27</sub>FN<sub>6</sub>O<sub>2</sub>: 463.2258; found: 463.2251.</div></div><div id="sec4_3_1_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> (1<i>S</i>,2<i>R</i>,3a<i>R</i>,4<i>R</i>,6a<i>R</i>)-4-((2-Amino-3-fluoroquinolin-7-yl)methyl)-2-(4-methyl-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-7-yl)hexahydropentalene-1,6a(1<i>H</i>)-diol (<b>73</b>)</h5><div class="NLM_p">Compound <b>73</b> was synthesized from the intermediate formed after step 12 (Suzuki coupling) for the synthesis of compound <b>68</b>. Under these Suzuki conditions, a minor diastereomer product was formed with the (<i>R</i>)-stereochemistry at the linker position (presumably resulting from incomplete facial selectivity of the borylation). This product could be cleanly isolated by chiral SFC (OJ-H column, 30% MeOH (with 0.1% NH<sub>4</sub>OH) modifier) and subjected to TFA deprotection conditions (step 13) to afford the final compound <b>73</b>.</div><div class="NLM_p last">Step 13 (TFA deprotection): 65%. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (s, 1H), 7.75 (d, <i>J</i> = 11.7 Hz, 1H), 7.72 (d, <i>J</i> = 3.6 Hz, 1H), 7.56 (d, <i>J</i> = 8.1 Hz, 1H), 7.33 (s, 1H), 7.11 (d, <i>J</i> = 8.2 Hz, 1H), 6.77 (s, 2H), 6.67 (d, <i>J</i> = 3.6 Hz, 1H), 4.91 (td, <i>J</i> = 11.0, 7.0 Hz, 1H), 4.79 (s, 1H), 4.55 (s, 1H), 4.11 (d, <i>J</i> = 10.3 Hz, 1H), 2.77 (d, <i>J</i> = 7.5 Hz, 2H), 2.63 (s, 3H), 2.07 (q, <i>J</i> = 7.0 Hz, 1H), 1.97 (q, <i>J</i> = 8.0 Hz, 1H), 1.91 (dt, <i>J</i> = 11.8, 8.0 Hz, 1H), 1.85 (h, <i>J</i> = 6.1 Hz, 1H), 1.81–1.73 (m, 2H), 1.61 (dq, <i>J</i> = 15.6, 8.1 Hz, 1H), 1.47 (td, <i>J</i> = 12.0, 8.2 Hz, 1H). HRMS (ESI+) <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calculated for C<sub>25</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>2</sub>: 448.2149; found: 448.2160. The relative stereochemistry of the compound was confirmed by 2D NMR to enable assignment of the (<i>R</i>)-isomer at the linker C5 carbon (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">Figure S8</a>).</div></div><div id="sec4_3_1_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> High-Throughput HPLC Log<i>D</i> pH 7 Measurements</h5><div class="NLM_p last">High-throughput Log<i>D</i> measurements at pH 7 were conducted from 10 mM DMSO stock solutions in a well plate format using a reverse-phase HPLC retention time method with UV–vis detection.</div></div><div id="sec4_3_1_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> High-Throughput Solubility Measurements at pH 2 and pH 7 and in FaSSIF (pH 6.5)</h5><div class="NLM_p last">High-throughput solubility measurements were conducted in a well plate format by addition of 10 mM DMSO stock solutions to 10 mM pH 2 and pH 7 potassium phosphate buffers and FaSSIF (resulting total concentration of 200 μM) followed by 24 h equilibration, filtration, and reverse-phase HPLC analysis using UV–vis detection.</div></div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> <i>In Vitro</i> Pharmacology General Materials and Methods</h4><div id="sec4_3_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> PRMT5 Cell Target Engagement (TE) Assay</h5><div class="NLM_p">The PRMT5 TE assay is a biomarker assay for identifying compounds that inhibit symmetric dimethylation of arginine (SDMA) of PRMT5 substrates. Specifically, symmetrically dimethylated nuclear proteins are detected using high-content imaging technology. Detection of the expression of symmetrically dimethylated nuclear proteins is through a mixture of primary rabbit monoclonal antibodies to SDMA (CST 13222), which in turn are recognized by an AlexaFluor 488 dye-conjugated anti-rabbit IgG secondary antibody. The IN Cell Analyzer 2200 or Opera Phenix measures nuclear AlexaFluor 488 fluorescent dye intensity that is directly related to the level of expression of symmetrically dimethylated nuclear proteins at the single cell level. Nuclear AF488 dye intensities are compared to the mean value for DMSO-treated cells (MIN) to report the percent of inhibition for each compound-treated well.</div><div class="NLM_p last">In this assay, the cell potency (EC<sub>50</sub>) of each compound was determined from a 10-point (1:3 serial dilution; top compound concentration of 10,000 nM) titration curve using the following outlined procedure. Each well of a BD falcon collagen-coated black/clear-bottom 384-well plate was seeded with 4000 MCF-7 cells in 30 μL of media and allowed to attach for 5 h. The medium is ATCC-formulated Eagle’s minimum essential medium (catalog no. 30-2003). To make the complete growth medium, the following components were added to the base medium: 0.01 mg/mL human recombinant insulin and fetal bovine serum to a final concentration of 10%. Additional 30 μL of media containing 2× compounds was added to each well. Cells were treated for 3 days in a 37 °C/5% CO<sub>2</sub> incubator. On day 3, cells were fixed with Cytofix, permeabilized with 0.4% Triton-X-100/Cytofix, and washed with D-PBS without Ca<sup>2+</sup>/Mg<sup>2+</sup>. Cells were blocked with LI-COR Odyssey blocking reagent for 1 h at room temperature, followed by incubation with anti-SDMA (1:1000) antibody at 4 °C overnight. The 1° antibody was removed, followed by three washings with DPBS without Ca<sup>2+</sup>/Mg<sup>2+</sup> and 0.05% Tween 20. Hoechst (5 mg/mL), Cell Mask deep red stain (1:2000), and Alexa488-conjugated goat anti-rabbit IgG (2 μg/mL) were added for 1 h at room temperature. A final washing step (three washes) was performed before sealing the plate for imaging on the In Cell Analyzer 2200 or Opera Phenix. Images from the analyzer were uploaded to Columbus (at Merck & Co., Inc., West Point, PA, USA, or Merck & Co., Inc., Boston, MA, USA) for image analysis. EC<sub>50</sub> values were determined by four-parameter robust fit of percent fluorescence units vs (Log10) compound concentrations.</div></div><div id="sec4_3_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> Z138 Cell Proliferation Assay</h5><div class="NLM_p last">Compounds were assessed for their effect in a 10 day Z138 cell proliferation assay. In this assay, the cell potency (EC<sub>50</sub>) of each compound was determined from a 10-point (1:3 serial dilution; top compound concentration of 10,000 nM) titration curve using the following outlined procedure. Fifty nanoliters of compound (or control) in DMSO was dispensed using Echo into each well of a BD falcon black/clear-bottom 384-well plate, and then 500 Z138 cells were directly seeded in 50 μL of medium (IMDM media, 10% Horse serum, and 1% 100× antibiotics) using a Hamilton liquid handler, followed by 1 min mixing on a plate shaker. Cells were allowed to grow for 10 days (37 °C CO<sub>2</sub> incubator) with two changes of fresh compound-medium (day 3 and day 7) to ensure that the concentrations of the compound and nutrients are constant throughout the experiment. For each compound-medium change, 30 μL of the culture medium in each well was replaced by 30 μL of fresh medium containing the same amount of the drug. On day 10, the living cell number from each well was estimated using the luciferase assay (Cell Titer-Glo 2.0). EC<sub>50</sub> values were determined by four-parameter robust fit of percent fluorescence units vs (Log10) compound concentrations.</div></div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> <i>In Vivo</i> Antitumor Efficacy Model General Materials and Methods</h4><div class="NLM_p">CB17.SCID female mice (Charles River Laboratories) were subcutaneously implanted with 5 × 10<sup>6</sup> Z138 cells. When tumors reached an average size of approximately 100 mm<sup>3</sup>, mice were pair-matched into the efficacy study (<i>n</i> = 10 mice per group) and daily PO dosing began (10, 30, or 60 mpk QD or 5 mpk BID). In addition to efficacy mice, satellite cohorts of animals were enrolled into the study for an earlier day 7 collection time point (<i>n</i> = 4 mice per group). The compound was formulated weekly using 0.5% methylcellulose (Dow) as a vehicle. Tumors and mouse body weights were captured twice weekly for the duration of the study and all animal procedures were performed in accordance with IACUC standards. Tumor volumes (TVs) were calculated as (<i>L</i> × <i>W</i><sup>2</sup>)/2 and %TGI was calculated at day 13 as [(ΔTV<sup>vehicle</sup> – ΔTV<sup>treatment</sup>)/(ΔTV<sup>vehicle</sup>)] × 100. <i>P</i>-values were calculated using two-sided Student <i>t</i>-test.</div><div class="NLM_p">The workflow to quantify SDMA SMB/B′ in tumors by LC–MS/MS involved tissue homogenization, affinity enrichment, protein reduction, alkylation, and digestion, and analyses of representative peptides by LC–MS/MS.</div><div class="NLM_p">Frozen tumor samples were cut and placed in Bullet Blender 1.5 mL Navy RNA Lysis kit tubes (Next Advance, Inc., Troy, NY). Homogenization buffer (50 mM Tris (pH 7.5), 200 mM NaCl, 2 mM EDTA, and 0.0004% RapiGest (Waters Corp, Milford, MA), with Halt protease inhibitor cocktail) was added to the tumor sample at a ratio of 15:1 mL/g. Tumor samples were then homogenized in a Bullet Blender 24 Gold (Next Advance, Inc., Troy, NY) for 10 min at a speed setting of 12 until no visible tissue pieces were seen. Samples were then centrifuged at 13,000<i>g</i> for 1 min at 4 °C. Eighty microliters of homogenate was mixed with 25 μL of an in-house custom-made anti-SMB/B′ antibody and 145 μL of cell lysis buffer (50 mM Tris (pH 7.5) and 200 mM NH<sub>4</sub>Cl) in an Eppendorf LoBind 500 μL 96-well plate (Eppendorf North America, Hauppauge, NY). The plate was incubated overnight at 4 °C with gentle shaking.</div><div class="NLM_p">The SMB/B′/anti-SMB/B′ complex was immunoprecipitated with Protein A/G magnetic beads (Pierce). Beads (62.5 μL) were prepared for each tumor homogenate in a 96-well 500 μL microtiter plate (Eppendorf LoBind, Eppendorf North America, Hauppauge, NY). Using a plate magnet, the beads were pulled to one side of the well and the storage buffer was removed. The beads were then washed three times with a wash buffer (50 mM Tris (pH 7.5), 200 mM NaCl, 2 mM EDTA, and 0.0004% RapiGest), removing the supernatant after every wash. The supernatant was removed after the third wash and the homogenate/anti-SMB/B′ antibody mixture (250 μL in total volume) was added to the beads. The samples were incubated at room temperature for 1.5 h with shaking to keep the magnetic beads in the solution, and beads were then pulled to the side of the wells with a magnet and the supernatant was removed. The beads were washed three times with the lysis buffer and three times with a mass spectrometry-friendly buffer (50 mM Tris (pH 7.5) and 200 mM NH<sub>4</sub>Cl), discarding the supernatant after every wash. Fifty microliters of 0.1% TFA was added to the wells and the plate was incubated for 10 min at room temperature with shaking to elute the captured protein from the magnetic beads. The beads were subsequently pulled to the side of the wells with a magnet and the supernatant containing the target antigen was collected.</div><div class="NLM_p">For sample digestion, 30 μL of digestion buffer (50 mM triethylammonium bicarbonate and 0.2% RapiGest (w/v) in water) was added to each well. To this, 20 μL of 50 mM DTT was added and the samples were incubated at 60 °C for 45 min with shaking. The samples were cooled down to room temperature, 3 μL of 500 mM iodoacetamide (Millipore Sigma, St. Louis, MO) was added, and the samples were incubated at room temperature in the dark for 30 min. Finally, 2 μg of trypsin (gold, mass spectrometer grade from Promega, Madison, WI) was added and the samples were incubated overnight at 37 °C with shaking. To precipitate RapiGest, 1.5 μL of TFA was added to each sample and incubated at 37 °C for 45 min with shaking. The plate was then spun down at maximum speed for 15 min at room temperature.</div><div class="NLM_p">Synthetic heavy-labeled and unlabeled peptide standards were obtained from New England Peptide (Gardner MA) for four unique SMB/B′ peptides. The VLGLVLLR peptide represents the total amount of SMB/B′. The peptide VPLAGAAGGPGIGR represents the amount of SMB/B′ that has not been methylated and, if both arginine residues have been methylated, then the peptide VPLAGAAGGPGIGR(dimethyl)AAGR(dimethyl)GIPAGVPMPQAPAGLAGPVR represents the amount of modified SMB/B′ in the sample. The peptide IFIGTFK is detectable for SMB/B′ but not related to the methylation site. All four peptides were combined into a single standard curve ranging from 0.25 to 100 fmol/μL. Since SMB/B′ is an endogenous protein, the standard curve was prepared using the unlabeled peptides in water. Each of the heavy-labeled peptides was combined at a concentration of 200 fmol/μL. Five microliters of the internal standard was added after digestion before injection on the mass spectrometer.</div><div class="NLM_p">Two microliters of the sample was analyzed with a Thermo Q Exactive HF Hybrid Quadrupole-Orbitrap mass spectrometer in nanospray mode coupled to a Waters nanoACQUITY LC system equipped with a vented trap column. The samples were first trapped on a trap column for 10 min at a flow rate of 10 μL/min (Waters nanoACQUITY UPLC 2G-V/Mtrap 5 μm Symmetry C18 180 μm × 20 mm) at 99.5% mobile phase A (0.1% formic acid in water) and then eluted off the trap column onto an analytical column (PicoChip Reprosil-Pur C18-AQ 3 μm 120A; 105 mm; 75 μm ID (New Objective, Woburn, MA)) with a 50 min gradient from 0.5% mobile phase B (0.1% formic acid in acetonitrile) to 30% B at a flow rate of 0.5 μL/min. After the gradient, the trap and analytical columns were re-equilibrated for 30 min at the starting condition with 99.5% A and 0.5% B. Data was collected in parallel reaction monitoring (PRM) mode and analyzed using Skyline (<a href="http://www.skyline.ms" class="extLink">www.skyline.ms</a>).</div><div class="NLM_p last">Unless specified, all reagents were purchased from Thermo Fisher Scientific, Waltham, MA.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i102"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02083" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02083?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02083</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Supplementary figures, tables, and plots; description of modeling methods; crystallography methods; LC traces for compounds <b>34</b> and <b>72</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Representative docking models for compounds <b>4</b>, <b>31</b>, <b>41</b>, <b>65</b>, and <b>73</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf">jm0c02083_si_001.pdf (2.99 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_002.pdb">jm0c02083_si_002.pdb (638.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_003.csv">jm0c02083_si_003.csv (2.89 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02083" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61275" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61275" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ryan V. Quiroz</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span>Present Address:
                        Merck & Co., Inc., 213 E. Grand Ave., South San Francisco, California 94080, United States (R.V.Q.)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6840-9636" title="Orcid link">http://orcid.org/0000-0001-6840-9636</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ccbeb5ada2e2bdb9a5bea3b68ca1a9beafa7e2afa3a1"><span class="__cf_email__" data-cfemail="85f7fce4ebabf4f0ecf7eaffc5e8e0f7e6eeabe6eae8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael H. Reutershan</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sebastian E. Schneider</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1233-8984" title="Orcid link">http://orcid.org/0000-0003-1233-8984</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Sloman</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian M. Lacey</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brooke M. Swalm</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span>Present Address:
                        Rheos Medicines, Inc., 245 First Street, Suite 200, Cambridge, Massachusetts 02142, United States (B.M.S.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles S. Yeung</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7320-7190" title="Orcid link">http://orcid.org/0000-0001-7320-7190</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Craig Gibeau</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel S. Spellman</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 770
Sumneytown Pike, Lansdale, Pennsylvania 19446, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7155-2329" title="Orcid link">http://orcid.org/0000-0001-7155-2329</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danica A. Rankic</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span>Present Address:
                        Pfizer Worldwide Research and Development, 280 Shennecossett Road, Groton, Connecticut 06340, United States (D.A.R.)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7326-8900" title="Orcid link">http://orcid.org/0000-0002-7326-8900</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dapeng Chen</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span>Present Address:
                        Kymera Therapeutics, 200 Arsenal Yards Blvd., Suite 230, Watertown, Massachusetts 02472, United States (D.C.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Witter</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span>Present Address:
                        Cullinan Oncology, One Main Street, Suite 520, Cambridge, Massachusetts 02142, United States (D.W.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Doug Linn</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erik Munsell</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guo Feng</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haiyan Xu</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan M. E. Hughes</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 126
East Lincoln Avenue, Rahway, New Jersey 07065, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jongwon Lim</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3402-7810" title="Orcid link">http://orcid.org/0000-0003-3402-7810</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josep Saurí</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristin Geddes</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 770
Sumneytown Pike, Lansdale, Pennsylvania 19446, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Murray Wan</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">My Sam Mansueto</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole E. Follmer</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick S. Fier</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 126
East Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6102-815X" title="Orcid link">http://orcid.org/0000-0002-6102-815X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phieng Siliphaivanh</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre Daublain</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachel L. Palte</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert P. Hayes</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 770
Sumneytown Pike, Lansdale, Pennsylvania 19446, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Lee</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 126
East Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1907-0263" title="Orcid link">http://orcid.org/0000-0003-1907-0263</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuhei Kawamura</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Silverman</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 126
East Lincoln Avenue, Rahway, New Jersey 07065, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0792-7071" title="Orcid link">http://orcid.org/0000-0003-0792-7071</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sulagna Sanyal</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy J. Henderson</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingchun Ye</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuanwei Gao</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 770
Sumneytown Pike, Lansdale, Pennsylvania 19446, United States</span>; 
    <span>Present Address:
                        Hong Kong Science and Technology Parks Corporation, 5/F, Building 5E, Hong Kong Science Park, Shatin, New Territory, Hong Kong (Y.G.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin Nicholson</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span>Present Address:
                        Xilio Therapeutics, 828 Winter Street, Suite 300, Waltham, Massachusetts 02451, Unites States (B.N.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle R. Machacek</span> - <span class="hlFld-Affiliation affiliation">Merck
& Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was prepared by R.V.Q. with contributions by all authors to the research.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work was funded entirely by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">PDB IDs of new crystal (X-ray) structures are as follows: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KIB">7KIB</a> (compound <b>4</b>), <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KIC">7KIC</a> (compound <b>34</b>), and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KID">7KID</a> (compound <b>72</b>). The authors will release the atomic coordinates upon article publication.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i112">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank Leo Joyce and the structural determination team for solving the absolute structure of the Pauson–Khand product. We would also like to thank the Merck & Co., Inc., Boston, MA, USA, purification team for their rapid and efficient work in purifying these complex structures on small and large scales. We acknowledge external chemistry members Lianyun Zhao and Wensheng Yu as well as Zhibo Zhang and her team at Pharmaron for contributions to compound synthesis. We thank Viva Biotech for help with crystallography and data collection. We thank Hendrik Falk and Ian Street from Cancer Therapeutics CRC (CTx) for enabling the development of the cell-based assays.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AAA</td><td class="NLM_def"><p class="first last">asymmetric allylic alkylation</p></td></tr><tr><td class="NLM_term">Ac<sub>2</sub>O</td><td class="NLM_def"><p class="first last">acetic anhydride</p></td></tr><tr><td class="NLM_term">ADDP</td><td class="NLM_def"><p class="first last">1,1′-(azodicarbonyl)dipiperidine</p></td></tr><tr><td class="NLM_term">API</td><td class="NLM_def"><p class="first last">active pharmaceutical ingredient</p></td></tr><tr><td class="NLM_term">9-BBN</td><td class="NLM_def"><p class="first last">9-borabicyclo[3.3.1]nonane</p></td></tr><tr><td class="NLM_term">BLQ</td><td class="NLM_def"><p class="first last">below the limit of quantification</p></td></tr><tr><td class="NLM_term">BnBr</td><td class="NLM_def"><p class="first last">benzyl bromide</p></td></tr><tr><td class="NLM_term">Cl<sub>p</sub></td><td class="NLM_def"><p class="first last">plasma clearance</p></td></tr><tr><td class="NLM_term">Cl<sub>u</sub></td><td class="NLM_def"><p class="first last">unbound plasma clearance</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMP</td><td class="NLM_def"><p class="first last">Dess–Martin periodinane</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">dppe</td><td class="NLM_def"><p class="first last">1,2-bis(diphenylphosphino)ethane</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">effective concentration for 50% response</p></td></tr><tr><td class="NLM_term">ECD</td><td class="NLM_def"><p class="first last">electronic circular dichroism</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">%<i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term"><i>F</i><sub>a</sub></td><td class="NLM_def"><p class="first last">fraction absorbed</p></td></tr><tr><td class="NLM_term"><i>F</i><sub>h</sub></td><td class="NLM_def"><p class="first last">fraction escaping hepatic metabolism and excretion</p></td></tr><tr><td class="NLM_term">H-bond</td><td class="NLM_def"><p class="first last">hydrogen bond</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor</p></td></tr><tr><td class="NLM_term">IBX</td><td class="NLM_def"><p class="first last">2-iodoxybenzoic acid</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MoA</td><td class="NLM_def"><p class="first last">mechanism of action</p></td></tr><tr><td class="NLM_term">mpk</td><td class="NLM_def"><p class="first last">mg/kg</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">MTA</td><td class="NLM_def"><p class="first last">methylthioadenosine</p></td></tr><tr><td class="NLM_term">MTAP</td><td class="NLM_def"><p class="first last">methylthioadenosine phosphorylase</p></td></tr><tr><td class="NLM_term">nbd</td><td class="NLM_def"><p class="first last">norbornadiene</p></td></tr><tr><td class="NLM_term">NMO</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine <i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylpyrrolidine</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PMB</td><td class="NLM_def"><p class="first last">4-methoxybenzyl</p></td></tr><tr><td class="NLM_term">POS</td><td class="NLM_def"><p class="first last">probability of success</p></td></tr><tr><td class="NLM_term">PRMT5</td><td class="NLM_def"><p class="first last">protein arginase methyl transferase 5</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once a day</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAM</td><td class="NLM_def"><p class="first last"><i>S</i>-adenosylmethionine</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SDMA</td><td class="NLM_def"><p class="first last">symmetric dimethylarginine</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">SMB/B′</td><td class="NLM_def"><p class="first last">small-molecule ribonucleoprotein-associated protein B and B′</p></td></tr><tr><td class="NLM_term">TDI</td><td class="NLM_def"><p class="first last">time-dependent inhibition</p></td></tr><tr><td class="NLM_term">TE</td><td class="NLM_def"><p class="first last">target engagement</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">TPS</td><td class="NLM_def"><p class="first last">triphenylsilyl</p></td></tr><tr><td class="NLM_term">TsCl</td><td class="NLM_def"><p class="first last">4-toluenesulfonyl chloride</p></td></tr><tr><td class="NLM_term">TsOH</td><td class="NLM_def"><p class="first last">4-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">Vd<sub>u</sub></td><td class="NLM_def"><p class="first last">unbound volume of distribution</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i114">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 64 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrueto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caminero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cash, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamichhane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, R. R.</span></span> <span> </span><span class="NLM_article-title">Resistance to checkpoint inhibition in cancer immunotherapy</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">100738</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2019.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.tranon.2019.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=32114384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A280%3ADC%252BB387nslWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=100738&author=L.+Barruetoauthor=F.+Camineroauthor=L.+Cashauthor=C.+Makrisauthor=P.+Lamichhaneauthor=R.+R.+Deshmukh&title=Resistance+to+checkpoint+inhibition+in+cancer+immunotherapy&doi=10.1016%2Fj.tranon.2019.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to Checkpoint Inhibition in Cancer Immunotherapy</span></div><div class="casAuthors">Barrueto Luisa; Caminero Francheska; Cash Lindsay; Makris Courtney; Lamichhane Purushottam; Deshmukh Rahul R</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">100738</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">The interaction of the host immune system with tumor cells in the tissue microenvironment is essential in understanding tumor immunity and development of successful cancer immunotherapy.  The presence of lymphocytes in tumors is highly correlated with an improved outcome.  T cells have a set of cell surface receptors termed immune checkpoints that when activated suppress T cell function.  Upregulation of immune checkpoint receptors such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) occurs during T cell activation in an effort to prevent damage from an excessive immune response.  Immune checkpoint inhibitors allow the adaptive immune system to respond to tumors more effectively.  There has been clinical success in different types of cancer blocking immune checkpoint receptors such as PD-1 and CTLA.  However, relapse has occurred.  The innate and acquired/therapy induced resistance to treatment has been encountered.  Aberrant cellular signal transduction is a major contributing factor to resistance to immunotherapy.  Combination therapies with other co-inhibitory immune checkpoints such as TIM-3, LAG3 and VISTA are currently being tested to overcome resistance to cancer immunotherapy.  Expression of TIM-3 has been associated with resistance to PD-1 blockade and combined blockade of TIM-3 and PD-1 has demonstrated improved responses in preclinical models.  LAG3 blockade has the potential to increase the responsiveness of cytotoxic T-cells to tumors.  Furthermore, tumors that were found to express VISTA had an increased rate of growth due to the T cell suppression.  The growing understanding of the inhibitory immune checkpoints' ligand biology, signaling mechanisms, and T-cell suppression in the tumor microenvironment continues to fuel preclinical and clinical advancements in design, testing, and approval of agents that block checkpoint molecules.  Our review seeks to bridge fundamental regulatory mechanisms across inhibitory immune checkpoint receptors that are of great importance in resistance to cancer immunotherapy.  We will summarize the biology of different checkpoint molecules, highlight the effect of individual checkpoint inhibition as anti-tumor therapies, and outline the literatures that explore mechanisms of resistance to individual checkpoint inhibition pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3hU_2rfFG_9FxYDaSSP8XfW6udTcc2eblkVotagwIq7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387nslWjsg%253D%253D&md5=4c3a471ab587fcfc68bc4c8c58cb590c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2019.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2019.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DBarrueto%26aufirst%3DL.%26aulast%3DCaminero%26aufirst%3DF.%26aulast%3DCash%26aufirst%3DL.%26aulast%3DMakris%26aufirst%3DC.%26aulast%3DLamichhane%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DR.%2BR.%26atitle%3DResistance%2520to%2520checkpoint%2520inhibition%2520in%2520cancer%2520immunotherapy%26jtitle%3DTransl.%2520Oncol.%26date%3D2020%26volume%3D13%26spage%3D100738%26doi%3D10.1016%2Fj.tranon.2019.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span> <span> </span><span class="NLM_article-title">Role of protein arginine methyltransferase 5 in human cancers</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">108790</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2019.108790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.biopha.2019.108790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30903920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtV2isb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2019&pages=108790&author=W.+Xiaoauthor=X.+Chenauthor=L.+Liuauthor=Y.+Shuauthor=M.+Zhangauthor=Y.+Zhong&title=Role+of+protein+arginine+methyltransferase+5+in+human+cancers&doi=10.1016%2Fj.biopha.2019.108790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Role of protein arginine methyltransferase 5 in human cancers</span></div><div class="casAuthors">Xiao, Wendi; Chen, Xiaoqing; Liu, Lisa; Shu, Yuansen; Zhang, Min; Zhong, Yucheng</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108790</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Protein arginine methyltransferases (PRMTs) play important roles in protein methylation.  PRMT5 is the major type II arginine methyltransferase that catalyzes the transfer of two Me groups sym. to the arginine residues of either histone or non-histone proteins.  In recent years, increasing evidence has shown that PRMT5, as an oncogene, plays an indispensable regulatory role in the pathol. progression of several human cancers by promoting the proliferation, invasion, and migration of cancer cells.  PRMT5 is overexpressed in many malignant tumors and plays an important role in the occurrence and development of cancer, which suggests that PRMT5 may become a potential biomarker or therapeutic target of cancer.  This article reviews the biol. function, mechanism, and clin. significance of PRMT5 in tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPOq7QOZDBmbVg90H21EOLACvtfcHk0liz0PltGRtXpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtV2isb4%253D&md5=db7dfee60fc048cd7408eb34d3cd1d6a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2019.108790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2019.108790%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DShu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhong%26aufirst%3DY.%26atitle%3DRole%2520of%2520protein%2520arginine%2520methyltransferase%25205%2520in%2520human%2520cancers%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2019%26volume%3D114%26spage%3D108790%26doi%3D10.1016%2Fj.biopha.2019.108790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span> <span> </span><span class="NLM_article-title">PRMT5 in gene regulation and hematologic malignancies</span>. <i>Genes Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.gendis.2019.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.gendis.2019.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=32042864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1KgsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=247-257&author=F.+Zhuauthor=L.+Rui&title=PRMT5+in+gene+regulation+and+hematologic+malignancies&doi=10.1016%2Fj.gendis.2019.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PRMT5 in gene regulation and hematologic malignancies</span></div><div class="casAuthors">Zhu, Fen; Rui, Lixin</div><div class="citationInfo"><span class="NLM_cas:title">Genes and Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-257</span>CODEN:
                <span class="NLM_cas:coden">GDEIAV</span>;
        ISSN:<span class="NLM_cas:issn">2352-3042</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arginine methylation is a common posttranslational modification that governs important cellular processes and impacts development, cell growth, proliferation, and differentiation.  Arginine methylation is catalyzed by protein arginine methyltransferases (PRMTs), which are classified as type I and type II enzymes responsible for the formation of asym. and sym. dimethylarginine, resp.  PRMT5 is the main type II enzyme that catalyzes sym. dimethylarginine of histone proteins to induce gene silencing by generating repressive histone marks, including H2AR3me2s, H3R8me2s, and H4R3me2s.  PRMT5 can also methylate nonhistone proteins such as the transcription factors p53, E2F1 and p65.  Modifications of these proteins by PRMT5 are involved in diverse cellular processes, including transcription, translation, DNA repair, RNA processing, and metab.  A growing literature demonstrates that PRMT5 expression is upregulated in hematol. malignancies, including leukemia and lymphoma, where PRMT5 regulates gene expression to promote cancer cell proliferation.  Targeting PRMT5 by specific inhibitors has emerged as a potential therapeutic strategy to treat these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJVhX2ajFoobVg90H21EOLACvtfcHk0liz0PltGRtXpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1KgsbfO&md5=ca3472cb24efa060a5c55f8920156e97</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.gendis.2019.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gendis.2019.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DRui%26aufirst%3DL.%26atitle%3DPRMT5%2520in%2520gene%2520regulation%2520and%2520hematologic%2520malignancies%26jtitle%3DGenes%2520Dis.%26date%3D2019%26volume%3D6%26spage%3D247%26epage%3D257%26doi%3D10.1016%2Fj.gendis.2019.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span> <span> </span><span class="NLM_article-title">Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1264</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.03.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.bmcl.2019.03.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30956011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslOit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1264-1269&author=H.+Linauthor=J.+I.+Luengo&title=Nucleoside+protein+arginine+methyltransferase+5+%28PRMT5%29+inhibitors&doi=10.1016%2Fj.bmcl.2019.03.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors</span></div><div class="casAuthors">Lin, Hong; Luengo, Juan I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1264-1269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein Arginine Methyltransferase 5 (PRMT5) is known to sym. dimethylate numerous cytosolic and nuclear proteins that are involved in a variety of cellular processes.  Recent findings have revealed its potential as a cancer therapeutic target.  PRMT5 selective inhibitors, GSK3326595, a substrate competitive inhibitor, and JNJ64619178, a SAM (S-adenosyl-L-methionine) mimetic/competitive inhibitor, have entered clinic trials for multiple cancer types.  This review focuses on the recent developments in SAM mimetic nucleoside PRMT5 inhibitors, their SAR and structural insight based on published co-crystal structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWzpjRzaVPBLVg90H21EOLACvtfcHk0lh4cBH6mx_YEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslOit70%253D&md5=f5889f2c5e084dc231f865805a241da6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.03.042%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26atitle%3DNucleoside%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1264%26epage%3D1269%26doi%3D10.1016%2Fj.bmcl.2019.03.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shailesh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakaria, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baiocchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sif, S.</span></span> <span> </span><span class="NLM_article-title">Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">36705</span>– <span class="NLM_lpage">36718</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.26404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.18632%2Foncotarget.26404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30613353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A280%3ADC%252BB3cnosVeqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=36705-36718&author=H.+Shaileshauthor=Z.+Z.+Zakariaauthor=R.+Baiocchiauthor=S.+Sif&title=Protein+arginine+methyltransferase+5+%28PRMT5%29+dysregulation+in+cancer&doi=10.18632%2Foncotarget.26404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer</span></div><div class="casAuthors">Shailesh Harshita; Zakaria Zain Z; Sif Said; Baiocchi Robert</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">94</span>),
    <span class="NLM_cas:pages">36705-36718</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein arginine methyltransferases (PRMTs) are known for their ability to catalyze methylation of specific arginine residues in a wide variety of cellular proteins, which are involved in a plethora of processes including signal transduction, transcription, and more recently DNA recombination.  All members of the PRMT family can be grouped into three main classes depending on the type of methylation they catalyze.  Type I PRMTs induce monomethylation and asymmetric dimethylation, while type II PRMTs catalyze monomethylation and symmetric dimethylation of specific arginine residues.  In contrast, type III PRMTs carry out only monomethylation of arginine residues.  In this review, we will focus on PRMT5, a type II PRMT essential for viability and normal development, which has been shown to be overexpressed in a wide variety of cancer cell types, owing it to the crucial role it plays in controlling key growth regulatory pathways.  Furthermore, the role of PRMT5 in regulating expression and stability of key transcription factors that control normal stem cell function as well as cancer stem cell renewal will be discussed.  We will review recent work that shows that through its ability to methylate various cellular proteins, PRMT5 functions as a master epigenetic regulator essential for growth and development, and we will highlight studies that have examined its dysregulation and the effects of its inhibition on cancer cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR97gCYYvDNxisZ1x6zOs0vfW6udTcc2eYYp0DDafWQ0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnosVeqtQ%253D%253D&md5=7d1bbff0d51464d13a46b391ab16b4a9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.26404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.26404%26sid%3Dliteratum%253Aachs%26aulast%3DShailesh%26aufirst%3DH.%26aulast%3DZakaria%26aufirst%3DZ.%2BZ.%26aulast%3DBaiocchi%26aufirst%3DR.%26aulast%3DSif%26aufirst%3DS.%26atitle%3DProtein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520dysregulation%2520in%2520cancer%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D36705%26epage%3D36718%26doi%3D10.18632%2Foncotarget.26404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span> <span> </span><span class="NLM_article-title">Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9429</span>– <span class="NLM_lpage">9441</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9429-9441&author=Y.+Wangauthor=W.+Huauthor=Y.+Yuan&title=Protein+arginine+methyltransferase+5+%28PRMT5%29+as+an+anticancer+target+and+its+inhibitor+discovery&doi=10.1021%2Facs.jmedchem.8b00598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery</span></div><div class="casAuthors">Wang, Yuanxiang; Hu, Wenhao; Yuan, Yanqiu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9429-9441</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PRMT5 is a major enzyme responsible for sym. dimethylation of arginine residues on both histone and non-histone proteins, regulating many biol. pathways in mammalian cells.  PRMT5 has been suggested as a therapeutic target in a variety of diseases including infectious disease, heart disease, and cancer.  Many PRMT5 inhibitors have been discovered in the past 5 years, and one entered clin. trial in 2015 for the treatment of solid tumor and mantle cell lymphoma (MCL).  The aim of this review is to summarize the current understanding of the roles of PRMT5 in cancer and the discovery of PRMT5 enzymic inhibitors.  By reviewing the structure-activity relationship (SAR) of known inhibitors of PRMT5, we hope to provide guidance for future drug designs and inhibitor optimization.  Opportunities and limitations of PRMT5 inhibitors for the treatment of cancer are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG2MM_2r6cc7Vg90H21EOLACvtfcHk0lh4cBH6mx_YEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLvJ&md5=1fffdd9a78a5edbe4c31357d3e08e2d8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00598%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DYuan%26aufirst%3DY.%26atitle%3DProtein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520as%2520an%2520anticancer%2520target%2520and%2520its%2520inhibitor%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9429%26epage%3D9441%26doi%3D10.1021%2Facs.jmedchem.8b00598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demir, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">39963</span>– <span class="NLM_lpage">39977</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.18102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.18632%2Foncotarget.18102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=28591716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A280%3ADC%252BC1cnmtVehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=39963-39977&author=L.+Prabhuauthor=H.+Weiauthor=L.+Chenauthor=%C3%96.+Demirauthor=G.+Sanduskyauthor=E.+Sunauthor=J.+Wangauthor=J.+Moauthor=L.+Zengauthor=M.+Fishelauthor=A.+Safaauthor=R.+Amaroauthor=M.+Korcauthor=Z.-Y.+Zhangauthor=T.+Lu&title=Adapting+AlphaLISA+high+throughput+screen+to+discover+a+novel+small-molecule+inhibitor+targeting+protein+arginine+methyltransferase+5+in+pancreatic+and+colorectal+cancers&doi=10.18632%2Foncotarget.18102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers</span></div><div class="casAuthors">Prabhu Lakshmi; Wei Han; Sun Emily; Wang John; Mo Jessica; Safa Ahmad; Lu Tao; Chen Lan; Zeng Lifan; Chen Lan; Zeng Lifan; Zhang Zhong-Yin; Lu Tao; Chen Lan; Zhang Zhong-Yin; Demir Ozlem; Amaro Rommie; Sandusky George; Fishel Melissa; Korc Murray; Lu Tao</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">39963-39977</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) are notoriously challenging for treatment.  Hyperactive nuclear factor κB (NF-κB) is a common culprit in both cancers.  Previously, we discovered that protein arginine methyltransferase 5 (PRMT5) methylated and activated NF-κB.  Here, we show that PRMT5 is highly expressed in PDAC and CRC.  Overexpression of PRMT5 promoted cancer progression, while shRNA knockdown showed an opposite effect.  Using an innovative AlphaLISA high throughput screen, we discovered a lead compound, PR5-LL-CM01, which exhibited robust tumor inhibition effects in both cancers.  An in silico structure prediction suggested that PR5-LL-CM01 inhibits PRMT5 by binding with its active pocket.  Importantly, PR5-LL-CM01 showed higher anti-tumor efficacy than the commercial PRMT5 inhibitor, EPZ015666, in both PDAC and CRC.  This study clearly highlights the significant potential of PRMT5 as a therapeutic target in PDAC and CRC, and establishes PR5-LL-CM01 as a promising basis for new drug development in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGp0p7OcE36IhLSh9fo81bfW6udTcc2eZ0aY3KdIsXDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnmtVehtw%253D%253D&md5=863065cdd403b37160fc31d17b625de2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.18102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.18102%26sid%3Dliteratum%253Aachs%26aulast%3DPrabhu%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDemir%26aufirst%3D%25C3%2596.%26aulast%3DSandusky%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DFishel%26aufirst%3DM.%26aulast%3DSafa%26aufirst%3DA.%26aulast%3DAmaro%26aufirst%3DR.%26aulast%3DKorc%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DAdapting%2520AlphaLISA%2520high%2520throughput%2520screen%2520to%2520discover%2520a%2520novel%2520small-molecule%2520inhibitor%2520targeting%2520protein%2520arginine%2520methyltransferase%25205%2520in%2520pancreatic%2520and%2520colorectal%2520cancers%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D39963%26epage%3D39977%26doi%3D10.18632%2Foncotarget.18102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1476</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.03.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.bmcl.2018.03.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=29628326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1aqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1476-1483&author=K.+Zhuauthor=C.+Jiangauthor=H.+Taoauthor=J.+Liuauthor=H.+Zhangauthor=C.+Luo&title=Identification+of+a+novel+selective+small-molecule+inhibitor+of+protein+arginine+methyltransferase+5+%28PRMT5%29+by+virtual+screening%2C+resynthesis+and+biological+evaluations&doi=10.1016%2Fj.bmcl.2018.03.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations</span></div><div class="casAuthors">Zhu, Kongkai; Jiang, Chengshi; Tao, Hongrui; Liu, Jingqiu; Zhang, Hua; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1476-1483</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As one of the most promising anticancer targets in protein arginine methyltransferase (PRMT) family, PRMT5 has been drawing more and more attention, and many efforts have been devoted to develop its inhibitors.  In this study, three PRMT5 inhibitors (9, 16, and 23) with novel scaffolds were identified by performing pharmacophore- and docking-based virtual screening combined with in vitro radiometric-based scintillation proximity assay (SPA).  Substructure search based on the scaffold of the most active 9 afforded 26 addnl. analogs, and SPA results indicated that two analogs (9-1 and 9-2) showed increased PRMT5 inhibitory activity compared with the parental compd.  Resynthesis of 9, 9-1, and 9-2 confirmed their PRMT5 enzymic inhibition activity.  In addn., compd. 9-1 displayed selectivity against PRMT5 over other key homol. members (PRMT1 and CARM1 (PRMT4)).  While the structure-activity relationship (SAR) of this series of compds. was discussed to provide clues for further structure optimization, the probable binding modes of active compds. were also probed by mol. docking and mol. dynamics simulations.  Finally, the antiproliferative effect of 9-1 on MV4-11 leukemia cell line was confirmed and its impact on regulating the target gene of PRMT5 was also validated.  The hit compds. identified have provided more novel scaffolds for future hit-to-lead optimization of small-mol. PRMT5 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6eDaTozQTprVg90H21EOLACvtfcHk0lhgFeCV7fS4BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1aqt7g%253D&md5=6d6d2eb1c1dcd5db74ee4e712ed4b3ce</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.03.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.03.087%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3DIdentification%2520of%2520a%2520novel%2520selective%2520small-molecule%2520inhibitor%2520of%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520by%2520virtual%2520screening%252C%2520resynthesis%2520and%2520biological%2520evaluations%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1476%26epage%3D1483%26doi%3D10.1016%2Fj.bmcl.2018.03.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boriack-Sjodin, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majer, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan-Penebre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuplast, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter
Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span> <span> </span><span class="NLM_article-title">Structure and property guided design in the identification of PRMT5 tool compound EPZ015666</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00380</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00380" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=162-166&author=K.+W.+Duncanauthor=N.+Riouxauthor=P.+A.+Boriack-Sjodinauthor=M.+J.+Munchhofauthor=L.+A.+Reiterauthor=C.+R.+Majerauthor=L.+Jinauthor=L.+D.+Johnstonauthor=E.+Chan-Penebreauthor=K.+G.+Kuplastauthor=M.+Porter%0AScottauthor=R.+M.+Pollockauthor=N.+J.+Watersauthor=J.+J.+Smithauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=R.+Chesworth&title=Structure+and+property+guided+design+in+the+identification+of+PRMT5+tool+compound+EPZ015666&doi=10.1021%2Facsmedchemlett.5b00380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666</span></div><div class="casAuthors">Duncan, Kenneth W.; Rioux, Nathalie; Boriack-Sjodin, P. Ann; Munchhof, Michael J.; Reiter, Lawrence A.; Majer, Christina R.; Jin, Lei; Johnston, L. Danielle; Chan-Penebre, Elayne; Kuplast, Kristy G.; Porter Scott, Margaret; Pollock, Roy M.; Waters, Nigel J.; Smith, Jesse J.; Moyer, Mikel P.; Copeland, Robert A.; Chesworth, Richard</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-166</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent publication of a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) provides the scientific community with in vivo-active tool compd. I (EPZ015666, GSK3235025) to probe the underlying pharmacol. of this key enzyme.  Herein, the authors report the design and optimization strategies employed on an initial hit compd. with poor in vitro clearance to yield in vivo tool compd. I and an addnl. potent in vitro tool mol. II (GSK3203591).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2V7LiQgVZjrVg90H21EOLACvtfcHk0lhgFeCV7fS4BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsr3L&md5=e7ac92c2d985da4994e9bb959adededf</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00380%26sid%3Dliteratum%253Aachs%26aulast%3DDuncan%26aufirst%3DK.%2BW.%26aulast%3DRioux%26aufirst%3DN.%26aulast%3DBoriack-Sjodin%26aufirst%3DP.%2BA.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DReiter%26aufirst%3DL.%2BA.%26aulast%3DMajer%26aufirst%3DC.%2BR.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DJohnston%26aufirst%3DL.%2BD.%26aulast%3DChan-Penebre%26aufirst%3DE.%26aulast%3DKuplast%26aufirst%3DK.%2BG.%26aulast%3DPorter%2BScott%26aufirst%3DM.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DChesworth%26aufirst%3DR.%26atitle%3DStructure%2520and%2520property%2520guided%2520design%2520in%2520the%2520identification%2520of%2520PRMT5%2520tool%2520compound%2520EPZ015666%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D162%26epage%3D166%26doi%3D10.1021%2Facsmedchemlett.5b00380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonday, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonysamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocchinfuso, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mader, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eram, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczyk, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsyte-Lovejoy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guccione, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. M.</span></span> <span> </span><span class="NLM_article-title">LLY-283, a potent and selective inhibitor of arginine methyltransferase 5, PRMT5, with antitumor activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFarurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=612-617&author=Z.+Q.+Bondayauthor=G.+S.+Cortezauthor=M.+J.+Groganauthor=S.+Antonysamyauthor=K.+Weichertauthor=W.+P.+Bocchinfusoauthor=F.+Liauthor=S.+Kennedyauthor=B.+Liauthor=M.+M.+Maderauthor=C.+H.+Arrowsmithauthor=P.+J.+Brownauthor=M.+S.+Eramauthor=M.+M.+Szewczykauthor=D.+Barsyte-Lovejoyauthor=M.+Vedadiauthor=E.+Guccioneauthor=R.+M.+Campbell&title=LLY-283%2C+a+potent+and+selective+inhibitor+of+arginine+methyltransferase+5%2C+PRMT5%2C+with+antitumor+activity&doi=10.1021%2Facsmedchemlett.8b00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity</span></div><div class="casAuthors">Bonday, Zahid Q.; Cortez, Guillermo S.; Grogan, Michael J.; Antonysamy, Stephen; Weichert, Ken; Bocchinfuso, Wayne P.; Li, Fengling; Kennedy, Steven; Li, Binghui; Mader, Mary M.; Arrowsmith, Cheryl H.; Brown, Peter J.; Eram, Mohammad S.; Szewczyk, Magdalena M.; Barsyte-Lovejoy, Dalia; Vedadi, Masoud; Guccione, Ernesto; Campbell, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">612-617</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the formation of sym. dimethylarginine in a no. of nuclear and cytoplasmic proteins.  Although the cellular functions of PRMT5 have not been fully unraveled, it has been implicated in a no. of cellular processes like RNA processing, signal transduction and transcriptional regulation.  PRMT5 is ubiquitously expressed in most tissues and its expression has been shown to be elevated in several cancers including breast cancer, gastric cancer, glioblastoma and lymphoma.  Here we describe the identification and characterization of a novel and selective PRMT5 inhibitor with potent in vitro and in vivo activity.  Compd. 1 (also called LLY-283) inhibited PRMT5 enzymic activity in vitro and in cells with IC50 of 22 ± 3 nM and 25 ± 1 nM, resp. while its diastereomer, compd. 2 (also called LLY-284) was much less active.  Compd. 1 also showed antitumor activity in mouse xenografts when dosed orally and can serve as an excellent probe mol. for understanding the biol. function of PRMT5 in normal and cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYIq2FC-EskrVg90H21EOLACvtfcHk0lhUr6x-gr7pzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFarurc%253D&md5=93517c34cf9f99d76730a538f594ddd7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00014%26sid%3Dliteratum%253Aachs%26aulast%3DBonday%26aufirst%3DZ.%2BQ.%26aulast%3DCortez%26aufirst%3DG.%2BS.%26aulast%3DGrogan%26aufirst%3DM.%2BJ.%26aulast%3DAntonysamy%26aufirst%3DS.%26aulast%3DWeichert%26aufirst%3DK.%26aulast%3DBocchinfuso%26aufirst%3DW.%2BP.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKennedy%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DMader%26aufirst%3DM.%2BM.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DEram%26aufirst%3DM.%2BS.%26aulast%3DSzewczyk%26aufirst%3DM.%2BM.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DGuccione%26aufirst%3DE.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26atitle%3DLLY-283%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520arginine%2520methyltransferase%25205%252C%2520PRMT5%252C%2520with%2520antitumor%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D612%26epage%3D617%26doi%3D10.1021%2Facsmedchemlett.8b00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.bioorg.2018.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30172110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1WmsrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=289-298&author=K.+Zhuauthor=H.+Taoauthor=J.-L.+Songauthor=L.+Jinauthor=Y.+Zhangauthor=J.+Liuauthor=Z.+Chenauthor=C.-S.+Jiangauthor=C.+Luoauthor=H.+Zhang&title=Identification+of+5-benzylidene-2-phenylthiazolones+as+potent+PRMT5+inhibitors+by+virtual+screening%2C+structural+optimization+and+biological+evaluations&doi=10.1016%2Fj.bioorg.2018.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations</span></div><div class="casAuthors">Zhu, Kongkai; Tao, Hongrui; Song, Jia-Li; Jin, Lu; Zhang, Yuanyuan; Liu, Jingqiu; Chen, Zhifeng; Jiang, Cheng-Shi; Luo, Cheng; Zhang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">289-298</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is an epigenetics related enzyme that has been validated as an important therapeutic target for glioblastoma and mantel cell lymphoma.  In the present study, 11 novel PRMT5 inhibitors with 5-benzylidene-2-phenylthiazolone scaffold were identified by mol. docking-based virtual screening and structural optimization.  Their IC50 values against PRMT5 at enzymic level were ranging from 0.77 to 23 μM.  As expected, the top two active hits (5 and 19) showed potent anti-proliferative activity against MV4-11 cells with EC50 values lower than 10 μM and reduced the cellular sym. arginine dimethylation levels of SmD3 protein.  Besides, 5 and 19 demonstrated the mechanism of cell killing in cell cycle arrest and apoptotic effect.  The probable binding modes of the two compds. were explored and further verified by mol. dynamics simulation.  The structure-activity relationship (SAR) of this class of structures was also discussed and further demonstrated by mol. docking simulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1K2TslS6a5bVg90H21EOLACvtfcHk0lhUr6x-gr7pzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1WmsrrK&md5=734c196a4312bac7c377ad1ca1ec4d81</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DJ.-L.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DC.-S.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DIdentification%2520of%25205-benzylidene-2-phenylthiazolones%2520as%2520potent%2520PRMT5%2520inhibitors%2520by%2520virtual%2520screening%252C%2520structural%2520optimization%2520and%2520biological%2520evaluations%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D289%26epage%3D298%26doi%3D10.1016%2Fj.bioorg.2018.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3693</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.bmcl.2018.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30366617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVSlsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3693-3699&author=K.+Zhuauthor=J.-L.+Songauthor=H.-R.+Taoauthor=Z.-Q.+Chengauthor=C.-S.+Jiangauthor=H.+Zhang&title=Discovery+of+new+potent+protein+arginine+methyltransferase+5+%28PRMT5%29+inhibitors+by+assembly+of+key+pharmacophores+from+known+inhibitors&doi=10.1016%2Fj.bmcl.2018.10.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors</span></div><div class="casAuthors">Zhu, Kongkai; Song, Jia-Li; Tao, Hong-Rui; Cheng, Zhi-Qiang; Jiang, Cheng-Shi; Zhang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">3693-3699</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is an epigenetics related enzyme that has been validated as a promising therapeutic target for human cancer.  Up to now, two small mol. PRMT5 inhibitors has been put into phase I clin. trial.  In the present study, a series of candidate mols. were designed by combining key pharmacophores of formerly reported PRMT5 inhibitors.  The in vitro PRMT5 inhibitory testing of compd. 4b14 revealed an IC50 of 2.71 μM, exhibiting high selectivity over PRMT1 and PRMT4 (>70-fold selective).  As expected, 4b14 exhibited potent anti-proliferative activity against a panel of leukemia and lymphoma cells, including MV4-11, Pfeiffer, SU-DHL-4 and KARPAS-422.  Besides, 4b14 showed significant cell cycle arrest and apoptosis-inducing effects, as well as reduced the cellular sym. arginine dimethylation level of SmD3 protein.  Finally, affinity profiling anal. indicated that hydrophobic interactions, π-π stacking and cation-π actions made the major contributions to the overall binding affinity.  This scaffold provides a new chem. template for further development of better lead compds. targeting PRMT5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUiq5gq-S5uLVg90H21EOLACvtfcHk0ljvmpqlwUS6Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVSlsLrP&md5=d397612b9684719d6696dff6362a8806</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DJ.-L.%26aulast%3DTao%26aufirst%3DH.-R.%26aulast%3DCheng%26aufirst%3DZ.-Q.%26aulast%3DJiang%26aufirst%3DC.-S.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520new%2520potent%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520inhibitors%2520by%2520assembly%2520of%2520key%2520pharmacophores%2520from%2520known%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3693%26epage%3D3699%26doi%3D10.1016%2Fj.bmcl.2018.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span> <span> </span><span class="NLM_article-title">Rational design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1007/s10822-019-00214-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1007%2Fs10822-019-00214-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=31312965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyiur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=775-785&author=K.+Zhuauthor=J.+Shaoauthor=H.+Taoauthor=X.+Yanauthor=C.+Luoauthor=H.+Zhangauthor=W.+Duan&title=Rational+design%2C+synthesis+and+biological+evaluation+of+novel+triazole+derivatives+as+potent+and+selective+PRMT5+inhibitors+with+antitumor+activity&doi=10.1007%2Fs10822-019-00214-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity</span></div><div class="casAuthors">Zhu, Kongkai; Shao, Jingwei; Tao, Hongrui; Yan, Xue; Luo, Cheng; Zhang, Hua; Duan, Wenhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">775-785</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is responsible for the mono-methylation and sym. dimethylation of arginine, and its expression level and Me transferring activity have been demonstrated to have a close relationship with tumorigenesis, development and poor clin. outcomes of human cancers.  Two PRMT5 small mol. inhibitors (GSK3326595 and JNJ-64619178) have been put forward into clin. trials.  Here, we describe the design, synthesis and biol. evaluation of a series of novel, potent and selective PRMT5 inhibitors with antiproliferative activity against Z-138 mantle cell lymphoma cell line.  Among them, compd. C_4 exhibited the highest potency with enzymic and cellular level IC50 values of 0.72 and 2.6 μM, resp., and displayed more than 270-fold selectivity toward PRMT5 over several other isoenzymes (PRMT1, PRMT4 and PRMT6).  Besides, C_4 demonstrated obvious cell apoptotic effect while reduced the cellular sym. arginine dimethylation levels of SmD3 protein.  The potency, small size, and synthetic accessibility of this compd. class provide promising hit scaffold for medicinal chemists to further explore this series of PRMT5 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1YVgRfHLMnrVg90H21EOLACvtfcHk0ljvmpqlwUS6Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyiur7I&md5=cb0ba8ca2854b233b13a830662d68041</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10822-019-00214-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-019-00214-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDuan%26aufirst%3DW.%26atitle%3DRational%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520triazole%2520derivatives%2520as%2520potent%2520and%2520selective%2520PRMT5%2520inhibitors%2520with%2520antitumor%2520activity%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2019%26volume%3D33%26spage%3D775%26epage%3D785%26doi%3D10.1007%2Fs10822-019-00214-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-substituted-<i>N</i>-(3-(3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: design, synthesis and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.ejmech.2018.12.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30605830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtl2nsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=317-333&author=J.+Shaoauthor=K.+Zhuauthor=D.+Duauthor=Y.+Zhangauthor=H.+Taoauthor=Z.+Chenauthor=H.+Jiangauthor=K.+Chenauthor=C.+Luoauthor=W.+Duan&title=Discovery+of+2-substituted-N-%283-%283%2C4-dihydroisoquinolin-2%281H%29-yl%29-2-hydroxypropyl%29-1%2C2%2C3%2C4-tetrahydroisoquinoline-6-carboxamide+as+potent+and+selective+protein+arginine+methyltransferases+5+inhibitors%3A+design%2C+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2018.12.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation</span></div><div class="casAuthors">Shao, Jingwei; Zhu, Kongkai; Du, Daohai; Zhang, Yuanyuan; Tao, Hongrui; Chen, Zhifeng; Jiang, Hualiang; Chen, Kaixian; Luo, Cheng; Duan, Wenhu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">317-333</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)amide derivs. targeting PRMT5 were designed with structure-based approach and synthesized.  Among them, compd. (S)-2-(4-bromobenzoyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide showed potent and selective PRMT5 inhibition activity with an IC50 of 8.5 nM, which was approx. equiv. with the phase I clin. trial PRMT5 inhibitor GSK-3326595 (IC50 = 5.5 nM).  Compd. (S)-2-(4-bromobenzoyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide also displayed pronounced anti-proliferative activity in MV4-11 cells (GI50 = 18 nM) and antitumor activity in MV4-11 mouse xenografts model.  This mol. served as an excellent tool compd. for probing the biol. function of PRMT5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8r5tDk63g07Vg90H21EOLACvtfcHk0ljvmpqlwUS6Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtl2nsw%253D%253D&md5=d04aaa30e120c8e89d0f9778130cb800</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.065%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DDu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25202-substituted-N-%25283-%25283%252C4-dihydroisoquinolin-2%25281H%2529-yl%2529-2-hydroxypropyl%2529-1%252C2%252C3%252C4-tetrahydroisoquinoline-6-carboxamide%2520as%2520potent%2520and%2520selective%2520protein%2520arginine%2520methyltransferases%25205%2520inhibitors%253A%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D317%26epage%3D333%26doi%3D10.1016%2Fj.ejmech.2018.12.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">Potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor developed by structure-based virtual screening and hit optimization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6289</span>– <span class="NLM_lpage">6304</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00587</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00587" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKitr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6289-6304&author=R.+Maoauthor=J.+Shaoauthor=K.+Zhuauthor=Y.+Zhangauthor=H.+Dingauthor=C.+Zhangauthor=Z.+Shiauthor=H.+Jiangauthor=D.+Sunauthor=W.+Duanauthor=C.+Luo&title=Potent%2C+selective%2C+and+cell+active+protein+arginine+methyltransferase+5+%28PRMT5%29+inhibitor+developed+by+structure-based+virtual+screening+and+hit+optimization&doi=10.1021%2Facs.jmedchem.7b00587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization</span></div><div class="casAuthors">Mao, Ruifeng; Shao, Jingwei; Zhu, Kongkai; Zhang, Yuanyuan; Ding, Hong; Zhang, Chenhua; Shi, Zhe; Jiang, Hualiang; Sun, Dequn; Duan, Wenhu; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6289-6304</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abstr. PRMT5 plays important roles in diverse cellular processes and is upregulated in several human malignancies.  Besides, PRMT5 has been validated as anticancer target in mantle cell lymphoma.  In this study, the authors found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization.  The identified compd. I (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases.  The direct binding of I to PRMT5 was validated by surface plasmon resonance expts., with a Kd of 0.987 μM.  Kinetic expts. indicated that I was a SAM competitive inhibitor other than substrate.  In addn., I showed selective antiproliferative effects against MV4-11 cells, and further studies indicated that the mechanism of cellular antitumor activity was due to inhibition of PRMT5 mediated SmD3 methylation. I may represent a promising lead compd. to understand more about PRMT5 and potentially assist the development of treatments for leukemia indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI1jnM_kEhRrVg90H21EOLACvtfcHk0ljqt4qYUci0uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKitr7E&md5=5e3687166e2e6b5558409806e3c4b9e5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00587%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DR.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3DPotent%252C%2520selective%252C%2520and%2520cell%2520active%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520inhibitor%2520developed%2520by%2520structure-based%2520virtual%2520screening%2520and%2520hit%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6289%26epage%3D6304%26doi%3D10.1021%2Facs.jmedchem.7b00587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan-Penebre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuplast, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majer, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boriack-Sjodin, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraj, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stickland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribich, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappalardi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, K. W.</span></span> <span> </span><span class="NLM_article-title">A selective inhibitor of PRMT5 with <i>in vivo</i> and <i>in vitro</i> potency in MCL models</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1038%2Fnchembio.1810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=25915199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotFartbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=432-437&author=E.+Chan-Penebreauthor=K.+G.+Kuplastauthor=C.+R.+Majerauthor=P.+A.+Boriack-Sjodinauthor=T.+J.+Wigleauthor=L.+D.+Johnstonauthor=N.+Riouxauthor=M.+J.+Munchhofauthor=L.+Jinauthor=S.+L.+Jacquesauthor=K.+A.+Westauthor=T.+Lingarajauthor=K.+Sticklandauthor=S.+A.+Ribichauthor=A.+Raimondiauthor=M.+P.+Scottauthor=N.+J.+Watersauthor=R.+M.+Pollockauthor=J.+J.+Smithauthor=O.+Barbashauthor=M.+Pappalardiauthor=T.+F.+Hoauthor=K.+Nurseauthor=K.+P.+Ozaauthor=K.+T.+Gallagherauthor=R.+Krugerauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=R.+Chesworthauthor=K.+W.+Duncan&title=A+selective+inhibitor+of+PRMT5+with+in+vivo+and+in+vitro+potency+in+MCL+models&doi=10.1038%2Fnchembio.1810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models</span></div><div class="casAuthors">Chan-Penebre, Elayne; Kuplast, Kristy G.; Majer, Christina R.; Boriack-Sjodin, P. Ann; Wigle, Tim J.; Johnston, L. Danielle; Rioux, Nathalie; Munchhof, Michael J.; Jin, Lei; Jacques, Suzanne L.; West, Kip A.; Lingaraj, Trupti; Stickland, Kimberly; Ribich, Scott A.; Raimondi, Alejandra; Scott, Margaret Porter; Waters, Nigel J.; Pollock, Roy M.; Smith, Jesse J.; Barbash, Olena; Pappalardi, Melissa; Ho, Thau F.; Nurse, Kelvin; Oza, Khyati P.; Gallagher, Kathleen T.; Kruger, Ryan; Moyer, Mikel P.; Copeland, Robert A.; Chesworth, Richard; Duncan, Kenneth W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">432-437</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase-5 (PRMT5) is reported to have a role in diverse cellular processes, including tumorigenesis, and its overexpression is obsd. in cell lines and primary patient samples derived from lymphomas, particularly mantle cell lymphoma (MCL).  Here we describe the identification and characterization of a potent and selective inhibitor of PRMT5 with antiproliferative effects in both in vitro and in vivo models of MCL.  EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 enzymic activity in biochem. assays with a half-maximal inhibitory concn. (IC50) of 22 nM and broad selectivity against a panel of other histone methyltransferases.  Treatment of MCL cell lines with EPZ015666 led to inhibition of SmD3 methylation and cell death, with IC50 values in the nanomolar range.  Oral dosing with EPZ015666 demonstrated dose-dependent antitumor activity in multiple MCL xenograft models.  EPZ015666 represents a validated chem. probe for further study of PRMT5 biol. and arginine methylation in cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJTtcvcqvOJLVg90H21EOLACvtfcHk0ljqt4qYUci0uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotFartbo%253D&md5=bf0686e1c2d9d96ac5deef22c0bf80b7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1810%26sid%3Dliteratum%253Aachs%26aulast%3DChan-Penebre%26aufirst%3DE.%26aulast%3DKuplast%26aufirst%3DK.%2BG.%26aulast%3DMajer%26aufirst%3DC.%2BR.%26aulast%3DBoriack-Sjodin%26aufirst%3DP.%2BA.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DJohnston%26aufirst%3DL.%2BD.%26aulast%3DRioux%26aufirst%3DN.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DWest%26aufirst%3DK.%2BA.%26aulast%3DLingaraj%26aufirst%3DT.%26aulast%3DStickland%26aufirst%3DK.%26aulast%3DRibich%26aufirst%3DS.%2BA.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DScott%26aufirst%3DM.%2BP.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DBarbash%26aufirst%3DO.%26aulast%3DPappalardi%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DT.%2BF.%26aulast%3DNurse%26aufirst%3DK.%26aulast%3DOza%26aufirst%3DK.%2BP.%26aulast%3DGallagher%26aufirst%3DK.%2BT.%26aulast%3DKruger%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DDuncan%26aufirst%3DK.%2BW.%26atitle%3DA%2520selective%2520inhibitor%2520of%2520PRMT5%2520with%2520in%2520vivo%2520and%2520in%2520vitro%2520potency%2520in%2520MCL%2520models%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D432%26epage%3D437%26doi%3D10.1038%2Fnchembio.1810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3648</span>– <span class="NLM_lpage">3661</span>, <span class="refDoi"> DOI: 10.1039/C7OB00070G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1039%2FC7OB00070G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=28397890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltl2mtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=3648-3661&author=Y.+Yeauthor=B.+Zhangauthor=R.+Maoauthor=C.+Zhangauthor=Y.+Wangauthor=J.+Xingauthor=Y.-C.+Liuauthor=X.+Luoauthor=H.+Dingauthor=Y.+Yangauthor=B.+Zhouauthor=H.+Jiangauthor=K.+Chenauthor=C.+Luoauthor=M.+Zheng&title=Discovery+and+optimization+of+selective+inhibitors+of+protein+arginine+methyltransferase+5+by+docking-based+virtual+screening&doi=10.1039%2FC7OB00070G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening</span></div><div class="casAuthors">Ye, Yan; Zhang, Bidong; Mao, Ruifeng; Zhang, Chenhua; Wang, Yulan; Xing, Jing; Liu, Yu-Chih; Luo, Xiaomin; Ding, Hong; Yang, Yaxi; Zhou, Bing; Jiang, Hualiang; Chen, Kaixian; Luo, Cheng; Zheng, Mingyue</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3648-3661</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is a type II PRMT enzyme crit. for diverse cellular processes and different types of cancers.  Many efforts have been made to discover novel scaffold PRMT5 inhibitors.  Herein, the authors report the discovery of DC_P33 as a hit compd. of PRMT5 inhibitor, identified by mol. docking based virtual screening and 3H-labeled radioactive methylation assays.  Structure-activity relationship (SAR) anal. was performed on the analogs of DC_P33 and then structural modifications were done to improve its activity.  Among the derivs., the compd. DC_C01 displayed an IC50 value of 2.8 μM, and good selectivity toward PRMT1, EZH2 and DNMT3A.  Moreover, DC_C01 exhibited anti-proliferation activities against Z-138, Maver-1, and Jeko-1 cancer cells with EC50 values of 12 μM, 12 μM, and 10.5 μM, resp.  Taken together, these results contribute to the development of specific inhibitors against PRMT5 and cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkWfdAd-COtbVg90H21EOLACvtfcHk0ljqt4qYUci0uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltl2mtr0%253D&md5=ead3b89fa64875e2dbf47c3a99714564</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1039%2FC7OB00070G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7OB00070G%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.-C.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520selective%2520inhibitors%2520of%2520protein%2520arginine%2520methyltransferase%25205%2520by%2520docking-based%2520virtual%2520screening%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2017%26volume%3D15%26spage%3D3648%26epage%3D3661%26doi%3D10.1039%2FC7OB00070G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, G.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Bryant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0181601</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0181601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1371%2Fjournal.pone.0181601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=28806746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2rtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=G.-M.+Kongauthor=M.+Yuauthor=Z.+Guauthor=Z.+Chenauthor=R.-M.+Xuauthor=D.+O%E2%80%99Bryantauthor=Z.+Wang&title=Selective+small-chemical+inhibitors+of+protein+arginine+methyltransferase+5+with+anti-lung+cancer+activity&doi=10.1371%2Fjournal.pone.0181601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity</span></div><div class="casAuthors">Kong, Gui-Mei; Yu, Min; Gu, Zhongping; Chen, Zhi; Xu, Rui-Ming; O'Bryant, Deon; Wang, Zhengxin</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0181601/1-e0181601/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) plays crit. roles in a wide variety of biol. processes, including tumorigenesis.  By screening a library of small chem. compds., we identified eight compds. that selectively inhibit the PRMT5 enzymic activity, with IC50 values ranging from 0.1 to 6 μM.  Mol. docking simulation and site directed mutagenesis indicated that identified compds. target the substrate-binding site in PRMT5.  Treatment of lung cancer cells with identified inhibitors led to inhibition of the sym. arginine methylation of SmD3 and histones and the cellular proliferation.  Oral administration of the inhibitor demonstrated antitumor activity in a lung tumor xenograft model.  Thus, identified PRMT5-specific small-mol. inhibitors would help elucidate the biol. roles of PRMT5 and serve as lead compds. for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHrmbn8I9YMLVg90H21EOLACvtfcHk0lgZKHghqLgwRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2rtbk%253D&md5=0306ed1351aac8a04d286df255c6e432</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0181601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0181601%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DG.-M.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DR.-M.%26aulast%3DO%25E2%2580%2599Bryant%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DSelective%2520small-chemical%2520inhibitors%2520of%2520protein%2520arginine%2520methyltransferase%25205%2520with%2520anti-lung%2520cancer%2520activity%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0181601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pande, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beke, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthelot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irving, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerpoel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nys, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viellevoye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuring, J. W.</span></span> <span> </span><span class="NLM_article-title">A chemical probe for the methyl transferase PRMT5 with a novel binding mode</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2231</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFartLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2227-2231&author=V.+Pandeauthor=W.+Sunauthor=L.+Bekeauthor=D.+Berthelotauthor=D.+Brehmerauthor=D.+Brownauthor=J.+Corberaauthor=S.+Irvingauthor=L.+Meerpoelauthor=T.+Nysauthor=M.+Paradeauthor=C.+Robinsonauthor=C.+Sommenauthor=M.+Viellevoyeauthor=T.+Wuauthor=J.+W.+Thuring&title=A+chemical+probe+for+the+methyl+transferase+PRMT5+with+a+novel+binding+mode&doi=10.1021%2Facsmedchemlett.0c00355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode</span></div><div class="casAuthors">Pande, Vineet; Sun, Weimei; Beke, Lijs; Berthelot, Didier; Brehmer, Dirk; Brown, David; Corbera, Jordi; Irving, Steve; Meerpoel, Lieven; Nys, Thomas; Parade, Marc; Robinson, Colin; Sommen, Cois; Viellevoye, Marcel; Wu, Tongfei; Thuring, Jan Willem</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2227-2231</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is an enzyme that can sym. dimethylate arginine residues in histones and nonhistone proteins by using S-adenosyl methionine (SAM) as the Me donating cofactor.  We have designed a library of SAM analogs and discovered potent, cell-active, and selective spiro diamines as inhibitors of the enzymic function of PRMT5.  Crystallog. studies confirmed a very interesting binding mode, involving protein flexibility, where both the cofactor pocket and part of substrate binding site are occupied by these inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8blAXBpCBsrVg90H21EOLACvtfcHk0lgZKHghqLgwRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFartLzF&md5=42905df2beb1d22965a0200fd0a23a4d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00355%26sid%3Dliteratum%253Aachs%26aulast%3DPande%26aufirst%3DV.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DBeke%26aufirst%3DL.%26aulast%3DBerthelot%26aufirst%3DD.%26aulast%3DBrehmer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DCorbera%26aufirst%3DJ.%26aulast%3DIrving%26aufirst%3DS.%26aulast%3DMeerpoel%26aufirst%3DL.%26aulast%3DNys%26aufirst%3DT.%26aulast%3DParade%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DSommen%26aufirst%3DC.%26aulast%3DViellevoye%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DThuring%26aufirst%3DJ.%2BW.%26atitle%3DA%2520chemical%2520probe%2520for%2520the%2520methyl%2520transferase%2520PRMT5%2520with%2520a%2520novel%2520binding%2520mode%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D2227%26epage%3D2231%26doi%3D10.1021%2Facsmedchemlett.0c00355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonysamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonday, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druzina, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheyi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungheim, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauder, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willard, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emtage, S.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human PRMT5:MEP50 complex</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">17960</span>– <span class="NLM_lpage">17965</span>, <span class="refDoi"> DOI: 10.1073/pnas.1209814109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1073%2Fpnas.1209814109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=23071334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2ktbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=17960-17965&author=S.+Antonysamyauthor=Z.+Bondayauthor=R.+M.+Campbellauthor=B.+Doyleauthor=Z.+Druzinaauthor=T.+Gheyiauthor=B.+Hanauthor=L.+N.+Jungheimauthor=Y.+Qianauthor=C.+Rauchauthor=M.+Russellauthor=J.+M.+Sauderauthor=S.+R.+Wassermanauthor=K.+Weichertauthor=F.+S.+Willardauthor=A.+Zhangauthor=S.+Emtage&title=Crystal+structure+of+the+human+PRMT5%3AMEP50+complex&doi=10.1073%2Fpnas.1209814109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human PRMT5:MEP50 complex</span></div><div class="casAuthors">Antonysamy, Stephen; Bonday, Zahid; Campbell, Robert M.; Doyle, Brandon; Druzina, Zhanna; Gheyi, Tarun; Han, Bomie; Jungheim, Louis N.; Qian, Yuewei; Rauch, Charles; Russell, Marijane; Sauder, J. Michael; Wasserman, Stephen R.; Wichert, Kenneth; Willard, Francis S.; Zhang, Aiping; Emtage, Spencer</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17960-17965, S17960/1-S17960/9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Protein arginine methyltransferases (PRMTs) play important roles in several cellular processes, including signaling, gene regulation, and transport of proteins and nucleic acids, to impact growth, differentiation, proliferation, and development.  PRMT5 sym. di-methylates the two-terminal ω-guanidino nitrogens of arginine residues on substrate proteins.  PRMT5 acts as part of a multimeric complex in concert with a variety of partner proteins that regulate its function and specificity.  A core component of these complexes is the WD40 protein MEP50/WDR77/p44, which mediates interactions with binding partners and substrates.  We have detd. the crystal structure of human PRMT5 in complex with MEP50 (methylosome protein 50), bound to an S-adenosylmethionine analog and a peptide substrate derived from histone H4.  The structure of the surprising hetero-octameric complex reveals the close interaction between the seven-bladed β-propeller MEP50 and the N-terminal domain of PRMT5, and delineates the structural elements of substrate recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkcWBh5CVI7LVg90H21EOLACvtfcHk0lgZKHghqLgwRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2ktbvL&md5=757af18cfd0787a02c88c840273109aa</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1209814109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1209814109%26sid%3Dliteratum%253Aachs%26aulast%3DAntonysamy%26aufirst%3DS.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26aulast%3DDoyle%26aufirst%3DB.%26aulast%3DDruzina%26aufirst%3DZ.%26aulast%3DGheyi%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DJungheim%26aufirst%3DL.%2BN.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DRauch%26aufirst%3DC.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DSauder%26aufirst%3DJ.%2BM.%26aulast%3DWasserman%26aufirst%3DS.%2BR.%26aulast%3DWeichert%26aufirst%3DK.%26aulast%3DWillard%26aufirst%3DF.%2BS.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DEmtage%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520PRMT5%253AMEP50%2520complex%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D17960%26epage%3D17965%26doi%3D10.1073%2Fpnas.1209814109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, C.</span></span> <span> </span><span class="NLM_article-title">Cryo-electron microscopy structure of a human PRMT5:MEP50 complex</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0193205</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0193205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1371%2Fjournal.pone.0193205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=29518110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWms7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=D.+E.+Timmauthor=V.+Bowmanauthor=R.+Madsenauthor=C.+Rauch&title=Cryo-electron+microscopy+structure+of+a+human+PRMT5%3AMEP50+complex&doi=10.1371%2Fjournal.pone.0193205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-electron microscopy structure of a human PRMT5:MEP50 complex</span></div><div class="casAuthors">Timm, David E.; Bowman, Valorie; Madsen, Russell; Rauch, Charles</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0193205/1-e0193205/13</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Protein arginine Me transferase 5 (PRMT5) is a signaling protein and histone modifying enzyme that is important in many cellular processes, including regulation of eukaryotic gene transcription.  Reported here is a 3.7 Å structure of PRMT5, solved in complex with regulatory binding subunit MEP50 (methylosome assocd. protein 50, WDR77, p44), by single particle (SP) cryo-Electron Microscopy (cryo-EM) using micrographs of particles that are visibly crowded and aggregated.  Despite suboptimal micrograph appearance, this cryo-EM structure is in good agreement with previously reported crystal structures of the complex, which revealed a 450 kDa hetero-octameric assembly having internal D2 symmetry.  The catalytic PRMT5 subunits form a core tetramer and the MEP50 subunits are arranged peripherally in complex with the PRMT5 N-terminal domain.  The cryo-EM reconstruction shows good side chain definition and shows a well-resolved peak for a bound dehydrosinefungin inhibitor mol.  These results demonstrate the applicability of cryo-EM in detg. structures of human protein complexes of biomedical significance and suggests cryo-EM could be further utilized to understand PRMT5 interactions with other biol. important binding proteins and ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVrd4Ga-2QJrVg90H21EOLACvtfcHk0ljCz0RN3kruRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWms7%252FO&md5=e2410a0d8b80ec2f9c37bb96b390b46f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0193205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0193205%26sid%3Dliteratum%253Aachs%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DBowman%26aufirst%3DV.%26aulast%3DMadsen%26aufirst%3DR.%26aulast%3DRauch%26aufirst%3DC.%26atitle%3DCryo-electron%2520microscopy%2520structure%2520of%2520a%2520human%2520PRMT5%253AMEP50%2520complex%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0193205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marjon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clasquin, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kernytsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konteatis, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murtie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biller, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, K. M.</span></span> <span> </span><span class="NLM_article-title">MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">574</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.03.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.celrep.2016.03.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=27068473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsleltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=574-587&author=K.+Marjonauthor=M.+J.+Cameronauthor=P.+Quangauthor=M.+F.+Clasquinauthor=E.+Mandleyauthor=K.+Kuniiauthor=M.+McVayauthor=S.+Choeauthor=A.+Kernytskyauthor=S.+Grossauthor=Z.+Konteatisauthor=J.+Murtieauthor=M.+L.+Blakeauthor=J.+Travinsauthor=M.+Dorschauthor=S.+A.+Billerauthor=K.+M.+Marks&title=MTAP+deletions+in+cancer+create+vulnerability+to+targeting+of+the+MAT2A%2FPRMT5%2FRIOK1+axis&doi=10.1016%2Fj.celrep.2016.03.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis</span></div><div class="casAuthors">Marjon, Katya; Cameron, Michael J.; Quang, Phong; Clasquin, Michelle F.; Mandley, Everton; Kunii, Kaiko; McVay, Michael; Choe, Sung; Kernytsky, Andrew; Gross, Stefan; Konteatis, Zenon; Murtie, Joshua; Blake, Michelle L.; Travins, Jeremy; Dorsch, Marion; Biller, Scott A.; Marks, Kevin M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">574-587</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Homozygous deletions of p16/CDKN2A are prevalent in cancer, and these mutations commonly involve co-deletion of adjacent genes, including methylthioadenosine phosphorylase (MTAP).  Here, we used shRNA screening and identified the metabolic enzyme, methionine adenosyltransferase II alpha (MAT2A), and the arginine methyltransferase, PRMT5, as vulnerable enzymes in cells with MTAP deletion.  Metabolomic and biochem. studies revealed a mechanistic basis for this synthetic lethality.  The MTAP substrate methylthioadenosine (MTA) accumulates upon MTAP loss.  Biochem. profiling of a methyltransferase enzyme panel revealed that MTA is a potent and selective inhibitor of PRMT5.  MTAP-deleted cells have reduced PRMT5 methylation activity and increased sensitivity to PRMT5 depletion.  MAT2A produces the PRMT5 substrate S-adenosylmethionine (SAM), and MAT2A depletion reduces growth and PRMT5 methylation activity selectively in MTAP-deleted cells.  Furthermore, this vulnerability extends to PRMT5 co-complex proteins such as RIOK1.  Thus, the unique biochem. features of PRMT5 create an axis of targets vulnerable in CDKN2A/MTAP-deleted cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokW739dwptcbVg90H21EOLACvtfcHk0ljCz0RN3kruRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsleltrk%253D&md5=73a6839e63b85a71f3661dc9e0c7b4ea</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.03.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.03.043%26sid%3Dliteratum%253Aachs%26aulast%3DMarjon%26aufirst%3DK.%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DQuang%26aufirst%3DP.%26aulast%3DClasquin%26aufirst%3DM.%2BF.%26aulast%3DMandley%26aufirst%3DE.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DMcVay%26aufirst%3DM.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DKernytsky%26aufirst%3DA.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DKonteatis%26aufirst%3DZ.%26aulast%3DMurtie%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DM.%2BL.%26aulast%3DTravins%26aufirst%3DJ.%26aulast%3DDorsch%26aufirst%3DM.%26aulast%3DBiller%26aufirst%3DS.%2BA.%26aulast%3DMarks%26aufirst%3DK.%2BM.%26atitle%3DMTAP%2520deletions%2520in%2520cancer%2520create%2520vulnerability%2520to%2520targeting%2520of%2520the%2520MAT2A%252FPRMT5%252FRIOK1%2520axis%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D15%26spage%3D574%26epage%3D587%26doi%3D10.1016%2Fj.celrep.2016.03.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mavrakis, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E. R.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlabach, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deWeck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deBeaumont, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan-Neale, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipp, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprague, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciccone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitari, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallarico, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickanin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmeier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1208</span>– <span class="NLM_lpage">1213</span>, <span class="refDoi"> DOI: 10.1126/science.aad5944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1126%2Fscience.aad5944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=26912361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs12gtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2016&pages=1208-1213&author=K.+J.+Mavrakisauthor=E.+R.+McDonaldauthor=M.+R.+Schlabachauthor=E.+Billyauthor=G.+R.+Hoffmanauthor=A.+deWeckauthor=D.+A.+Ruddyauthor=K.+Venkatesanauthor=J.+Yuauthor=G.+McAllisterauthor=M.+Stumpauthor=R.+deBeaumontauthor=S.+Hoauthor=Y.+Yueauthor=Y.+Liuauthor=Y.+Yan-Nealeauthor=G.+Yangauthor=F.+Linauthor=H.+Yinauthor=H.+Gaoauthor=D.+R.+Kippauthor=S.+Zhaoauthor=J.+T.+McNamaraauthor=E.+R.+Spragueauthor=B.+Zhengauthor=Y.+Linauthor=Y.+S.+Choauthor=J.+Guauthor=K.+Crawfordauthor=D.+Cicconeauthor=A.+C.+Vitariauthor=A.+Laiauthor=V.+Capkaauthor=K.+Hurovauthor=J.+A.+Porterauthor=J.+Tallaricoauthor=C.+Mickaninauthor=E.+Leesauthor=R.+Pagliariniauthor=N.+Keenauthor=T.+Schmelzleauthor=F.+Hofmannauthor=F.+Stegmeierauthor=W.+R.+Sellers&title=Disordered+methionine+metabolism+in+MTAP%2FCDKN2A-deleted+cancers+leads+to+dependence+on+PRMT5&doi=10.1126%2Fscience.aad5944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5</span></div><div class="casAuthors">Mavrakis, Konstantinos J.; McDonald, E. Robert, III; Schlabach, Michael R.; Billy, Eric; Hoffman, Gregory R.; de Weck, Antoine; Ruddy, David A.; Venkatesan, Kavitha; Yu, Jianjun; McAllister, Gregg; Stump, Mark; de Beaumont, Rosalie; Ho, Samuel; Yue, Yingzi; Liu, Yue; Yan-Neale, Yan; Yang, Guizhi; Lin, Fallon; Yin, Hong; Gao, Hui; Kipp, D. Randal; Zhao, Songping; McNamara, Joshua T.; Sprague, Elizabeth R.; Zheng, Bing; Lin, Ying; Cho, Young Shin; Gu, Justin; Crawford, Kenneth; Ciccone, David; Vitari, Alberto C.; Lai, Albert; Capka, Vladimir; Hurov, Kristen; Porter, Jeffery A.; Tallarico, John; Mickanin, Craig; Lees, Emma; Pagliarini, Raymond; Keen, Nicholas; Schmelzle, Tobias; Hofmann, Francesco; Stegmeier, Frank; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">6278</span>),
    <span class="NLM_cas:pages">1208-1213</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">5-Methylthioadenosine phosphorylase (MTAP) is a key enzyme in the methionine salvage pathway.  The MTAP gene is frequently deleted in human cancers because of its chromosomal proximity to the tumor suppressor gene CDKN2A.  By interrogating data from a large-scale short hairpin RNA-mediated screen across 390 cancer cell line models, we found that the viability of MTAP-deficient cancer cells is impaired by depletion of the protein arginine methyltransferase PRMT5.  MTAP-deleted cells accumulate the metabolite methylthioadenosine (MTA), which we found to inhibit PRMT5 methyltransferase activity.  Deletion of MTAP in MTAP-proficient cells rendered them sensitive to PRMT5 depletion.  Conversely, reconstitution of MTAP in an MTAP-deficient cell line rescued PRMT5 dependence.  Thus, MTA accumulation in MTAP-deleted cancers creates a hypomorphic PRMT5 state that is selectively sensitized toward further PRMT5 inhibition.  Inhibitors of PRMT5 that leverage this dysregulated metabolic state merit further investigation as a potential therapy for MTAP/CDKN2A-deleted tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNsuzYFo1qn7Vg90H21EOLACvtfcHk0lgKqFWpBtqpRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs12gtr0%253D&md5=d77531ea765db9762d6815840d39ee4a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad5944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad5944%26sid%3Dliteratum%253Aachs%26aulast%3DMavrakis%26aufirst%3DK.%2BJ.%26aulast%3DMcDonald%26aufirst%3DE.%2BR.%26aulast%3DSchlabach%26aufirst%3DM.%2BR.%26aulast%3DBilly%26aufirst%3DE.%26aulast%3DHoffman%26aufirst%3DG.%2BR.%26aulast%3DdeWeck%26aufirst%3DA.%26aulast%3DRuddy%26aufirst%3DD.%2BA.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DStump%26aufirst%3DM.%26aulast%3DdeBeaumont%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DYue%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYan-Neale%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DKipp%26aufirst%3DD.%2BR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DJ.%2BT.%26aulast%3DSprague%26aufirst%3DE.%2BR.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DCiccone%26aufirst%3DD.%26aulast%3DVitari%26aufirst%3DA.%2BC.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DCapka%26aufirst%3DV.%26aulast%3DHurov%26aufirst%3DK.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DTallarico%26aufirst%3DJ.%26aulast%3DMickanin%26aufirst%3DC.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DPagliarini%26aufirst%3DR.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DSchmelzle%26aufirst%3DT.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DStegmeier%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DDisordered%2520methionine%2520metabolism%2520in%2520MTAP%252FCDKN2A-deleted%2520cancers%2520leads%2520to%2520dependence%2520on%2520PRMT5%26jtitle%3DScience%26date%3D2016%26volume%3D351%26spage%3D1208%26epage%3D1213%26doi%3D10.1126%2Fscience.aad5944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kryukov, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruth, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsherniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielski, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Root, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span> <span> </span><span class="NLM_article-title"><i>MTAP</i> deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1214</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1126/science.aad5214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1126%2Fscience.aad5214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=26912360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs12gtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2016&pages=1214-1218&author=G.+V.+Kryukovauthor=F.+H.+Wilsonauthor=J.+R.+Ruthauthor=J.+Paulkauthor=A.+Tsherniakauthor=S.+E.+Marlowauthor=F.+Vazquezauthor=B.+A.+Weirauthor=M.+E.+Fitzgeraldauthor=M.+Tanakaauthor=C.+M.+Bielskiauthor=J.+M.+Scottauthor=C.+Dennisauthor=G.+S.+Cowleyauthor=J.+S.+Boehmauthor=D.+E.+Rootauthor=T.+R.+Golubauthor=C.+B.+Clishauthor=J.+E.+Bradnerauthor=W.+C.+Hahnauthor=L.+A.+Garraway&title=MTAP+deletion+confers+enhanced+dependency+on+the+PRMT5+arginine+methyltransferase+in+cancer+cells&doi=10.1126%2Fscience.aad5214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells</span></div><div class="casAuthors">Kryukov, Gregory V.; Wilson, Frederick H.; Ruth, Jason R.; Paulk, Joshiawa; Tsherniak, Aviad; Marlow, Sara E.; Vazquez, Francisca; Weir, Barbara A.; Fitzgerald, Mark E.; Tanaka, Minoru; Bielski, Craig M.; Scott, Justin M.; Dennis, Courtney; Cowley, Glenn S.; Boehm, Jesse S.; Root, David E.; Golub, Todd R.; Clish, Clary B.; Bradner, James E.; Hahn, William C.; Garraway, Levi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">6278</span>),
    <span class="NLM_cas:pages">1214-1218</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The discovery of cancer dependencies has the potential to inform therapeutic strategies and to identify putative drug targets.  Integrating data from comprehensive genomic profiling of cancer cell lines and from functional characterization of cancer cell dependencies, we discovered that loss of the enzyme methylthioadenosine phosphorylase (MTAP) confers a selective dependence on protein arginine methyltransferase 5 (PRMT5) and its binding partner WDR77.  MTAP is frequently lost due to its proximity to the commonly deleted tumor suppressor gene, CDKN2A.  We obsd. increased intracellular concns. of methylthioadenosine (MTA, the metabolite cleaved by MTAP) in cells harboring MTAP deletions.  Furthermore, MTA specifically inhibited PRMT5 enzymic activity.  Administration of either MTA or a small-mol. PRMT5 inhibitor showed a modest preferential impairment of cell viability for MTAP-null cancer cell lines compared with isogenic MTAP-expressing counterparts.  Together, our findings reveal PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common "passenger" genomic alteration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr94dQPnMgrqbVg90H21EOLACvtfcHk0lgKqFWpBtqpRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs12gtro%253D&md5=2b017a8c54972828c9024a9d85ff2e2d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad5214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad5214%26sid%3Dliteratum%253Aachs%26aulast%3DKryukov%26aufirst%3DG.%2BV.%26aulast%3DWilson%26aufirst%3DF.%2BH.%26aulast%3DRuth%26aufirst%3DJ.%2BR.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DTsherniak%26aufirst%3DA.%26aulast%3DMarlow%26aufirst%3DS.%2BE.%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DFitzgerald%26aufirst%3DM.%2BE.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DBielski%26aufirst%3DC.%2BM.%26aulast%3DScott%26aufirst%3DJ.%2BM.%26aulast%3DDennis%26aufirst%3DC.%26aulast%3DCowley%26aufirst%3DG.%2BS.%26aulast%3DBoehm%26aufirst%3DJ.%2BS.%26aulast%3DRoot%26aufirst%3DD.%2BE.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DMTAP%2520deletion%2520confers%2520enhanced%2520dependency%2520on%2520the%2520PRMT5%2520arginine%2520methyltransferase%2520in%2520cancer%2520cells%26jtitle%3DScience%26date%3D2016%26volume%3D351%26spage%3D1214%26epage%3D1218%26doi%3D10.1126%2Fscience.aad5214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbarino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namagerdi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolino, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proietti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Santi, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guazzo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirtoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Indovina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">PRMT5 silencing selectively affects <i>MTAP</i>-deleted mesothelioma: in vitro evidence of a novel promising approach</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5565</span>– <span class="NLM_lpage">5577</span>, <span class="refDoi"> DOI: 10.1111/jcmm.15213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1111%2Fjcmm.15213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=32301278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovFGisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=5565-5577&author=M.+Barbarinoauthor=D.+Cesariauthor=M.+Bottaroauthor=L.+Luzziauthor=A.+Namagerdiauthor=F.+M.+Bertolinoauthor=C.+Bellanauthor=F.+Proiettiauthor=P.+Sommaauthor=M.+Micheliauthor=M.+M.+de+Santiauthor=R.+Guazzoauthor=L.+Muttiauthor=L.+Pirtoliauthor=P.+Paladiniauthor=P.+Indovinaauthor=A.+Giordano&title=PRMT5+silencing+selectively+affects+MTAP-deleted+mesothelioma%3A+in+vitro+evidence+of+a+novel+promising+approach&doi=10.1111%2Fjcmm.15213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach</span></div><div class="casAuthors">Barbarino, Marcella; Cesari, Daniele; Bottaro, Maria; Luzzi, Luca; Namagerdi, Asadoor; Bertolino, Franca Maria; Bellan, Cristiana; Proietti, Fabrizio; Somma, Pasquale; Micheli, Mariacarolina; de Santi, Maria Margherita; Guazzo, Raffaella; Mutti, Luciano; Pirtoli, Luigi; Paladini, Piero; Indovina, Paola; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5565-5577</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Malignant mesothelioma (MM) is an aggressive asbestos-related cancer of the serous membranes.  Despite intensive treatment regimens, MM is still a fatal disease, mainly due to the intrinsic resistance to current therapies and the lack of predictive markers and new valuable mol. targets.  Protein arginine methyltransferase 5 (PRMT5) inhibition has recently emerged as a potential therapy against methylthioadenosine phosphorylase (MTAP)-deficient cancers, in which the accumulation of the substrate 5'-methylthioadenosine (MTA) inhibits PRMT5 activity, thus sensitizing the cells to further PRMT5 inhibition.  Considering that the MTAP gene is frequently codeleted with the adjacent cyclin-dependent kinase inhibitor 2A (CDKN2A) locus in MM, we assessed whether PRMT5 could represent a therapeutic target also for this cancer type.  We evaluated PRMT5 expression, the MTAP status and MTA content in normal mesothelial and MM cell lines.  We found that both administration of exogenous MTA and stable PRMT5 knock-down, by short hairpin RNAs (shRNAs), selectively reduced the growth of MTAP-deleted MM cells.  We also obsd. that PRMT5 knock-down in MTAP-deficient MM cells reduced the expression of E2F1 target genes involved in cell cycle progression and of factors implicated in epithelial-to-mesenchymal transition.  Therefore, PRMT5 targeting could represent a promising new therapeutic strategy against MTAP-deleted MMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxtUD-iMY29bVg90H21EOLACvtfcHk0lgKqFWpBtqpRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovFGisrg%253D&md5=401f56cd01d53640943ed2abb80dc17f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.15213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.15213%26sid%3Dliteratum%253Aachs%26aulast%3DBarbarino%26aufirst%3DM.%26aulast%3DCesari%26aufirst%3DD.%26aulast%3DBottaro%26aufirst%3DM.%26aulast%3DLuzzi%26aufirst%3DL.%26aulast%3DNamagerdi%26aufirst%3DA.%26aulast%3DBertolino%26aufirst%3DF.%2BM.%26aulast%3DBellan%26aufirst%3DC.%26aulast%3DProietti%26aufirst%3DF.%26aulast%3DSomma%26aufirst%3DP.%26aulast%3DMicheli%26aufirst%3DM.%26aulast%3Dde%2BSanti%26aufirst%3DM.%2BM.%26aulast%3DGuazzo%26aufirst%3DR.%26aulast%3DMutti%26aufirst%3DL.%26aulast%3DPirtoli%26aufirst%3DL.%26aulast%3DPaladini%26aufirst%3DP.%26aulast%3DIndovina%26aufirst%3DP.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DPRMT5%2520silencing%2520selectively%2520affects%2520MTAP-deleted%2520mesothelioma%253A%2520in%2520vitro%2520evidence%2520of%2520a%2520novel%2520promising%2520approach%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2020%26volume%3D24%26spage%3D5565%26epage%3D5577%26doi%3D10.1111%2Fjcmm.15213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palte, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansueto, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reutershan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliphaivanh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machacek, M. R.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of protein arginine methyltransferase 5 (PRMT5)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1688</span>– <span class="NLM_lpage">1693</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00525</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00525" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFehtb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1688-1693&author=R.+L.+Palteauthor=S.+E.+Schneiderauthor=M.+D.+Altmanauthor=R.+P.+Hayesauthor=S.+Kawamuraauthor=B.+M.+Laceyauthor=M.+S.+Mansuetoauthor=M.+Reutershanauthor=P.+Siliphaivanhauthor=C.+Sondeyauthor=H.+Xuauthor=Z.+Xuauthor=Y.+Yeauthor=M.+R.+Machacek&title=Allosteric+modulation+of+protein+arginine+methyltransferase+5+%28PRMT5%29&doi=10.1021%2Facsmedchemlett.9b00525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)</span></div><div class="casAuthors">Palte, Rachel L.; Schneider, Sebastian E.; Altman, Michael D.; Hayes, Robert P.; Kawamura, Shuhei; Lacey, Brian M.; Mansueto, My Sam; Reutershan, Michael; Siliphaivanh, Phieng; Sondey, Christopher; Xu, Haiyan; Xu, Zangwei; Ye, Yingchun; Machacek, Michelle R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1688-1693</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) belongs to a family of enzymes that regulate the posttranslational modification of histones and other proteins via methylation of arginine.  Methylation of histones is linked to an increase in transcription and regulates a manifold of functions such as signal transduction and transcriptional regulation.  PRMT5 has been shown to be upregulated in the tumor environment of several cancer types, and the inhibition of PRMT5 activity was identified as a potential way to reduce tumor growth.  Previously, four different modes of PRMT5 inhibition were known-competing (covalently or non-covalently) with the essential cofactor S-adenosyl methionine (SAM), blocking the substrate binding pocket, or blocking both simultaneously.  Herein we describe an unprecedented conformation of PRMT5 in which the formation of an allosteric binding pocket abrogates the enzyme's canonical binding site and present the discovery of potent small mol. allosteric PRMT5 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFkbnJkLKiL7Vg90H21EOLACvtfcHk0lhEZlNg-Ot2bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFehtb7P&md5=75a8f75e60a3e20444af90b79c5af810</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00525%26sid%3Dliteratum%253Aachs%26aulast%3DPalte%26aufirst%3DR.%2BL.%26aulast%3DSchneider%26aufirst%3DS.%2BE.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DHayes%26aufirst%3DR.%2BP.%26aulast%3DKawamura%26aufirst%3DS.%26aulast%3DLacey%26aufirst%3DB.%2BM.%26aulast%3DMansueto%26aufirst%3DM.%2BS.%26aulast%3DReutershan%26aufirst%3DM.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DMachacek%26aufirst%3DM.%2BR.%26atitle%3DAllosteric%2520modulation%2520of%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1688%26epage%3D1693%26doi%3D10.1021%2Facsmedchemlett.9b00525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective covalent protein arginine methyltransferase 5 (PRMT5) inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00074</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00074" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A280%3ADC%252BB3MzotVeltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1033-1038&author=H.+Linauthor=M.+Wangauthor=Y.+W.+Zhangauthor=S.+Tongauthor=R.+A.+Lealauthor=R.+Shettyauthor=K.+Vaddiauthor=J.+I.+Luengo&title=Discovery+of+potent+and+selective+covalent+protein+arginine+methyltransferase+5+%28PRMT5%29+inhibitors&doi=10.1021%2Facsmedchemlett.9b00074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors</span></div><div class="casAuthors">Lin Hong; Wang Min; Zhang Yang W; Leal Raul A; Shetty Rupa; Vaddi Kris; Luengo Juan I; Tong Shuilong</div><div class="citationInfo"><span class="NLM_cas:title">ACS medicinal chemistry letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1033-1038</span>
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is known to symmetrically dimethylate numerous cytosolic and nuclear proteins that are involved in a variety of cellular processes.  Recent findings have revealed its potential as a cancer therapeutic target.  PRMT5 possesses a cysteine (C449) in the active site, unique to PRMT5.  Therefore, covalent PRMT5 inhibition is an attractive chemical approach.  Herein, we report an exciting discovery of a series of novel hemiaminals that under physiological conditions can be converted to aldehydes and react with C449 to form covalent adducts, which presumably undergo an unprecedented elimination to form the thiol-vinyl ethers, as indicated by electron density in the co-crystal structure of the PRMT5/MEP50 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdNDVSKB6iezW1zwg2yUK5fW6udTcc2eblh-jQ9ojutrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzotVeltQ%253D%253D&md5=4b5b08dc3e3615144ece564f70bf3bd0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00074%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%2BW.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DLeal%26aufirst%3DR.%2BA.%26aulast%3DShetty%26aufirst%3DR.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520covalent%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1033%26epage%3D1038%26doi%3D10.1021%2Facsmedchemlett.9b00074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guccione, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedford, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9977</span>– <span class="NLM_lpage">9989</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01111</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01111" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFOisLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9977-9989&author=Y.+Shenauthor=G.+Gaoauthor=X.+Yuauthor=H.+Kimauthor=L.+Wangauthor=L.+Xieauthor=M.+Schwarzauthor=X.+Chenauthor=E.+Guccioneauthor=J.+Liuauthor=M.+T.+Bedfordauthor=J.+Jin&title=Discovery+of+first-in-class+protein+arginine+methyltransferase+5+%28PRMT5%29+degraders&doi=10.1021%2Facs.jmedchem.0c01111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders</span></div><div class="casAuthors">Shen, Yudao; Gao, Guozhen; Yu, Xufen; Kim, Huensuk; Wang, Li; Xie, Ling; Schwarz, Megan; Chen, Xian; Guccione, Ernesto; Liu, Jing; Bedford, Mark T.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9977-9989</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aberrant expression of protein arginine methyltransferase 5 (PRMT5) has been assocd. with multiple cancers.  Using the proteolysis targeting chimera technol., we discovered a first-in-class PRMT5 degrader 15 (MS4322).  Here, we report the design, synthesis, and characterization of compd. 15 and two structurally similar controls 17 (MS4370) and 21 (MS4369), with impaired binding to the von Hippel-Lindau E3 ligase and PRMT5, resp.  Compd. 15, but not 17 and 21, effectively reduced the PRMT5 protein level in MCF-7 cells.  Our mechanism studies indicate that compd. 15 degraded PRMT5 in an E3 ligase- and proteasome-dependent manner.  Compd. 15 also effectively reduced the PRMT5 protein level and inhibited growth in multiple cancer cell lines.  Moreover, compd. 15 was highly selective for PRMT5 in a global proteomic study and exhibited good plasma exposure in mice.  Collectively, compd. 15 and its two controls 17 and 21 are valuable chem. tools for exploring the PRMT5 functions in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZoL-YbkPwxrVg90H21EOLACvtfcHk0lhEZlNg-Ot2bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFOisLrE&md5=5400a4b400d1a420eff5b24f735de462</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01111%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DSchwarz%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGuccione%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBedford%26aufirst%3DM.%2BT.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520first-in-class%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520degraders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9977%26epage%3D9989%26doi%3D10.1021%2Facs.jmedchem.0c01111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span>; <span class="NLM_string-name">Brehmer, D.</span>; <span class="NLM_string-name">Beke, L.</span>; <span class="NLM_string-name">Boeckx, A.</span>; <span class="NLM_string-name">Diels, G. S. M.</span>; <span class="NLM_string-name">Gilissen, R. A. H. J.</span>; <span class="NLM_string-name">Lawson, E. C.</span>; <span class="NLM_string-name">Pande, V.</span>; <span class="NLM_string-name">Paradé, M. C. B. C.</span>; <span class="NLM_string-name">Schepens, W. B. G.</span>; <span class="NLM_string-name">Thuring, J. W. J. F.</span>; <span class="NLM_string-name">Viellevoye, M.</span>; <span class="NLM_string-name">Sun, W.</span>; <span class="NLM_string-name">Meerpoel, L.</span></span> <span> </span><span class="NLM_article-title">6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors</span>. U.S. Patent <span class="NLM_patent">10,653,711 B2</span>, May 19, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=T.+Wu&author=D.+Brehmer&author=L.+Beke&author=A.+Boeckx&author=G.+S.+M.+Diels&author=R.+A.+H.+J.+Gilissen&author=E.+C.+Lawson&author=V.+Pande&author=M.+C.+B.+C.+Parad%C3%A9&author=W.+B.+G.+Schepens&author=J.+W.+J.+F.+Thuring&author=M.+Viellevoye&author=W.+Sun&author=L.+Meerpoel&title=6-6+bicyclic+aromatic+ring+substituted+nucleoside+analogues+for+use+as+PRMT5+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DT.%26atitle%3D6-6%2520bicyclic%2520aromatic%2520ring%2520substituted%2520nucleoside%2520analogues%2520for%2520use%2520as%2520PRMT5%2520inhibitors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. B.</span></span> <span> </span><span class="NLM_article-title">Conformational control in structure-based drug design</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2825</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.bmcl.2017.04.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=28479196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFamtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2825-2837&author=Y.+Zhengauthor=C.+M.+Ticeauthor=S.+B.+Singh&title=Conformational+control+in+structure-based+drug+design&doi=10.1016%2Fj.bmcl.2017.04.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational control in structure-based drug design</span></div><div class="casAuthors">Zheng, Yajun; Tice, Colin M.; Singh, Suresh B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2825-2837</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In structure-based drug design, the basic goal is to design mols. that fit complementarily to a given binding pocket.  Since such computationally modeled mols. may not adopt the intended bound conformation outside the binding pocket, one challenge is to ensure that the designed ligands adopt similar low energy conformations both inside and outside of the binding pocket.  Computational chem. methods and conformational preferences of small mols. from PDB and Cambridge Structural Database (CSD) can be used to predict the bound structures of the designed mols.  Herein, we review applications of conformational control in structure-based drug design using selected examples from the recent medicinal chem. literature.  The main purpose is to highlight some intriguing conformational features that can be applied to other drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbfYQ3iP4BT7Vg90H21EOLACvtfcHk0li0Ipiqyw1Prg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFamtr8%253D&md5=aef5a7aa51f9b6a8454345a4e38d95db</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.079%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DTice%26aufirst%3DC.%2BM.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DConformational%2520control%2520in%2520structure-based%2520drug%2520design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2825%26epage%3D2837%26doi%3D10.1016%2Fj.bmcl.2017.04.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rai, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sresht, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiowetz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakken, G. A.</span></span> <span> </span><span class="NLM_article-title">Comprehensive assessment of torsional strain in crystal structures of small molecules and protein-ligand complexes using ab initio calculations</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4195</span>– <span class="NLM_lpage">4208</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.9b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.9b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVylsLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=4195-4208&author=B.+K.+Raiauthor=V.+Sreshtauthor=Q.+Yangauthor=R.+Unwallaauthor=M.+Tuauthor=A.+M.+Mathiowetzauthor=G.+A.+Bakken&title=Comprehensive+assessment+of+torsional+strain+in+crystal+structures+of+small+molecules+and+protein-ligand+complexes+using+ab+initio+calculations&doi=10.1021%2Facs.jcim.9b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive Assessment of Torsional Strain in Crystal Structures of Small Molecules and Protein-Ligand Complexes using ab Initio Calculations</span></div><div class="casAuthors">Rai, Brajesh K.; Sresht, Vishnu; Yang, Qingyi; Unwalla, Ray; Tu, Meihua; Mathiowetz, Alan M.; Bakken, Gregory A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4195-4208</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The energetics of rotation around single bonds (torsions) is a key determinant of the 3D shape that drug-like mols. adopt in soln., the solid state, and in different biol. environments, which in turn defines their unique phys. and pharmacol. properties.  Therefore, accurate characterization of torsion angle preference and energetics is essential for the success of computational drug discovery and design.  Here, the authors analyze torsional strain in crystal structures of drug-like mols. in CSD and bioactive ligand conformations in PDB, expressing the total strain energy as a sum of strain energy from constituent rotatable bonds.  The authors utilized Cloud computing to generate torsion scan profiles of a very large collection of chem. diverse neutral fragments at DFT(B3LYP)/6-31G*//6-31G** or DFT(B3LYP)/6-31+G*//6-31+G** (for sulfur-contg. mol.).  With the data generated from these ab initio calcns., the authors performed rigorous anal. of strain due to deviation of obsd. torsion angles relative to their ideal gas-phase geometries.  Contrary to the previous studies based on mol. mechanics, the authors find that in the cryst.-state mols. generally adopt low-strain conformations, with median per-torsion strain energy in CSD and PDB under 1/10th and 1/3rd of a kcal/mol, resp.  However, for a small fraction (<5%) of motifs, external effects such as steric hindrance and hydrogen bonds result in strain penalty exceeding 2.5 kcal/mol.  The authors find that due to poor quality of PDB structures in general, bioactive structures tend to have higher torsional strain compared to small mol. crystal conformations.  However, in the absence of structural fitting artifacts in PDB structures, protein-induced strain in bioactive conformations is quant. similar to those due to the packing forces in small mol. crystal structures.  This anal. allows us to establish strain energy thresholds to help to identify biol. relevant conformers in a given ensemble.  The work presented here is the most comprehensive study to date that demonstrates the utility and feasibility of gas-phase QM calcns. to study conformational preference and energetics of drug-size mols.  Potential applications of this study in computational lead discovery and structure-based design are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-hW26jnNxD7Vg90H21EOLACvtfcHk0li0Ipiqyw1Prg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVylsLzP&md5=d8da7e8bc163683f544f7c1c7968485f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.9b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.9b00373%26sid%3Dliteratum%253Aachs%26aulast%3DRai%26aufirst%3DB.%2BK.%26aulast%3DSresht%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DUnwalla%26aufirst%3DR.%26aulast%3DTu%26aufirst%3DM.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DBakken%26aufirst%3DG.%2BA.%26atitle%3DComprehensive%2520assessment%2520of%2520torsional%2520strain%2520in%2520crystal%2520structures%2520of%2520small%2520molecules%2520and%2520protein-ligand%2520complexes%2520using%2520ab%2520initio%2520calculations%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2019%26volume%3D59%26spage%3D4195%26epage%3D4208%26doi%3D10.1021%2Facs.jcim.9b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of bicyclic nucleosides by ring-closing metathesis</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1039/b101364p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1039%2Fb101364p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFCgurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=985-993&author=J.+Ravnauthor=P.+Nielsen&title=Synthesis+of+bicyclic+nucleosides+by+ring-closing+metathesis&doi=10.1039%2Fb101364p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of bicyclic nucleosides by ring-closing metathesis</span></div><div class="casAuthors">Ravn, Jacob; Nielsen, Poul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">985-993</span>CODEN:
                <span class="NLM_cas:coden">JCSPCE</span>;
        ISSN:<span class="NLM_cas:issn">1472-7781</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The ring-closing metathesis method is applied in the construction of conformationally restricted bicyclic nucleosides.  From diacetone-D-glucose, the unsatd. bicyclic carbohydrate deriv. is efficiently obtained through two vinyl group Grignard addns., subsequent metathesis of the double bonds, and resoln. of the stereochem. by an oxidn./redn. reaction sequence.  Two sep. routes differing in the 3-O-protecting group are compared.  Thus, an addnl. protecting step improves the yields significantly.  Std. conversions of the unsatd. bicyclic carbohydrate deriv. give the bicyclic nucleoside contg. an olefinic moiety with a high potential for further functionalization.  As examples, two simple bicyclic ribo-nucleoside analogs, which are restricted to the unusual South-type conformations, are synthesized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwwLYKtbsobVg90H21EOLACvtfcHk0li0Ipiqyw1Prg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFCgurc%253D&md5=8c9dba5b8a48182459804e2d3cd5610b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1039%2Fb101364p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb101364p%26sid%3Dliteratum%253Aachs%26aulast%3DRavn%26aufirst%3DJ.%26aulast%3DNielsen%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520bicyclic%2520nucleosides%2520by%2520ring-closing%2520metathesis%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D2001%26spage%3D985%26epage%3D993%26doi%3D10.1039%2Fb101364p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haziri, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silhar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renneberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leumann, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the sugar building block of bicyclo-RNA</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">827</span>, <span class="refDoi"> DOI: 10.1055/s-0029-1218650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1055%2Fs-0029-1218650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVOltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=823-827&author=A.+I.+Haziriauthor=P.+Silharauthor=D.+Rennebergauthor=C.+J.+Leumann&title=Synthesis+of+the+sugar+building+block+of+bicyclo-RNA&doi=10.1055%2Fs-0029-1218650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the sugar building block of bicyclo-RNA</span></div><div class="casAuthors">Haziri, Arben I.; Silhar, Peter; Renneberg, Dorte; Leumann, Christian J.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">823-827</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">We present the novel synthesis of two sugar units that are central intermediates for the formation of members of the bicyclo-DNA and -RNA family.  The synthesis starts from com. available 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose.  The key step involves the elaboration of a carbocyclic ring in a furanoside by rhodium(I)-catalyzed hydroacylation.  Via this pathway, one of the sugar units is available in 8 steps and in an overall yield of 27%, while its deoxy deriv. is obtained in 11 steps, which is 5 steps fewer than in our previous synthesis of this compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZkPeZrCTJr7Vg90H21EOLACvtfcHk0lipo-j5js6NDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVOltrs%253D&md5=da90f33c44ffdc4c41a10fe1366c0029</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1218650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1218650%26sid%3Dliteratum%253Aachs%26aulast%3DHaziri%26aufirst%3DA.%2BI.%26aulast%3DSilhar%26aufirst%3DP.%26aulast%3DRenneberg%26aufirst%3DD.%26aulast%3DLeumann%26aufirst%3DC.%2BJ.%26atitle%3DSynthesis%2520of%2520the%2520sugar%2520building%2520block%2520of%2520bicyclo-RNA%26jtitle%3DSynthesis%26date%3D2010%26spage%3D823%26epage%3D827%26doi%3D10.1055%2Fs-0029-1218650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haziri, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leumann, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pairing properties of oligodeoxynucleotides containing bicyclo-RNA and bicyclo-ANA modifications</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5861</span>– <span class="NLM_lpage">5869</span>, <span class="refDoi"> DOI: 10.1021/jo300554w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo300554w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Sntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=5861-5869&author=A.+I.+Haziriauthor=C.+J.+Leumann&title=Synthesis+and+pairing+properties+of+oligodeoxynucleotides+containing+bicyclo-RNA+and+bicyclo-ANA+modifications&doi=10.1021%2Fjo300554w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pairing Properties of Oligodeoxynucleotides Containing Bicyclo-RNA and Bicyclo-ANA Modifications</span></div><div class="casAuthors">Haziri, Arben I.; Leumann, Christian J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5861-5869</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of the ribo(bc-rT)- and arabino(bc-araT)-version of bicyclothymidine (bc-dT) has been achieved.  A conformational anal. by X-ray and/or 1H NMR spectroscopy on the corresponding 3',5'-benzyl-protected nucleosides featured a rigid C(2')-endo conformation for the furanose ring, irresp. of the configuration of the OH group at C(2').  The conformation of the carbocyclic ring in these nucleosides was found to be less defined and thus more flexible.  Both nucleosides were converted into the corresponding phosphoramidites and incorporated into oligodeoxynucleotides by std. DNA chem.  Tm-data of duplexes with cDNA and RNA revealed that a bc-rT unit strongly destabilized duplexes with cDNA and RNA by 6-8 °C/mod, while bc-araT was almost Tm neutral.  A rationale based on a previous structure of a bc-DNA mini duplex suggests that the strong destabilization caused by a bc-rT unit arises from unfavorable steric interactions of the equatorial 2'-OH group with the sugar residue of the 3'-neighboring nucleotide unit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbl_8e6HNGZ7Vg90H21EOLACvtfcHk0lipo-j5js6NDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Sntb8%253D&md5=95de71b967e4f49c0108c934421c7ebf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjo300554w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo300554w%26sid%3Dliteratum%253Aachs%26aulast%3DHaziri%26aufirst%3DA.%2BI.%26aulast%3DLeumann%26aufirst%3DC.%2BJ.%26atitle%3DSynthesis%2520and%2520pairing%2520properties%2520of%2520oligodeoxynucleotides%2520containing%2520bicyclo-RNA%2520and%2520bicyclo-ANA%2520modifications%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2012%26volume%3D77%26spage%3D5861%26epage%3D5869%26doi%3D10.1021%2Fjo300554w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downey, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roithová, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocek, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of nucleosides through direct glycosylation of nucleobases with 5-<i>O</i>-monoprotected or 5-modified ribose: improved protocol, scope, and mechanism</span>. <i>Chem. – Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3910</span>– <span class="NLM_lpage">3917</span>, <span class="refDoi"> DOI: 10.1002/chem.201604955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1002%2Fchem.201604955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=28112876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislGnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3910-3917&author=A.+M.+Downeyauthor=R.+Pohlauthor=J.+Roithov%C3%A1author=M.+Hocek&title=Synthesis+of+nucleosides+through+direct+glycosylation+of+nucleobases+with+5-O-monoprotected+or+5-modified+ribose%3A+improved+protocol%2C+scope%2C+and+mechanism&doi=10.1002%2Fchem.201604955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Nucleosides through Direct Glycosylation of Nucleobases with 5-O-Mono-protected or 5-Modified Ribose: Improved Protocol, Scope, and Mechanism</span></div><div class="casAuthors">Downey, A. Michael; Pohl, Radek; Roithova, Jana; Hocek, Michal</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3910-3917</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Simplifying access to synthetic nucleosides is of interest due to their widespread use as biochem. or anticancer and antiviral agents.  Herein, a direct stereoselective method to access an expansive range of both natural and synthetic nucleosides, e.g. I, up to a gram scale, through direct glycosylation of nucleobases with 5-O-tritylribose and other C5-modified ribose derivs., is discussed in detail.  The reaction proceeds through nucleophilic epoxide ring opening of an in situ formed 1,2-anhydrosugar (termed "anhydrose") under modified Mitsunobu reaction conditions.  The scope of the reaction in the synthesis of diverse nucleosides and other 1-substituted riboside derivs. is described.  In addn., a mechanistic insight into the formation of this key glycosyl donor intermediate is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo76bTMZMtGsbVg90H21EOLACvtfcHk0lipo-j5js6NDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislGnsLY%253D&md5=15c10b2f5c36b7549bed8827951b04e9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fchem.201604955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201604955%26sid%3Dliteratum%253Aachs%26aulast%3DDowney%26aufirst%3DA.%2BM.%26aulast%3DPohl%26aufirst%3DR.%26aulast%3DRoithov%25C3%25A1%26aufirst%3DJ.%26aulast%3DHocek%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520nucleosides%2520through%2520direct%2520glycosylation%2520of%2520nucleobases%2520with%25205-O-monoprotected%2520or%25205-modified%2520ribose%253A%2520improved%2520protocol%252C%2520scope%252C%2520and%2520mechanism%26jtitle%3DChem.%2520%25E2%2580%2593%2520Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D3910%26epage%3D3917%26doi%3D10.1002%2Fchem.201604955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lilsIEpJnW76g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Physicochemical descriptors of aromatic character and their use in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7215</span>, <span class="refDoi"> DOI: 10.1021/jm500515d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500515d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7206-7215&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=Physicochemical+descriptors+of+aromatic+character+and+their+use+in+drug+discovery&doi=10.1021%2Fjm500515d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7206-7215</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Published physicochem. descriptors of mols. that convey aromaticity-related character are reviewed in the context of drug design and discovery.  Studies that have employed arom. descriptors are discussed, and several descriptors are compared and contrasted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogc1vxNtUQl7Vg90H21EOLACvtfcHk0lilsIEpJnW76g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D&md5=7aca9f7309bb5dd806aeb4c2b4ff8eab</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm500515d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500515d%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DPhysicochemical%2520descriptors%2520of%2520aromatic%2520character%2520and%2520their%2520use%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7206%26epage%3D7215%26doi%3D10.1021%2Fjm500515d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arnott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planey, S. L.</span></span> <span> </span><span class="NLM_article-title">The influence of lipophilicity in drug discovery and design</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1517/17460441.2012.714363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1517%2F17460441.2012.714363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=22992175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=863-875&author=J.+A.+Arnottauthor=S.+L.+Planey&title=The+influence+of+lipophilicity+in+drug+discovery+and+design&doi=10.1517%2F17460441.2012.714363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of lipophilicity in drug discovery and design</span></div><div class="casAuthors">Arnott, John A.; Planey, Sonia Lobo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">863-875</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The role of lipophilicity in drug discovery and design is a crit. one.  Lipophilicity is a key physicochem. property that plays a crucial role in detg. ADMET (absorption, distribution, metab., excretion, and toxicity) properties and the overall suitability of drug candidates.  There is increasing evidence to suggest that control of physicochem. properties such as lipophilicity, within a defined optimal range, can improve compd. quality and the likelihood of therapeutic success.Areas covered: This review focuses on understanding lipophilicity, techniques used to measure lipophilicity, and summarizes the importance of lipophilicity in drug discovery and development, including a discussion of its impact on individual ADMET parameters as well as its overall influence on the drug discovery and design process, specifically within the past 15 years.Expert opinion: A current review of the literature reveals a continued reliance on the synthesis of novel structures with increased potency, rather than a focus on maintaining optimal physicochem. properties assocd. with ADMET throughout drug optimization.  Particular attention to the optimum region of lipophilicity, as well as monitoring of lipophilic efficiency indexes, may contribute significantly to the overall quality of candidate drugs at different stages of discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolWJgvv9yK87Vg90H21EOLACvtfcHk0lilsIEpJnW76g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsbvJ&md5=4dc5d7268216c9a59fcbd841fbf66735</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.714363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.714363%26sid%3Dliteratum%253Aachs%26aulast%3DArnott%26aufirst%3DJ.%2BA.%26aulast%3DPlaney%26aufirst%3DS.%2BL.%26atitle%3DThe%2520influence%2520of%2520lipophilicity%2520in%2520drug%2520discovery%2520and%2520design%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D863%26epage%3D875%26doi%3D10.1517%2F17460441.2012.714363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Augustijns, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuyts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, J.</span></span> <span> </span><span class="NLM_article-title">A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2013.08.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.ejps.2013.08.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=23994640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyltL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=322-332&author=P.+Augustijnsauthor=B.+Wuytsauthor=B.+Hensauthor=P.+Annaertauthor=J.+Butlerauthor=J.+Brouwers&title=A+review+of+drug+solubility+in+human+intestinal+fluids%3A+implications+for+the+prediction+of+oral+absorption&doi=10.1016%2Fj.ejps.2013.08.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption</span></div><div class="casAuthors">Augustijns, Patrick; Wuyts, Benjamin; Hens, Bart; Annaert, Pieter; Butler, James; Brouwers, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">322-332</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The purpose of this paper is to collate all recently published soly. data of orally administered drugs in human intestinal fluids (HIF) that were aspirated from the upper small intestine (duodenum and jejunum).  The data set comprises in total 102 soly. values in fasted state HIF and 37 soly. values in fed state HIF, covering 59 different drugs.  Despite differences in the protocol for HIF sampling and subsequent handling, this summary of HIF solubilities provides a crit. ref. data set to judge the value of simulated media for intestinal soly. estn.  In this regard, the review includes correlations between the reported solubilizing capacity of HIF and fasted or fed state simulated intestinal fluid (FaSSIF/FeSSIF).  Correlating with HIF solubilities enables the optimal use of soly. measurements in simulated biorelevant media to obtain accurate ests. of intestinal soly. during drug development.  Considering the fraction of poorly sol. new mol. entities in contemporary drug discovery, adequate prediction of intestinal soly. is crit. for efficient lead optimization, early candidate profiling, and further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8IijZQJ8SKrVg90H21EOLACvtfcHk0ljgHPHVpnPJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyltL3L&md5=4e7a43d3d0cfe514577f6b10a1ba0c97</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2013.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2013.08.027%26sid%3Dliteratum%253Aachs%26aulast%3DAugustijns%26aufirst%3DP.%26aulast%3DWuyts%26aufirst%3DB.%26aulast%3DHens%26aufirst%3DB.%26aulast%3DAnnaert%26aufirst%3DP.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DBrouwers%26aufirst%3DJ.%26atitle%3DA%2520review%2520of%2520drug%2520solubility%2520in%2520human%2520intestinal%2520fluids%253A%2520implications%2520for%2520the%2520prediction%2520of%2520oral%2520absorption%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D57%26spage%3D322%26epage%3D332%26doi%3D10.1016%2Fj.ejps.2013.08.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Estévez, D.</span></span> <span> </span><span class="NLM_article-title">Targeted cancer therapy: interactions with other medicines</span>. <i>Clin. Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1007/s12094-016-1509-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1007%2Fs12094-016-1509-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=27112938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFOms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=21-30&author=D.+Conde-Est%C3%A9vez&title=Targeted+cancer+therapy%3A+interactions+with+other+medicines&doi=10.1007%2Fs12094-016-1509-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted cancer therapy: interactions with other medicines</span></div><div class="casAuthors">Conde-Estevez, D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">CTOLAM</span>;
        ISSN:<span class="NLM_cas:issn">1699-048X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia S.r.l.</span>)
        </div><div class="casAbstract">Targeted therapy drugs, mainly those within the signal transduction inhibitors, are used more chronically than cytotoxic drugs and are metabolised by cytochrome P 450 isoenzymes so patients are at high risk of having drug-drug interactions (DDI).  Not only this, as the majority of them are given orally, new drug-drug interactions concerning gastrointestinal absorption can occur (e.g., with proton pump inhibitors).  DDI can lead to changed systemic exposure, resulting in variations in drug response of the co-administered.  In addn., concomitant ingestion of dietary supplements could also alter systemic exposure of drugs, thus leading to adverse drug reactions or loss of efficacy.  In this review, we give an overview of the current existing data of known or suspected DDI between targeted therapy and other medicines.  A review of package inserts was performed to identify drug-drug interactions for all targeted antineoplastic agents.  Tertiary databases such as Lexicomp, Drugs, Martindale, Facts and Comparisons, and AHFS Drug Information were also referenced.  This study covered 40 targeted antineoplastic agents (28 signal transduction inhibitors, 9 monoclonal antibodies and 3 other drugs, 2 monoclonal antibody conjugates and 1 fusion protein).  Most of targeted therapy drugs are major CYP3A4 substrates with P-gp playing an important role in disposition too.  Thus, there is a very common thread here that these agents will likely be sensitive victims to strong CYP3A4/P-gp inhibitors and inducers.  It is essential that health care providers monitor patients for potential DDI to avoid a loss in efficacy or risk of greater toxicity from targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKUB3U6bMSZbVg90H21EOLACvtfcHk0ljgHPHVpnPJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFOms7c%253D&md5=4bb25a20dff7880b48fd96cca8861079</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs12094-016-1509-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12094-016-1509-x%26sid%3Dliteratum%253Aachs%26aulast%3DConde-Est%25C3%25A9vez%26aufirst%3DD.%26atitle%3DTargeted%2520cancer%2520therapy%253A%2520interactions%2520with%2520other%2520medicines%26jtitle%3DClin.%2520Transl.%2520Oncol.%26date%3D2017%26volume%3D19%26spage%3D21%26epage%3D30%26doi%3D10.1007%2Fs12094-016-1509-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galano, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christlieb, M.</span></span> <span> </span><span class="NLM_article-title">Enantioselective total synthesis of (−)-xialenon A</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_fpage">2436</span>– <span class="NLM_lpage">2437</span>, <span class="refDoi"> DOI: 10.1039/B208485F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1039%2FB208485F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=12430478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD38XnslKjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=2436-2437&author=D.+M.+Hodgsonauthor=J.-M.+Galanoauthor=M.+Christlieb&title=Enantioselective+total+synthesis+of+%28%E2%88%92%29-xialenon+A&doi=10.1039%2FB208485F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective total synthesis of (-)-xialenon A</span></div><div class="casAuthors">Hodgson, David M.; Galano, Jean-Marie; Christlieb, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2436-2437</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The first total synthesis of (-)-xialenon A via conjugate allylation of a 1,5-cyclooctadiene-derived bicyclo[3.3.0]octenone I (R = SiMe2CMe3) and an α'-hydroxylation on the more hindered face of enone II (R = SiMe2CMe3), using hypervalent iodine chem., is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcsYTdHxpZJ7Vg90H21EOLACvtfcHk0ljgHPHVpnPJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnslKjsbY%253D&md5=78f7f5c8524d988ca6687cc3aa80ea60</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2FB208485F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB208485F%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DD.%2BM.%26aulast%3DGalano%26aufirst%3DJ.-M.%26aulast%3DChristlieb%26aufirst%3DM.%26atitle%3DEnantioselective%2520total%2520synthesis%2520of%2520%2528%25E2%2588%2592%2529-xialenon%2520A%26jtitle%3DChem.%2520Commun.%26date%3D2002%26spage%3D2436%26epage%3D2437%26doi%3D10.1039%2FB208485F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchweitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laschat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalbe, H.</span></span> <span> </span><span class="NLM_article-title">Total synthesis and NMR investigations of cylindramide</span>. <i>Chem. – Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2488</span>– <span class="NLM_lpage">2503</span>, <span class="refDoi"> DOI: 10.1002/chem.200501274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1002%2Fchem.200501274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=16389623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtVemsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2488-2503&author=N.+Cramerauthor=M.+Buchweitzauthor=S.+Laschatauthor=W.+Freyauthor=A.+Baroauthor=D.+Mathieuauthor=C.+Richterauthor=H.+Schwalbe&title=Total+synthesis+and+NMR+investigations+of+cylindramide&doi=10.1002%2Fchem.200501274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis and NMR investigations of cylindramide</span></div><div class="casAuthors">Cramer, Nicolai; Buchweitz, Maria; Laschat, Sabine; Frey, Wolfgang; Baro, Angelika; Mathieu, Daniel; Richter, Christian; Schwalbe, Harald</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2488-2503</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cylindramide (I) was built up from three components: a hydroxyornithine deriv. II, a tetrazolylsulfone III, and a substituted pentalene subunit IV.  Deriv. II was prepd. in a six-step reaction sequence involving the Wittig reaction and a Sharpless asym. dihydroxylation starting from N-Boc-3-aminopropanal.  Tetrazolylsulfone III was accessible in four steps from dioxinone V.  The synthesis of the pentalene fragment IV started from cycloocta-1,5-diene, that was converted into an enantiopure bicyclo-[3.3.0]octanedione.  The latter was functionalized to give deriv. IV.  The total synthesis was accomplished by inducing C-C bond formation by Sonogashira coupling of derivs. IV and II followed by olefination with tetrazolylsulfone III under Julia-Kocienski conditions, macrocyclization, and subsequent Lacey-Dieckmann condensation to form the tetramic acid unit.  As indicated by extensive 1H and 13C NMR spectroscopic investigations (DQF-COSY, ROESY spectra), the stereochem. of synthetic I corresponds with that of the naturally occurring product.  ROE data were used for mol. modeling of the lowest-energy structures for cylindramide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGpYRusqPQI7Vg90H21EOLACvtfcHk0ljgHPHVpnPJlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtVemsbs%253D&md5=fd13898765b08253e0a3feb455b1d2a8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fchem.200501274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200501274%26sid%3Dliteratum%253Aachs%26aulast%3DCramer%26aufirst%3DN.%26aulast%3DBuchweitz%26aufirst%3DM.%26aulast%3DLaschat%26aufirst%3DS.%26aulast%3DFrey%26aufirst%3DW.%26aulast%3DBaro%26aufirst%3DA.%26aulast%3DMathieu%26aufirst%3DD.%26aulast%3DRichter%26aufirst%3DC.%26aulast%3DSchwalbe%26aufirst%3DH.%26atitle%3DTotal%2520synthesis%2520and%2520NMR%2520investigations%2520of%2520cylindramide%26jtitle%3DChem.%2520%25E2%2580%2593%2520Eur.%2520J.%26date%3D2006%26volume%3D12%26spage%3D2488%26epage%3D2503%26doi%3D10.1002%2Fchem.200501274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, I. D.</span></span> <span> </span><span class="NLM_article-title">Functionalized bicyclo[3.3.0]octanes by enantioselective transannular desymmetrization</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/ol006947n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol006947n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=441-444&author=D.+M.+Hodgsonauthor=I.+D.+Cameron&title=Functionalized+bicyclo%5B3.3.0%5Doctanes+by+enantioselective+transannular+desymmetrization&doi=10.1021%2Fol006947n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Functionalized Bicyclo[3.3.0]octanes by Enantioselective Transannular Desymmetrization</span></div><div class="casAuthors">Hodgson, David M.; Cameron, Iain D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-444</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Enantioselective α-deprotonation-rearrangement of achiral substituted cyclooctene oxides using organolithiums in the presence of (-)-sparteine or (-)-α-isosparteine gives the functionalized bicyclo[3.3.0]octan-2-ols in 56-72% yields and 83-89% ee's.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0XKqEolVur7Vg90H21EOLACvtfcHk0lhR0ABDhQYCUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVehsg%253D%253D&md5=0c01c692fd48b3addcbbe3521e51c5bc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fol006947n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol006947n%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DD.%2BM.%26aulast%3DCameron%26aufirst%3DI.%2BD.%26atitle%3DFunctionalized%2520bicyclo%255B3.3.0%255Doctanes%2520by%2520enantioselective%2520transannular%2520desymmetrization%26jtitle%3DOrg.%2520Lett.%26date%3D2001%26volume%3D3%26spage%3D441%26epage%3D444%26doi%3D10.1021%2Fol006947n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosser, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caine, D.</span></span> <span> </span><span class="NLM_article-title">On the α-lithiation-rearrangement of <i>N</i>-toluensulfonyl aziridines: mechanistic and synthetic aspects</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9779</span>– <span class="NLM_lpage">9791</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2003.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.tet.2003.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVSgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2003&pages=9779-9791&author=P.+O%E2%80%99Brienauthor=C.+M.+Rosserauthor=D.+Caine&title=On+the+%CE%B1-lithiation-rearrangement+of+N-toluensulfonyl+aziridines%3A+mechanistic+and+synthetic+aspects&doi=10.1016%2Fj.tet.2003.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">On the α-lithiation-rearrangement of N-toluenesulfonyl aziridines: mechanistic and synthetic aspects</span></div><div class="casAuthors">O'Brien, Peter; Rosser, Clare M.; Caine, Darren</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">9779-9791</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A detailed study of the rearrangement of five cycloalkene-derived N-sulfonyl aziridines, e.g. I (n = 0 - 3; Ts = 4-methylphenylsulfonyl), using sec-butyllithium (with and without added ligands such as (-)-sparteine and TMEDA) has been carried out.  Allylic sulfonamides II were the main products from the cyclopentene and cyclohexene aziridines whereas bicyclic sulfonamides, e.g. III from I (n = 3), were obtained from the cycloheptene and cyclooctene aziridines.  In most cases, p-toluenesulfonamide (TsNH2) was produced as a byproduct and a mechanistic explanation for its formation is forwarded.  These reactions are believed to involve α-lithiation to a lithiated aziridine which can then partition through two pathways: (i) rearrangement to allylic or bicyclic sulfonamides via C-H insertion reactions or (ii) reductive alkylation to alkenes via attack by sec-butyllithium and subsequent elimination of TsNH2.  In the (-)-sparteine reactions, the products were generated with 38-66% ee and the sense of asym. induction involved lithiation of the S-aziridine stereocenter.  This is opposite to that obsd. with epoxides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhqyA_cZgta7Vg90H21EOLACvtfcHk0lhR0ABDhQYCUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVSgtb0%253D&md5=48128642b2ce6e1039856436166b1e7a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2003.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2003.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DP.%26aulast%3DRosser%26aufirst%3DC.%2BM.%26aulast%3DCaine%26aufirst%3DD.%26atitle%3DOn%2520the%2520%25CE%25B1-lithiation-rearrangement%2520of%2520N-toluensulfonyl%2520aziridines%253A%2520mechanistic%2520and%2520synthetic%2520aspects%26jtitle%3DTetrahedron%26date%3D2003%26volume%3D59%26spage%3D9779%26epage%3D9791%26doi%3D10.1016%2Fj.tet.2003.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zydowsky, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlj, R.</span></span> <span> </span><span class="NLM_article-title">Studies directed toward the synthesis of the unusual antileukemic diterpene jatrophatrione. 1. A solution to the problem of chirality merger during elaboration of the entire carbotricyclic framework</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">3244</span>– <span class="NLM_lpage">3254</span>, <span class="refDoi"> DOI: 10.1021/jo9825254</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo9825254" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK1MXis1OqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=3244-3254&author=L.+A.+Paquetteauthor=S.+Nakataniauthor=T.+M.+Zydowskyauthor=S.+D.+Edmondsonauthor=L.-Q.+Sunauthor=R.+Skerlj&title=Studies+directed+toward+the+synthesis+of+the+unusual+antileukemic+diterpene+jatrophatrione.+1.+A+solution+to+the+problem+of+chirality+merger+during+elaboration+of+the+entire+carbotricyclic+framework&doi=10.1021%2Fjo9825254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Studies directed toward the synthesis of the unusual antileukemic diterpene jatrophatrione. 1. A solution to the problem of chirality merger during elaboration of the entire carbotricyclic framework</span></div><div class="casAuthors">Paquette, Leo A.; Nakatani, Shogo; Zydowsky, Thomas M.; Edmondson, Scott D.; Sun, Li-Qiang; Skerlj, Renato</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3244-3254</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical route for elaboration of the [5.9.5] tricyclic nucleus of jatrophatrione (I; R = α-H) is reported.  The two key steps involve an oxyanionic Cope rearrangement and a Grob fragmentation.  The building blocks required to reach II are the bicyclo[3.3.0]octanone III and the cyclopentadienyl bromide IV.  The former was obtained in 12 steps from methylcyclopentadiene.  The route to the latter began with 4,4-dimethylcyclopentenone.  The charge-accelerated [3,3]-sigmatropic isomerization within II proceeds via a chairlike transition state to deliver, after enolate methylation, a highly strained product carrying a trans double bond in a medium-sized ring, one consequence of which is rapid transannular ring closure via an ene pathway.  Acid hydrolysis of this enol ether and conversion to hydroxy mesylate V (Ms = SO2Me) was followed by exposure to base.  This sequence resulted in ring opening to provide the strategic advanced intermediate VI.  The synthetic pathway developed here is expected to open a route to 9-epijatrophatrione (I; R = β-H) for the ultimate purpose of examg. its anticipated isomerization to I (R = α-H) under mildly basic conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG8yyMCkooCbVg90H21EOLACvtfcHk0lhR0ABDhQYCUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXis1OqtL0%253D&md5=91122d034e9e78579593a0d1a99c71f3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjo9825254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9825254%26sid%3Dliteratum%253Aachs%26aulast%3DPaquette%26aufirst%3DL.%2BA.%26aulast%3DNakatani%26aufirst%3DS.%26aulast%3DZydowsky%26aufirst%3DT.%2BM.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DSkerlj%26aufirst%3DR.%26atitle%3DStudies%2520directed%2520toward%2520the%2520synthesis%2520of%2520the%2520unusual%2520antileukemic%2520diterpene%2520jatrophatrione.%25201.%2520A%2520solution%2520to%2520the%2520problem%2520of%2520chirality%2520merger%2520during%2520elaboration%2520of%2520the%2520entire%2520carbotricyclic%2520framework%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D3244%26epage%3D3254%26doi%3D10.1021%2Fjo9825254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trost, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, D. P.</span></span> <span> </span><span class="NLM_article-title">On the stereochemistry of the bis-nor-wieland-miescher ketome</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4929</span>– <span class="NLM_lpage">4932</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)92384-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2FS0040-4039%2801%2992384-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaL38XhvFyksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1981&pages=4929-4932&author=B.+M.+Trostauthor=D.+P.+Curran&title=On+the+stereochemistry+of+the+bis-nor-wieland-miescher+ketome&doi=10.1016%2FS0040-4039%2801%2992384-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">On the stereochemistry of the bis-nor-Wieland-Miescher ketone</span></div><div class="casAuthors">Trost, Barry M.; Curran, Dennis P.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">4929-32</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">Both the 'ate' complex from DIBAL-H and BuLi and BH3-Me2S chemo- and stereoselectively reduce the title compd. (I; RR1 = O) (II) to I (R = OH, R1 = H) (III); the latter reagent is preferred.  The abs. configuration of II was detd. by 13C NMR study of II and III.  The origin of the asym. induction in the prepn. of II and its (S)-isomer by intramol. Wittig reaction of IV was studied using a variety of phosphines for formation of the ylide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVhekMupmYh7Vg90H21EOLACvtfcHk0lg9uZebNrSC_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhvFyksLY%253D&md5=2a7464663a410edd017433a969582d34</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2992384-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252992384-6%26sid%3Dliteratum%253Aachs%26aulast%3DTrost%26aufirst%3DB.%2BM.%26aulast%3DCurran%26aufirst%3DD.%2BP.%26atitle%3DOn%2520the%2520stereochemistry%2520of%2520the%2520bis-nor-wieland-miescher%2520ketome%26jtitle%3DTetrahedron%2520Lett.%26date%3D1981%26volume%3D22%26spage%3D4929%26epage%3D4932%26doi%3D10.1016%2FS0040-4039%2801%2992384-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raudla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aav, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müürisepp, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopp, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and derivatization of bis-nor Wieland-Miescher ketone</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_fpage">3147</span>– <span class="NLM_lpage">3151</span>, <span class="refDoi"> DOI: 10.1055/s-2005-916025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1055%2Fs-2005-916025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ynsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=3147-3151&author=T.+Kangerauthor=K.+Raudlaauthor=R.+Aavauthor=A.-M.+M%C3%BC%C3%BCriseppauthor=T.+Pehkauthor=M.+Lopp&title=Synthesis+and+derivatization+of+bis-nor+Wieland-Miescher+ketone&doi=10.1055%2Fs-2005-916025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and derivatization of bis-nor Wieland-Miescher ketone</span></div><div class="casAuthors">Kanger, Tonis; Raudla, Kristin; Aav, Riina; Muurisepp, Aleksander-Mati; Pehk, Tonis; Lopp, Margus</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3147-3151</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">An efficient synthesis of bis-nor Wieland-Miescher ketone (I) and its derivs. starting from com. available 2-allyl-2-methylcyclopenta-1,3-dione is described.  Derivatization of I was carried out via selective alkylation of the enone fragment or conversion into 1,2-diketones via epoxides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAWqVoNHdT67Vg90H21EOLACvtfcHk0lg9uZebNrSC_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ynsrjP&md5=120349a026cca3bd77552a2f7cdedd79</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-916025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-916025%26sid%3Dliteratum%253Aachs%26aulast%3DKanger%26aufirst%3DT.%26aulast%3DRaudla%26aufirst%3DK.%26aulast%3DAav%26aufirst%3DR.%26aulast%3DM%25C3%25BC%25C3%25BCrisepp%26aufirst%3DA.-M.%26aulast%3DPehk%26aufirst%3DT.%26aulast%3DLopp%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520derivatization%2520of%2520bis-nor%2520Wieland-Miescher%2520ketone%26jtitle%3DSynthesis%26date%3D2005%26spage%3D3147%26epage%3D3151%26doi%3D10.1055%2Fs-2005-916025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsantali, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakis, I. M.</span></span> <span> </span><span class="NLM_article-title">Expeditious copper-catalyzed conjugate 1,4-addition of bromo[2-(1,3-dioxolan-2-yl)ethyl]magnesium to α,β-cycloalkenones and subsequent transformations</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">6455</span>– <span class="NLM_lpage">6458</span>, <span class="refDoi"> DOI: 10.1021/jo034350q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo034350q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltF2rt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=6455-6458&author=G.+G.+Tsantaliauthor=I.+M.+Takakis&title=Expeditious+copper-catalyzed+conjugate+1%2C4-addition+of+bromo%5B2-%281%2C3-dioxolan-2-yl%29ethyl%5Dmagnesium+to+%CE%B1%2C%CE%B2-cycloalkenones+and+subsequent+transformations&doi=10.1021%2Fjo034350q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Expeditious Copper-Catalyzed Conjugate 1,4-Addition of Bromo[2-(1,3-dioxolan-2-yl)ethyl]magnesium to α,β-Cycloalkenones and Subsequent Transformations</span></div><div class="casAuthors">Tsantali, Georgia G.; Takakis, Ioannis M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6455-6458</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expeditious CuI-catalyzed conjugate 1,4-addn. of bromo[2-(1,3-dioxolan-2-yl)ethyl]magnesium to the five-, six-, seven-, and eight-membered α,β-cycloalkenones is described.  The reaction times are decreased dramatically compared to CuBr-Me2S catalysis.  The resulting keto acetals were cyclized to bicyclic β-hydroxy ketones and α,β-enones, followed by further transformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPhThVQFVYqLVg90H21EOLACvtfcHk0lg9uZebNrSC_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltF2rt7o%253D&md5=a4b5af78d7da16aa2a3444dc3e80f73e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjo034350q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo034350q%26sid%3Dliteratum%253Aachs%26aulast%3DTsantali%26aufirst%3DG.%2BG.%26aulast%3DTakakis%26aufirst%3DI.%2BM.%26atitle%3DExpeditious%2520copper-catalyzed%2520conjugate%25201%252C4-addition%2520of%2520bromo%255B2-%25281%252C3-dioxolan-2-yl%2529ethyl%255Dmagnesium%2520to%2520%25CE%25B1%252C%25CE%25B2-cycloalkenones%2520and%2520subsequent%2520transformations%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D6455%26epage%3D6458%26doi%3D10.1021%2Fjo034350q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallucci, J. C.</span></span> <span> </span><span class="NLM_article-title">Competitive stereochemical control operative during conrotatory electrocyclization of helically equilibrating diquinanyl-substituted 1,3,5,7-octatetraenyl bisenolates</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">8154</span>– <span class="NLM_lpage">8161</span>, <span class="refDoi"> DOI: 10.1021/jo0513919</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0513919" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFarsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=8154-8161&author=L.+A.+Paquetteauthor=Z.+Liuauthor=C.+Ramseyauthor=J.+C.+Gallucci&title=Competitive+stereochemical+control+operative+during+conrotatory+electrocyclization+of+helically+equilibrating+diquinanyl-substituted+1%2C3%2C5%2C7-octatetraenyl+bisenolates&doi=10.1021%2Fjo0513919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Competitive Stereochemical Control Operative during Conrotatory Electrocyclization of Helically Equilibrating Diquinanyl-Substituted 1,3,5,7-Octatetraenyl Bisenolates</span></div><div class="casAuthors">Paquette, Leo A.; Liu, Zuosheng; Ramsey, Charla; Gallucci, Judith C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8154-8161</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activation of the squarate ester cascade by adding the lithiated bicyclo[3.3.0]octene 20 and vinyllithium sequentially to 1 results in the isolation of the four tetracyclic products 21-24.  The structures of the topog. complex products were deduced by 2D NMR spectroscopy and X-ray diffraction studies.  The mechanistic insights gained by these findings are discussed.  The product distribution is telltale evidence for predominant 1,2-addn. of the second alkenyl anion.  Product stereochem. is in turn diagnostic of the preferred mode of conrotatory ring closure operating within equilibrating helical intermediates of opposite pitch.  A competing pathway for the elimination of methanol in these highly functionalized intermediates has been obsd. for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojlJjr5St1FLVg90H21EOLACvtfcHk0lgADh5KGk4WAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFarsLw%253D&md5=833cf7aae32d75c193086f85fcace77f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjo0513919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0513919%26sid%3Dliteratum%253Aachs%26aulast%3DPaquette%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DRamsey%26aufirst%3DC.%26aulast%3DGallucci%26aufirst%3DJ.%2BC.%26atitle%3DCompetitive%2520stereochemical%2520control%2520operative%2520during%2520conrotatory%2520electrocyclization%2520of%2520helically%2520equilibrating%2520diquinanyl-substituted%25201%252C3%252C5%252C7-octatetraenyl%2520bisenolates%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D8154%26epage%3D8161%26doi%3D10.1021%2Fjo0513919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibasaki, M.</span></span> <span> </span><span class="NLM_article-title">Catalytic asymmetric conjugate addition of α-cyanoketones for the construction of a quaternary stereogenic center</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1484</span>– <span class="NLM_lpage">1487</span>, <span class="refDoi"> DOI: 10.1021/ol100183s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol100183s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC3cXislKitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=1484-1487&author=Y.+Kawatoauthor=N.+Takahashiauthor=N.+Kumagaiauthor=M.+Shibasaki&title=Catalytic+asymmetric+conjugate+addition+of+%CE%B1-cyanoketones+for+the+construction+of+a+quaternary+stereogenic+center&doi=10.1021%2Fol100183s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Asymmetric Conjugate Addition of α-Cyanoketones for the Construction of a Quaternary Stereogenic Center</span></div><div class="casAuthors">Kawato, Yuji; Takahashi, Noriko; Kumagai, Naoya; Shibasaki, Masakatsu</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1484-1487</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The catalytic asym. conjugate addn. of cyclic α-cyanoketone pronucleophiles to vinyl ketones promoted by an Y/I catalyst is described.  High enantioselectivity was obsd. for a range of arom. vinyl ketones, providing 1,5-dicarbonyl compds. bearing an all-carbon quaternary stereogenic center.  The product was successfully converted to a spiro-piperidine entity and a bicyclo[3.3.0]octane framework through either the redn. of the nitrile or intramol. pinacol coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoT5AlLeysXbVg90H21EOLACvtfcHk0ljqroCZZGRrqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXislKitbk%253D&md5=908efdbb26fdcafe07c19be0b94025ef</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fol100183s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol100183s%26sid%3Dliteratum%253Aachs%26aulast%3DKawato%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DKumagai%26aufirst%3DN.%26aulast%3DShibasaki%26aufirst%3DM.%26atitle%3DCatalytic%2520asymmetric%2520conjugate%2520addition%2520of%2520%25CE%25B1-cyanoketones%2520for%2520the%2520construction%2520of%2520a%2520quaternary%2520stereogenic%2520center%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D1484%26epage%3D1487%26doi%3D10.1021%2Fol100183s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S. G.</span></span> <span> </span><span class="NLM_article-title">Conversion of ketones having δ, ϵ-π-functions to cyclopentanols by zinc-trimethylchlorosilane</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2821</span>– <span class="NLM_lpage">2824</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)88033-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2FS0040-4039%2800%2988033-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaL3sXlslGht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1983&pages=2821-2824&author=E.+J.+Coreyauthor=S.+G.+Pyne&title=Conversion+of+ketones+having+%CE%B4%2C+%CF%B5-%CF%80-functions+to+cyclopentanols+by+zinc-trimethylchlorosilane&doi=10.1016%2FS0040-4039%2800%2988033-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Conversion of ketones having δ,ε-π-functions to cyclopentanols by zinc-trimethylchlorosilane</span></div><div class="casAuthors">Corey, E. J.; Pyne, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">2821-4</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">A new method for five-membered ring annulation is described which involves free radical generation from ketones by Zn-Me3SiCl followed by internal addn. to a π-bond.  Thus, treating cyclopentanones I (R = C≡CH, CH:CH2, CH:CHCO2Me, -CN, CHO, CH:NOMe) with Zn-Me3SiCl in the presence of lutidine gave bicyclooctanols II (R1R2 = CH2, O; R1 = H, R2 = Me, CH2CO2Me, OH, NHOMe).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxpsJoRPthX7Vg90H21EOLACvtfcHk0ljqroCZZGRrqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlslGht7o%253D&md5=532b6f54b9220b407ea6ef4d3055ecc8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2988033-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252988033-8%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DPyne%26aufirst%3DS.%2BG.%26atitle%3DConversion%2520of%2520ketones%2520having%2520%25CE%25B4%252C%2520%25CF%25B5-%25CF%2580-functions%2520to%2520cyclopentanols%2520by%2520zinc-trimethylchlorosilane%26jtitle%3DTetrahedron%2520Lett.%26date%3D1983%26volume%3D24%26spage%3D2821%26epage%3D2824%26doi%3D10.1016%2FS0040-4039%2800%2988033-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, B. K.</span></span> <span> </span><span class="NLM_article-title">Activation parameters for 1,5-hydrogen transfer and intramolecular cycloaddition in a thermally generated cyclopentane-1,3-diyl</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">5466</span>– <span class="NLM_lpage">5478</span>, <span class="refDoi"> DOI: 10.1021/ja00066a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00066a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK3sXlsF2nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1993&pages=5466-5478&author=T.+H.+Petersonauthor=B.+K.+Carpenter&title=Activation+parameters+for+1%2C5-hydrogen+transfer+and+intramolecular+cycloaddition+in+a+thermally+generated+cyclopentane-1%2C3-diyl&doi=10.1021%2Fja00066a016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Activation parameters for 1,5-hydrogen transfer and intramolecular cycloaddition in a thermally generated cyclopentane-1,3-diyl</span></div><div class="casAuthors">Peterson, Thomas H.; Carpenter, Barry K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5466-78</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The biradical 2-methyl-2-(3-phenylpropyl)cyclopentane-1,3-diyl is generated reversibly by gas-phase pyrolysis of a stereoisomeric mixt. of the corresponding bicyclo[2.1.0]pentane derivs.  Three reactions of the biradical (besides ring closure) are detected.  One is ring opening to 3-methyl-3-(3-phenylpropyl)-1,4-pentadiene.  A second is intramol. transfer of a benzylic hydrogen to the cyclopentane-1,3-diyl.  An activation enthalpy of 8 kcal/mol is estd. for this 1,5-hydrogen transfer.  The third reaction is intramol. cycloaddn. of the 1,3-diyl to the Ph ring.  An activation enthalpy of 7 kcal/mol is estd. for this cycloaddn. reaction.  Two reactions of the new biradical generated by 1,5-hydrogen transfer are detected.  One is ring closure to give stereoisomeric cis-1-methyl-4-phenylbicyclo[3.3.0]octanes; the other is transfer of a second hydrogen in a reaction analogous to the disproportionation of alkyl radicals.  The ring closure and second hydrogen transfer exhibit no temp. dependence in the ratio of their rate consts. and are thus judged to be activationless processes.  These reactions of thermally generated, presumably singlet biradicals are compared with the reactions of related monoradicals.  The cyclopentane-1,3-diyl deriv. is judged to have very little in the way of dipolar character and thus to be near one end of a hypothetical spectrum of intermediates encompassing singlet biradicals and zwitterions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKifTxeWctXbVg90H21EOLACvtfcHk0ljqroCZZGRrqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsF2nt70%253D&md5=83991c349cc59b6314167c601dc7539a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fja00066a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00066a016%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DT.%2BH.%26aulast%3DCarpenter%26aufirst%3DB.%2BK.%26atitle%3DActivation%2520parameters%2520for%25201%252C5-hydrogen%2520transfer%2520and%2520intramolecular%2520cycloaddition%2520in%2520a%2520thermally%2520generated%2520cyclopentane-1%252C3-diyl%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1993%26volume%3D115%26spage%3D5466%26epage%3D5478%26doi%3D10.1021%2Fja00066a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yates, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, K. E.</span></span> <span> </span><span class="NLM_article-title">Bicyclopentanoid sesquiterpenes. The synthesis of cedranoid sesquiterpenes via the photo-rearrangement of bicyclo[2.2.2]octenones</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">4401</span>– <span class="NLM_lpage">4410</span>, <span class="refDoi"> DOI: 10.1016/0040-4020(81)80006-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2F0040-4020%2881%2980006-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaL38XktVKmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1981&pages=4401-4410&author=P.+Yatesauthor=K.+E.+Stevens&title=Bicyclopentanoid+sesquiterpenes.+The+synthesis+of+cedranoid+sesquiterpenes+via+the+photo-rearrangement+of+bicyclo%5B2.2.2%5Doctenones&doi=10.1016%2F0040-4020%2881%2980006-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclopentanoid sesquiterpenes.  The synthesis of cedranoid sesquiterpenes via the photorearrangement of bicyclo[2.2.2]octenones</span></div><div class="casAuthors">Yates, Peter; Stevens, K. E.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4401-10</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">The bicyclooctenone I, prepd. in 3 steps from the diepoxide II, underwent photosensitized oxa-di-π-rearrangement to give tricyclooctanone III.  III was subsequently converted in 7 steps to the β-diketone IV (RR1 = R3R4 = O, R2 = H), a known precursor of cedrol (IV; R = R1 = R2 = H, R3 = Me, R4 = OH).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGzxnkYibgabVg90H21EOLACvtfcHk0ljqroCZZGRrqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XktVKmtrs%253D&md5=2f74b40559a136bcc121b5391dfb841d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2881%2980006-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252881%252980006-3%26sid%3Dliteratum%253Aachs%26aulast%3DYates%26aufirst%3DP.%26aulast%3DStevens%26aufirst%3DK.%2BE.%26atitle%3DBicyclopentanoid%2520sesquiterpenes.%2520The%2520synthesis%2520of%2520cedranoid%2520sesquiterpenes%2520via%2520the%2520photo-rearrangement%2520of%2520bicyclo%255B2.2.2%255Doctenones%26jtitle%3DTetrahedron%26date%3D1981%26volume%3D37%26spage%3D4401%26epage%3D4410%26doi%3D10.1016%2F0040-4020%2881%2980006-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonehara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuyama, T.</span></span> <span> </span><span class="NLM_article-title">A novel synthesis of bicyclo[3.3.0]octane ring system via a desymmetric C-H insertion reaction</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_fpage">1583</span>– <span class="NLM_lpage">1585</span>, <span class="refDoi"> DOI: 10.1055/s-2006-941603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1055%2Fs-2006-941603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslOrurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=1583-1585&author=T.+Kanauthor=T.+Inoueauthor=Y.+Kawamotoauthor=M.+Yoneharaauthor=T.+Fukuyama&title=A+novel+synthesis+of+bicyclo%5B3.3.0%5Doctane+ring+system+via+a+desymmetric+C-H+insertion+reaction&doi=10.1055%2Fs-2006-941603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A novel synthesis of bicyclo[3.3.0]octane ring system via a desymmetric C-H insertion reaction</span></div><div class="casAuthors">Kan, Toshiyuki; Inoue, Tohru; Kawamoto, Yuichiro; Yonehara, Mitsuhiro; Fukuyama, Tohru</div><div class="citationInfo"><span class="NLM_cas:title">Synlett</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1583-1585</span>CODEN:
                <span class="NLM_cas:coden">SYNLES</span>;
        ISSN:<span class="NLM_cas:issn">0936-5214</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">An optically active bicyclo[3.3.0]octane ring was synthesized by an intramol. C-H insertion reaction.  Upon treatment with a catalytic amt. of Rh2(S-DOSP)4, a chiral-auxiliary-contg. diazo ester underwent a C-H insertion reaction to give the desired bicyclo[3.3.0]octane system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA8Q_9DtFFYbVg90H21EOLACvtfcHk0li_YtqK9vj9Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslOrurY%253D&md5=793be08a9d60dd14e86782dd0fa8cfc6</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-941603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-941603%26sid%3Dliteratum%253Aachs%26aulast%3DKan%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DY.%26aulast%3DYonehara%26aufirst%3DM.%26aulast%3DFukuyama%26aufirst%3DT.%26atitle%3DA%2520novel%2520synthesis%2520of%2520bicyclo%255B3.3.0%255Doctane%2520ring%2520system%2520via%2520a%2520desymmetric%2520C-H%2520insertion%2520reaction%26jtitle%3DSynlett%26date%3D2006%26spage%3D1583%26epage%3D1585%26doi%3D10.1055%2Fs-2006-941603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trost, B. M.</span></span> <span> </span><span class="NLM_article-title">[3+2] cycloaddition approaches to five-membered rings via trimethylenemethane and its equivalents [New Synthetic Methods (55)]</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1002/anie.198600013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1002%2Fanie.198600013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1986&pages=1-20&author=B.+M.+Trost&title=%5B3%2B2%5D+cycloaddition+approaches+to+five-membered+rings+via+trimethylenemethane+and+its+equivalents+%5BNew+Synthetic+Methods+%2855%29%5D&doi=10.1002%2Fanie.198600013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fanie.198600013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.198600013%26sid%3Dliteratum%253Aachs%26aulast%3DTrost%26aufirst%3DB.%2BM.%26atitle%3D%255B3%252B2%255D%2520cycloaddition%2520approaches%2520to%2520five-membered%2520rings%2520via%2520trimethylenemethane%2520and%2520its%2520equivalents%2520%255BNew%2520Synthetic%2520Methods%2520%252855%2529%255D%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1986%26volume%3D25%26spage%3D1%26epage%3D20%26doi%3D10.1002%2Fanie.198600013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. A.</span></span> <span> </span><span class="NLM_article-title">The preparation and reactions with an o-silylated enolate of an allylsilane bifunctional [3 + 2] annulating reagent</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">4233</span>– <span class="NLM_lpage">4242</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(01)86669-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2FS0040-4020%2801%2986669-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaL1MXhtlGgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1988&pages=4233-4242&author=T.+V.+Leeauthor=R.+J.+Boucherauthor=J.+R.+Porterauthor=D.+A.+Taylor&title=The+preparation+and+reactions+with+an+o-silylated+enolate+of+an+allylsilane+bifunctional+%5B3+%2B+2%5D+annulating+reagent&doi=10.1016%2FS0040-4020%2801%2986669-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The preparation and reactions with an O-silylated enolate of an allylsilane bifunctional [3 + 2] annulating reagent</span></div><div class="casAuthors">Lee, Thomas V.; Boucher, Raymond J.; Porter, John R.; Taylor, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4233-42</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">The prepn. and reactions of Me3SiCH2C(:CH2)CH(OMe)2 (I) with various silyl enol ethers are described.  This results in the one-pot synthesis of fused and spiro cyclopentanes by using a 1,3-bifunctional annulating reagent in which the two reactive centers are activated by one set of conditions.  Thus, treatment of 1-trimethylsiloxyheptenone with CF3SO3SiMe3 and I gives a mixt. of (silylbutenyl)cycloheptanones II (R = H, R1 OMe; R = OMe, R1 = H) which are annulated in the presence of TiCl4 to give methylenebicyclodecanes III (same R, R1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdx5Xqxm3-RLVg90H21EOLACvtfcHk0li_YtqK9vj9Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhtlGgsL4%253D&md5=575557c690b5690a87676c5e8e4de59e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2801%2986669-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252801%252986669-2%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DT.%2BV.%26aulast%3DBoucher%26aufirst%3DR.%2BJ.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DTaylor%26aufirst%3DD.%2BA.%26atitle%3DThe%2520preparation%2520and%2520reactions%2520with%2520an%2520o-silylated%2520enolate%2520of%2520an%2520allylsilane%2520bifunctional%2520%255B3%2520%252B%25202%255D%2520annulating%2520reagent%26jtitle%3DTetrahedron%26date%3D1988%26volume%3D44%26spage%3D4233%26epage%3D4242%26doi%3D10.1016%2FS0040-4020%2801%2986669-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kablaoui, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Titanocene-catalyzed cyclocarbonylation of enynes to cyclopentenones</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">9450</span>– <span class="NLM_lpage">9451</span>, <span class="refDoi"> DOI: 10.1021/ja9621509</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9621509" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK28XlsFCqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=9450-9451&author=F.+A.+Hicksauthor=N.+M.+Kablaouiauthor=S.+L.+Buchwald&title=Titanocene-catalyzed+cyclocarbonylation+of+enynes+to+cyclopentenones&doi=10.1021%2Fja9621509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Titanocene-Catalyzed Cyclocarbonylation of Enynes to Cyclopentenones</span></div><div class="casAuthors">Hicks, Frederick A.; Kablaoui, Natasha M.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">9450-9451</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The conversion of enynes to cyclopentenones catalyzed by Cp2Ti(CO)2 is described.  This system produces cyclopentenones in excellent yields (75-95%) and displays functional group tolerance unprecedented in Group 4 metallocene chem.  Substrates contg. 1,2-disubstituted olefins are also cleanly cyclized, leading to the first transition metal-catalyzed cyclocarbonylative route to tricyclic cyclopentenones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9_cgVR72R57Vg90H21EOLACvtfcHk0lhfUmAcVlcvEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlsFCqtbo%253D&md5=dab7492e8cc2cce8c720b386a0572728</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fja9621509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9621509%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DF.%2BA.%26aulast%3DKablaoui%26aufirst%3DN.%2BM.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DTitanocene-catalyzed%2520cyclocarbonylation%2520of%2520enynes%2520to%2520cyclopentenones%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D9450%26epage%3D9451%26doi%3D10.1021%2Fja9621509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berk, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A practical titanium-catalyzed synthesis of bicyclic cyclopentenones and allylic amines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2713</span>– <span class="NLM_lpage">2718</span>, <span class="refDoi"> DOI: 10.1021/jo951763l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo951763l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK28XhvFWrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1996&pages=2713-2718&author=F.+A.+Hicksauthor=S.+C.+Berkauthor=S.+L.+Buchwald&title=A+practical+titanium-catalyzed+synthesis+of+bicyclic+cyclopentenones+and+allylic+amines&doi=10.1021%2Fjo951763l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A Practical Titanium-Catalyzed Synthesis of Bicyclic Cyclopentenones and Allylic Amines</span></div><div class="casAuthors">Hicks, Frederick A.; Berk, Scott C.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2713-18</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical titanium-catalyzed synthesis of bicyclic cyclopentenones and allylic amines was described.  In this process enynes were converted to iminocyclopentenes using 10 mol% of the air- and moisture-stable precatalyst Cp2TiCl2 in the presence of n-BuLi and triethylsilyl cyanide.  The resulting iminocyclopentenes can be hydrolyzed to cyclopentenones in good yields or reduced to allylic silylamines with Red-Al or DIBALH.  Treatment of the crude silylamines with acetyl chloride allows isolation of allylic amides in excellent yields.  For example, the cyclization of [3-(2-propenyloxy)-1-propynyl]benzene gave 3a,4-dihydro-6-phenyl-1H-cyclopenta[c]furan-5(3H)-one (82% yield).  Treatment of [3-(2-propenyloxy)-1-propynyl]benzene with dicyclopentadienyltitanium dichloride followed by treatment with triethylsilyl cyanide and subsequent redn. gave N-acetyl-3a,4,5-tetrahydro-1H-Cyclopenta[c]furan-5-amine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRSC4wAUzukbVg90H21EOLACvtfcHk0lhfUmAcVlcvEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvFWrtbw%253D&md5=79d6fcf81d50242a382d3f6e66a1d03c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjo951763l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo951763l%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DF.%2BA.%26aulast%3DBerk%26aufirst%3DS.%2BC.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520practical%2520titanium-catalyzed%2520synthesis%2520of%2520bicyclic%2520cyclopentenones%2520and%2520allylic%2520amines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1996%26volume%3D61%26spage%3D2713%26epage%3D2718%26doi%3D10.1021%2Fjo951763l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krafft, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaga, L. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirosawa, C.</span></span> <span> </span><span class="NLM_article-title">Modification and limitations of the livinghouse catalytic pauson-khand reaction</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">9171</span>– <span class="NLM_lpage">9175</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(99)01960-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2FS0040-4039%2899%2901960-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK1MXotVyitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=9171-9175&author=M.+E.+Krafftauthor=L.+V.+R.+Bonagaauthor=C.+Hirosawa&title=Modification+and+limitations+of+the+livinghouse+catalytic+pauson-khand+reaction&doi=10.1016%2FS0040-4039%2899%2901960-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Modification and limitations of the Livinghouse catalytic Pauson-Khand reaction</span></div><div class="casAuthors">Krafft, M. E.; Bonaga, L. V. R.; Hirosawa, C.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">9171-9175</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The difficult and impractical purifn. of Co2(CO)8 is not necessary in the catalytic thermal Pauson-Khand reaction previously described by Livinghouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHWXAi2Lbh7LVg90H21EOLACvtfcHk0lhfUmAcVlcvEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotVyitb4%253D&md5=00d8a5290cb7c8384a5fa58205b2f9d6</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2899%2901960-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252899%252901960-7%26sid%3Dliteratum%253Aachs%26aulast%3DKrafft%26aufirst%3DM.%2BE.%26aulast%3DBonaga%26aufirst%3DL.%2BV.%2BR.%26aulast%3DHirosawa%26aufirst%3DC.%26atitle%3DModification%2520and%2520limitations%2520of%2520the%2520livinghouse%2520catalytic%2520pauson-khand%2520reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D1999%26volume%3D40%26spage%3D9171%26epage%3D9175%26doi%3D10.1016%2FS0040-4039%2899%2901960-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, R. B.</span></span> <span> </span><span class="NLM_article-title">Pauson-khand approach to chiral, diastereomerically pure group 4 ansa-metallocene complexes</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(98)01099-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2FS0040-4020%2898%2901099-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK1MXhtFynt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1999&pages=919-934&author=R.+B.+Grossman&title=Pauson-khand+approach+to+chiral%2C+diastereomerically+pure+group+4+ansa-metallocene+complexes&doi=10.1016%2FS0040-4020%2898%2901099-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Pauson-Khand approach to chiral, diastereomerically pure Group 4 ansa-metallocene complexes</span></div><div class="casAuthors">Grossman, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">919-934</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The C2-sym. bis(1,6-enynes), threo-1,10-diphenyl-5,6-divinyl-1,9-decadiyne and threo-9,10-divinyl-5,13-octadecadiyne undergo the intramol. Pauson-Khand reaction regioselectively and stereoselectively to give C2-sym. bis(enones) with two bicyclo[3.3.0]octyl moieties joined at the C6 position.  Expts. aimed at converting the bis(enones) into chiral, diastereopure ansa-bridged group 4 metallocene complexes are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKvCi4FJPhbVg90H21EOLACvtfcHk0lhfUmAcVlcvEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtFynt78%253D&md5=39e11ec7d1c93f14a305d47f9b714193</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2898%2901099-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252898%252901099-0%26sid%3Dliteratum%253Aachs%26aulast%3DGrossman%26aufirst%3DR.%2BB.%26atitle%3DPauson-khand%2520approach%2520to%2520chiral%252C%2520diastereomerically%2520pure%2520group%25204%2520ansa-metallocene%2520complexes%26jtitle%3DTetrahedron%26date%3D1999%26volume%3D55%26spage%3D919%26epage%3D934%26doi%3D10.1016%2FS0040-4020%2898%2901099-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez
Rivero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, J. C.</span></span> <span> </span><span class="NLM_article-title">Intramolecular pauson-khand reactions of α,β-unsaturated esters and related electron-deficient olefins</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2975</span>– <span class="NLM_lpage">2978</span>, <span class="refDoi"> DOI: 10.1021/jo026828g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo026828g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=2975-2978&author=M.+Rodr%C3%ADguez%0ARiveroauthor=J.+C.+Carretero&title=Intramolecular+pauson-khand+reactions+of+%CE%B1%2C%CE%B2-unsaturated+esters+and+related+electron-deficient+olefins&doi=10.1021%2Fjo026828g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Intramolecular Pauson-Khand Reactions of α,β-Unsaturated Esters and Related Electron-Deficient Olefins</span></div><div class="casAuthors">Rodriguez Rivero, Marta; Carretero, Juan Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2975-2978</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The intramol. Pauson-Khand reaction of a variety of electron-poor enynes, e.g. I [R1 = H, Me, Ph; R2 = H, Me; R3 = H, EtOCH2O, (Me2CH)3SiO; R4 = CN, EtO2C, (EtO)2PO], having an ester, cyano, or phosphonate group at the olefin terminus, is described.  Thus, the Co2(CO)8-catalyzed intramol. cyclization of enynes I led preferentially to the exocyclic 1,3-dienes II or to pentalenones III depending on the reaction conditions and the enyne substitution.  In general, II was obtained as the major product under N-oxide-promoted conditions, while III was selectively formed in refluxing acetonitrile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2x40FwWBxTLVg90H21EOLACvtfcHk0lhswar8mlpL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSltro%253D&md5=006853f9439a3f6fdac1df79111e2e10</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjo026828g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo026828g%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez%2BRivero%26aufirst%3DM.%26aulast%3DCarretero%26aufirst%3DJ.%2BC.%26atitle%3DIntramolecular%2520pauson-khand%2520reactions%2520of%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520esters%2520and%2520related%2520electron-deficient%2520olefins%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D2975%26epage%3D2978%26doi%3D10.1021%2Fjo026828g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Urgoiti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An̈orbe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Serrano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domínguez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Castells, J.</span></span> <span> </span><span class="NLM_article-title">The pauson-khand reaction, a powerful synthetic tool for the synthesis of complex molecules</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1039/B300976A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1039%2FB300976A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=14737507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvV2ksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=32-42&author=J.+Blanco-Urgoitiauthor=L.+An%CC%88orbeauthor=L.+P%C3%A9rez-Serranoauthor=G.+Dom%C3%ADnguezauthor=J.+P%C3%A9rez-Castells&title=The+pauson-khand+reaction%2C+a+powerful+synthetic+tool+for+the+synthesis+of+complex+molecules&doi=10.1039%2FB300976A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The Pauson-Khand reaction, a powerful synthetic tool for the synthesis of complex molecules</span></div><div class="casAuthors">Blanco-Urgoiti, Jaime; Anorbe, Loreto; Perez-Serrano, Leticia; Dominguez, Gema; Perez-Castells, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The Pauson-Khand reaction (PKR) is a powerful transformation that has now been sufficiently well developed to be routinely considered when planning a synthesis, esp. of polycyclic complex mols.  This tutorial aims to encourage the use of this process explaining the best ways of performing a PKR both in the stoichiometric and the catalytic version, showing the scope of the process and its limitations.  Addnl., asymmetry can be introduced in the reaction using several strategies, which will be discussed.  The most recent examples of the synthetic applications of the PKR in natural product synthesis will give the reader an idea of the great usefulness of this reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNRrMHoHpACbVg90H21EOLACvtfcHk0lhswar8mlpL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvV2ksLk%253D&md5=db048965b28cae7be4c057f1a4256eaa</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1039%2FB300976A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB300976A%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco-Urgoiti%26aufirst%3DJ.%26aulast%3DAn%25CC%2588orbe%26aufirst%3DL.%26aulast%3DP%25C3%25A9rez-Serrano%26aufirst%3DL.%26aulast%3DDom%25C3%25ADnguez%26aufirst%3DG.%26aulast%3DP%25C3%25A9rez-Castells%26aufirst%3DJ.%26atitle%3DThe%2520pauson-khand%2520reaction%252C%2520a%2520powerful%2520synthetic%2520tool%2520for%2520the%2520synthesis%2520of%2520complex%2520molecules%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2004%26volume%3D33%26spage%3D32%26epage%3D42%26doi%3D10.1039%2FB300976A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M.</span></span> <span> </span><span class="NLM_article-title">Natural product syntheses <i>via</i> carbonylative cyclizations</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1039/C8NP00033F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1039%2FC8NP00033F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=29923586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKgtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=174-219&author=K.+Maauthor=B.+S.+Martinauthor=X.+Yinauthor=M.+Dai&title=Natural+product+syntheses+via+carbonylative+cyclizations&doi=10.1039%2FC8NP00033F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Natural product syntheses via carbonylative cyclizations</span></div><div class="casAuthors">Ma, Kaiqing; Martin, Brandon S.; Yin, Xianglin; Dai, Mingji</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-219</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Examples of natural product total syntheses employing transition metal-mediated/catalyzed carbonylative cyclization strategies to build key ring systems.  It mainly covers carbonylative cyclizations for the construction of O-heterocycles, N-heterocycles and carbocycles including cyclic ketones and phenols.  The reaction types include carbonylation of epoxide to β-lactones, carbonylative (macro)lactonization/lactamization, the Semmelhack reaction, tandem hydroformylation-cyclization, the Pauson-Khand reaction, carbonylative C-H activation cyclization, the Stille/Suzuki carbonylation, [n + m + 1] carbonylative cycloaddn., the Dotz annulation, and others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfNiiBNqO7-rVg90H21EOLACvtfcHk0lhswar8mlpL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKgtrfK&md5=00a6256823827b2b7999e7ecc1347992</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1039%2FC8NP00033F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8NP00033F%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DB.%2BS.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DDai%26aufirst%3DM.%26atitle%3DNatural%2520product%2520syntheses%2520via%2520carbonylative%2520cyclizations%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2019%26volume%3D36%26spage%3D174%26epage%3D219%26doi%3D10.1039%2FC8NP00033F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seley, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneller, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattendi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, C. J.</span></span> <span> </span><span class="NLM_article-title">(+)-7-Deaza-5‘-noraristeromycin as an Anti-Trypanosomal Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1021/jm9605039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9605039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVSrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=622-624&author=K.+L.+Seleyauthor=S.+W.+Schnellerauthor=D.+Rattendiauthor=C.+J.+Bacchi&title=%28%2B%29-7-Deaza-5%E2%80%98-noraristeromycin+as+an+Anti-Trypanosomal+Agent&doi=10.1021%2Fjm9605039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">(+)-7-Deaza-5'-noraristeromycin as an Antitrypanosomal Agent</span></div><div class="casAuthors">Seley, Katherine L.; Schneller, Stewart W.; Rattendi, Donna; Bacchi, Cyrus J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">622-624</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The (+)-enantiomer of 7-deaza-5'-noraristeromycin has been found to show IC50 values ranging from 0.16 to 5.3 μM against four strains of African trypanosomes, one Trypanosoma brucei brucei isolate, and several clin. isolates of Trypanosoma brucei rhodesiense (agent of east African sleeping sickness), including a multidrug resistant clone of one isolate.  While this compd. was originally designed to inhibit S-adenosyl-L-homocysteine hydrolase, it has been found to have no effect on this enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYzKrGz8-lX7Vg90H21EOLACvtfcHk0lgy5Sk9xy28HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVSrsbo%253D&md5=623d8edeffc6b3d6864c3512408d83b3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm9605039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9605039%26sid%3Dliteratum%253Aachs%26aulast%3DSeley%26aufirst%3DK.%2BL.%26aulast%3DSchneller%26aufirst%3DS.%2BW.%26aulast%3DRattendi%26aufirst%3DD.%26aulast%3DBacchi%26aufirst%3DC.%2BJ.%26atitle%3D%2528%252B%2529-7-Deaza-5%25E2%2580%2598-noraristeromycin%2520as%2520an%2520Anti-Trypanosomal%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D622%26epage%3D624%26doi%3D10.1021%2Fjm9605039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">David A. Candito, Yingchun Ye, Ryan V. Quiroz, Michael H. Reutershan, David Witter, Surendra B. Gadamsetty, Hongming Li, Josep Saurí, Sebastian E. Schneider, Yu-hong Lam, <span class="NLM_string-name hlFld-ContribAuthor">Rachel L. Palte</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Flexible and Robust Synthesis of Tetrahydrofuro[3,4-b]furan Nucleoside Analogues. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (7)
                                     , 5142-5151. <a href="https://doi.org/10.1021/acs.joc.0c02969" title="DOI URL">https://doi.org/10.1021/acs.joc.0c02969</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c02969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c02969%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDevelopment%252Bof%252Ba%252BFlexible%252Band%252BRobust%252BSynthesis%252Bof%252BTetrahydrofuro%25255B3%25252C4-b%25255Dfuran%252BNucleoside%252BAnalogues%26aulast%3DCandito%26aufirst%3DDavid%2BA.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D05012021%26date%3D23032021%26volume%3D86%26issue%3D7%26spage%3D5142%26epage%3D5151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0025.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Binding of SAM (green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X61">4X61</a>) to PRMT5 overlaid with the H4 peptide (salmon, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GQB">4GQB</a>). Main interactions highlighted with yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Binding mode of SAM (<b>1</b>, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X61">4X61</a>). Prominent interactions with the protein are shown with yellow dashed lines. (B) Binding mode of the H4 peptide arginine residue in the PRMT5 catalytic site (pink, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FA5">5FA5</a>) overlaid with the SAM binding mode (green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X61">4X61</a>). The arginine is in close proximity to the methyl group of SAM, anchored by Glu444.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Inspired by <b>3</b>, designing a lower-strain 5,5-bicyclic system by fusing 3′ and 4′ led to the more potent inhibitor <b>4</b>. (B) Retention of the key nucleoside binding pharmacophore for <b>4</b> was validated by X-ray crystallography (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KIB">7KIB</a>). H-bonds shown in dashed yellow lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Analysis of predicted protein–ligand interaction energy (MMGBSA) and predicted global strain identified different 5,5-fused cores as having a high POS for delivering high-affinity inhibitors, which was validated by TE potencies. Unfilled shapes were designed but not made.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Representative Synthetic Route to Access Ether-Linked Bicyclic Ribose Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Synthetic Route to Access Methylene-Linked Bicyclic Ribose Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. C6-methyl nucleobase inhibitor <b>34</b> retains key binding interactions (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KIC">7KIC</a>). H-bonds shown in dashed yellow lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Analysis of the balance between rat %<i>F</i>, Log<i>D</i>, rat MRT, and Z138 potency for 5,5-bicyclic ribose compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Representative Synthetic Route to Access All-Carbon 5,5-Bicyclic Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Key binding interactions were retained with all-carbon inhibitor <b>72</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KID">7KID</a>). H-bonds shown in dashed yellow lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/medium/jm0c02083_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In vivo</i> antitumor efficacy of PRMT5 inhibitor <b>34</b>. (A) Tumor growth inhibition curves for compound <b>34</b> at four different doses (PO) relative to vehicle control revealed significant TGI and even tumor regression. (B) Tumor SDMA-SMB/B′ levels were used as <i>in vivo</i> markers of target engagement, with <b>34</b> demonstrating a robust reduction in PRMT5 inhibition over the duration of the study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02083/20210331/images/large/jm0c02083_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02083&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i114">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83520" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83520" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 64 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barrueto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caminero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cash, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamichhane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, R. R.</span></span> <span> </span><span class="NLM_article-title">Resistance to checkpoint inhibition in cancer immunotherapy</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">100738</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2019.12.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.tranon.2019.12.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=32114384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A280%3ADC%252BB387nslWjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=100738&author=L.+Barruetoauthor=F.+Camineroauthor=L.+Cashauthor=C.+Makrisauthor=P.+Lamichhaneauthor=R.+R.+Deshmukh&title=Resistance+to+checkpoint+inhibition+in+cancer+immunotherapy&doi=10.1016%2Fj.tranon.2019.12.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to Checkpoint Inhibition in Cancer Immunotherapy</span></div><div class="casAuthors">Barrueto Luisa; Caminero Francheska; Cash Lindsay; Makris Courtney; Lamichhane Purushottam; Deshmukh Rahul R</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">100738</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">The interaction of the host immune system with tumor cells in the tissue microenvironment is essential in understanding tumor immunity and development of successful cancer immunotherapy.  The presence of lymphocytes in tumors is highly correlated with an improved outcome.  T cells have a set of cell surface receptors termed immune checkpoints that when activated suppress T cell function.  Upregulation of immune checkpoint receptors such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) occurs during T cell activation in an effort to prevent damage from an excessive immune response.  Immune checkpoint inhibitors allow the adaptive immune system to respond to tumors more effectively.  There has been clinical success in different types of cancer blocking immune checkpoint receptors such as PD-1 and CTLA.  However, relapse has occurred.  The innate and acquired/therapy induced resistance to treatment has been encountered.  Aberrant cellular signal transduction is a major contributing factor to resistance to immunotherapy.  Combination therapies with other co-inhibitory immune checkpoints such as TIM-3, LAG3 and VISTA are currently being tested to overcome resistance to cancer immunotherapy.  Expression of TIM-3 has been associated with resistance to PD-1 blockade and combined blockade of TIM-3 and PD-1 has demonstrated improved responses in preclinical models.  LAG3 blockade has the potential to increase the responsiveness of cytotoxic T-cells to tumors.  Furthermore, tumors that were found to express VISTA had an increased rate of growth due to the T cell suppression.  The growing understanding of the inhibitory immune checkpoints' ligand biology, signaling mechanisms, and T-cell suppression in the tumor microenvironment continues to fuel preclinical and clinical advancements in design, testing, and approval of agents that block checkpoint molecules.  Our review seeks to bridge fundamental regulatory mechanisms across inhibitory immune checkpoint receptors that are of great importance in resistance to cancer immunotherapy.  We will summarize the biology of different checkpoint molecules, highlight the effect of individual checkpoint inhibition as anti-tumor therapies, and outline the literatures that explore mechanisms of resistance to individual checkpoint inhibition pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3hU_2rfFG_9FxYDaSSP8XfW6udTcc2eYDB5Ana_uJzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387nslWjsg%253D%253D&md5=4c3a471ab587fcfc68bc4c8c58cb590c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2019.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2019.12.010%26sid%3Dliteratum%253Aachs%26aulast%3DBarrueto%26aufirst%3DL.%26aulast%3DCaminero%26aufirst%3DF.%26aulast%3DCash%26aufirst%3DL.%26aulast%3DMakris%26aufirst%3DC.%26aulast%3DLamichhane%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DR.%2BR.%26atitle%3DResistance%2520to%2520checkpoint%2520inhibition%2520in%2520cancer%2520immunotherapy%26jtitle%3DTransl.%2520Oncol.%26date%3D2020%26volume%3D13%26spage%3D100738%26doi%3D10.1016%2Fj.tranon.2019.12.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span> <span> </span><span class="NLM_article-title">Role of protein arginine methyltransferase 5 in human cancers</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">108790</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2019.108790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.biopha.2019.108790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30903920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtV2isb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2019&pages=108790&author=W.+Xiaoauthor=X.+Chenauthor=L.+Liuauthor=Y.+Shuauthor=M.+Zhangauthor=Y.+Zhong&title=Role+of+protein+arginine+methyltransferase+5+in+human+cancers&doi=10.1016%2Fj.biopha.2019.108790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Role of protein arginine methyltransferase 5 in human cancers</span></div><div class="casAuthors">Xiao, Wendi; Chen, Xiaoqing; Liu, Lisa; Shu, Yuansen; Zhang, Min; Zhong, Yucheng</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108790</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Protein arginine methyltransferases (PRMTs) play important roles in protein methylation.  PRMT5 is the major type II arginine methyltransferase that catalyzes the transfer of two Me groups sym. to the arginine residues of either histone or non-histone proteins.  In recent years, increasing evidence has shown that PRMT5, as an oncogene, plays an indispensable regulatory role in the pathol. progression of several human cancers by promoting the proliferation, invasion, and migration of cancer cells.  PRMT5 is overexpressed in many malignant tumors and plays an important role in the occurrence and development of cancer, which suggests that PRMT5 may become a potential biomarker or therapeutic target of cancer.  This article reviews the biol. function, mechanism, and clin. significance of PRMT5 in tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPOq7QOZDBmbVg90H21EOLACvtfcHk0lhxU9QvwaR3Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtV2isb4%253D&md5=db7dfee60fc048cd7408eb34d3cd1d6a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2019.108790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2019.108790%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DShu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhong%26aufirst%3DY.%26atitle%3DRole%2520of%2520protein%2520arginine%2520methyltransferase%25205%2520in%2520human%2520cancers%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2019%26volume%3D114%26spage%3D108790%26doi%3D10.1016%2Fj.biopha.2019.108790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, L.</span></span> <span> </span><span class="NLM_article-title">PRMT5 in gene regulation and hematologic malignancies</span>. <i>Genes Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.gendis.2019.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.gendis.2019.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=32042864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1KgsbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=247-257&author=F.+Zhuauthor=L.+Rui&title=PRMT5+in+gene+regulation+and+hematologic+malignancies&doi=10.1016%2Fj.gendis.2019.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PRMT5 in gene regulation and hematologic malignancies</span></div><div class="casAuthors">Zhu, Fen; Rui, Lixin</div><div class="citationInfo"><span class="NLM_cas:title">Genes and Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-257</span>CODEN:
                <span class="NLM_cas:coden">GDEIAV</span>;
        ISSN:<span class="NLM_cas:issn">2352-3042</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arginine methylation is a common posttranslational modification that governs important cellular processes and impacts development, cell growth, proliferation, and differentiation.  Arginine methylation is catalyzed by protein arginine methyltransferases (PRMTs), which are classified as type I and type II enzymes responsible for the formation of asym. and sym. dimethylarginine, resp.  PRMT5 is the main type II enzyme that catalyzes sym. dimethylarginine of histone proteins to induce gene silencing by generating repressive histone marks, including H2AR3me2s, H3R8me2s, and H4R3me2s.  PRMT5 can also methylate nonhistone proteins such as the transcription factors p53, E2F1 and p65.  Modifications of these proteins by PRMT5 are involved in diverse cellular processes, including transcription, translation, DNA repair, RNA processing, and metab.  A growing literature demonstrates that PRMT5 expression is upregulated in hematol. malignancies, including leukemia and lymphoma, where PRMT5 regulates gene expression to promote cancer cell proliferation.  Targeting PRMT5 by specific inhibitors has emerged as a potential therapeutic strategy to treat these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJVhX2ajFoobVg90H21EOLACvtfcHk0lhxU9QvwaR3Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1KgsbfO&md5=ca3472cb24efa060a5c55f8920156e97</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.gendis.2019.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gendis.2019.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DF.%26aulast%3DRui%26aufirst%3DL.%26atitle%3DPRMT5%2520in%2520gene%2520regulation%2520and%2520hematologic%2520malignancies%26jtitle%3DGenes%2520Dis.%26date%3D2019%26volume%3D6%26spage%3D247%26epage%3D257%26doi%3D10.1016%2Fj.gendis.2019.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span> <span> </span><span class="NLM_article-title">Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1264</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.03.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.bmcl.2019.03.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30956011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslOit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1264-1269&author=H.+Linauthor=J.+I.+Luengo&title=Nucleoside+protein+arginine+methyltransferase+5+%28PRMT5%29+inhibitors&doi=10.1016%2Fj.bmcl.2019.03.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors</span></div><div class="casAuthors">Lin, Hong; Luengo, Juan I.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1264-1269</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein Arginine Methyltransferase 5 (PRMT5) is known to sym. dimethylate numerous cytosolic and nuclear proteins that are involved in a variety of cellular processes.  Recent findings have revealed its potential as a cancer therapeutic target.  PRMT5 selective inhibitors, GSK3326595, a substrate competitive inhibitor, and JNJ64619178, a SAM (S-adenosyl-L-methionine) mimetic/competitive inhibitor, have entered clinic trials for multiple cancer types.  This review focuses on the recent developments in SAM mimetic nucleoside PRMT5 inhibitors, their SAR and structural insight based on published co-crystal structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWzpjRzaVPBLVg90H21EOLACvtfcHk0lhTspKJ56qYKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslOit70%253D&md5=f5889f2c5e084dc231f865805a241da6</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.03.042%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26atitle%3DNucleoside%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D1264%26epage%3D1269%26doi%3D10.1016%2Fj.bmcl.2019.03.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shailesh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakaria, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baiocchi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sif, S.</span></span> <span> </span><span class="NLM_article-title">Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">36705</span>– <span class="NLM_lpage">36718</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.26404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.18632%2Foncotarget.26404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30613353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A280%3ADC%252BB3cnosVeqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=36705-36718&author=H.+Shaileshauthor=Z.+Z.+Zakariaauthor=R.+Baiocchiauthor=S.+Sif&title=Protein+arginine+methyltransferase+5+%28PRMT5%29+dysregulation+in+cancer&doi=10.18632%2Foncotarget.26404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer</span></div><div class="casAuthors">Shailesh Harshita; Zakaria Zain Z; Sif Said; Baiocchi Robert</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">94</span>),
    <span class="NLM_cas:pages">36705-36718</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein arginine methyltransferases (PRMTs) are known for their ability to catalyze methylation of specific arginine residues in a wide variety of cellular proteins, which are involved in a plethora of processes including signal transduction, transcription, and more recently DNA recombination.  All members of the PRMT family can be grouped into three main classes depending on the type of methylation they catalyze.  Type I PRMTs induce monomethylation and asymmetric dimethylation, while type II PRMTs catalyze monomethylation and symmetric dimethylation of specific arginine residues.  In contrast, type III PRMTs carry out only monomethylation of arginine residues.  In this review, we will focus on PRMT5, a type II PRMT essential for viability and normal development, which has been shown to be overexpressed in a wide variety of cancer cell types, owing it to the crucial role it plays in controlling key growth regulatory pathways.  Furthermore, the role of PRMT5 in regulating expression and stability of key transcription factors that control normal stem cell function as well as cancer stem cell renewal will be discussed.  We will review recent work that shows that through its ability to methylate various cellular proteins, PRMT5 functions as a master epigenetic regulator essential for growth and development, and we will highlight studies that have examined its dysregulation and the effects of its inhibition on cancer cell growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR97gCYYvDNxisZ1x6zOs0vfW6udTcc2eaSxIjOIsQCKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnosVeqtQ%253D%253D&md5=7d1bbff0d51464d13a46b391ab16b4a9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.26404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.26404%26sid%3Dliteratum%253Aachs%26aulast%3DShailesh%26aufirst%3DH.%26aulast%3DZakaria%26aufirst%3DZ.%2BZ.%26aulast%3DBaiocchi%26aufirst%3DR.%26aulast%3DSif%26aufirst%3DS.%26atitle%3DProtein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520dysregulation%2520in%2520cancer%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D36705%26epage%3D36718%26doi%3D10.18632%2Foncotarget.26404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span> <span> </span><span class="NLM_article-title">Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9429</span>– <span class="NLM_lpage">9441</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9429-9441&author=Y.+Wangauthor=W.+Huauthor=Y.+Yuan&title=Protein+arginine+methyltransferase+5+%28PRMT5%29+as+an+anticancer+target+and+its+inhibitor+discovery&doi=10.1021%2Facs.jmedchem.8b00598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery</span></div><div class="casAuthors">Wang, Yuanxiang; Hu, Wenhao; Yuan, Yanqiu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9429-9441</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PRMT5 is a major enzyme responsible for sym. dimethylation of arginine residues on both histone and non-histone proteins, regulating many biol. pathways in mammalian cells.  PRMT5 has been suggested as a therapeutic target in a variety of diseases including infectious disease, heart disease, and cancer.  Many PRMT5 inhibitors have been discovered in the past 5 years, and one entered clin. trial in 2015 for the treatment of solid tumor and mantle cell lymphoma (MCL).  The aim of this review is to summarize the current understanding of the roles of PRMT5 in cancer and the discovery of PRMT5 enzymic inhibitors.  By reviewing the structure-activity relationship (SAR) of known inhibitors of PRMT5, we hope to provide guidance for future drug designs and inhibitor optimization.  Opportunities and limitations of PRMT5 inhibitors for the treatment of cancer are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG2MM_2r6cc7Vg90H21EOLACvtfcHk0lgrJjgafu5wWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLvJ&md5=1fffdd9a78a5edbe4c31357d3e08e2d8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00598%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DYuan%26aufirst%3DY.%26atitle%3DProtein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520as%2520an%2520anticancer%2520target%2520and%2520its%2520inhibitor%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9429%26epage%3D9441%26doi%3D10.1021%2Facs.jmedchem.8b00598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demir, Ö.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korc, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span> <span> </span><span class="NLM_article-title">Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">39963</span>– <span class="NLM_lpage">39977</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.18102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.18632%2Foncotarget.18102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=28591716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A280%3ADC%252BC1cnmtVehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=39963-39977&author=L.+Prabhuauthor=H.+Weiauthor=L.+Chenauthor=%C3%96.+Demirauthor=G.+Sanduskyauthor=E.+Sunauthor=J.+Wangauthor=J.+Moauthor=L.+Zengauthor=M.+Fishelauthor=A.+Safaauthor=R.+Amaroauthor=M.+Korcauthor=Z.-Y.+Zhangauthor=T.+Lu&title=Adapting+AlphaLISA+high+throughput+screen+to+discover+a+novel+small-molecule+inhibitor+targeting+protein+arginine+methyltransferase+5+in+pancreatic+and+colorectal+cancers&doi=10.18632%2Foncotarget.18102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Adapting AlphaLISA high throughput screen to discover a novel small-molecule inhibitor targeting protein arginine methyltransferase 5 in pancreatic and colorectal cancers</span></div><div class="casAuthors">Prabhu Lakshmi; Wei Han; Sun Emily; Wang John; Mo Jessica; Safa Ahmad; Lu Tao; Chen Lan; Zeng Lifan; Chen Lan; Zeng Lifan; Zhang Zhong-Yin; Lu Tao; Chen Lan; Zhang Zhong-Yin; Demir Ozlem; Amaro Rommie; Sandusky George; Fishel Melissa; Korc Murray; Lu Tao</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">39963-39977</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) are notoriously challenging for treatment.  Hyperactive nuclear factor κB (NF-κB) is a common culprit in both cancers.  Previously, we discovered that protein arginine methyltransferase 5 (PRMT5) methylated and activated NF-κB.  Here, we show that PRMT5 is highly expressed in PDAC and CRC.  Overexpression of PRMT5 promoted cancer progression, while shRNA knockdown showed an opposite effect.  Using an innovative AlphaLISA high throughput screen, we discovered a lead compound, PR5-LL-CM01, which exhibited robust tumor inhibition effects in both cancers.  An in silico structure prediction suggested that PR5-LL-CM01 inhibits PRMT5 by binding with its active pocket.  Importantly, PR5-LL-CM01 showed higher anti-tumor efficacy than the commercial PRMT5 inhibitor, EPZ015666, in both PDAC and CRC.  This study clearly highlights the significant potential of PRMT5 as a therapeutic target in PDAC and CRC, and establishes PR5-LL-CM01 as a promising basis for new drug development in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGp0p7OcE36IhLSh9fo81bfW6udTcc2ear0nH0RBr4S7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnmtVehtw%253D%253D&md5=863065cdd403b37160fc31d17b625de2</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.18102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.18102%26sid%3Dliteratum%253Aachs%26aulast%3DPrabhu%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDemir%26aufirst%3D%25C3%2596.%26aulast%3DSandusky%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DFishel%26aufirst%3DM.%26aulast%3DSafa%26aufirst%3DA.%26aulast%3DAmaro%26aufirst%3DR.%26aulast%3DKorc%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DZ.-Y.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DAdapting%2520AlphaLISA%2520high%2520throughput%2520screen%2520to%2520discover%2520a%2520novel%2520small-molecule%2520inhibitor%2520targeting%2520protein%2520arginine%2520methyltransferase%25205%2520in%2520pancreatic%2520and%2520colorectal%2520cancers%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D39963%26epage%3D39977%26doi%3D10.18632%2Foncotarget.18102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1476</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.03.087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.bmcl.2018.03.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=29628326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1aqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1476-1483&author=K.+Zhuauthor=C.+Jiangauthor=H.+Taoauthor=J.+Liuauthor=H.+Zhangauthor=C.+Luo&title=Identification+of+a+novel+selective+small-molecule+inhibitor+of+protein+arginine+methyltransferase+5+%28PRMT5%29+by+virtual+screening%2C+resynthesis+and+biological+evaluations&doi=10.1016%2Fj.bmcl.2018.03.087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations</span></div><div class="casAuthors">Zhu, Kongkai; Jiang, Chengshi; Tao, Hongrui; Liu, Jingqiu; Zhang, Hua; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1476-1483</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As one of the most promising anticancer targets in protein arginine methyltransferase (PRMT) family, PRMT5 has been drawing more and more attention, and many efforts have been devoted to develop its inhibitors.  In this study, three PRMT5 inhibitors (9, 16, and 23) with novel scaffolds were identified by performing pharmacophore- and docking-based virtual screening combined with in vitro radiometric-based scintillation proximity assay (SPA).  Substructure search based on the scaffold of the most active 9 afforded 26 addnl. analogs, and SPA results indicated that two analogs (9-1 and 9-2) showed increased PRMT5 inhibitory activity compared with the parental compd.  Resynthesis of 9, 9-1, and 9-2 confirmed their PRMT5 enzymic inhibition activity.  In addn., compd. 9-1 displayed selectivity against PRMT5 over other key homol. members (PRMT1 and CARM1 (PRMT4)).  While the structure-activity relationship (SAR) of this series of compds. was discussed to provide clues for further structure optimization, the probable binding modes of active compds. were also probed by mol. docking and mol. dynamics simulations.  Finally, the antiproliferative effect of 9-1 on MV4-11 leukemia cell line was confirmed and its impact on regulating the target gene of PRMT5 was also validated.  The hit compds. identified have provided more novel scaffolds for future hit-to-lead optimization of small-mol. PRMT5 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6eDaTozQTprVg90H21EOLACvtfcHk0lgELJRa8BUXgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1aqt7g%253D&md5=6d6d2eb1c1dcd5db74ee4e712ed4b3ce</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.03.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.03.087%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DJiang%26aufirst%3DC.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3DIdentification%2520of%2520a%2520novel%2520selective%2520small-molecule%2520inhibitor%2520of%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520by%2520virtual%2520screening%252C%2520resynthesis%2520and%2520biological%2520evaluations%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1476%26epage%3D1483%26doi%3D10.1016%2Fj.bmcl.2018.03.087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boriack-Sjodin, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majer, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan-Penebre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuplast, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter
Scott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span> <span> </span><span class="NLM_article-title">Structure and property guided design in the identification of PRMT5 tool compound EPZ015666</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00380</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00380" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=162-166&author=K.+W.+Duncanauthor=N.+Riouxauthor=P.+A.+Boriack-Sjodinauthor=M.+J.+Munchhofauthor=L.+A.+Reiterauthor=C.+R.+Majerauthor=L.+Jinauthor=L.+D.+Johnstonauthor=E.+Chan-Penebreauthor=K.+G.+Kuplastauthor=M.+Porter%0AScottauthor=R.+M.+Pollockauthor=N.+J.+Watersauthor=J.+J.+Smithauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=R.+Chesworth&title=Structure+and+property+guided+design+in+the+identification+of+PRMT5+tool+compound+EPZ015666&doi=10.1021%2Facsmedchemlett.5b00380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666</span></div><div class="casAuthors">Duncan, Kenneth W.; Rioux, Nathalie; Boriack-Sjodin, P. Ann; Munchhof, Michael J.; Reiter, Lawrence A.; Majer, Christina R.; Jin, Lei; Johnston, L. Danielle; Chan-Penebre, Elayne; Kuplast, Kristy G.; Porter Scott, Margaret; Pollock, Roy M.; Waters, Nigel J.; Smith, Jesse J.; Moyer, Mikel P.; Copeland, Robert A.; Chesworth, Richard</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-166</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent publication of a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) provides the scientific community with in vivo-active tool compd. I (EPZ015666, GSK3235025) to probe the underlying pharmacol. of this key enzyme.  Herein, the authors report the design and optimization strategies employed on an initial hit compd. with poor in vitro clearance to yield in vivo tool compd. I and an addnl. potent in vitro tool mol. II (GSK3203591).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2V7LiQgVZjrVg90H21EOLACvtfcHk0lgELJRa8BUXgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsr3L&md5=e7ac92c2d985da4994e9bb959adededf</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00380%26sid%3Dliteratum%253Aachs%26aulast%3DDuncan%26aufirst%3DK.%2BW.%26aulast%3DRioux%26aufirst%3DN.%26aulast%3DBoriack-Sjodin%26aufirst%3DP.%2BA.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DReiter%26aufirst%3DL.%2BA.%26aulast%3DMajer%26aufirst%3DC.%2BR.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DJohnston%26aufirst%3DL.%2BD.%26aulast%3DChan-Penebre%26aufirst%3DE.%26aulast%3DKuplast%26aufirst%3DK.%2BG.%26aulast%3DPorter%2BScott%26aufirst%3DM.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DChesworth%26aufirst%3DR.%26atitle%3DStructure%2520and%2520property%2520guided%2520design%2520in%2520the%2520identification%2520of%2520PRMT5%2520tool%2520compound%2520EPZ015666%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D162%26epage%3D166%26doi%3D10.1021%2Facsmedchemlett.5b00380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonday, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonysamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocchinfuso, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mader, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eram, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szewczyk, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsyte-Lovejoy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guccione, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. M.</span></span> <span> </span><span class="NLM_article-title">LLY-283, a potent and selective inhibitor of arginine methyltransferase 5, PRMT5, with antitumor activity</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFarurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=612-617&author=Z.+Q.+Bondayauthor=G.+S.+Cortezauthor=M.+J.+Groganauthor=S.+Antonysamyauthor=K.+Weichertauthor=W.+P.+Bocchinfusoauthor=F.+Liauthor=S.+Kennedyauthor=B.+Liauthor=M.+M.+Maderauthor=C.+H.+Arrowsmithauthor=P.+J.+Brownauthor=M.+S.+Eramauthor=M.+M.+Szewczykauthor=D.+Barsyte-Lovejoyauthor=M.+Vedadiauthor=E.+Guccioneauthor=R.+M.+Campbell&title=LLY-283%2C+a+potent+and+selective+inhibitor+of+arginine+methyltransferase+5%2C+PRMT5%2C+with+antitumor+activity&doi=10.1021%2Facsmedchemlett.8b00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity</span></div><div class="casAuthors">Bonday, Zahid Q.; Cortez, Guillermo S.; Grogan, Michael J.; Antonysamy, Stephen; Weichert, Ken; Bocchinfuso, Wayne P.; Li, Fengling; Kennedy, Steven; Li, Binghui; Mader, Mary M.; Arrowsmith, Cheryl H.; Brown, Peter J.; Eram, Mohammad S.; Szewczyk, Magdalena M.; Barsyte-Lovejoy, Dalia; Vedadi, Masoud; Guccione, Ernesto; Campbell, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">612-617</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that catalyzes the formation of sym. dimethylarginine in a no. of nuclear and cytoplasmic proteins.  Although the cellular functions of PRMT5 have not been fully unraveled, it has been implicated in a no. of cellular processes like RNA processing, signal transduction and transcriptional regulation.  PRMT5 is ubiquitously expressed in most tissues and its expression has been shown to be elevated in several cancers including breast cancer, gastric cancer, glioblastoma and lymphoma.  Here we describe the identification and characterization of a novel and selective PRMT5 inhibitor with potent in vitro and in vivo activity.  Compd. 1 (also called LLY-283) inhibited PRMT5 enzymic activity in vitro and in cells with IC50 of 22 ± 3 nM and 25 ± 1 nM, resp. while its diastereomer, compd. 2 (also called LLY-284) was much less active.  Compd. 1 also showed antitumor activity in mouse xenografts when dosed orally and can serve as an excellent probe mol. for understanding the biol. function of PRMT5 in normal and cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYIq2FC-EskrVg90H21EOLACvtfcHk0liOerTONt_2Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFarurc%253D&md5=93517c34cf9f99d76730a538f594ddd7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00014%26sid%3Dliteratum%253Aachs%26aulast%3DBonday%26aufirst%3DZ.%2BQ.%26aulast%3DCortez%26aufirst%3DG.%2BS.%26aulast%3DGrogan%26aufirst%3DM.%2BJ.%26aulast%3DAntonysamy%26aufirst%3DS.%26aulast%3DWeichert%26aufirst%3DK.%26aulast%3DBocchinfuso%26aufirst%3DW.%2BP.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKennedy%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DMader%26aufirst%3DM.%2BM.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DEram%26aufirst%3DM.%2BS.%26aulast%3DSzewczyk%26aufirst%3DM.%2BM.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DGuccione%26aufirst%3DE.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26atitle%3DLLY-283%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520arginine%2520methyltransferase%25205%252C%2520PRMT5%252C%2520with%2520antitumor%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D612%26epage%3D617%26doi%3D10.1021%2Facsmedchemlett.8b00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.08.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.bioorg.2018.08.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30172110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1WmsrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=289-298&author=K.+Zhuauthor=H.+Taoauthor=J.-L.+Songauthor=L.+Jinauthor=Y.+Zhangauthor=J.+Liuauthor=Z.+Chenauthor=C.-S.+Jiangauthor=C.+Luoauthor=H.+Zhang&title=Identification+of+5-benzylidene-2-phenylthiazolones+as+potent+PRMT5+inhibitors+by+virtual+screening%2C+structural+optimization+and+biological+evaluations&doi=10.1016%2Fj.bioorg.2018.08.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations</span></div><div class="casAuthors">Zhu, Kongkai; Tao, Hongrui; Song, Jia-Li; Jin, Lu; Zhang, Yuanyuan; Liu, Jingqiu; Chen, Zhifeng; Jiang, Cheng-Shi; Luo, Cheng; Zhang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">289-298</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is an epigenetics related enzyme that has been validated as an important therapeutic target for glioblastoma and mantel cell lymphoma.  In the present study, 11 novel PRMT5 inhibitors with 5-benzylidene-2-phenylthiazolone scaffold were identified by mol. docking-based virtual screening and structural optimization.  Their IC50 values against PRMT5 at enzymic level were ranging from 0.77 to 23 μM.  As expected, the top two active hits (5 and 19) showed potent anti-proliferative activity against MV4-11 cells with EC50 values lower than 10 μM and reduced the cellular sym. arginine dimethylation levels of SmD3 protein.  Besides, 5 and 19 demonstrated the mechanism of cell killing in cell cycle arrest and apoptotic effect.  The probable binding modes of the two compds. were explored and further verified by mol. dynamics simulation.  The structure-activity relationship (SAR) of this class of structures was also discussed and further demonstrated by mol. docking simulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1K2TslS6a5bVg90H21EOLACvtfcHk0lj3VsWe_E2wpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1WmsrrK&md5=734c196a4312bac7c377ad1ca1ec4d81</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.08.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.08.021%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DJ.-L.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DC.-S.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DIdentification%2520of%25205-benzylidene-2-phenylthiazolones%2520as%2520potent%2520PRMT5%2520inhibitors%2520by%2520virtual%2520screening%252C%2520structural%2520optimization%2520and%2520biological%2520evaluations%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D289%26epage%3D298%26doi%3D10.1016%2Fj.bioorg.2018.08.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">3693</span>– <span class="NLM_lpage">3699</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.bmcl.2018.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30366617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVSlsLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=3693-3699&author=K.+Zhuauthor=J.-L.+Songauthor=H.-R.+Taoauthor=Z.-Q.+Chengauthor=C.-S.+Jiangauthor=H.+Zhang&title=Discovery+of+new+potent+protein+arginine+methyltransferase+5+%28PRMT5%29+inhibitors+by+assembly+of+key+pharmacophores+from+known+inhibitors&doi=10.1016%2Fj.bmcl.2018.10.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors</span></div><div class="casAuthors">Zhu, Kongkai; Song, Jia-Li; Tao, Hong-Rui; Cheng, Zhi-Qiang; Jiang, Cheng-Shi; Zhang, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">3693-3699</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is an epigenetics related enzyme that has been validated as a promising therapeutic target for human cancer.  Up to now, two small mol. PRMT5 inhibitors has been put into phase I clin. trial.  In the present study, a series of candidate mols. were designed by combining key pharmacophores of formerly reported PRMT5 inhibitors.  The in vitro PRMT5 inhibitory testing of compd. 4b14 revealed an IC50 of 2.71 μM, exhibiting high selectivity over PRMT1 and PRMT4 (>70-fold selective).  As expected, 4b14 exhibited potent anti-proliferative activity against a panel of leukemia and lymphoma cells, including MV4-11, Pfeiffer, SU-DHL-4 and KARPAS-422.  Besides, 4b14 showed significant cell cycle arrest and apoptosis-inducing effects, as well as reduced the cellular sym. arginine dimethylation level of SmD3 protein.  Finally, affinity profiling anal. indicated that hydrophobic interactions, π-π stacking and cation-π actions made the major contributions to the overall binding affinity.  This scaffold provides a new chem. template for further development of better lead compds. targeting PRMT5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUiq5gq-S5uLVg90H21EOLACvtfcHk0lj3VsWe_E2wpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVSlsLrP&md5=d397612b9684719d6696dff6362a8806</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DJ.-L.%26aulast%3DTao%26aufirst%3DH.-R.%26aulast%3DCheng%26aufirst%3DZ.-Q.%26aulast%3DJiang%26aufirst%3DC.-S.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520new%2520potent%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520inhibitors%2520by%2520assembly%2520of%2520key%2520pharmacophores%2520from%2520known%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D3693%26epage%3D3699%26doi%3D10.1016%2Fj.bmcl.2018.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span> <span> </span><span class="NLM_article-title">Rational design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1007/s10822-019-00214-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1007%2Fs10822-019-00214-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=31312965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlyiur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=775-785&author=K.+Zhuauthor=J.+Shaoauthor=H.+Taoauthor=X.+Yanauthor=C.+Luoauthor=H.+Zhangauthor=W.+Duan&title=Rational+design%2C+synthesis+and+biological+evaluation+of+novel+triazole+derivatives+as+potent+and+selective+PRMT5+inhibitors+with+antitumor+activity&doi=10.1007%2Fs10822-019-00214-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity</span></div><div class="casAuthors">Zhu, Kongkai; Shao, Jingwei; Tao, Hongrui; Yan, Xue; Luo, Cheng; Zhang, Hua; Duan, Wenhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">775-785</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is responsible for the mono-methylation and sym. dimethylation of arginine, and its expression level and Me transferring activity have been demonstrated to have a close relationship with tumorigenesis, development and poor clin. outcomes of human cancers.  Two PRMT5 small mol. inhibitors (GSK3326595 and JNJ-64619178) have been put forward into clin. trials.  Here, we describe the design, synthesis and biol. evaluation of a series of novel, potent and selective PRMT5 inhibitors with antiproliferative activity against Z-138 mantle cell lymphoma cell line.  Among them, compd. C_4 exhibited the highest potency with enzymic and cellular level IC50 values of 0.72 and 2.6 μM, resp., and displayed more than 270-fold selectivity toward PRMT5 over several other isoenzymes (PRMT1, PRMT4 and PRMT6).  Besides, C_4 demonstrated obvious cell apoptotic effect while reduced the cellular sym. arginine dimethylation levels of SmD3 protein.  The potency, small size, and synthetic accessibility of this compd. class provide promising hit scaffold for medicinal chemists to further explore this series of PRMT5 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1YVgRfHLMnrVg90H21EOLACvtfcHk0liBEeCieHS9rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlyiur7I&md5=cb0ba8ca2854b233b13a830662d68041</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10822-019-00214-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-019-00214-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDuan%26aufirst%3DW.%26atitle%3DRational%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520triazole%2520derivatives%2520as%2520potent%2520and%2520selective%2520PRMT5%2520inhibitors%2520with%2520antitumor%2520activity%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2019%26volume%3D33%26spage%3D775%26epage%3D785%26doi%3D10.1007%2Fs10822-019-00214-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-substituted-<i>N</i>-(3-(3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: design, synthesis and biological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.ejmech.2018.12.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=30605830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtl2nsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=317-333&author=J.+Shaoauthor=K.+Zhuauthor=D.+Duauthor=Y.+Zhangauthor=H.+Taoauthor=Z.+Chenauthor=H.+Jiangauthor=K.+Chenauthor=C.+Luoauthor=W.+Duan&title=Discovery+of+2-substituted-N-%283-%283%2C4-dihydroisoquinolin-2%281H%29-yl%29-2-hydroxypropyl%29-1%2C2%2C3%2C4-tetrahydroisoquinoline-6-carboxamide+as+potent+and+selective+protein+arginine+methyltransferases+5+inhibitors%3A+design%2C+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2018.12.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation</span></div><div class="casAuthors">Shao, Jingwei; Zhu, Kongkai; Du, Daohai; Zhang, Yuanyuan; Tao, Hongrui; Chen, Zhifeng; Jiang, Hualiang; Chen, Kaixian; Luo, Cheng; Duan, Wenhu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">317-333</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)amide derivs. targeting PRMT5 were designed with structure-based approach and synthesized.  Among them, compd. (S)-2-(4-bromobenzoyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide showed potent and selective PRMT5 inhibition activity with an IC50 of 8.5 nM, which was approx. equiv. with the phase I clin. trial PRMT5 inhibitor GSK-3326595 (IC50 = 5.5 nM).  Compd. (S)-2-(4-bromobenzoyl)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide also displayed pronounced anti-proliferative activity in MV4-11 cells (GI50 = 18 nM) and antitumor activity in MV4-11 mouse xenografts model.  This mol. served as an excellent tool compd. for probing the biol. function of PRMT5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8r5tDk63g07Vg90H21EOLACvtfcHk0liBEeCieHS9rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtl2nsw%253D%253D&md5=d04aaa30e120c8e89d0f9778130cb800</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.065%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DDu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DW.%26atitle%3DDiscovery%2520of%25202-substituted-N-%25283-%25283%252C4-dihydroisoquinolin-2%25281H%2529-yl%2529-2-hydroxypropyl%2529-1%252C2%252C3%252C4-tetrahydroisoquinoline-6-carboxamide%2520as%2520potent%2520and%2520selective%2520protein%2520arginine%2520methyltransferases%25205%2520inhibitors%253A%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D317%26epage%3D333%26doi%3D10.1016%2Fj.ejmech.2018.12.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">Potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor developed by structure-based virtual screening and hit optimization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6289</span>– <span class="NLM_lpage">6304</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00587</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00587" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVKitr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6289-6304&author=R.+Maoauthor=J.+Shaoauthor=K.+Zhuauthor=Y.+Zhangauthor=H.+Dingauthor=C.+Zhangauthor=Z.+Shiauthor=H.+Jiangauthor=D.+Sunauthor=W.+Duanauthor=C.+Luo&title=Potent%2C+selective%2C+and+cell+active+protein+arginine+methyltransferase+5+%28PRMT5%29+inhibitor+developed+by+structure-based+virtual+screening+and+hit+optimization&doi=10.1021%2Facs.jmedchem.7b00587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization</span></div><div class="casAuthors">Mao, Ruifeng; Shao, Jingwei; Zhu, Kongkai; Zhang, Yuanyuan; Ding, Hong; Zhang, Chenhua; Shi, Zhe; Jiang, Hualiang; Sun, Dequn; Duan, Wenhu; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6289-6304</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abstr. PRMT5 plays important roles in diverse cellular processes and is upregulated in several human malignancies.  Besides, PRMT5 has been validated as anticancer target in mantle cell lymphoma.  In this study, the authors found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization.  The identified compd. I (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases.  The direct binding of I to PRMT5 was validated by surface plasmon resonance expts., with a Kd of 0.987 μM.  Kinetic expts. indicated that I was a SAM competitive inhibitor other than substrate.  In addn., I showed selective antiproliferative effects against MV4-11 cells, and further studies indicated that the mechanism of cellular antitumor activity was due to inhibition of PRMT5 mediated SmD3 methylation. I may represent a promising lead compd. to understand more about PRMT5 and potentially assist the development of treatments for leukemia indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI1jnM_kEhRrVg90H21EOLACvtfcHk0lh1wVqoaLBJ4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVKitr7E&md5=5e3687166e2e6b5558409806e3c4b9e5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00587%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DR.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3DPotent%252C%2520selective%252C%2520and%2520cell%2520active%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520inhibitor%2520developed%2520by%2520structure-based%2520virtual%2520screening%2520and%2520hit%2520optimization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6289%26epage%3D6304%26doi%3D10.1021%2Facs.jmedchem.7b00587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan-Penebre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuplast, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majer, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boriack-Sjodin, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rioux, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingaraj, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stickland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribich, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbash, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappalardi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurse, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oza, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesworth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, K. W.</span></span> <span> </span><span class="NLM_article-title">A selective inhibitor of PRMT5 with <i>in vivo</i> and <i>in vitro</i> potency in MCL models</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">432</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1038%2Fnchembio.1810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=25915199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotFartbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=432-437&author=E.+Chan-Penebreauthor=K.+G.+Kuplastauthor=C.+R.+Majerauthor=P.+A.+Boriack-Sjodinauthor=T.+J.+Wigleauthor=L.+D.+Johnstonauthor=N.+Riouxauthor=M.+J.+Munchhofauthor=L.+Jinauthor=S.+L.+Jacquesauthor=K.+A.+Westauthor=T.+Lingarajauthor=K.+Sticklandauthor=S.+A.+Ribichauthor=A.+Raimondiauthor=M.+P.+Scottauthor=N.+J.+Watersauthor=R.+M.+Pollockauthor=J.+J.+Smithauthor=O.+Barbashauthor=M.+Pappalardiauthor=T.+F.+Hoauthor=K.+Nurseauthor=K.+P.+Ozaauthor=K.+T.+Gallagherauthor=R.+Krugerauthor=M.+P.+Moyerauthor=R.+A.+Copelandauthor=R.+Chesworthauthor=K.+W.+Duncan&title=A+selective+inhibitor+of+PRMT5+with+in+vivo+and+in+vitro+potency+in+MCL+models&doi=10.1038%2Fnchembio.1810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models</span></div><div class="casAuthors">Chan-Penebre, Elayne; Kuplast, Kristy G.; Majer, Christina R.; Boriack-Sjodin, P. Ann; Wigle, Tim J.; Johnston, L. Danielle; Rioux, Nathalie; Munchhof, Michael J.; Jin, Lei; Jacques, Suzanne L.; West, Kip A.; Lingaraj, Trupti; Stickland, Kimberly; Ribich, Scott A.; Raimondi, Alejandra; Scott, Margaret Porter; Waters, Nigel J.; Pollock, Roy M.; Smith, Jesse J.; Barbash, Olena; Pappalardi, Melissa; Ho, Thau F.; Nurse, Kelvin; Oza, Khyati P.; Gallagher, Kathleen T.; Kruger, Ryan; Moyer, Mikel P.; Copeland, Robert A.; Chesworth, Richard; Duncan, Kenneth W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">432-437</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase-5 (PRMT5) is reported to have a role in diverse cellular processes, including tumorigenesis, and its overexpression is obsd. in cell lines and primary patient samples derived from lymphomas, particularly mantle cell lymphoma (MCL).  Here we describe the identification and characterization of a potent and selective inhibitor of PRMT5 with antiproliferative effects in both in vitro and in vivo models of MCL.  EPZ015666 (GSK3235025) is an orally available inhibitor of PRMT5 enzymic activity in biochem. assays with a half-maximal inhibitory concn. (IC50) of 22 nM and broad selectivity against a panel of other histone methyltransferases.  Treatment of MCL cell lines with EPZ015666 led to inhibition of SmD3 methylation and cell death, with IC50 values in the nanomolar range.  Oral dosing with EPZ015666 demonstrated dose-dependent antitumor activity in multiple MCL xenograft models.  EPZ015666 represents a validated chem. probe for further study of PRMT5 biol. and arginine methylation in cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJTtcvcqvOJLVg90H21EOLACvtfcHk0lh1wVqoaLBJ4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotFartbo%253D&md5=bf0686e1c2d9d96ac5deef22c0bf80b7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1810%26sid%3Dliteratum%253Aachs%26aulast%3DChan-Penebre%26aufirst%3DE.%26aulast%3DKuplast%26aufirst%3DK.%2BG.%26aulast%3DMajer%26aufirst%3DC.%2BR.%26aulast%3DBoriack-Sjodin%26aufirst%3DP.%2BA.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DJohnston%26aufirst%3DL.%2BD.%26aulast%3DRioux%26aufirst%3DN.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DWest%26aufirst%3DK.%2BA.%26aulast%3DLingaraj%26aufirst%3DT.%26aulast%3DStickland%26aufirst%3DK.%26aulast%3DRibich%26aufirst%3DS.%2BA.%26aulast%3DRaimondi%26aufirst%3DA.%26aulast%3DScott%26aufirst%3DM.%2BP.%26aulast%3DWaters%26aufirst%3DN.%2BJ.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DSmith%26aufirst%3DJ.%2BJ.%26aulast%3DBarbash%26aufirst%3DO.%26aulast%3DPappalardi%26aufirst%3DM.%26aulast%3DHo%26aufirst%3DT.%2BF.%26aulast%3DNurse%26aufirst%3DK.%26aulast%3DOza%26aufirst%3DK.%2BP.%26aulast%3DGallagher%26aufirst%3DK.%2BT.%26aulast%3DKruger%26aufirst%3DR.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DDuncan%26aufirst%3DK.%2BW.%26atitle%3DA%2520selective%2520inhibitor%2520of%2520PRMT5%2520with%2520in%2520vivo%2520and%2520in%2520vitro%2520potency%2520in%2520MCL%2520models%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D432%26epage%3D437%26doi%3D10.1038%2Fnchembio.1810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3648</span>– <span class="NLM_lpage">3661</span>, <span class="refDoi"> DOI: 10.1039/C7OB00070G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1039%2FC7OB00070G" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=28397890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltl2mtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=3648-3661&author=Y.+Yeauthor=B.+Zhangauthor=R.+Maoauthor=C.+Zhangauthor=Y.+Wangauthor=J.+Xingauthor=Y.-C.+Liuauthor=X.+Luoauthor=H.+Dingauthor=Y.+Yangauthor=B.+Zhouauthor=H.+Jiangauthor=K.+Chenauthor=C.+Luoauthor=M.+Zheng&title=Discovery+and+optimization+of+selective+inhibitors+of+protein+arginine+methyltransferase+5+by+docking-based+virtual+screening&doi=10.1039%2FC7OB00070G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening</span></div><div class="casAuthors">Ye, Yan; Zhang, Bidong; Mao, Ruifeng; Zhang, Chenhua; Wang, Yulan; Xing, Jing; Liu, Yu-Chih; Luo, Xiaomin; Ding, Hong; Yang, Yaxi; Zhou, Bing; Jiang, Hualiang; Chen, Kaixian; Luo, Cheng; Zheng, Mingyue</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3648-3661</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is a type II PRMT enzyme crit. for diverse cellular processes and different types of cancers.  Many efforts have been made to discover novel scaffold PRMT5 inhibitors.  Herein, the authors report the discovery of DC_P33 as a hit compd. of PRMT5 inhibitor, identified by mol. docking based virtual screening and 3H-labeled radioactive methylation assays.  Structure-activity relationship (SAR) anal. was performed on the analogs of DC_P33 and then structural modifications were done to improve its activity.  Among the derivs., the compd. DC_C01 displayed an IC50 value of 2.8 μM, and good selectivity toward PRMT1, EZH2 and DNMT3A.  Moreover, DC_C01 exhibited anti-proliferation activities against Z-138, Maver-1, and Jeko-1 cancer cells with EC50 values of 12 μM, 12 μM, and 10.5 μM, resp.  Taken together, these results contribute to the development of specific inhibitors against PRMT5 and cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkWfdAd-COtbVg90H21EOLACvtfcHk0lit_v9DHNAR8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltl2mtr0%253D&md5=ead3b89fa64875e2dbf47c3a99714564</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1039%2FC7OB00070G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7OB00070G%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.-C.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520selective%2520inhibitors%2520of%2520protein%2520arginine%2520methyltransferase%25205%2520by%2520docking-based%2520virtual%2520screening%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2017%26volume%3D15%26spage%3D3648%26epage%3D3661%26doi%3D10.1039%2FC7OB00070G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, G.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Bryant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0181601</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0181601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1371%2Fjournal.pone.0181601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=28806746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2rtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=G.-M.+Kongauthor=M.+Yuauthor=Z.+Guauthor=Z.+Chenauthor=R.-M.+Xuauthor=D.+O%E2%80%99Bryantauthor=Z.+Wang&title=Selective+small-chemical+inhibitors+of+protein+arginine+methyltransferase+5+with+anti-lung+cancer+activity&doi=10.1371%2Fjournal.pone.0181601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity</span></div><div class="casAuthors">Kong, Gui-Mei; Yu, Min; Gu, Zhongping; Chen, Zhi; Xu, Rui-Ming; O'Bryant, Deon; Wang, Zhengxin</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0181601/1-e0181601/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) plays crit. roles in a wide variety of biol. processes, including tumorigenesis.  By screening a library of small chem. compds., we identified eight compds. that selectively inhibit the PRMT5 enzymic activity, with IC50 values ranging from 0.1 to 6 μM.  Mol. docking simulation and site directed mutagenesis indicated that identified compds. target the substrate-binding site in PRMT5.  Treatment of lung cancer cells with identified inhibitors led to inhibition of the sym. arginine methylation of SmD3 and histones and the cellular proliferation.  Oral administration of the inhibitor demonstrated antitumor activity in a lung tumor xenograft model.  Thus, identified PRMT5-specific small-mol. inhibitors would help elucidate the biol. roles of PRMT5 and serve as lead compds. for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHrmbn8I9YMLVg90H21EOLACvtfcHk0lit_v9DHNAR8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2rtbk%253D&md5=0306ed1351aac8a04d286df255c6e432</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0181601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0181601%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DG.-M.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DR.-M.%26aulast%3DO%25E2%2580%2599Bryant%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DSelective%2520small-chemical%2520inhibitors%2520of%2520protein%2520arginine%2520methyltransferase%25205%2520with%2520anti-lung%2520cancer%2520activity%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0181601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pande, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beke, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthelot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbera, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irving, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerpoel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nys, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parade, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viellevoye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuring, J. W.</span></span> <span> </span><span class="NLM_article-title">A chemical probe for the methyl transferase PRMT5 with a novel binding mode</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2231</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFartLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2227-2231&author=V.+Pandeauthor=W.+Sunauthor=L.+Bekeauthor=D.+Berthelotauthor=D.+Brehmerauthor=D.+Brownauthor=J.+Corberaauthor=S.+Irvingauthor=L.+Meerpoelauthor=T.+Nysauthor=M.+Paradeauthor=C.+Robinsonauthor=C.+Sommenauthor=M.+Viellevoyeauthor=T.+Wuauthor=J.+W.+Thuring&title=A+chemical+probe+for+the+methyl+transferase+PRMT5+with+a+novel+binding+mode&doi=10.1021%2Facsmedchemlett.0c00355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemical Probe for the Methyl Transferase PRMT5 with a Novel Binding Mode</span></div><div class="casAuthors">Pande, Vineet; Sun, Weimei; Beke, Lijs; Berthelot, Didier; Brehmer, Dirk; Brown, David; Corbera, Jordi; Irving, Steve; Meerpoel, Lieven; Nys, Thomas; Parade, Marc; Robinson, Colin; Sommen, Cois; Viellevoye, Marcel; Wu, Tongfei; Thuring, Jan Willem</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2227-2231</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is an enzyme that can sym. dimethylate arginine residues in histones and nonhistone proteins by using S-adenosyl methionine (SAM) as the Me donating cofactor.  We have designed a library of SAM analogs and discovered potent, cell-active, and selective spiro diamines as inhibitors of the enzymic function of PRMT5.  Crystallog. studies confirmed a very interesting binding mode, involving protein flexibility, where both the cofactor pocket and part of substrate binding site are occupied by these inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8blAXBpCBsrVg90H21EOLACvtfcHk0lgXmy027NKU7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFartLzF&md5=42905df2beb1d22965a0200fd0a23a4d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00355%26sid%3Dliteratum%253Aachs%26aulast%3DPande%26aufirst%3DV.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DBeke%26aufirst%3DL.%26aulast%3DBerthelot%26aufirst%3DD.%26aulast%3DBrehmer%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DCorbera%26aufirst%3DJ.%26aulast%3DIrving%26aufirst%3DS.%26aulast%3DMeerpoel%26aufirst%3DL.%26aulast%3DNys%26aufirst%3DT.%26aulast%3DParade%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DSommen%26aufirst%3DC.%26aulast%3DViellevoye%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DThuring%26aufirst%3DJ.%2BW.%26atitle%3DA%2520chemical%2520probe%2520for%2520the%2520methyl%2520transferase%2520PRMT5%2520with%2520a%2520novel%2520binding%2520mode%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D2227%26epage%3D2231%26doi%3D10.1021%2Facsmedchemlett.0c00355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antonysamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonday, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druzina, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gheyi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungheim, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauder, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasserman, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weichert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willard, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emtage, S.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human PRMT5:MEP50 complex</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">17960</span>– <span class="NLM_lpage">17965</span>, <span class="refDoi"> DOI: 10.1073/pnas.1209814109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1073%2Fpnas.1209814109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=23071334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2ktbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=17960-17965&author=S.+Antonysamyauthor=Z.+Bondayauthor=R.+M.+Campbellauthor=B.+Doyleauthor=Z.+Druzinaauthor=T.+Gheyiauthor=B.+Hanauthor=L.+N.+Jungheimauthor=Y.+Qianauthor=C.+Rauchauthor=M.+Russellauthor=J.+M.+Sauderauthor=S.+R.+Wassermanauthor=K.+Weichertauthor=F.+S.+Willardauthor=A.+Zhangauthor=S.+Emtage&title=Crystal+structure+of+the+human+PRMT5%3AMEP50+complex&doi=10.1073%2Fpnas.1209814109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human PRMT5:MEP50 complex</span></div><div class="casAuthors">Antonysamy, Stephen; Bonday, Zahid; Campbell, Robert M.; Doyle, Brandon; Druzina, Zhanna; Gheyi, Tarun; Han, Bomie; Jungheim, Louis N.; Qian, Yuewei; Rauch, Charles; Russell, Marijane; Sauder, J. Michael; Wasserman, Stephen R.; Wichert, Kenneth; Willard, Francis S.; Zhang, Aiping; Emtage, Spencer</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">17960-17965, S17960/1-S17960/9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Protein arginine methyltransferases (PRMTs) play important roles in several cellular processes, including signaling, gene regulation, and transport of proteins and nucleic acids, to impact growth, differentiation, proliferation, and development.  PRMT5 sym. di-methylates the two-terminal ω-guanidino nitrogens of arginine residues on substrate proteins.  PRMT5 acts as part of a multimeric complex in concert with a variety of partner proteins that regulate its function and specificity.  A core component of these complexes is the WD40 protein MEP50/WDR77/p44, which mediates interactions with binding partners and substrates.  We have detd. the crystal structure of human PRMT5 in complex with MEP50 (methylosome protein 50), bound to an S-adenosylmethionine analog and a peptide substrate derived from histone H4.  The structure of the surprising hetero-octameric complex reveals the close interaction between the seven-bladed β-propeller MEP50 and the N-terminal domain of PRMT5, and delineates the structural elements of substrate recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkcWBh5CVI7LVg90H21EOLACvtfcHk0lit-8F0BTS36g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2ktbvL&md5=757af18cfd0787a02c88c840273109aa</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1209814109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1209814109%26sid%3Dliteratum%253Aachs%26aulast%3DAntonysamy%26aufirst%3DS.%26aulast%3DBonday%26aufirst%3DZ.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26aulast%3DDoyle%26aufirst%3DB.%26aulast%3DDruzina%26aufirst%3DZ.%26aulast%3DGheyi%26aufirst%3DT.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DJungheim%26aufirst%3DL.%2BN.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DRauch%26aufirst%3DC.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DSauder%26aufirst%3DJ.%2BM.%26aulast%3DWasserman%26aufirst%3DS.%2BR.%26aulast%3DWeichert%26aufirst%3DK.%26aulast%3DWillard%26aufirst%3DF.%2BS.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DEmtage%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520PRMT5%253AMEP50%2520complex%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2012%26volume%3D109%26spage%3D17960%26epage%3D17965%26doi%3D10.1073%2Fpnas.1209814109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timm, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, C.</span></span> <span> </span><span class="NLM_article-title">Cryo-electron microscopy structure of a human PRMT5:MEP50 complex</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0193205</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0193205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1371%2Fjournal.pone.0193205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=29518110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslWms7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=D.+E.+Timmauthor=V.+Bowmanauthor=R.+Madsenauthor=C.+Rauch&title=Cryo-electron+microscopy+structure+of+a+human+PRMT5%3AMEP50+complex&doi=10.1371%2Fjournal.pone.0193205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-electron microscopy structure of a human PRMT5:MEP50 complex</span></div><div class="casAuthors">Timm, David E.; Bowman, Valorie; Madsen, Russell; Rauch, Charles</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0193205/1-e0193205/13</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Protein arginine Me transferase 5 (PRMT5) is a signaling protein and histone modifying enzyme that is important in many cellular processes, including regulation of eukaryotic gene transcription.  Reported here is a 3.7 Å structure of PRMT5, solved in complex with regulatory binding subunit MEP50 (methylosome assocd. protein 50, WDR77, p44), by single particle (SP) cryo-Electron Microscopy (cryo-EM) using micrographs of particles that are visibly crowded and aggregated.  Despite suboptimal micrograph appearance, this cryo-EM structure is in good agreement with previously reported crystal structures of the complex, which revealed a 450 kDa hetero-octameric assembly having internal D2 symmetry.  The catalytic PRMT5 subunits form a core tetramer and the MEP50 subunits are arranged peripherally in complex with the PRMT5 N-terminal domain.  The cryo-EM reconstruction shows good side chain definition and shows a well-resolved peak for a bound dehydrosinefungin inhibitor mol.  These results demonstrate the applicability of cryo-EM in detg. structures of human protein complexes of biomedical significance and suggests cryo-EM could be further utilized to understand PRMT5 interactions with other biol. important binding proteins and ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVrd4Ga-2QJrVg90H21EOLACvtfcHk0lit-8F0BTS36g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslWms7%252FO&md5=e2410a0d8b80ec2f9c37bb96b390b46f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0193205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0193205%26sid%3Dliteratum%253Aachs%26aulast%3DTimm%26aufirst%3DD.%2BE.%26aulast%3DBowman%26aufirst%3DV.%26aulast%3DMadsen%26aufirst%3DR.%26aulast%3DRauch%26aufirst%3DC.%26atitle%3DCryo-electron%2520microscopy%2520structure%2520of%2520a%2520human%2520PRMT5%253AMEP50%2520complex%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0193205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marjon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clasquin, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunii, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kernytsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konteatis, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murtie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biller, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, K. M.</span></span> <span> </span><span class="NLM_article-title">MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">574</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.03.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.celrep.2016.03.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=27068473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsleltrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=574-587&author=K.+Marjonauthor=M.+J.+Cameronauthor=P.+Quangauthor=M.+F.+Clasquinauthor=E.+Mandleyauthor=K.+Kuniiauthor=M.+McVayauthor=S.+Choeauthor=A.+Kernytskyauthor=S.+Grossauthor=Z.+Konteatisauthor=J.+Murtieauthor=M.+L.+Blakeauthor=J.+Travinsauthor=M.+Dorschauthor=S.+A.+Billerauthor=K.+M.+Marks&title=MTAP+deletions+in+cancer+create+vulnerability+to+targeting+of+the+MAT2A%2FPRMT5%2FRIOK1+axis&doi=10.1016%2Fj.celrep.2016.03.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis</span></div><div class="casAuthors">Marjon, Katya; Cameron, Michael J.; Quang, Phong; Clasquin, Michelle F.; Mandley, Everton; Kunii, Kaiko; McVay, Michael; Choe, Sung; Kernytsky, Andrew; Gross, Stefan; Konteatis, Zenon; Murtie, Joshua; Blake, Michelle L.; Travins, Jeremy; Dorsch, Marion; Biller, Scott A.; Marks, Kevin M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">574-587</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Homozygous deletions of p16/CDKN2A are prevalent in cancer, and these mutations commonly involve co-deletion of adjacent genes, including methylthioadenosine phosphorylase (MTAP).  Here, we used shRNA screening and identified the metabolic enzyme, methionine adenosyltransferase II alpha (MAT2A), and the arginine methyltransferase, PRMT5, as vulnerable enzymes in cells with MTAP deletion.  Metabolomic and biochem. studies revealed a mechanistic basis for this synthetic lethality.  The MTAP substrate methylthioadenosine (MTA) accumulates upon MTAP loss.  Biochem. profiling of a methyltransferase enzyme panel revealed that MTA is a potent and selective inhibitor of PRMT5.  MTAP-deleted cells have reduced PRMT5 methylation activity and increased sensitivity to PRMT5 depletion.  MAT2A produces the PRMT5 substrate S-adenosylmethionine (SAM), and MAT2A depletion reduces growth and PRMT5 methylation activity selectively in MTAP-deleted cells.  Furthermore, this vulnerability extends to PRMT5 co-complex proteins such as RIOK1.  Thus, the unique biochem. features of PRMT5 create an axis of targets vulnerable in CDKN2A/MTAP-deleted cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokW739dwptcbVg90H21EOLACvtfcHk0lit-8F0BTS36g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsleltrk%253D&md5=73a6839e63b85a71f3661dc9e0c7b4ea</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.03.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.03.043%26sid%3Dliteratum%253Aachs%26aulast%3DMarjon%26aufirst%3DK.%26aulast%3DCameron%26aufirst%3DM.%2BJ.%26aulast%3DQuang%26aufirst%3DP.%26aulast%3DClasquin%26aufirst%3DM.%2BF.%26aulast%3DMandley%26aufirst%3DE.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DMcVay%26aufirst%3DM.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DKernytsky%26aufirst%3DA.%26aulast%3DGross%26aufirst%3DS.%26aulast%3DKonteatis%26aufirst%3DZ.%26aulast%3DMurtie%26aufirst%3DJ.%26aulast%3DBlake%26aufirst%3DM.%2BL.%26aulast%3DTravins%26aufirst%3DJ.%26aulast%3DDorsch%26aufirst%3DM.%26aulast%3DBiller%26aufirst%3DS.%2BA.%26aulast%3DMarks%26aufirst%3DK.%2BM.%26atitle%3DMTAP%2520deletions%2520in%2520cancer%2520create%2520vulnerability%2520to%2520targeting%2520of%2520the%2520MAT2A%252FPRMT5%252FRIOK1%2520axis%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D15%26spage%3D574%26epage%3D587%26doi%3D10.1016%2Fj.celrep.2016.03.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mavrakis, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E. R.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlabach, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deWeck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stump, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">deBeaumont, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan-Neale, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipp, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprague, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciccone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitari, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallarico, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickanin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmeier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1208</span>– <span class="NLM_lpage">1213</span>, <span class="refDoi"> DOI: 10.1126/science.aad5944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1126%2Fscience.aad5944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=26912361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs12gtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2016&pages=1208-1213&author=K.+J.+Mavrakisauthor=E.+R.+McDonaldauthor=M.+R.+Schlabachauthor=E.+Billyauthor=G.+R.+Hoffmanauthor=A.+deWeckauthor=D.+A.+Ruddyauthor=K.+Venkatesanauthor=J.+Yuauthor=G.+McAllisterauthor=M.+Stumpauthor=R.+deBeaumontauthor=S.+Hoauthor=Y.+Yueauthor=Y.+Liuauthor=Y.+Yan-Nealeauthor=G.+Yangauthor=F.+Linauthor=H.+Yinauthor=H.+Gaoauthor=D.+R.+Kippauthor=S.+Zhaoauthor=J.+T.+McNamaraauthor=E.+R.+Spragueauthor=B.+Zhengauthor=Y.+Linauthor=Y.+S.+Choauthor=J.+Guauthor=K.+Crawfordauthor=D.+Cicconeauthor=A.+C.+Vitariauthor=A.+Laiauthor=V.+Capkaauthor=K.+Hurovauthor=J.+A.+Porterauthor=J.+Tallaricoauthor=C.+Mickaninauthor=E.+Leesauthor=R.+Pagliariniauthor=N.+Keenauthor=T.+Schmelzleauthor=F.+Hofmannauthor=F.+Stegmeierauthor=W.+R.+Sellers&title=Disordered+methionine+metabolism+in+MTAP%2FCDKN2A-deleted+cancers+leads+to+dependence+on+PRMT5&doi=10.1126%2Fscience.aad5944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5</span></div><div class="casAuthors">Mavrakis, Konstantinos J.; McDonald, E. Robert, III; Schlabach, Michael R.; Billy, Eric; Hoffman, Gregory R.; de Weck, Antoine; Ruddy, David A.; Venkatesan, Kavitha; Yu, Jianjun; McAllister, Gregg; Stump, Mark; de Beaumont, Rosalie; Ho, Samuel; Yue, Yingzi; Liu, Yue; Yan-Neale, Yan; Yang, Guizhi; Lin, Fallon; Yin, Hong; Gao, Hui; Kipp, D. Randal; Zhao, Songping; McNamara, Joshua T.; Sprague, Elizabeth R.; Zheng, Bing; Lin, Ying; Cho, Young Shin; Gu, Justin; Crawford, Kenneth; Ciccone, David; Vitari, Alberto C.; Lai, Albert; Capka, Vladimir; Hurov, Kristen; Porter, Jeffery A.; Tallarico, John; Mickanin, Craig; Lees, Emma; Pagliarini, Raymond; Keen, Nicholas; Schmelzle, Tobias; Hofmann, Francesco; Stegmeier, Frank; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">6278</span>),
    <span class="NLM_cas:pages">1208-1213</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">5-Methylthioadenosine phosphorylase (MTAP) is a key enzyme in the methionine salvage pathway.  The MTAP gene is frequently deleted in human cancers because of its chromosomal proximity to the tumor suppressor gene CDKN2A.  By interrogating data from a large-scale short hairpin RNA-mediated screen across 390 cancer cell line models, we found that the viability of MTAP-deficient cancer cells is impaired by depletion of the protein arginine methyltransferase PRMT5.  MTAP-deleted cells accumulate the metabolite methylthioadenosine (MTA), which we found to inhibit PRMT5 methyltransferase activity.  Deletion of MTAP in MTAP-proficient cells rendered them sensitive to PRMT5 depletion.  Conversely, reconstitution of MTAP in an MTAP-deficient cell line rescued PRMT5 dependence.  Thus, MTA accumulation in MTAP-deleted cancers creates a hypomorphic PRMT5 state that is selectively sensitized toward further PRMT5 inhibition.  Inhibitors of PRMT5 that leverage this dysregulated metabolic state merit further investigation as a potential therapy for MTAP/CDKN2A-deleted tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNsuzYFo1qn7Vg90H21EOLACvtfcHk0lgvo-bjOaGCJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs12gtr0%253D&md5=d77531ea765db9762d6815840d39ee4a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad5944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad5944%26sid%3Dliteratum%253Aachs%26aulast%3DMavrakis%26aufirst%3DK.%2BJ.%26aulast%3DMcDonald%26aufirst%3DE.%2BR.%26aulast%3DSchlabach%26aufirst%3DM.%2BR.%26aulast%3DBilly%26aufirst%3DE.%26aulast%3DHoffman%26aufirst%3DG.%2BR.%26aulast%3DdeWeck%26aufirst%3DA.%26aulast%3DRuddy%26aufirst%3DD.%2BA.%26aulast%3DVenkatesan%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DStump%26aufirst%3DM.%26aulast%3DdeBeaumont%26aufirst%3DR.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DYue%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYan-Neale%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DKipp%26aufirst%3DD.%2BR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DMcNamara%26aufirst%3DJ.%2BT.%26aulast%3DSprague%26aufirst%3DE.%2BR.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DCiccone%26aufirst%3DD.%26aulast%3DVitari%26aufirst%3DA.%2BC.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DCapka%26aufirst%3DV.%26aulast%3DHurov%26aufirst%3DK.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DTallarico%26aufirst%3DJ.%26aulast%3DMickanin%26aufirst%3DC.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DPagliarini%26aufirst%3DR.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DSchmelzle%26aufirst%3DT.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DStegmeier%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DDisordered%2520methionine%2520metabolism%2520in%2520MTAP%252FCDKN2A-deleted%2520cancers%2520leads%2520to%2520dependence%2520on%2520PRMT5%26jtitle%3DScience%26date%3D2016%26volume%3D351%26spage%3D1208%26epage%3D1213%26doi%3D10.1126%2Fscience.aad5944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kryukov, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruth, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsherniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielski, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Root, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golub, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garraway, L. A.</span></span> <span> </span><span class="NLM_article-title"><i>MTAP</i> deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1214</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1126/science.aad5214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1126%2Fscience.aad5214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=26912360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs12gtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2016&pages=1214-1218&author=G.+V.+Kryukovauthor=F.+H.+Wilsonauthor=J.+R.+Ruthauthor=J.+Paulkauthor=A.+Tsherniakauthor=S.+E.+Marlowauthor=F.+Vazquezauthor=B.+A.+Weirauthor=M.+E.+Fitzgeraldauthor=M.+Tanakaauthor=C.+M.+Bielskiauthor=J.+M.+Scottauthor=C.+Dennisauthor=G.+S.+Cowleyauthor=J.+S.+Boehmauthor=D.+E.+Rootauthor=T.+R.+Golubauthor=C.+B.+Clishauthor=J.+E.+Bradnerauthor=W.+C.+Hahnauthor=L.+A.+Garraway&title=MTAP+deletion+confers+enhanced+dependency+on+the+PRMT5+arginine+methyltransferase+in+cancer+cells&doi=10.1126%2Fscience.aad5214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells</span></div><div class="casAuthors">Kryukov, Gregory V.; Wilson, Frederick H.; Ruth, Jason R.; Paulk, Joshiawa; Tsherniak, Aviad; Marlow, Sara E.; Vazquez, Francisca; Weir, Barbara A.; Fitzgerald, Mark E.; Tanaka, Minoru; Bielski, Craig M.; Scott, Justin M.; Dennis, Courtney; Cowley, Glenn S.; Boehm, Jesse S.; Root, David E.; Golub, Todd R.; Clish, Clary B.; Bradner, James E.; Hahn, William C.; Garraway, Levi A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">6278</span>),
    <span class="NLM_cas:pages">1214-1218</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The discovery of cancer dependencies has the potential to inform therapeutic strategies and to identify putative drug targets.  Integrating data from comprehensive genomic profiling of cancer cell lines and from functional characterization of cancer cell dependencies, we discovered that loss of the enzyme methylthioadenosine phosphorylase (MTAP) confers a selective dependence on protein arginine methyltransferase 5 (PRMT5) and its binding partner WDR77.  MTAP is frequently lost due to its proximity to the commonly deleted tumor suppressor gene, CDKN2A.  We obsd. increased intracellular concns. of methylthioadenosine (MTA, the metabolite cleaved by MTAP) in cells harboring MTAP deletions.  Furthermore, MTA specifically inhibited PRMT5 enzymic activity.  Administration of either MTA or a small-mol. PRMT5 inhibitor showed a modest preferential impairment of cell viability for MTAP-null cancer cell lines compared with isogenic MTAP-expressing counterparts.  Together, our findings reveal PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common "passenger" genomic alteration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr94dQPnMgrqbVg90H21EOLACvtfcHk0lhVsI_mIy_dDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs12gtro%253D&md5=2b017a8c54972828c9024a9d85ff2e2d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad5214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad5214%26sid%3Dliteratum%253Aachs%26aulast%3DKryukov%26aufirst%3DG.%2BV.%26aulast%3DWilson%26aufirst%3DF.%2BH.%26aulast%3DRuth%26aufirst%3DJ.%2BR.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DTsherniak%26aufirst%3DA.%26aulast%3DMarlow%26aufirst%3DS.%2BE.%26aulast%3DVazquez%26aufirst%3DF.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DFitzgerald%26aufirst%3DM.%2BE.%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DBielski%26aufirst%3DC.%2BM.%26aulast%3DScott%26aufirst%3DJ.%2BM.%26aulast%3DDennis%26aufirst%3DC.%26aulast%3DCowley%26aufirst%3DG.%2BS.%26aulast%3DBoehm%26aufirst%3DJ.%2BS.%26aulast%3DRoot%26aufirst%3DD.%2BE.%26aulast%3DGolub%26aufirst%3DT.%2BR.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DHahn%26aufirst%3DW.%2BC.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26atitle%3DMTAP%2520deletion%2520confers%2520enhanced%2520dependency%2520on%2520the%2520PRMT5%2520arginine%2520methyltransferase%2520in%2520cancer%2520cells%26jtitle%3DScience%26date%3D2016%26volume%3D351%26spage%3D1214%26epage%3D1218%26doi%3D10.1126%2Fscience.aad5214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbarino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namagerdi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertolino, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proietti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Micheli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Santi, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guazzo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirtoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Indovina, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">PRMT5 silencing selectively affects <i>MTAP</i>-deleted mesothelioma: in vitro evidence of a novel promising approach</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">5565</span>– <span class="NLM_lpage">5577</span>, <span class="refDoi"> DOI: 10.1111/jcmm.15213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1111%2Fjcmm.15213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=32301278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovFGisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=5565-5577&author=M.+Barbarinoauthor=D.+Cesariauthor=M.+Bottaroauthor=L.+Luzziauthor=A.+Namagerdiauthor=F.+M.+Bertolinoauthor=C.+Bellanauthor=F.+Proiettiauthor=P.+Sommaauthor=M.+Micheliauthor=M.+M.+de+Santiauthor=R.+Guazzoauthor=L.+Muttiauthor=L.+Pirtoliauthor=P.+Paladiniauthor=P.+Indovinaauthor=A.+Giordano&title=PRMT5+silencing+selectively+affects+MTAP-deleted+mesothelioma%3A+in+vitro+evidence+of+a+novel+promising+approach&doi=10.1111%2Fjcmm.15213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach</span></div><div class="casAuthors">Barbarino, Marcella; Cesari, Daniele; Bottaro, Maria; Luzzi, Luca; Namagerdi, Asadoor; Bertolino, Franca Maria; Bellan, Cristiana; Proietti, Fabrizio; Somma, Pasquale; Micheli, Mariacarolina; de Santi, Maria Margherita; Guazzo, Raffaella; Mutti, Luciano; Pirtoli, Luigi; Paladini, Piero; Indovina, Paola; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5565-5577</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Malignant mesothelioma (MM) is an aggressive asbestos-related cancer of the serous membranes.  Despite intensive treatment regimens, MM is still a fatal disease, mainly due to the intrinsic resistance to current therapies and the lack of predictive markers and new valuable mol. targets.  Protein arginine methyltransferase 5 (PRMT5) inhibition has recently emerged as a potential therapy against methylthioadenosine phosphorylase (MTAP)-deficient cancers, in which the accumulation of the substrate 5'-methylthioadenosine (MTA) inhibits PRMT5 activity, thus sensitizing the cells to further PRMT5 inhibition.  Considering that the MTAP gene is frequently codeleted with the adjacent cyclin-dependent kinase inhibitor 2A (CDKN2A) locus in MM, we assessed whether PRMT5 could represent a therapeutic target also for this cancer type.  We evaluated PRMT5 expression, the MTAP status and MTA content in normal mesothelial and MM cell lines.  We found that both administration of exogenous MTA and stable PRMT5 knock-down, by short hairpin RNAs (shRNAs), selectively reduced the growth of MTAP-deleted MM cells.  We also obsd. that PRMT5 knock-down in MTAP-deficient MM cells reduced the expression of E2F1 target genes involved in cell cycle progression and of factors implicated in epithelial-to-mesenchymal transition.  Therefore, PRMT5 targeting could represent a promising new therapeutic strategy against MTAP-deleted MMs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxtUD-iMY29bVg90H21EOLACvtfcHk0lidWQVFjxmcUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovFGisrg%253D&md5=401f56cd01d53640943ed2abb80dc17f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.15213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.15213%26sid%3Dliteratum%253Aachs%26aulast%3DBarbarino%26aufirst%3DM.%26aulast%3DCesari%26aufirst%3DD.%26aulast%3DBottaro%26aufirst%3DM.%26aulast%3DLuzzi%26aufirst%3DL.%26aulast%3DNamagerdi%26aufirst%3DA.%26aulast%3DBertolino%26aufirst%3DF.%2BM.%26aulast%3DBellan%26aufirst%3DC.%26aulast%3DProietti%26aufirst%3DF.%26aulast%3DSomma%26aufirst%3DP.%26aulast%3DMicheli%26aufirst%3DM.%26aulast%3Dde%2BSanti%26aufirst%3DM.%2BM.%26aulast%3DGuazzo%26aufirst%3DR.%26aulast%3DMutti%26aufirst%3DL.%26aulast%3DPirtoli%26aufirst%3DL.%26aulast%3DPaladini%26aufirst%3DP.%26aulast%3DIndovina%26aufirst%3DP.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DPRMT5%2520silencing%2520selectively%2520affects%2520MTAP-deleted%2520mesothelioma%253A%2520in%2520vitro%2520evidence%2520of%2520a%2520novel%2520promising%2520approach%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2020%26volume%3D24%26spage%3D5565%26epage%3D5577%26doi%3D10.1111%2Fjcmm.15213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palte, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansueto, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reutershan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliphaivanh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machacek, M. R.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of protein arginine methyltransferase 5 (PRMT5)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1688</span>– <span class="NLM_lpage">1693</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00525</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00525" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFehtb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1688-1693&author=R.+L.+Palteauthor=S.+E.+Schneiderauthor=M.+D.+Altmanauthor=R.+P.+Hayesauthor=S.+Kawamuraauthor=B.+M.+Laceyauthor=M.+S.+Mansuetoauthor=M.+Reutershanauthor=P.+Siliphaivanhauthor=C.+Sondeyauthor=H.+Xuauthor=Z.+Xuauthor=Y.+Yeauthor=M.+R.+Machacek&title=Allosteric+modulation+of+protein+arginine+methyltransferase+5+%28PRMT5%29&doi=10.1021%2Facsmedchemlett.9b00525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)</span></div><div class="casAuthors">Palte, Rachel L.; Schneider, Sebastian E.; Altman, Michael D.; Hayes, Robert P.; Kawamura, Shuhei; Lacey, Brian M.; Mansueto, My Sam; Reutershan, Michael; Siliphaivanh, Phieng; Sondey, Christopher; Xu, Haiyan; Xu, Zangwei; Ye, Yingchun; Machacek, Michelle R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1688-1693</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) belongs to a family of enzymes that regulate the posttranslational modification of histones and other proteins via methylation of arginine.  Methylation of histones is linked to an increase in transcription and regulates a manifold of functions such as signal transduction and transcriptional regulation.  PRMT5 has been shown to be upregulated in the tumor environment of several cancer types, and the inhibition of PRMT5 activity was identified as a potential way to reduce tumor growth.  Previously, four different modes of PRMT5 inhibition were known-competing (covalently or non-covalently) with the essential cofactor S-adenosyl methionine (SAM), blocking the substrate binding pocket, or blocking both simultaneously.  Herein we describe an unprecedented conformation of PRMT5 in which the formation of an allosteric binding pocket abrogates the enzyme's canonical binding site and present the discovery of potent small mol. allosteric PRMT5 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFkbnJkLKiL7Vg90H21EOLACvtfcHk0lidWQVFjxmcUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFehtb7P&md5=75a8f75e60a3e20444af90b79c5af810</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00525%26sid%3Dliteratum%253Aachs%26aulast%3DPalte%26aufirst%3DR.%2BL.%26aulast%3DSchneider%26aufirst%3DS.%2BE.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DHayes%26aufirst%3DR.%2BP.%26aulast%3DKawamura%26aufirst%3DS.%26aulast%3DLacey%26aufirst%3DB.%2BM.%26aulast%3DMansueto%26aufirst%3DM.%2BS.%26aulast%3DReutershan%26aufirst%3DM.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DSondey%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DMachacek%26aufirst%3DM.%2BR.%26atitle%3DAllosteric%2520modulation%2520of%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1688%26epage%3D1693%26doi%3D10.1021%2Facsmedchemlett.9b00525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leal, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetty, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luengo, J. I.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective covalent protein arginine methyltransferase 5 (PRMT5) inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00074</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00074" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A280%3ADC%252BB3MzotVeltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1033-1038&author=H.+Linauthor=M.+Wangauthor=Y.+W.+Zhangauthor=S.+Tongauthor=R.+A.+Lealauthor=R.+Shettyauthor=K.+Vaddiauthor=J.+I.+Luengo&title=Discovery+of+potent+and+selective+covalent+protein+arginine+methyltransferase+5+%28PRMT5%29+inhibitors&doi=10.1021%2Facsmedchemlett.9b00074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors</span></div><div class="casAuthors">Lin Hong; Wang Min; Zhang Yang W; Leal Raul A; Shetty Rupa; Vaddi Kris; Luengo Juan I; Tong Shuilong</div><div class="citationInfo"><span class="NLM_cas:title">ACS medicinal chemistry letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1033-1038</span>
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    </div><div class="casAbstract">Protein arginine methyltransferase 5 (PRMT5) is known to symmetrically dimethylate numerous cytosolic and nuclear proteins that are involved in a variety of cellular processes.  Recent findings have revealed its potential as a cancer therapeutic target.  PRMT5 possesses a cysteine (C449) in the active site, unique to PRMT5.  Therefore, covalent PRMT5 inhibition is an attractive chemical approach.  Herein, we report an exciting discovery of a series of novel hemiaminals that under physiological conditions can be converted to aldehydes and react with C449 to form covalent adducts, which presumably undergo an unprecedented elimination to form the thiol-vinyl ethers, as indicated by electron density in the co-crystal structure of the PRMT5/MEP50 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdNDVSKB6iezW1zwg2yUK5fW6udTcc2ebrWr4h7y5jF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzotVeltQ%253D%253D&md5=4b5b08dc3e3615144ece564f70bf3bd0</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00074%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DY.%2BW.%26aulast%3DTong%26aufirst%3DS.%26aulast%3DLeal%26aufirst%3DR.%2BA.%26aulast%3DShetty%26aufirst%3DR.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520covalent%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1033%26epage%3D1038%26doi%3D10.1021%2Facsmedchemlett.9b00074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guccione, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedford, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">9977</span>– <span class="NLM_lpage">9989</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01111</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01111" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFOisLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=9977-9989&author=Y.+Shenauthor=G.+Gaoauthor=X.+Yuauthor=H.+Kimauthor=L.+Wangauthor=L.+Xieauthor=M.+Schwarzauthor=X.+Chenauthor=E.+Guccioneauthor=J.+Liuauthor=M.+T.+Bedfordauthor=J.+Jin&title=Discovery+of+first-in-class+protein+arginine+methyltransferase+5+%28PRMT5%29+degraders&doi=10.1021%2Facs.jmedchem.0c01111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders</span></div><div class="casAuthors">Shen, Yudao; Gao, Guozhen; Yu, Xufen; Kim, Huensuk; Wang, Li; Xie, Ling; Schwarz, Megan; Chen, Xian; Guccione, Ernesto; Liu, Jing; Bedford, Mark T.; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">9977-9989</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aberrant expression of protein arginine methyltransferase 5 (PRMT5) has been assocd. with multiple cancers.  Using the proteolysis targeting chimera technol., we discovered a first-in-class PRMT5 degrader 15 (MS4322).  Here, we report the design, synthesis, and characterization of compd. 15 and two structurally similar controls 17 (MS4370) and 21 (MS4369), with impaired binding to the von Hippel-Lindau E3 ligase and PRMT5, resp.  Compd. 15, but not 17 and 21, effectively reduced the PRMT5 protein level in MCF-7 cells.  Our mechanism studies indicate that compd. 15 degraded PRMT5 in an E3 ligase- and proteasome-dependent manner.  Compd. 15 also effectively reduced the PRMT5 protein level and inhibited growth in multiple cancer cell lines.  Moreover, compd. 15 was highly selective for PRMT5 in a global proteomic study and exhibited good plasma exposure in mice.  Collectively, compd. 15 and its two controls 17 and 21 are valuable chem. tools for exploring the PRMT5 functions in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZoL-YbkPwxrVg90H21EOLACvtfcHk0liahbLD3IBmrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFOisLrE&md5=5400a4b400d1a420eff5b24f735de462</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01111%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DSchwarz%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DGuccione%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBedford%26aufirst%3DM.%2BT.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520first-in-class%2520protein%2520arginine%2520methyltransferase%25205%2520%2528PRMT5%2529%2520degraders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D9977%26epage%3D9989%26doi%3D10.1021%2Facs.jmedchem.0c01111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span>; <span class="NLM_string-name">Brehmer, D.</span>; <span class="NLM_string-name">Beke, L.</span>; <span class="NLM_string-name">Boeckx, A.</span>; <span class="NLM_string-name">Diels, G. S. M.</span>; <span class="NLM_string-name">Gilissen, R. A. H. J.</span>; <span class="NLM_string-name">Lawson, E. C.</span>; <span class="NLM_string-name">Pande, V.</span>; <span class="NLM_string-name">Paradé, M. C. B. C.</span>; <span class="NLM_string-name">Schepens, W. B. G.</span>; <span class="NLM_string-name">Thuring, J. W. J. F.</span>; <span class="NLM_string-name">Viellevoye, M.</span>; <span class="NLM_string-name">Sun, W.</span>; <span class="NLM_string-name">Meerpoel, L.</span></span> <span> </span><span class="NLM_article-title">6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors</span>. U.S. Patent <span class="NLM_patent">10,653,711 B2</span>, May 19, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=T.+Wu&author=D.+Brehmer&author=L.+Beke&author=A.+Boeckx&author=G.+S.+M.+Diels&author=R.+A.+H.+J.+Gilissen&author=E.+C.+Lawson&author=V.+Pande&author=M.+C.+B.+C.+Parad%C3%A9&author=W.+B.+G.+Schepens&author=J.+W.+J.+F.+Thuring&author=M.+Viellevoye&author=W.+Sun&author=L.+Meerpoel&title=6-6+bicyclic+aromatic+ring+substituted+nucleoside+analogues+for+use+as+PRMT5+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DT.%26atitle%3D6-6%2520bicyclic%2520aromatic%2520ring%2520substituted%2520nucleoside%2520analogues%2520for%2520use%2520as%2520PRMT5%2520inhibitors%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. B.</span></span> <span> </span><span class="NLM_article-title">Conformational control in structure-based drug design</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2825</span>– <span class="NLM_lpage">2837</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.bmcl.2017.04.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=28479196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFamtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2825-2837&author=Y.+Zhengauthor=C.+M.+Ticeauthor=S.+B.+Singh&title=Conformational+control+in+structure-based+drug+design&doi=10.1016%2Fj.bmcl.2017.04.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational control in structure-based drug design</span></div><div class="casAuthors">Zheng, Yajun; Tice, Colin M.; Singh, Suresh B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2825-2837</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In structure-based drug design, the basic goal is to design mols. that fit complementarily to a given binding pocket.  Since such computationally modeled mols. may not adopt the intended bound conformation outside the binding pocket, one challenge is to ensure that the designed ligands adopt similar low energy conformations both inside and outside of the binding pocket.  Computational chem. methods and conformational preferences of small mols. from PDB and Cambridge Structural Database (CSD) can be used to predict the bound structures of the designed mols.  Herein, we review applications of conformational control in structure-based drug design using selected examples from the recent medicinal chem. literature.  The main purpose is to highlight some intriguing conformational features that can be applied to other drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbfYQ3iP4BT7Vg90H21EOLACvtfcHk0ljRhhH7liuuQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFamtr8%253D&md5=aef5a7aa51f9b6a8454345a4e38d95db</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.079%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DTice%26aufirst%3DC.%2BM.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DConformational%2520control%2520in%2520structure-based%2520drug%2520design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2825%26epage%3D2837%26doi%3D10.1016%2Fj.bmcl.2017.04.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rai, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sresht, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathiowetz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakken, G. A.</span></span> <span> </span><span class="NLM_article-title">Comprehensive assessment of torsional strain in crystal structures of small molecules and protein-ligand complexes using ab initio calculations</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4195</span>– <span class="NLM_lpage">4208</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.9b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.9b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVylsLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=4195-4208&author=B.+K.+Raiauthor=V.+Sreshtauthor=Q.+Yangauthor=R.+Unwallaauthor=M.+Tuauthor=A.+M.+Mathiowetzauthor=G.+A.+Bakken&title=Comprehensive+assessment+of+torsional+strain+in+crystal+structures+of+small+molecules+and+protein-ligand+complexes+using+ab+initio+calculations&doi=10.1021%2Facs.jcim.9b00373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive Assessment of Torsional Strain in Crystal Structures of Small Molecules and Protein-Ligand Complexes using ab Initio Calculations</span></div><div class="casAuthors">Rai, Brajesh K.; Sresht, Vishnu; Yang, Qingyi; Unwalla, Ray; Tu, Meihua; Mathiowetz, Alan M.; Bakken, Gregory A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4195-4208</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The energetics of rotation around single bonds (torsions) is a key determinant of the 3D shape that drug-like mols. adopt in soln., the solid state, and in different biol. environments, which in turn defines their unique phys. and pharmacol. properties.  Therefore, accurate characterization of torsion angle preference and energetics is essential for the success of computational drug discovery and design.  Here, the authors analyze torsional strain in crystal structures of drug-like mols. in CSD and bioactive ligand conformations in PDB, expressing the total strain energy as a sum of strain energy from constituent rotatable bonds.  The authors utilized Cloud computing to generate torsion scan profiles of a very large collection of chem. diverse neutral fragments at DFT(B3LYP)/6-31G*//6-31G** or DFT(B3LYP)/6-31+G*//6-31+G** (for sulfur-contg. mol.).  With the data generated from these ab initio calcns., the authors performed rigorous anal. of strain due to deviation of obsd. torsion angles relative to their ideal gas-phase geometries.  Contrary to the previous studies based on mol. mechanics, the authors find that in the cryst.-state mols. generally adopt low-strain conformations, with median per-torsion strain energy in CSD and PDB under 1/10th and 1/3rd of a kcal/mol, resp.  However, for a small fraction (<5%) of motifs, external effects such as steric hindrance and hydrogen bonds result in strain penalty exceeding 2.5 kcal/mol.  The authors find that due to poor quality of PDB structures in general, bioactive structures tend to have higher torsional strain compared to small mol. crystal conformations.  However, in the absence of structural fitting artifacts in PDB structures, protein-induced strain in bioactive conformations is quant. similar to those due to the packing forces in small mol. crystal structures.  This anal. allows us to establish strain energy thresholds to help to identify biol. relevant conformers in a given ensemble.  The work presented here is the most comprehensive study to date that demonstrates the utility and feasibility of gas-phase QM calcns. to study conformational preference and energetics of drug-size mols.  Potential applications of this study in computational lead discovery and structure-based design are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-hW26jnNxD7Vg90H21EOLACvtfcHk0ljRhhH7liuuQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVylsLzP&md5=d8da7e8bc163683f544f7c1c7968485f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.9b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.9b00373%26sid%3Dliteratum%253Aachs%26aulast%3DRai%26aufirst%3DB.%2BK.%26aulast%3DSresht%26aufirst%3DV.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DUnwalla%26aufirst%3DR.%26aulast%3DTu%26aufirst%3DM.%26aulast%3DMathiowetz%26aufirst%3DA.%2BM.%26aulast%3DBakken%26aufirst%3DG.%2BA.%26atitle%3DComprehensive%2520assessment%2520of%2520torsional%2520strain%2520in%2520crystal%2520structures%2520of%2520small%2520molecules%2520and%2520protein-ligand%2520complexes%2520using%2520ab%2520initio%2520calculations%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2019%26volume%3D59%26spage%3D4195%26epage%3D4208%26doi%3D10.1021%2Facs.jcim.9b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis of bicyclic nucleosides by ring-closing metathesis</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1039/b101364p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1039%2Fb101364p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjtFCgurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&pages=985-993&author=J.+Ravnauthor=P.+Nielsen&title=Synthesis+of+bicyclic+nucleosides+by+ring-closing+metathesis&doi=10.1039%2Fb101364p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of bicyclic nucleosides by ring-closing metathesis</span></div><div class="casAuthors">Ravn, Jacob; Nielsen, Poul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">985-993</span>CODEN:
                <span class="NLM_cas:coden">JCSPCE</span>;
        ISSN:<span class="NLM_cas:issn">1472-7781</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The ring-closing metathesis method is applied in the construction of conformationally restricted bicyclic nucleosides.  From diacetone-D-glucose, the unsatd. bicyclic carbohydrate deriv. is efficiently obtained through two vinyl group Grignard addns., subsequent metathesis of the double bonds, and resoln. of the stereochem. by an oxidn./redn. reaction sequence.  Two sep. routes differing in the 3-O-protecting group are compared.  Thus, an addnl. protecting step improves the yields significantly.  Std. conversions of the unsatd. bicyclic carbohydrate deriv. give the bicyclic nucleoside contg. an olefinic moiety with a high potential for further functionalization.  As examples, two simple bicyclic ribo-nucleoside analogs, which are restricted to the unusual South-type conformations, are synthesized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwwLYKtbsobVg90H21EOLACvtfcHk0lhSCq-IPHTlNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjtFCgurc%253D&md5=8c9dba5b8a48182459804e2d3cd5610b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1039%2Fb101364p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb101364p%26sid%3Dliteratum%253Aachs%26aulast%3DRavn%26aufirst%3DJ.%26aulast%3DNielsen%26aufirst%3DP.%26atitle%3DSynthesis%2520of%2520bicyclic%2520nucleosides%2520by%2520ring-closing%2520metathesis%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D2001%26spage%3D985%26epage%3D993%26doi%3D10.1039%2Fb101364p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haziri, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silhar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renneberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leumann, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of the sugar building block of bicyclo-RNA</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">827</span>, <span class="refDoi"> DOI: 10.1055/s-0029-1218650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1055%2Fs-0029-1218650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVOltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&pages=823-827&author=A.+I.+Haziriauthor=P.+Silharauthor=D.+Rennebergauthor=C.+J.+Leumann&title=Synthesis+of+the+sugar+building+block+of+bicyclo-RNA&doi=10.1055%2Fs-0029-1218650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of the sugar building block of bicyclo-RNA</span></div><div class="casAuthors">Haziri, Arben I.; Silhar, Peter; Renneberg, Dorte; Leumann, Christian J.</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">823-827</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">We present the novel synthesis of two sugar units that are central intermediates for the formation of members of the bicyclo-DNA and -RNA family.  The synthesis starts from com. available 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose.  The key step involves the elaboration of a carbocyclic ring in a furanoside by rhodium(I)-catalyzed hydroacylation.  Via this pathway, one of the sugar units is available in 8 steps and in an overall yield of 27%, while its deoxy deriv. is obtained in 11 steps, which is 5 steps fewer than in our previous synthesis of this compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZkPeZrCTJr7Vg90H21EOLACvtfcHk0lhSCq-IPHTlNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVOltrs%253D&md5=da90f33c44ffdc4c41a10fe1366c0029</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1218650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1218650%26sid%3Dliteratum%253Aachs%26aulast%3DHaziri%26aufirst%3DA.%2BI.%26aulast%3DSilhar%26aufirst%3DP.%26aulast%3DRenneberg%26aufirst%3DD.%26aulast%3DLeumann%26aufirst%3DC.%2BJ.%26atitle%3DSynthesis%2520of%2520the%2520sugar%2520building%2520block%2520of%2520bicyclo-RNA%26jtitle%3DSynthesis%26date%3D2010%26spage%3D823%26epage%3D827%26doi%3D10.1055%2Fs-0029-1218650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haziri, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leumann, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pairing properties of oligodeoxynucleotides containing bicyclo-RNA and bicyclo-ANA modifications</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">5861</span>– <span class="NLM_lpage">5869</span>, <span class="refDoi"> DOI: 10.1021/jo300554w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo300554w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Sntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=5861-5869&author=A.+I.+Haziriauthor=C.+J.+Leumann&title=Synthesis+and+pairing+properties+of+oligodeoxynucleotides+containing+bicyclo-RNA+and+bicyclo-ANA+modifications&doi=10.1021%2Fjo300554w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pairing Properties of Oligodeoxynucleotides Containing Bicyclo-RNA and Bicyclo-ANA Modifications</span></div><div class="casAuthors">Haziri, Arben I.; Leumann, Christian J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5861-5869</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis of the ribo(bc-rT)- and arabino(bc-araT)-version of bicyclothymidine (bc-dT) has been achieved.  A conformational anal. by X-ray and/or 1H NMR spectroscopy on the corresponding 3',5'-benzyl-protected nucleosides featured a rigid C(2')-endo conformation for the furanose ring, irresp. of the configuration of the OH group at C(2').  The conformation of the carbocyclic ring in these nucleosides was found to be less defined and thus more flexible.  Both nucleosides were converted into the corresponding phosphoramidites and incorporated into oligodeoxynucleotides by std. DNA chem.  Tm-data of duplexes with cDNA and RNA revealed that a bc-rT unit strongly destabilized duplexes with cDNA and RNA by 6-8 °C/mod, while bc-araT was almost Tm neutral.  A rationale based on a previous structure of a bc-DNA mini duplex suggests that the strong destabilization caused by a bc-rT unit arises from unfavorable steric interactions of the equatorial 2'-OH group with the sugar residue of the 3'-neighboring nucleotide unit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbl_8e6HNGZ7Vg90H21EOLACvtfcHk0liOmBHwyLsfRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Sntb8%253D&md5=95de71b967e4f49c0108c934421c7ebf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjo300554w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo300554w%26sid%3Dliteratum%253Aachs%26aulast%3DHaziri%26aufirst%3DA.%2BI.%26aulast%3DLeumann%26aufirst%3DC.%2BJ.%26atitle%3DSynthesis%2520and%2520pairing%2520properties%2520of%2520oligodeoxynucleotides%2520containing%2520bicyclo-RNA%2520and%2520bicyclo-ANA%2520modifications%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2012%26volume%3D77%26spage%3D5861%26epage%3D5869%26doi%3D10.1021%2Fjo300554w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Downey, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roithová, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocek, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of nucleosides through direct glycosylation of nucleobases with 5-<i>O</i>-monoprotected or 5-modified ribose: improved protocol, scope, and mechanism</span>. <i>Chem. – Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3910</span>– <span class="NLM_lpage">3917</span>, <span class="refDoi"> DOI: 10.1002/chem.201604955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1002%2Fchem.201604955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=28112876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislGnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3910-3917&author=A.+M.+Downeyauthor=R.+Pohlauthor=J.+Roithov%C3%A1author=M.+Hocek&title=Synthesis+of+nucleosides+through+direct+glycosylation+of+nucleobases+with+5-O-monoprotected+or+5-modified+ribose%3A+improved+protocol%2C+scope%2C+and+mechanism&doi=10.1002%2Fchem.201604955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Nucleosides through Direct Glycosylation of Nucleobases with 5-O-Mono-protected or 5-Modified Ribose: Improved Protocol, Scope, and Mechanism</span></div><div class="casAuthors">Downey, A. Michael; Pohl, Radek; Roithova, Jana; Hocek, Michal</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3910-3917</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Simplifying access to synthetic nucleosides is of interest due to their widespread use as biochem. or anticancer and antiviral agents.  Herein, a direct stereoselective method to access an expansive range of both natural and synthetic nucleosides, e.g. I, up to a gram scale, through direct glycosylation of nucleobases with 5-O-tritylribose and other C5-modified ribose derivs., is discussed in detail.  The reaction proceeds through nucleophilic epoxide ring opening of an in situ formed 1,2-anhydrosugar (termed "anhydrose") under modified Mitsunobu reaction conditions.  The scope of the reaction in the synthesis of diverse nucleosides and other 1-substituted riboside derivs. is described.  In addn., a mechanistic insight into the formation of this key glycosyl donor intermediate is provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo76bTMZMtGsbVg90H21EOLACvtfcHk0liOmBHwyLsfRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislGnsLY%253D&md5=15c10b2f5c36b7549bed8827951b04e9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fchem.201604955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201604955%26sid%3Dliteratum%253Aachs%26aulast%3DDowney%26aufirst%3DA.%2BM.%26aulast%3DPohl%26aufirst%3DR.%26aulast%3DRoithov%25C3%25A1%26aufirst%3DJ.%26aulast%3DHocek%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520nucleosides%2520through%2520direct%2520glycosylation%2520of%2520nucleobases%2520with%25205-O-monoprotected%2520or%25205-modified%2520ribose%253A%2520improved%2520protocol%252C%2520scope%252C%2520and%2520mechanism%26jtitle%3DChem.%2520%25E2%2580%2593%2520Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D3910%26epage%3D3917%26doi%3D10.1002%2Fchem.201604955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0liOmBHwyLsfRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Physicochemical descriptors of aromatic character and their use in drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7215</span>, <span class="refDoi"> DOI: 10.1021/jm500515d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500515d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7206-7215&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=Physicochemical+descriptors+of+aromatic+character+and+their+use+in+drug+discovery&doi=10.1021%2Fjm500515d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7206-7215</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Published physicochem. descriptors of mols. that convey aromaticity-related character are reviewed in the context of drug design and discovery.  Studies that have employed arom. descriptors are discussed, and several descriptors are compared and contrasted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogc1vxNtUQl7Vg90H21EOLACvtfcHk0lixjMv6yb_MIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D&md5=7aca9f7309bb5dd806aeb4c2b4ff8eab</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm500515d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500515d%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DPhysicochemical%2520descriptors%2520of%2520aromatic%2520character%2520and%2520their%2520use%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7206%26epage%3D7215%26doi%3D10.1021%2Fjm500515d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arnott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planey, S. L.</span></span> <span> </span><span class="NLM_article-title">The influence of lipophilicity in drug discovery and design</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1517/17460441.2012.714363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1517%2F17460441.2012.714363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=22992175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=863-875&author=J.+A.+Arnottauthor=S.+L.+Planey&title=The+influence+of+lipophilicity+in+drug+discovery+and+design&doi=10.1517%2F17460441.2012.714363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of lipophilicity in drug discovery and design</span></div><div class="casAuthors">Arnott, John A.; Planey, Sonia Lobo</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">863-875</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The role of lipophilicity in drug discovery and design is a crit. one.  Lipophilicity is a key physicochem. property that plays a crucial role in detg. ADMET (absorption, distribution, metab., excretion, and toxicity) properties and the overall suitability of drug candidates.  There is increasing evidence to suggest that control of physicochem. properties such as lipophilicity, within a defined optimal range, can improve compd. quality and the likelihood of therapeutic success.Areas covered: This review focuses on understanding lipophilicity, techniques used to measure lipophilicity, and summarizes the importance of lipophilicity in drug discovery and development, including a discussion of its impact on individual ADMET parameters as well as its overall influence on the drug discovery and design process, specifically within the past 15 years.Expert opinion: A current review of the literature reveals a continued reliance on the synthesis of novel structures with increased potency, rather than a focus on maintaining optimal physicochem. properties assocd. with ADMET throughout drug optimization.  Particular attention to the optimum region of lipophilicity, as well as monitoring of lipophilic efficiency indexes, may contribute significantly to the overall quality of candidate drugs at different stages of discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolWJgvv9yK87Vg90H21EOLACvtfcHk0lixjMv6yb_MIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsbvJ&md5=4dc5d7268216c9a59fcbd841fbf66735</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.714363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.714363%26sid%3Dliteratum%253Aachs%26aulast%3DArnott%26aufirst%3DJ.%2BA.%26aulast%3DPlaney%26aufirst%3DS.%2BL.%26atitle%3DThe%2520influence%2520of%2520lipophilicity%2520in%2520drug%2520discovery%2520and%2520design%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D863%26epage%3D875%26doi%3D10.1517%2F17460441.2012.714363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Augustijns, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuyts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, J.</span></span> <span> </span><span class="NLM_article-title">A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2013.08.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.ejps.2013.08.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=23994640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyltL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=322-332&author=P.+Augustijnsauthor=B.+Wuytsauthor=B.+Hensauthor=P.+Annaertauthor=J.+Butlerauthor=J.+Brouwers&title=A+review+of+drug+solubility+in+human+intestinal+fluids%3A+implications+for+the+prediction+of+oral+absorption&doi=10.1016%2Fj.ejps.2013.08.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption</span></div><div class="casAuthors">Augustijns, Patrick; Wuyts, Benjamin; Hens, Bart; Annaert, Pieter; Butler, James; Brouwers, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">322-332</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The purpose of this paper is to collate all recently published soly. data of orally administered drugs in human intestinal fluids (HIF) that were aspirated from the upper small intestine (duodenum and jejunum).  The data set comprises in total 102 soly. values in fasted state HIF and 37 soly. values in fed state HIF, covering 59 different drugs.  Despite differences in the protocol for HIF sampling and subsequent handling, this summary of HIF solubilities provides a crit. ref. data set to judge the value of simulated media for intestinal soly. estn.  In this regard, the review includes correlations between the reported solubilizing capacity of HIF and fasted or fed state simulated intestinal fluid (FaSSIF/FeSSIF).  Correlating with HIF solubilities enables the optimal use of soly. measurements in simulated biorelevant media to obtain accurate ests. of intestinal soly. during drug development.  Considering the fraction of poorly sol. new mol. entities in contemporary drug discovery, adequate prediction of intestinal soly. is crit. for efficient lead optimization, early candidate profiling, and further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8IijZQJ8SKrVg90H21EOLACvtfcHk0ljiLNDFFsgswA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyltL3L&md5=4e7a43d3d0cfe514577f6b10a1ba0c97</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2013.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2013.08.027%26sid%3Dliteratum%253Aachs%26aulast%3DAugustijns%26aufirst%3DP.%26aulast%3DWuyts%26aufirst%3DB.%26aulast%3DHens%26aufirst%3DB.%26aulast%3DAnnaert%26aufirst%3DP.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DBrouwers%26aufirst%3DJ.%26atitle%3DA%2520review%2520of%2520drug%2520solubility%2520in%2520human%2520intestinal%2520fluids%253A%2520implications%2520for%2520the%2520prediction%2520of%2520oral%2520absorption%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D57%26spage%3D322%26epage%3D332%26doi%3D10.1016%2Fj.ejps.2013.08.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Estévez, D.</span></span> <span> </span><span class="NLM_article-title">Targeted cancer therapy: interactions with other medicines</span>. <i>Clin. Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1007/s12094-016-1509-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1007%2Fs12094-016-1509-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=27112938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFOms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=21-30&author=D.+Conde-Est%C3%A9vez&title=Targeted+cancer+therapy%3A+interactions+with+other+medicines&doi=10.1007%2Fs12094-016-1509-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted cancer therapy: interactions with other medicines</span></div><div class="casAuthors">Conde-Estevez, D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-30</span>CODEN:
                <span class="NLM_cas:coden">CTOLAM</span>;
        ISSN:<span class="NLM_cas:issn">1699-048X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag Italia S.r.l.</span>)
        </div><div class="casAbstract">Targeted therapy drugs, mainly those within the signal transduction inhibitors, are used more chronically than cytotoxic drugs and are metabolised by cytochrome P 450 isoenzymes so patients are at high risk of having drug-drug interactions (DDI).  Not only this, as the majority of them are given orally, new drug-drug interactions concerning gastrointestinal absorption can occur (e.g., with proton pump inhibitors).  DDI can lead to changed systemic exposure, resulting in variations in drug response of the co-administered.  In addn., concomitant ingestion of dietary supplements could also alter systemic exposure of drugs, thus leading to adverse drug reactions or loss of efficacy.  In this review, we give an overview of the current existing data of known or suspected DDI between targeted therapy and other medicines.  A review of package inserts was performed to identify drug-drug interactions for all targeted antineoplastic agents.  Tertiary databases such as Lexicomp, Drugs, Martindale, Facts and Comparisons, and AHFS Drug Information were also referenced.  This study covered 40 targeted antineoplastic agents (28 signal transduction inhibitors, 9 monoclonal antibodies and 3 other drugs, 2 monoclonal antibody conjugates and 1 fusion protein).  Most of targeted therapy drugs are major CYP3A4 substrates with P-gp playing an important role in disposition too.  Thus, there is a very common thread here that these agents will likely be sensitive victims to strong CYP3A4/P-gp inhibitors and inducers.  It is essential that health care providers monitor patients for potential DDI to avoid a loss in efficacy or risk of greater toxicity from targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKUB3U6bMSZbVg90H21EOLACvtfcHk0ljiLNDFFsgswA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFOms7c%253D&md5=4bb25a20dff7880b48fd96cca8861079</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs12094-016-1509-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12094-016-1509-x%26sid%3Dliteratum%253Aachs%26aulast%3DConde-Est%25C3%25A9vez%26aufirst%3DD.%26atitle%3DTargeted%2520cancer%2520therapy%253A%2520interactions%2520with%2520other%2520medicines%26jtitle%3DClin.%2520Transl.%2520Oncol.%26date%3D2017%26volume%3D19%26spage%3D21%26epage%3D30%26doi%3D10.1007%2Fs12094-016-1509-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galano, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christlieb, M.</span></span> <span> </span><span class="NLM_article-title">Enantioselective total synthesis of (−)-xialenon A</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_fpage">2436</span>– <span class="NLM_lpage">2437</span>, <span class="refDoi"> DOI: 10.1039/B208485F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1039%2FB208485F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=12430478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD38XnslKjsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&pages=2436-2437&author=D.+M.+Hodgsonauthor=J.-M.+Galanoauthor=M.+Christlieb&title=Enantioselective+total+synthesis+of+%28%E2%88%92%29-xialenon+A&doi=10.1039%2FB208485F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective total synthesis of (-)-xialenon A</span></div><div class="casAuthors">Hodgson, David M.; Galano, Jean-Marie; Christlieb, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2436-2437</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The first total synthesis of (-)-xialenon A via conjugate allylation of a 1,5-cyclooctadiene-derived bicyclo[3.3.0]octenone I (R = SiMe2CMe3) and an α'-hydroxylation on the more hindered face of enone II (R = SiMe2CMe3), using hypervalent iodine chem., is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcsYTdHxpZJ7Vg90H21EOLACvtfcHk0ljiLNDFFsgswA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnslKjsbY%253D&md5=78f7f5c8524d988ca6687cc3aa80ea60</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2FB208485F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB208485F%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DD.%2BM.%26aulast%3DGalano%26aufirst%3DJ.-M.%26aulast%3DChristlieb%26aufirst%3DM.%26atitle%3DEnantioselective%2520total%2520synthesis%2520of%2520%2528%25E2%2588%2592%2529-xialenon%2520A%26jtitle%3DChem.%2520Commun.%26date%3D2002%26spage%3D2436%26epage%3D2437%26doi%3D10.1039%2FB208485F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchweitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laschat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalbe, H.</span></span> <span> </span><span class="NLM_article-title">Total synthesis and NMR investigations of cylindramide</span>. <i>Chem. – Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2488</span>– <span class="NLM_lpage">2503</span>, <span class="refDoi"> DOI: 10.1002/chem.200501274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1002%2Fchem.200501274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=16389623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtVemsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2488-2503&author=N.+Cramerauthor=M.+Buchweitzauthor=S.+Laschatauthor=W.+Freyauthor=A.+Baroauthor=D.+Mathieuauthor=C.+Richterauthor=H.+Schwalbe&title=Total+synthesis+and+NMR+investigations+of+cylindramide&doi=10.1002%2Fchem.200501274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Total synthesis and NMR investigations of cylindramide</span></div><div class="casAuthors">Cramer, Nicolai; Buchweitz, Maria; Laschat, Sabine; Frey, Wolfgang; Baro, Angelika; Mathieu, Daniel; Richter, Christian; Schwalbe, Harald</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2488-2503</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cylindramide (I) was built up from three components: a hydroxyornithine deriv. II, a tetrazolylsulfone III, and a substituted pentalene subunit IV.  Deriv. II was prepd. in a six-step reaction sequence involving the Wittig reaction and a Sharpless asym. dihydroxylation starting from N-Boc-3-aminopropanal.  Tetrazolylsulfone III was accessible in four steps from dioxinone V.  The synthesis of the pentalene fragment IV started from cycloocta-1,5-diene, that was converted into an enantiopure bicyclo-[3.3.0]octanedione.  The latter was functionalized to give deriv. IV.  The total synthesis was accomplished by inducing C-C bond formation by Sonogashira coupling of derivs. IV and II followed by olefination with tetrazolylsulfone III under Julia-Kocienski conditions, macrocyclization, and subsequent Lacey-Dieckmann condensation to form the tetramic acid unit.  As indicated by extensive 1H and 13C NMR spectroscopic investigations (DQF-COSY, ROESY spectra), the stereochem. of synthetic I corresponds with that of the naturally occurring product.  ROE data were used for mol. modeling of the lowest-energy structures for cylindramide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGpYRusqPQI7Vg90H21EOLACvtfcHk0lh-IKlbBFLFXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtVemsbs%253D&md5=fd13898765b08253e0a3feb455b1d2a8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fchem.200501274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.200501274%26sid%3Dliteratum%253Aachs%26aulast%3DCramer%26aufirst%3DN.%26aulast%3DBuchweitz%26aufirst%3DM.%26aulast%3DLaschat%26aufirst%3DS.%26aulast%3DFrey%26aufirst%3DW.%26aulast%3DBaro%26aufirst%3DA.%26aulast%3DMathieu%26aufirst%3DD.%26aulast%3DRichter%26aufirst%3DC.%26aulast%3DSchwalbe%26aufirst%3DH.%26atitle%3DTotal%2520synthesis%2520and%2520NMR%2520investigations%2520of%2520cylindramide%26jtitle%3DChem.%2520%25E2%2580%2593%2520Eur.%2520J.%26date%3D2006%26volume%3D12%26spage%3D2488%26epage%3D2503%26doi%3D10.1002%2Fchem.200501274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, I. D.</span></span> <span> </span><span class="NLM_article-title">Functionalized bicyclo[3.3.0]octanes by enantioselective transannular desymmetrization</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/ol006947n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol006947n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=441-444&author=D.+M.+Hodgsonauthor=I.+D.+Cameron&title=Functionalized+bicyclo%5B3.3.0%5Doctanes+by+enantioselective+transannular+desymmetrization&doi=10.1021%2Fol006947n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Functionalized Bicyclo[3.3.0]octanes by Enantioselective Transannular Desymmetrization</span></div><div class="casAuthors">Hodgson, David M.; Cameron, Iain D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-444</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Enantioselective α-deprotonation-rearrangement of achiral substituted cyclooctene oxides using organolithiums in the presence of (-)-sparteine or (-)-α-isosparteine gives the functionalized bicyclo[3.3.0]octan-2-ols in 56-72% yields and 83-89% ee's.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0XKqEolVur7Vg90H21EOLACvtfcHk0lh-IKlbBFLFXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVehsg%253D%253D&md5=0c01c692fd48b3addcbbe3521e51c5bc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fol006947n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol006947n%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DD.%2BM.%26aulast%3DCameron%26aufirst%3DI.%2BD.%26atitle%3DFunctionalized%2520bicyclo%255B3.3.0%255Doctanes%2520by%2520enantioselective%2520transannular%2520desymmetrization%26jtitle%3DOrg.%2520Lett.%26date%3D2001%26volume%3D3%26spage%3D441%26epage%3D444%26doi%3D10.1021%2Fol006947n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosser, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caine, D.</span></span> <span> </span><span class="NLM_article-title">On the α-lithiation-rearrangement of <i>N</i>-toluensulfonyl aziridines: mechanistic and synthetic aspects</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9779</span>– <span class="NLM_lpage">9791</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2003.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2Fj.tet.2003.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptVSgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2003&pages=9779-9791&author=P.+O%E2%80%99Brienauthor=C.+M.+Rosserauthor=D.+Caine&title=On+the+%CE%B1-lithiation-rearrangement+of+N-toluensulfonyl+aziridines%3A+mechanistic+and+synthetic+aspects&doi=10.1016%2Fj.tet.2003.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">On the α-lithiation-rearrangement of N-toluenesulfonyl aziridines: mechanistic and synthetic aspects</span></div><div class="casAuthors">O'Brien, Peter; Rosser, Clare M.; Caine, Darren</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">9779-9791</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A detailed study of the rearrangement of five cycloalkene-derived N-sulfonyl aziridines, e.g. I (n = 0 - 3; Ts = 4-methylphenylsulfonyl), using sec-butyllithium (with and without added ligands such as (-)-sparteine and TMEDA) has been carried out.  Allylic sulfonamides II were the main products from the cyclopentene and cyclohexene aziridines whereas bicyclic sulfonamides, e.g. III from I (n = 3), were obtained from the cycloheptene and cyclooctene aziridines.  In most cases, p-toluenesulfonamide (TsNH2) was produced as a byproduct and a mechanistic explanation for its formation is forwarded.  These reactions are believed to involve α-lithiation to a lithiated aziridine which can then partition through two pathways: (i) rearrangement to allylic or bicyclic sulfonamides via C-H insertion reactions or (ii) reductive alkylation to alkenes via attack by sec-butyllithium and subsequent elimination of TsNH2.  In the (-)-sparteine reactions, the products were generated with 38-66% ee and the sense of asym. induction involved lithiation of the S-aziridine stereocenter.  This is opposite to that obsd. with epoxides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhqyA_cZgta7Vg90H21EOLACvtfcHk0lh-IKlbBFLFXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptVSgtb0%253D&md5=48128642b2ce6e1039856436166b1e7a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2003.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2003.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DP.%26aulast%3DRosser%26aufirst%3DC.%2BM.%26aulast%3DCaine%26aufirst%3DD.%26atitle%3DOn%2520the%2520%25CE%25B1-lithiation-rearrangement%2520of%2520N-toluensulfonyl%2520aziridines%253A%2520mechanistic%2520and%2520synthetic%2520aspects%26jtitle%3DTetrahedron%26date%3D2003%26volume%3D59%26spage%3D9779%26epage%3D9791%26doi%3D10.1016%2Fj.tet.2003.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zydowsky, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlj, R.</span></span> <span> </span><span class="NLM_article-title">Studies directed toward the synthesis of the unusual antileukemic diterpene jatrophatrione. 1. A solution to the problem of chirality merger during elaboration of the entire carbotricyclic framework</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">3244</span>– <span class="NLM_lpage">3254</span>, <span class="refDoi"> DOI: 10.1021/jo9825254</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo9825254" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK1MXis1OqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=3244-3254&author=L.+A.+Paquetteauthor=S.+Nakataniauthor=T.+M.+Zydowskyauthor=S.+D.+Edmondsonauthor=L.-Q.+Sunauthor=R.+Skerlj&title=Studies+directed+toward+the+synthesis+of+the+unusual+antileukemic+diterpene+jatrophatrione.+1.+A+solution+to+the+problem+of+chirality+merger+during+elaboration+of+the+entire+carbotricyclic+framework&doi=10.1021%2Fjo9825254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Studies directed toward the synthesis of the unusual antileukemic diterpene jatrophatrione. 1. A solution to the problem of chirality merger during elaboration of the entire carbotricyclic framework</span></div><div class="casAuthors">Paquette, Leo A.; Nakatani, Shogo; Zydowsky, Thomas M.; Edmondson, Scott D.; Sun, Li-Qiang; Skerlj, Renato</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3244-3254</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical route for elaboration of the [5.9.5] tricyclic nucleus of jatrophatrione (I; R = α-H) is reported.  The two key steps involve an oxyanionic Cope rearrangement and a Grob fragmentation.  The building blocks required to reach II are the bicyclo[3.3.0]octanone III and the cyclopentadienyl bromide IV.  The former was obtained in 12 steps from methylcyclopentadiene.  The route to the latter began with 4,4-dimethylcyclopentenone.  The charge-accelerated [3,3]-sigmatropic isomerization within II proceeds via a chairlike transition state to deliver, after enolate methylation, a highly strained product carrying a trans double bond in a medium-sized ring, one consequence of which is rapid transannular ring closure via an ene pathway.  Acid hydrolysis of this enol ether and conversion to hydroxy mesylate V (Ms = SO2Me) was followed by exposure to base.  This sequence resulted in ring opening to provide the strategic advanced intermediate VI.  The synthetic pathway developed here is expected to open a route to 9-epijatrophatrione (I; R = β-H) for the ultimate purpose of examg. its anticipated isomerization to I (R = α-H) under mildly basic conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG8yyMCkooCbVg90H21EOLACvtfcHk0lhUEAzUWQ8yvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXis1OqtL0%253D&md5=91122d034e9e78579593a0d1a99c71f3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjo9825254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo9825254%26sid%3Dliteratum%253Aachs%26aulast%3DPaquette%26aufirst%3DL.%2BA.%26aulast%3DNakatani%26aufirst%3DS.%26aulast%3DZydowsky%26aufirst%3DT.%2BM.%26aulast%3DEdmondson%26aufirst%3DS.%2BD.%26aulast%3DSun%26aufirst%3DL.-Q.%26aulast%3DSkerlj%26aufirst%3DR.%26atitle%3DStudies%2520directed%2520toward%2520the%2520synthesis%2520of%2520the%2520unusual%2520antileukemic%2520diterpene%2520jatrophatrione.%25201.%2520A%2520solution%2520to%2520the%2520problem%2520of%2520chirality%2520merger%2520during%2520elaboration%2520of%2520the%2520entire%2520carbotricyclic%2520framework%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D3244%26epage%3D3254%26doi%3D10.1021%2Fjo9825254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trost, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, D. P.</span></span> <span> </span><span class="NLM_article-title">On the stereochemistry of the bis-nor-wieland-miescher ketome</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4929</span>– <span class="NLM_lpage">4932</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(01)92384-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2FS0040-4039%2801%2992384-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaL38XhvFyksLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1981&pages=4929-4932&author=B.+M.+Trostauthor=D.+P.+Curran&title=On+the+stereochemistry+of+the+bis-nor-wieland-miescher+ketome&doi=10.1016%2FS0040-4039%2801%2992384-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">On the stereochemistry of the bis-nor-Wieland-Miescher ketone</span></div><div class="casAuthors">Trost, Barry M.; Curran, Dennis P.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">4929-32</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">Both the 'ate' complex from DIBAL-H and BuLi and BH3-Me2S chemo- and stereoselectively reduce the title compd. (I; RR1 = O) (II) to I (R = OH, R1 = H) (III); the latter reagent is preferred.  The abs. configuration of II was detd. by 13C NMR study of II and III.  The origin of the asym. induction in the prepn. of II and its (S)-isomer by intramol. Wittig reaction of IV was studied using a variety of phosphines for formation of the ylide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVhekMupmYh7Vg90H21EOLACvtfcHk0lhUEAzUWQ8yvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhvFyksLY%253D&md5=2a7464663a410edd017433a969582d34</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2992384-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252992384-6%26sid%3Dliteratum%253Aachs%26aulast%3DTrost%26aufirst%3DB.%2BM.%26aulast%3DCurran%26aufirst%3DD.%2BP.%26atitle%3DOn%2520the%2520stereochemistry%2520of%2520the%2520bis-nor-wieland-miescher%2520ketome%26jtitle%3DTetrahedron%2520Lett.%26date%3D1981%26volume%3D22%26spage%3D4929%26epage%3D4932%26doi%3D10.1016%2FS0040-4039%2801%2992384-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raudla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aav, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müürisepp, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pehk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopp, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and derivatization of bis-nor Wieland-Miescher ketone</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_fpage">3147</span>– <span class="NLM_lpage">3151</span>, <span class="refDoi"> DOI: 10.1055/s-2005-916025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1055%2Fs-2005-916025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ynsrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=3147-3151&author=T.+Kangerauthor=K.+Raudlaauthor=R.+Aavauthor=A.-M.+M%C3%BC%C3%BCriseppauthor=T.+Pehkauthor=M.+Lopp&title=Synthesis+and+derivatization+of+bis-nor+Wieland-Miescher+ketone&doi=10.1055%2Fs-2005-916025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and derivatization of bis-nor Wieland-Miescher ketone</span></div><div class="casAuthors">Kanger, Tonis; Raudla, Kristin; Aav, Riina; Muurisepp, Aleksander-Mati; Pehk, Tonis; Lopp, Margus</div><div class="citationInfo"><span class="NLM_cas:title">Synthesis</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3147-3151</span>CODEN:
                <span class="NLM_cas:coden">SYNTBF</span>;
        ISSN:<span class="NLM_cas:issn">0039-7881</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">An efficient synthesis of bis-nor Wieland-Miescher ketone (I) and its derivs. starting from com. available 2-allyl-2-methylcyclopenta-1,3-dione is described.  Derivatization of I was carried out via selective alkylation of the enone fragment or conversion into 1,2-diketones via epoxides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAWqVoNHdT67Vg90H21EOLACvtfcHk0lhUEAzUWQ8yvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ynsrjP&md5=120349a026cca3bd77552a2f7cdedd79</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-916025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-916025%26sid%3Dliteratum%253Aachs%26aulast%3DKanger%26aufirst%3DT.%26aulast%3DRaudla%26aufirst%3DK.%26aulast%3DAav%26aufirst%3DR.%26aulast%3DM%25C3%25BC%25C3%25BCrisepp%26aufirst%3DA.-M.%26aulast%3DPehk%26aufirst%3DT.%26aulast%3DLopp%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520derivatization%2520of%2520bis-nor%2520Wieland-Miescher%2520ketone%26jtitle%3DSynthesis%26date%3D2005%26spage%3D3147%26epage%3D3151%26doi%3D10.1055%2Fs-2005-916025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsantali, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakis, I. M.</span></span> <span> </span><span class="NLM_article-title">Expeditious copper-catalyzed conjugate 1,4-addition of bromo[2-(1,3-dioxolan-2-yl)ethyl]magnesium to α,β-cycloalkenones and subsequent transformations</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">6455</span>– <span class="NLM_lpage">6458</span>, <span class="refDoi"> DOI: 10.1021/jo034350q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo034350q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltF2rt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=6455-6458&author=G.+G.+Tsantaliauthor=I.+M.+Takakis&title=Expeditious+copper-catalyzed+conjugate+1%2C4-addition+of+bromo%5B2-%281%2C3-dioxolan-2-yl%29ethyl%5Dmagnesium+to+%CE%B1%2C%CE%B2-cycloalkenones+and+subsequent+transformations&doi=10.1021%2Fjo034350q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Expeditious Copper-Catalyzed Conjugate 1,4-Addition of Bromo[2-(1,3-dioxolan-2-yl)ethyl]magnesium to α,β-Cycloalkenones and Subsequent Transformations</span></div><div class="casAuthors">Tsantali, Georgia G.; Takakis, Ioannis M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6455-6458</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expeditious CuI-catalyzed conjugate 1,4-addn. of bromo[2-(1,3-dioxolan-2-yl)ethyl]magnesium to the five-, six-, seven-, and eight-membered α,β-cycloalkenones is described.  The reaction times are decreased dramatically compared to CuBr-Me2S catalysis.  The resulting keto acetals were cyclized to bicyclic β-hydroxy ketones and α,β-enones, followed by further transformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPhThVQFVYqLVg90H21EOLACvtfcHk0lgvyMx4B_L4MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltF2rt7o%253D&md5=a4b5af78d7da16aa2a3444dc3e80f73e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjo034350q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo034350q%26sid%3Dliteratum%253Aachs%26aulast%3DTsantali%26aufirst%3DG.%2BG.%26aulast%3DTakakis%26aufirst%3DI.%2BM.%26atitle%3DExpeditious%2520copper-catalyzed%2520conjugate%25201%252C4-addition%2520of%2520bromo%255B2-%25281%252C3-dioxolan-2-yl%2529ethyl%255Dmagnesium%2520to%2520%25CE%25B1%252C%25CE%25B2-cycloalkenones%2520and%2520subsequent%2520transformations%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D6455%26epage%3D6458%26doi%3D10.1021%2Fjo034350q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paquette, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallucci, J. C.</span></span> <span> </span><span class="NLM_article-title">Competitive stereochemical control operative during conrotatory electrocyclization of helically equilibrating diquinanyl-substituted 1,3,5,7-octatetraenyl bisenolates</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">8154</span>– <span class="NLM_lpage">8161</span>, <span class="refDoi"> DOI: 10.1021/jo0513919</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0513919" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFarsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2005&pages=8154-8161&author=L.+A.+Paquetteauthor=Z.+Liuauthor=C.+Ramseyauthor=J.+C.+Gallucci&title=Competitive+stereochemical+control+operative+during+conrotatory+electrocyclization+of+helically+equilibrating+diquinanyl-substituted+1%2C3%2C5%2C7-octatetraenyl+bisenolates&doi=10.1021%2Fjo0513919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Competitive Stereochemical Control Operative during Conrotatory Electrocyclization of Helically Equilibrating Diquinanyl-Substituted 1,3,5,7-Octatetraenyl Bisenolates</span></div><div class="casAuthors">Paquette, Leo A.; Liu, Zuosheng; Ramsey, Charla; Gallucci, Judith C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8154-8161</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activation of the squarate ester cascade by adding the lithiated bicyclo[3.3.0]octene 20 and vinyllithium sequentially to 1 results in the isolation of the four tetracyclic products 21-24.  The structures of the topog. complex products were deduced by 2D NMR spectroscopy and X-ray diffraction studies.  The mechanistic insights gained by these findings are discussed.  The product distribution is telltale evidence for predominant 1,2-addn. of the second alkenyl anion.  Product stereochem. is in turn diagnostic of the preferred mode of conrotatory ring closure operating within equilibrating helical intermediates of opposite pitch.  A competing pathway for the elimination of methanol in these highly functionalized intermediates has been obsd. for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojlJjr5St1FLVg90H21EOLACvtfcHk0lgvyMx4B_L4MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFarsLw%253D&md5=833cf7aae32d75c193086f85fcace77f</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjo0513919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0513919%26sid%3Dliteratum%253Aachs%26aulast%3DPaquette%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DRamsey%26aufirst%3DC.%26aulast%3DGallucci%26aufirst%3DJ.%2BC.%26atitle%3DCompetitive%2520stereochemical%2520control%2520operative%2520during%2520conrotatory%2520electrocyclization%2520of%2520helically%2520equilibrating%2520diquinanyl-substituted%25201%252C3%252C5%252C7-octatetraenyl%2520bisenolates%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2005%26volume%3D70%26spage%3D8154%26epage%3D8161%26doi%3D10.1021%2Fjo0513919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumagai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibasaki, M.</span></span> <span> </span><span class="NLM_article-title">Catalytic asymmetric conjugate addition of α-cyanoketones for the construction of a quaternary stereogenic center</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1484</span>– <span class="NLM_lpage">1487</span>, <span class="refDoi"> DOI: 10.1021/ol100183s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol100183s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC3cXislKitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=1484-1487&author=Y.+Kawatoauthor=N.+Takahashiauthor=N.+Kumagaiauthor=M.+Shibasaki&title=Catalytic+asymmetric+conjugate+addition+of+%CE%B1-cyanoketones+for+the+construction+of+a+quaternary+stereogenic+center&doi=10.1021%2Fol100183s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Asymmetric Conjugate Addition of α-Cyanoketones for the Construction of a Quaternary Stereogenic Center</span></div><div class="casAuthors">Kawato, Yuji; Takahashi, Noriko; Kumagai, Naoya; Shibasaki, Masakatsu</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1484-1487</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The catalytic asym. conjugate addn. of cyclic α-cyanoketone pronucleophiles to vinyl ketones promoted by an Y/I catalyst is described.  High enantioselectivity was obsd. for a range of arom. vinyl ketones, providing 1,5-dicarbonyl compds. bearing an all-carbon quaternary stereogenic center.  The product was successfully converted to a spiro-piperidine entity and a bicyclo[3.3.0]octane framework through either the redn. of the nitrile or intramol. pinacol coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoT5AlLeysXbVg90H21EOLACvtfcHk0lgvyMx4B_L4MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXislKitbk%253D&md5=908efdbb26fdcafe07c19be0b94025ef</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fol100183s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol100183s%26sid%3Dliteratum%253Aachs%26aulast%3DKawato%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DKumagai%26aufirst%3DN.%26aulast%3DShibasaki%26aufirst%3DM.%26atitle%3DCatalytic%2520asymmetric%2520conjugate%2520addition%2520of%2520%25CE%25B1-cyanoketones%2520for%2520the%2520construction%2520of%2520a%2520quaternary%2520stereogenic%2520center%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D1484%26epage%3D1487%26doi%3D10.1021%2Fol100183s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S. G.</span></span> <span> </span><span class="NLM_article-title">Conversion of ketones having δ, ϵ-π-functions to cyclopentanols by zinc-trimethylchlorosilane</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2821</span>– <span class="NLM_lpage">2824</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)88033-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2FS0040-4039%2800%2988033-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaL3sXlslGht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1983&pages=2821-2824&author=E.+J.+Coreyauthor=S.+G.+Pyne&title=Conversion+of+ketones+having+%CE%B4%2C+%CF%B5-%CF%80-functions+to+cyclopentanols+by+zinc-trimethylchlorosilane&doi=10.1016%2FS0040-4039%2800%2988033-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Conversion of ketones having δ,ε-π-functions to cyclopentanols by zinc-trimethylchlorosilane</span></div><div class="casAuthors">Corey, E. J.; Pyne, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">2821-4</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">A new method for five-membered ring annulation is described which involves free radical generation from ketones by Zn-Me3SiCl followed by internal addn. to a π-bond.  Thus, treating cyclopentanones I (R = C≡CH, CH:CH2, CH:CHCO2Me, -CN, CHO, CH:NOMe) with Zn-Me3SiCl in the presence of lutidine gave bicyclooctanols II (R1R2 = CH2, O; R1 = H, R2 = Me, CH2CO2Me, OH, NHOMe).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxpsJoRPthX7Vg90H21EOLACvtfcHk0lgvyMx4B_L4MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlslGht7o%253D&md5=532b6f54b9220b407ea6ef4d3055ecc8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2988033-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252988033-8%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DPyne%26aufirst%3DS.%2BG.%26atitle%3DConversion%2520of%2520ketones%2520having%2520%25CE%25B4%252C%2520%25CF%25B5-%25CF%2580-functions%2520to%2520cyclopentanols%2520by%2520zinc-trimethylchlorosilane%26jtitle%3DTetrahedron%2520Lett.%26date%3D1983%26volume%3D24%26spage%3D2821%26epage%3D2824%26doi%3D10.1016%2FS0040-4039%2800%2988033-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, B. K.</span></span> <span> </span><span class="NLM_article-title">Activation parameters for 1,5-hydrogen transfer and intramolecular cycloaddition in a thermally generated cyclopentane-1,3-diyl</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">5466</span>– <span class="NLM_lpage">5478</span>, <span class="refDoi"> DOI: 10.1021/ja00066a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00066a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK3sXlsF2nt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1993&pages=5466-5478&author=T.+H.+Petersonauthor=B.+K.+Carpenter&title=Activation+parameters+for+1%2C5-hydrogen+transfer+and+intramolecular+cycloaddition+in+a+thermally+generated+cyclopentane-1%2C3-diyl&doi=10.1021%2Fja00066a016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Activation parameters for 1,5-hydrogen transfer and intramolecular cycloaddition in a thermally generated cyclopentane-1,3-diyl</span></div><div class="casAuthors">Peterson, Thomas H.; Carpenter, Barry K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5466-78</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The biradical 2-methyl-2-(3-phenylpropyl)cyclopentane-1,3-diyl is generated reversibly by gas-phase pyrolysis of a stereoisomeric mixt. of the corresponding bicyclo[2.1.0]pentane derivs.  Three reactions of the biradical (besides ring closure) are detected.  One is ring opening to 3-methyl-3-(3-phenylpropyl)-1,4-pentadiene.  A second is intramol. transfer of a benzylic hydrogen to the cyclopentane-1,3-diyl.  An activation enthalpy of 8 kcal/mol is estd. for this 1,5-hydrogen transfer.  The third reaction is intramol. cycloaddn. of the 1,3-diyl to the Ph ring.  An activation enthalpy of 7 kcal/mol is estd. for this cycloaddn. reaction.  Two reactions of the new biradical generated by 1,5-hydrogen transfer are detected.  One is ring closure to give stereoisomeric cis-1-methyl-4-phenylbicyclo[3.3.0]octanes; the other is transfer of a second hydrogen in a reaction analogous to the disproportionation of alkyl radicals.  The ring closure and second hydrogen transfer exhibit no temp. dependence in the ratio of their rate consts. and are thus judged to be activationless processes.  These reactions of thermally generated, presumably singlet biradicals are compared with the reactions of related monoradicals.  The cyclopentane-1,3-diyl deriv. is judged to have very little in the way of dipolar character and thus to be near one end of a hypothetical spectrum of intermediates encompassing singlet biradicals and zwitterions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKifTxeWctXbVg90H21EOLACvtfcHk0lhmnQ6G05-_hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlsF2nt70%253D&md5=83991c349cc59b6314167c601dc7539a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fja00066a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00066a016%26sid%3Dliteratum%253Aachs%26aulast%3DPeterson%26aufirst%3DT.%2BH.%26aulast%3DCarpenter%26aufirst%3DB.%2BK.%26atitle%3DActivation%2520parameters%2520for%25201%252C5-hydrogen%2520transfer%2520and%2520intramolecular%2520cycloaddition%2520in%2520a%2520thermally%2520generated%2520cyclopentane-1%252C3-diyl%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1993%26volume%3D115%26spage%3D5466%26epage%3D5478%26doi%3D10.1021%2Fja00066a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yates, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, K. E.</span></span> <span> </span><span class="NLM_article-title">Bicyclopentanoid sesquiterpenes. The synthesis of cedranoid sesquiterpenes via the photo-rearrangement of bicyclo[2.2.2]octenones</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">4401</span>– <span class="NLM_lpage">4410</span>, <span class="refDoi"> DOI: 10.1016/0040-4020(81)80006-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2F0040-4020%2881%2980006-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaL38XktVKmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1981&pages=4401-4410&author=P.+Yatesauthor=K.+E.+Stevens&title=Bicyclopentanoid+sesquiterpenes.+The+synthesis+of+cedranoid+sesquiterpenes+via+the+photo-rearrangement+of+bicyclo%5B2.2.2%5Doctenones&doi=10.1016%2F0040-4020%2881%2980006-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclopentanoid sesquiterpenes.  The synthesis of cedranoid sesquiterpenes via the photorearrangement of bicyclo[2.2.2]octenones</span></div><div class="casAuthors">Yates, Peter; Stevens, K. E.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4401-10</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">The bicyclooctenone I, prepd. in 3 steps from the diepoxide II, underwent photosensitized oxa-di-π-rearrangement to give tricyclooctanone III.  III was subsequently converted in 7 steps to the β-diketone IV (RR1 = R3R4 = O, R2 = H), a known precursor of cedrol (IV; R = R1 = R2 = H, R3 = Me, R4 = OH).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGzxnkYibgabVg90H21EOLACvtfcHk0lhmnQ6G05-_hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XktVKmtrs%253D&md5=2f74b40559a136bcc121b5391dfb841d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2F0040-4020%2881%2980006-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0040-4020%252881%252980006-3%26sid%3Dliteratum%253Aachs%26aulast%3DYates%26aufirst%3DP.%26aulast%3DStevens%26aufirst%3DK.%2BE.%26atitle%3DBicyclopentanoid%2520sesquiterpenes.%2520The%2520synthesis%2520of%2520cedranoid%2520sesquiterpenes%2520via%2520the%2520photo-rearrangement%2520of%2520bicyclo%255B2.2.2%255Doctenones%26jtitle%3DTetrahedron%26date%3D1981%26volume%3D37%26spage%3D4401%26epage%3D4410%26doi%3D10.1016%2F0040-4020%2881%2980006-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonehara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuyama, T.</span></span> <span> </span><span class="NLM_article-title">A novel synthesis of bicyclo[3.3.0]octane ring system via a desymmetric C-H insertion reaction</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_fpage">1583</span>– <span class="NLM_lpage">1585</span>, <span class="refDoi"> DOI: 10.1055/s-2006-941603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1055%2Fs-2006-941603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslOrurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=1583-1585&author=T.+Kanauthor=T.+Inoueauthor=Y.+Kawamotoauthor=M.+Yoneharaauthor=T.+Fukuyama&title=A+novel+synthesis+of+bicyclo%5B3.3.0%5Doctane+ring+system+via+a+desymmetric+C-H+insertion+reaction&doi=10.1055%2Fs-2006-941603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">A novel synthesis of bicyclo[3.3.0]octane ring system via a desymmetric C-H insertion reaction</span></div><div class="casAuthors">Kan, Toshiyuki; Inoue, Tohru; Kawamoto, Yuichiro; Yonehara, Mitsuhiro; Fukuyama, Tohru</div><div class="citationInfo"><span class="NLM_cas:title">Synlett</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1583-1585</span>CODEN:
                <span class="NLM_cas:coden">SYNLES</span>;
        ISSN:<span class="NLM_cas:issn">0936-5214</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">An optically active bicyclo[3.3.0]octane ring was synthesized by an intramol. C-H insertion reaction.  Upon treatment with a catalytic amt. of Rh2(S-DOSP)4, a chiral-auxiliary-contg. diazo ester underwent a C-H insertion reaction to give the desired bicyclo[3.3.0]octane system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA8Q_9DtFFYbVg90H21EOLACvtfcHk0lhmnQ6G05-_hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslOrurY%253D&md5=793be08a9d60dd14e86782dd0fa8cfc6</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-941603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-941603%26sid%3Dliteratum%253Aachs%26aulast%3DKan%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DY.%26aulast%3DYonehara%26aufirst%3DM.%26aulast%3DFukuyama%26aufirst%3DT.%26atitle%3DA%2520novel%2520synthesis%2520of%2520bicyclo%255B3.3.0%255Doctane%2520ring%2520system%2520via%2520a%2520desymmetric%2520C-H%2520insertion%2520reaction%26jtitle%3DSynlett%26date%3D2006%26spage%3D1583%26epage%3D1585%26doi%3D10.1055%2Fs-2006-941603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trost, B. M.</span></span> <span> </span><span class="NLM_article-title">[3+2] cycloaddition approaches to five-membered rings via trimethylenemethane and its equivalents [New Synthetic Methods (55)]</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1002/anie.198600013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1002%2Fanie.198600013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1986&pages=1-20&author=B.+M.+Trost&title=%5B3%2B2%5D+cycloaddition+approaches+to+five-membered+rings+via+trimethylenemethane+and+its+equivalents+%5BNew+Synthetic+Methods+%2855%29%5D&doi=10.1002%2Fanie.198600013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1002%2Fanie.198600013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.198600013%26sid%3Dliteratum%253Aachs%26aulast%3DTrost%26aufirst%3DB.%2BM.%26atitle%3D%255B3%252B2%255D%2520cycloaddition%2520approaches%2520to%2520five-membered%2520rings%2520via%2520trimethylenemethane%2520and%2520its%2520equivalents%2520%255BNew%2520Synthetic%2520Methods%2520%252855%2529%255D%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D1986%26volume%3D25%26spage%3D1%26epage%3D20%26doi%3D10.1002%2Fanie.198600013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. A.</span></span> <span> </span><span class="NLM_article-title">The preparation and reactions with an o-silylated enolate of an allylsilane bifunctional [3 + 2] annulating reagent</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">4233</span>– <span class="NLM_lpage">4242</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(01)86669-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2FS0040-4020%2801%2986669-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaL1MXhtlGgsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1988&pages=4233-4242&author=T.+V.+Leeauthor=R.+J.+Boucherauthor=J.+R.+Porterauthor=D.+A.+Taylor&title=The+preparation+and+reactions+with+an+o-silylated+enolate+of+an+allylsilane+bifunctional+%5B3+%2B+2%5D+annulating+reagent&doi=10.1016%2FS0040-4020%2801%2986669-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">The preparation and reactions with an O-silylated enolate of an allylsilane bifunctional [3 + 2] annulating reagent</span></div><div class="casAuthors">Lee, Thomas V.; Boucher, Raymond J.; Porter, John R.; Taylor, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4233-42</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    </div><div class="casAbstract">The prepn. and reactions of Me3SiCH2C(:CH2)CH(OMe)2 (I) with various silyl enol ethers are described.  This results in the one-pot synthesis of fused and spiro cyclopentanes by using a 1,3-bifunctional annulating reagent in which the two reactive centers are activated by one set of conditions.  Thus, treatment of 1-trimethylsiloxyheptenone with CF3SO3SiMe3 and I gives a mixt. of (silylbutenyl)cycloheptanones II (R = H, R1 OMe; R = OMe, R1 = H) which are annulated in the presence of TiCl4 to give methylenebicyclodecanes III (same R, R1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdx5Xqxm3-RLVg90H21EOLACvtfcHk0lhgHzdNbXNRrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhtlGgsL4%253D&md5=575557c690b5690a87676c5e8e4de59e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2801%2986669-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252801%252986669-2%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DT.%2BV.%26aulast%3DBoucher%26aufirst%3DR.%2BJ.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DTaylor%26aufirst%3DD.%2BA.%26atitle%3DThe%2520preparation%2520and%2520reactions%2520with%2520an%2520o-silylated%2520enolate%2520of%2520an%2520allylsilane%2520bifunctional%2520%255B3%2520%252B%25202%255D%2520annulating%2520reagent%26jtitle%3DTetrahedron%26date%3D1988%26volume%3D44%26spage%3D4233%26epage%3D4242%26doi%3D10.1016%2FS0040-4020%2801%2986669-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kablaoui, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Titanocene-catalyzed cyclocarbonylation of enynes to cyclopentenones</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">9450</span>– <span class="NLM_lpage">9451</span>, <span class="refDoi"> DOI: 10.1021/ja9621509</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja9621509" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK28XlsFCqtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1996&pages=9450-9451&author=F.+A.+Hicksauthor=N.+M.+Kablaouiauthor=S.+L.+Buchwald&title=Titanocene-catalyzed+cyclocarbonylation+of+enynes+to+cyclopentenones&doi=10.1021%2Fja9621509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Titanocene-Catalyzed Cyclocarbonylation of Enynes to Cyclopentenones</span></div><div class="casAuthors">Hicks, Frederick A.; Kablaoui, Natasha M.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">9450-9451</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The conversion of enynes to cyclopentenones catalyzed by Cp2Ti(CO)2 is described.  This system produces cyclopentenones in excellent yields (75-95%) and displays functional group tolerance unprecedented in Group 4 metallocene chem.  Substrates contg. 1,2-disubstituted olefins are also cleanly cyclized, leading to the first transition metal-catalyzed cyclocarbonylative route to tricyclic cyclopentenones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9_cgVR72R57Vg90H21EOLACvtfcHk0lhgHzdNbXNRrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlsFCqtbo%253D&md5=dab7492e8cc2cce8c720b386a0572728</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fja9621509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja9621509%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DF.%2BA.%26aulast%3DKablaoui%26aufirst%3DN.%2BM.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DTitanocene-catalyzed%2520cyclocarbonylation%2520of%2520enynes%2520to%2520cyclopentenones%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1996%26volume%3D118%26spage%3D9450%26epage%3D9451%26doi%3D10.1021%2Fja9621509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berk, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A practical titanium-catalyzed synthesis of bicyclic cyclopentenones and allylic amines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2713</span>– <span class="NLM_lpage">2718</span>, <span class="refDoi"> DOI: 10.1021/jo951763l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo951763l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK28XhvFWrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1996&pages=2713-2718&author=F.+A.+Hicksauthor=S.+C.+Berkauthor=S.+L.+Buchwald&title=A+practical+titanium-catalyzed+synthesis+of+bicyclic+cyclopentenones+and+allylic+amines&doi=10.1021%2Fjo951763l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A Practical Titanium-Catalyzed Synthesis of Bicyclic Cyclopentenones and Allylic Amines</span></div><div class="casAuthors">Hicks, Frederick A.; Berk, Scott C.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2713-18</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical titanium-catalyzed synthesis of bicyclic cyclopentenones and allylic amines was described.  In this process enynes were converted to iminocyclopentenes using 10 mol% of the air- and moisture-stable precatalyst Cp2TiCl2 in the presence of n-BuLi and triethylsilyl cyanide.  The resulting iminocyclopentenes can be hydrolyzed to cyclopentenones in good yields or reduced to allylic silylamines with Red-Al or DIBALH.  Treatment of the crude silylamines with acetyl chloride allows isolation of allylic amides in excellent yields.  For example, the cyclization of [3-(2-propenyloxy)-1-propynyl]benzene gave 3a,4-dihydro-6-phenyl-1H-cyclopenta[c]furan-5(3H)-one (82% yield).  Treatment of [3-(2-propenyloxy)-1-propynyl]benzene with dicyclopentadienyltitanium dichloride followed by treatment with triethylsilyl cyanide and subsequent redn. gave N-acetyl-3a,4,5-tetrahydro-1H-Cyclopenta[c]furan-5-amine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRSC4wAUzukbVg90H21EOLACvtfcHk0lglXq_k3XxvWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvFWrtbw%253D&md5=79d6fcf81d50242a382d3f6e66a1d03c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjo951763l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo951763l%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DF.%2BA.%26aulast%3DBerk%26aufirst%3DS.%2BC.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520practical%2520titanium-catalyzed%2520synthesis%2520of%2520bicyclic%2520cyclopentenones%2520and%2520allylic%2520amines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1996%26volume%3D61%26spage%3D2713%26epage%3D2718%26doi%3D10.1021%2Fjo951763l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krafft, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaga, L. V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirosawa, C.</span></span> <span> </span><span class="NLM_article-title">Modification and limitations of the livinghouse catalytic pauson-khand reaction</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">9171</span>– <span class="NLM_lpage">9175</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(99)01960-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2FS0040-4039%2899%2901960-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK1MXotVyitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1999&pages=9171-9175&author=M.+E.+Krafftauthor=L.+V.+R.+Bonagaauthor=C.+Hirosawa&title=Modification+and+limitations+of+the+livinghouse+catalytic+pauson-khand+reaction&doi=10.1016%2FS0040-4039%2899%2901960-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Modification and limitations of the Livinghouse catalytic Pauson-Khand reaction</span></div><div class="casAuthors">Krafft, M. E.; Bonaga, L. V. R.; Hirosawa, C.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">9171-9175</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The difficult and impractical purifn. of Co2(CO)8 is not necessary in the catalytic thermal Pauson-Khand reaction previously described by Livinghouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHWXAi2Lbh7LVg90H21EOLACvtfcHk0lglXq_k3XxvWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotVyitb4%253D&md5=00d8a5290cb7c8384a5fa58205b2f9d6</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2899%2901960-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252899%252901960-7%26sid%3Dliteratum%253Aachs%26aulast%3DKrafft%26aufirst%3DM.%2BE.%26aulast%3DBonaga%26aufirst%3DL.%2BV.%2BR.%26aulast%3DHirosawa%26aufirst%3DC.%26atitle%3DModification%2520and%2520limitations%2520of%2520the%2520livinghouse%2520catalytic%2520pauson-khand%2520reaction%26jtitle%3DTetrahedron%2520Lett.%26date%3D1999%26volume%3D40%26spage%3D9171%26epage%3D9175%26doi%3D10.1016%2FS0040-4039%2899%2901960-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, R. B.</span></span> <span> </span><span class="NLM_article-title">Pauson-khand approach to chiral, diastereomerically pure group 4 ansa-metallocene complexes</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1016/S0040-4020(98)01099-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1016%2FS0040-4020%2898%2901099-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK1MXhtFynt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1999&pages=919-934&author=R.+B.+Grossman&title=Pauson-khand+approach+to+chiral%2C+diastereomerically+pure+group+4+ansa-metallocene+complexes&doi=10.1016%2FS0040-4020%2898%2901099-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Pauson-Khand approach to chiral, diastereomerically pure Group 4 ansa-metallocene complexes</span></div><div class="casAuthors">Grossman, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">919-934</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The C2-sym. bis(1,6-enynes), threo-1,10-diphenyl-5,6-divinyl-1,9-decadiyne and threo-9,10-divinyl-5,13-octadecadiyne undergo the intramol. Pauson-Khand reaction regioselectively and stereoselectively to give C2-sym. bis(enones) with two bicyclo[3.3.0]octyl moieties joined at the C6 position.  Expts. aimed at converting the bis(enones) into chiral, diastereopure ansa-bridged group 4 metallocene complexes are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpKvCi4FJPhbVg90H21EOLACvtfcHk0lglXq_k3XxvWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtFynt78%253D&md5=39e11ec7d1c93f14a305d47f9b714193</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2898%2901099-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252898%252901099-0%26sid%3Dliteratum%253Aachs%26aulast%3DGrossman%26aufirst%3DR.%2BB.%26atitle%3DPauson-khand%2520approach%2520to%2520chiral%252C%2520diastereomerically%2520pure%2520group%25204%2520ansa-metallocene%2520complexes%26jtitle%3DTetrahedron%26date%3D1999%26volume%3D55%26spage%3D919%26epage%3D934%26doi%3D10.1016%2FS0040-4020%2898%2901099-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez
Rivero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, J. C.</span></span> <span> </span><span class="NLM_article-title">Intramolecular pauson-khand reactions of α,β-unsaturated esters and related electron-deficient olefins</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2975</span>– <span class="NLM_lpage">2978</span>, <span class="refDoi"> DOI: 10.1021/jo026828g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo026828g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=2975-2978&author=M.+Rodr%C3%ADguez%0ARiveroauthor=J.+C.+Carretero&title=Intramolecular+pauson-khand+reactions+of+%CE%B1%2C%CE%B2-unsaturated+esters+and+related+electron-deficient+olefins&doi=10.1021%2Fjo026828g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Intramolecular Pauson-Khand Reactions of α,β-Unsaturated Esters and Related Electron-Deficient Olefins</span></div><div class="casAuthors">Rodriguez Rivero, Marta; Carretero, Juan Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2975-2978</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The intramol. Pauson-Khand reaction of a variety of electron-poor enynes, e.g. I [R1 = H, Me, Ph; R2 = H, Me; R3 = H, EtOCH2O, (Me2CH)3SiO; R4 = CN, EtO2C, (EtO)2PO], having an ester, cyano, or phosphonate group at the olefin terminus, is described.  Thus, the Co2(CO)8-catalyzed intramol. cyclization of enynes I led preferentially to the exocyclic 1,3-dienes II or to pentalenones III depending on the reaction conditions and the enyne substitution.  In general, II was obtained as the major product under N-oxide-promoted conditions, while III was selectively formed in refluxing acetonitrile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2x40FwWBxTLVg90H21EOLACvtfcHk0ljm5pbmT98lvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSltro%253D&md5=006853f9439a3f6fdac1df79111e2e10</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fjo026828g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo026828g%26sid%3Dliteratum%253Aachs%26aulast%3DRodr%25C3%25ADguez%2BRivero%26aufirst%3DM.%26aulast%3DCarretero%26aufirst%3DJ.%2BC.%26atitle%3DIntramolecular%2520pauson-khand%2520reactions%2520of%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520esters%2520and%2520related%2520electron-deficient%2520olefins%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D2975%26epage%3D2978%26doi%3D10.1021%2Fjo026828g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Urgoiti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An̈orbe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Serrano, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domínguez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Castells, J.</span></span> <span> </span><span class="NLM_article-title">The pauson-khand reaction, a powerful synthetic tool for the synthesis of complex molecules</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1039/B300976A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1039%2FB300976A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=14737507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvV2ksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2004&pages=32-42&author=J.+Blanco-Urgoitiauthor=L.+An%CC%88orbeauthor=L.+P%C3%A9rez-Serranoauthor=G.+Dom%C3%ADnguezauthor=J.+P%C3%A9rez-Castells&title=The+pauson-khand+reaction%2C+a+powerful+synthetic+tool+for+the+synthesis+of+complex+molecules&doi=10.1039%2FB300976A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The Pauson-Khand reaction, a powerful synthetic tool for the synthesis of complex molecules</span></div><div class="casAuthors">Blanco-Urgoiti, Jaime; Anorbe, Loreto; Perez-Serrano, Leticia; Dominguez, Gema; Perez-Castells, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The Pauson-Khand reaction (PKR) is a powerful transformation that has now been sufficiently well developed to be routinely considered when planning a synthesis, esp. of polycyclic complex mols.  This tutorial aims to encourage the use of this process explaining the best ways of performing a PKR both in the stoichiometric and the catalytic version, showing the scope of the process and its limitations.  Addnl., asymmetry can be introduced in the reaction using several strategies, which will be discussed.  The most recent examples of the synthetic applications of the PKR in natural product synthesis will give the reader an idea of the great usefulness of this reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNRrMHoHpACbVg90H21EOLACvtfcHk0ljm5pbmT98lvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvV2ksLk%253D&md5=db048965b28cae7be4c057f1a4256eaa</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1039%2FB300976A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB300976A%26sid%3Dliteratum%253Aachs%26aulast%3DBlanco-Urgoiti%26aufirst%3DJ.%26aulast%3DAn%25CC%2588orbe%26aufirst%3DL.%26aulast%3DP%25C3%25A9rez-Serrano%26aufirst%3DL.%26aulast%3DDom%25C3%25ADnguez%26aufirst%3DG.%26aulast%3DP%25C3%25A9rez-Castells%26aufirst%3DJ.%26atitle%3DThe%2520pauson-khand%2520reaction%252C%2520a%2520powerful%2520synthetic%2520tool%2520for%2520the%2520synthesis%2520of%2520complex%2520molecules%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2004%26volume%3D33%26spage%3D32%26epage%3D42%26doi%3D10.1039%2FB300976A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M.</span></span> <span> </span><span class="NLM_article-title">Natural product syntheses <i>via</i> carbonylative cyclizations</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1039/C8NP00033F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=10.1039%2FC8NP00033F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=29923586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKgtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2019&pages=174-219&author=K.+Maauthor=B.+S.+Martinauthor=X.+Yinauthor=M.+Dai&title=Natural+product+syntheses+via+carbonylative+cyclizations&doi=10.1039%2FC8NP00033F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Natural product syntheses via carbonylative cyclizations</span></div><div class="casAuthors">Ma, Kaiqing; Martin, Brandon S.; Yin, Xianglin; Dai, Mingji</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-219</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Examples of natural product total syntheses employing transition metal-mediated/catalyzed carbonylative cyclization strategies to build key ring systems.  It mainly covers carbonylative cyclizations for the construction of O-heterocycles, N-heterocycles and carbocycles including cyclic ketones and phenols.  The reaction types include carbonylation of epoxide to β-lactones, carbonylative (macro)lactonization/lactamization, the Semmelhack reaction, tandem hydroformylation-cyclization, the Pauson-Khand reaction, carbonylative C-H activation cyclization, the Stille/Suzuki carbonylation, [n + m + 1] carbonylative cycloaddn., the Dotz annulation, and others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfNiiBNqO7-rVg90H21EOLACvtfcHk0liQVajPoC0Qdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKgtrfK&md5=00a6256823827b2b7999e7ecc1347992</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1039%2FC8NP00033F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8NP00033F%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DB.%2BS.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DDai%26aufirst%3DM.%26atitle%3DNatural%2520product%2520syntheses%2520via%2520carbonylative%2520cyclizations%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2019%26volume%3D36%26spage%3D174%26epage%3D219%26doi%3D10.1039%2FC8NP00033F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seley, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneller, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattendi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacchi, C. J.</span></span> <span> </span><span class="NLM_article-title">(+)-7-Deaza-5‘-noraristeromycin as an Anti-Trypanosomal Agent</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">624</span>, <span class="refDoi"> DOI: 10.1021/jm9605039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9605039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVSrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=622-624&author=K.+L.+Seleyauthor=S.+W.+Schnellerauthor=D.+Rattendiauthor=C.+J.+Bacchi&title=%28%2B%29-7-Deaza-5%E2%80%98-noraristeromycin+as+an+Anti-Trypanosomal+Agent&doi=10.1021%2Fjm9605039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">(+)-7-Deaza-5'-noraristeromycin as an Antitrypanosomal Agent</span></div><div class="casAuthors">Seley, Katherine L.; Schneller, Stewart W.; Rattendi, Donna; Bacchi, Cyrus J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">622-624</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The (+)-enantiomer of 7-deaza-5'-noraristeromycin has been found to show IC50 values ranging from 0.16 to 5.3 μM against four strains of African trypanosomes, one Trypanosoma brucei brucei isolate, and several clin. isolates of Trypanosoma brucei rhodesiense (agent of east African sleeping sickness), including a multidrug resistant clone of one isolate.  While this compd. was originally designed to inhibit S-adenosyl-L-homocysteine hydrolase, it has been found to have no effect on this enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYzKrGz8-lX7Vg90H21EOLACvtfcHk0liQVajPoC0Qdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVSrsbo%253D&md5=623d8edeffc6b3d6864c3512408d83b3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm9605039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9605039%26sid%3Dliteratum%253Aachs%26aulast%3DSeley%26aufirst%3DK.%2BL.%26aulast%3DSchneller%26aufirst%3DS.%2BW.%26aulast%3DRattendi%26aufirst%3DD.%26aulast%3DBacchi%26aufirst%3DC.%2BJ.%26atitle%3D%2528%252B%2529-7-Deaza-5%25E2%2580%2598-noraristeromycin%2520as%2520an%2520Anti-Trypanosomal%2520Agent%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D622%26epage%3D624%26doi%3D10.1021%2Fjm9605039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X61" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4X61','PDB','4X61'); return false;">PDB: 4X61</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GQB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GQB','PDB','4GQB'); return false;">PDB: 4GQB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FA5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5FA5','PDB','5FA5'); return false;">PDB: 5FA5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KIB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KIB','PDB','7KIB'); return false;">PDB: 7KIB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KIC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KIC','PDB','7KIC'); return false;">PDB: 7KIC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KID" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7KID','PDB','7KID'); return false;">PDB: 7KID</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i102"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02083">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_67842"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02083?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02083</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Supplementary figures, tables, and plots; description of modeling methods; crystallography methods; LC traces for compounds <b>34</b> and <b>72</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Representative docking models for compounds <b>4</b>, <b>31</b>, <b>41</b>, <b>65</b>, and <b>73</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_001.pdf">jm0c02083_si_001.pdf (2.99 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_002.pdb">jm0c02083_si_002.pdb (638.13 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02083/suppl_file/jm0c02083_si_003.csv">jm0c02083_si_003.csv (2.89 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02083&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02083%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02083" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679975e47b843dc4","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
